ChIP-Atlas / in silico ChIP for GWAS

Search for proteins significantly bound around GWAS SNPs.

GWAS trait	Enrichment	Clustering	Intersections	Num of LD-DHS	Min(Log P)	Min(Log Q)
1,5-anhydroglucitol levels	HTML, TSV	Image, TSV	BED	1	-2.5	0.0
3-hydroxy-1-methylpropylmercapturic acid levels in smokers	HTML, TSV	Image, TSV	BED	571	-4.0	0.0
3-hydroxypropylmercapturic acid levels in smokers	HTML, TSV	Image, TSV	BED	745	-4.4	-0.2
3-month functional outcome in ischaemic stroke (modified Rankin score)	HTML, TSV	Image, TSV	BED	142	-4.1	0.0
3-month functional outcome in lacunar ischaemic stroke (modified Rankin score)	HTML, TSV	Image, TSV	BED	10	-1.8	0.0
3-month functional outcome in non-lacunar ischaemic stroke (modified Rankin score)	HTML, TSV	Image, TSV	BED	27	-3.9	-0.2
6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction)	HTML, TSV	Image, TSV	BED	237	-3.3	0.0
Abdominal aortic aneurysm	HTML, TSV	Image, TSV	BED	24	-5.3	-1.3
Ability to confide in someone	HTML, TSV	Image, TSV	BED	39	-2.6	0.0
Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis)	HTML, TSV	Image, TSV	BED	3	-5.2	-1.0
Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction)	HTML, TSV	Image, TSV	BED	33	-2.9	0.0
Accelerometer-based physical activity measurement (average acceleration)	HTML, TSV	Image, TSV	BED	23	-4.2	-0.3
Accelerometer-based physical activity measurement (fraction of time with accelerations >425 milli-gravities)	HTML, TSV	Image, TSV	BED	1	-2.3	0.0
Achilles tendinopathy	HTML, TSV	Image, TSV	BED	5	-3.3	0.0
Acne (severe)	HTML, TSV,	Image, TSV	BED	122	-7.0	-3.0
Acoustic startle blink response	HTML, TSV	Image, TSV	BED	42	-2.9	0.0
ACPA-positive rheumatoid arthritis (smoking interaction)	HTML, TSV	Image, TSV	BED	5	-3.2	0.0
Activated partial thromboplastin time	HTML, TSV	Image, TSV	BED	49	-2.9	0.0
Acute anterior uveitis in ankylosing spondylitis	HTML, TSV	Image, TSV	BED	118	-3.4	0.0
Acute anterior uveitis (with or without ankylosing spondylitis)	HTML, TSV	Image, TSV	BED	12	-4.8	-0.8
Acute graft versus host disease in bone marrow transplantation (donor effect)	HTML, TSV	Image, TSV	BED	68	-4.0	-0.0
Acute graft versus host disease in bone marrow transplantation (recipient effect)	HTML, TSV	Image, TSV	BED	60	-4.7	-0.5
Acute insulin response	HTML, TSV	Image, TSV	BED	68	-4.9	-0.8
Acute kidney injury in coronary artery bypass surgery (creatinine rise)	HTML, TSV	Image, TSV	BED	5	-2.9	0.0
Acute kidney injury in critical illness	HTML, TSV	Image, TSV	BED	6	-3.1	0.0
Acute lymphoblastic leukemia (adolescents and young adults)	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
Acute lymphoblastic leukemia (B-cell precursor)	HTML, TSV,	Image, TSV	BED	48	-6.8	-2.6
Acute lymphoblastic leukemia (childhood)	HTML, TSV	Image, TSV	BED	222	-5.8	-1.7
Acute lymphoblastic leukemia in childhood (B cell precursor)	HTML, TSV	Image, TSV	BED	44	-5.3	-1.2
Acute-on-chronic liver failure in hepatitis B	HTML, TSV	Image, TSV	BED	1	-2.8	-0.1
Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced)	HTML, TSV	Image, TSV	BED	50	-1.9	0.0
ADAMTS13 activity	HTML, TSV	Image, TSV	BED	1	-2.4	0.0
Addiction	HTML, TSV	Image, TSV	BED	12	-5.7	-1.6
Adenocarcinoma	HTML, TSV,	Image, TSV	BED	17	-8.4	-4.2
Adiponectin levels	HTML, TSV	Image, TSV	BED	314	-3.7	0.0
Adiponectin levels (BMI-adjusted)	HTML, TSV	Image, TSV	BED	31	-4.3	-0.6
Adiponectin levels in pregnancy	HTML, TSV	Image, TSV	BED	5	-2.5	0.0
Adiposity	HTML, TSV,	Image, TSV	BED	48	-6.1	-2.3
Adolescent idiopathic scoliosis	HTML, TSV,	Image, TSV	BED	6975	-11.5	-7.3
Adolescent idiopathic scoliosis (severe)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Adult asthma	HTML, TSV	Image, TSV	BED	65	-3.0	0.0
Advanced age-related macular degeneration	HTML, TSV	Image, TSV	BED	127	-5.0	-0.9
Advanced glycation end-product levels	HTML, TSV	Image, TSV	BED	16	-4.9	-0.7
Adventurousness	HTML, TSV	Image, TSV	BED	989	-4.6	-0.7
Adverse response to antithyroid drugs in Graves disease	HTML, TSV	Image, TSV	BED	2	-1.5	0.0
Adverse response to aromatase inhibitors	HTML, TSV	Image, TSV	BED	6	-4.1	0.0
Adverse response to chemotherapy in breast cancer (alopecia)	HTML, TSV	Image, TSV	BED	2	-1.1	0.0
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)	HTML, TSV	Image, TSV	BED	54	-3.8	0.0
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)	HTML, TSV	Image, TSV	BED	13	-2.8	0.0
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)	HTML, TSV	Image, TSV	BED	5	-3.0	0.0
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)	HTML, TSV	Image, TSV	BED	42	-4.1	0.0
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)	HTML, TSV	Image, TSV	BED	41	-5.4	-1.2
Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)	HTML, TSV	Image, TSV	BED	26	-2.6	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)	HTML, TSV	Image, TSV	BED	41	-4.3	-0.2
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)	HTML, TSV	Image, TSV	BED	6	0.0	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)	HTML, TSV	Image, TSV	BED	84	-3.8	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)	HTML, TSV,	Image, TSV	BED	30	-6.3	-2.2
Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)	HTML, TSV	Image, TSV	BED	18	-2.4	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)	HTML, TSV	Image, TSV	BED	13	-3.5	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)	HTML, TSV,	Image, TSV	BED	21	-9.3	-5.2
Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	HTML, TSV	Image, TSV	BED	86	-3.5	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)	HTML, TSV	Image, TSV	BED	9	-4.1	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)	HTML, TSV	Image, TSV	BED	20	-4.5	-0.4
Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)	HTML, TSV,	Image, TSV	BED	21	-6.0	-2.1
Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)	HTML, TSV	Image, TSV	BED	9	-2.9	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)	HTML, TSV	Image, TSV	BED	29	-2.8	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)	HTML, TSV	Image, TSV	BED	14	-4.1	0.0
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)	HTML, TSV	Image, TSV	BED	31	-3.9	-0.0
Adverse response to lamotrigine and phenytoin	HTML, TSV	Image, TSV	BED	59	-4.3	-0.2
Adverse response to radiation therapy	HTML, TSV	Image, TSV	BED	30	-4.4	-0.2
Affective disorder and suicide attempts	HTML, TSV	Image, TSV	BED	81	-4.0	0.0
Age at first birth	HTML, TSV	Image, TSV	BED	22	-3.0	0.0
Age at first sexual intercourse	HTML, TSV	Image, TSV	BED	89	-3.1	0.0
Age at loss of ambulation in Duchenne muscular dystrophy	HTML, TSV	Image, TSV	BED	112	-2.9	0.0
Age at menopause	HTML, TSV	Image, TSV	BED	176	-4.8	-0.7
Age at smoking initiation in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	56	-2.8	0.0
Age at voice drop	HTML, TSV	Image, TSV	BED	57	-5.3	-1.2
Age of smoking initiation	HTML, TSV	Image, TSV	BED	137	-2.8	0.0
Age of smoking initiation (MTAG)	HTML, TSV,	Image, TSV	BED	1008	-9.2	-5.4
Age-related cataracts	HTML, TSV	Image, TSV	BED	6	-2.5	0.0
Age-related disease endophenotypes	HTML, TSV	Image, TSV	BED	93	-5.0	-1.1
Age-related diseases and mortality	HTML, TSV	Image, TSV	BED	77	-4.0	0.0
Age-related diseases, mortality and associated endophenotypes	HTML, TSV	Image, TSV	BED	166	-4.3	-0.2
Age-related hearing impairment	HTML, TSV	Image, TSV	BED	161	-3.2	0.0
Age-related macular degeneration	HTML, TSV	Image, TSV	BED	159	-5.7	-1.7
Age-related macular degeneration (choroidal neovascularisation)	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Age-related macular degeneration (geographic atrophy)	HTML, TSV	Image, TSV	BED	3	-2.8	0.0
Age-related macular degeneration (smoking status interaction)	HTML, TSV	Image, TSV	BED	10	-1.5	0.0
Age-related nuclear cataracts	HTML, TSV	Image, TSV	BED	119	-4.1	-0.0
Age spots	HTML, TSV	Image, TSV	BED	10	-3.2	0.0
Aggressiveness in attention deficit hyperactivity disorder	HTML, TSV	Image, TSV	BED	125	-3.2	0.0
Aggressive periodontitis	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Aggressive periodontitis (sex interaction)	HTML, TSV	Image, TSV	BED	18	-3.8	0.0
Aging	HTML, TSV	Image, TSV	BED	54	-4.1	-0.1
Aging (facial)	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Aging (time to death)	HTML, TSV	Image, TSV	BED	15	-2.4	0.0
Aging (time to event)	HTML, TSV	Image, TSV	BED	64	-4.0	-0.1
Aging traits	HTML, TSV	Image, TSV	BED	77	-3.4	0.0
AIDS	HTML, TSV	Image, TSV	BED	19	-3.2	0.0
AIDS progression	HTML, TSV	Image, TSV	BED	13	-4.3	-0.4
Airflow obstruction	HTML, TSV	Image, TSV	BED	108	-3.0	0.0
Airway imaging phenotypes	HTML, TSV	Image, TSV	BED	96	-3.1	0.0
Airway responsiveness in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	58	-4.9	-1.0
Airway wall thickness	HTML, TSV	Image, TSV	BED	42	-3.1	0.0
Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	HTML, TSV	Image, TSV	BED	146	-4.5	-0.3
Alanine aminotransferase levels	HTML, TSV,	Image, TSV	BED	378	-8.8	-4.6
Alanine aminotransferase levels in excessive alcohol consumption	HTML, TSV	Image, TSV	BED	59	-5.4	-1.2
Alanine aminotransferase levels in low alcohol consumption	HTML, TSV	Image, TSV	BED	109	-3.6	0.0
Alanine transaminase levels	HTML, TSV	Image, TSV	BED	77	0.0	0.0
Albumin-globulin ratio	HTML, TSV	Image, TSV	BED	93	-4.4	-0.4
Alcohol and nicotine co-dependence	HTML, TSV	Image, TSV	BED	23	-4.4	-0.2
Alcohol consumption	HTML, TSV	Image, TSV	BED	247	-2.8	0.0
Alcohol consumption (drinkers vs non-drinkers)	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Alcohol consumption (drinks per week)	HTML, TSV	Image, TSV	BED	724	-4.6	-0.4
Alcohol consumption (drinks per week) (MTAG)	HTML, TSV	Image, TSV	BED	1210	-4.2	-0.3
Alcohol consumption (heavy vs. light/non-drinkers)	HTML, TSV,	Image, TSV	BED	37	-6.8	-2.8
Alcohol consumption in current drinkers	HTML, TSV	Image, TSV	BED	3	-1.6	0.0
Alcohol consumption (max-drinks)	HTML, TSV	Image, TSV	BED	33	-5.6	-1.4
Alcohol consumption over the past year	HTML, TSV	Image, TSV	BED	7	-1.9	0.0
Alcohol consumption (transferrin glycosylation)	HTML, TSV	Image, TSV	BED	1	-3.3	-0.4
Alcohol dependence	HTML, TSV,	Image, TSV	BED	223	-7.5	-3.3
Alcohol dependence (age at onset)	HTML, TSV	Image, TSV	BED	169	-3.5	0.0
Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis	HTML, TSV	Image, TSV	BED	5	-1.9	0.0
Alcohol dependence symptom count	HTML, TSV	Image, TSV	BED	130	-4.2	-0.0
Alcoholic chronic pancreatitis	HTML, TSV,	Image, TSV	BED	182	-9.9	-5.8
Alcoholism (12-month weekly alcohol consumption)	HTML, TSV	Image, TSV	BED	38	-5.2	-1.3
Alcoholism (alcohol dependence factor score)	HTML, TSV	Image, TSV	BED	15	-5.4	-1.7
Alcoholism (alcohol use disorder factor score)	HTML, TSV	Image, TSV	BED	5	-2.5	0.0
Alcoholism (heaviness of drinking)	HTML, TSV	Image, TSV	BED	37	-3.3	0.0
Alcohol misuse (trauma interaction)	HTML, TSV	Image, TSV	BED	7	-3.8	0.0
Alcohol use disorder (consumption score)	HTML, TSV,	Image, TSV	BED	144	-7.1	-2.9
Alcohol use disorder (dependence and problematic use scores)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Alcohol use disorder (total score)	HTML, TSV,	Image, TSV	BED	37	-7.0	-3.0
Allergic dermatitis (nickel)	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Allergic disease (asthma, hay fever or eczema)	HTML, TSV,	Image, TSV	BED	711	-16.1	-11.9
Allergic rhinitis	HTML, TSV,	Image, TSV	BED	390	-6.5	-2.6
Allergic rhinitis in asthma	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
Allergic rhinitis in non-asthmatics	HTML, TSV	Image, TSV	BED	39	-2.9	0.0
Allergic sensitization	HTML, TSV,	Image, TSV	BED	100	-7.2	-3.0
Allergy	HTML, TSV	Image, TSV	BED	62	-4.4	-0.5
Alloimmunization response to pregnancy (HLA class I)	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Alloimmunization response to red blood cell transfusion in sickle cell anemia	HTML, TSV	Image, TSV	BED	2	-4.1	-0.4
Alopecia areata	HTML, TSV,	Image, TSV	BED	141	-6.9	-2.8
Alzheimer disease and age of onset	HTML, TSV	Image, TSV	BED	590	-3.0	0.0
Alzheimer's disease	HTML, TSV,	Image, TSV	BED	266	-8.3	-4.1
Alzheimer's disease (age of onset)	HTML, TSV	Image, TSV	BED	39	-3.3	0.0
Alzheimer's disease (APOE e4 interaction)	HTML, TSV	Image, TSV	BED	8	-3.2	0.0
Alzheimer's disease biomarkers	HTML, TSV	Image, TSV	BED	33	-5.4	-1.3
Alzheimer's disease (cognitive decline)	HTML, TSV	Image, TSV	BED	73	-3.4	0.0
Alzheimer's disease in APOE e4+ carriers	HTML, TSV	Image, TSV	BED	47	-3.4	0.0
Alzheimer's disease in APOE e4- carriers	HTML, TSV	Image, TSV	BED	102	-4.4	-0.4
Alzheimer's disease (late onset)	HTML, TSV	Image, TSV	BED	374	-6.0	-2.0
Alzheimer's disease or family history of Alzheimer's disease	HTML, TSV,	Image, TSV	BED	395	-12.8	-8.7
Alzheimer's disease progression score	HTML, TSV	Image, TSV	BED	40	-2.5	0.0
Alzheimer's disease (survival time)	HTML, TSV	Image, TSV	BED	19	-4.8	-0.6
Alzheimer's disease with language domain impairment	HTML, TSV	Image, TSV	BED	31	-3.7	0.0
Alzheimer's disease with memory domain impairment	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
Alzheimer's disease with multiple cognitive domain impairments	HTML, TSV	Image, TSV	BED	10	-4.7	-0.5
Alzheimer's disease with no specific cognitive domain impairment	HTML, TSV	Image, TSV	BED	16	-4.6	-0.7
Alzheimer's disease with visuospatial domain impairment	HTML, TSV	Image, TSV	BED	123	-5.1	-1.0
Amino acid levels	HTML, TSV	Image, TSV	BED	30	-3.4	0.0
Amyotrophic lateral sclerosis	HTML, TSV,	Image, TSV	BED	324	-6.2	-2.0
Amyotrophic lateral sclerosis (age of onset)	HTML, TSV	Image, TSV	BED	46	-4.0	-0.3
Amyotrophic lateral sclerosis (C9orf72 mutation interaction)	HTML, TSV	Image, TSV	BED	8	-5.7	-1.5
Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals	HTML, TSV	Image, TSV	BED	20	-4.0	-0.1
Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals	HTML, TSV	Image, TSV	BED	37	-2.1	0.0
Amyotrophic lateral sclerosis (sporadic)	HTML, TSV	Image, TSV	BED	482	-5.5	-1.4
Androgen levels	HTML, TSV	Image, TSV	BED	4	-2.0	0.0
Anger	HTML, TSV	Image, TSV	BED	65	-4.4	-0.7
Angiotensin-converting enzyme activity	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Angiotensin-converting enzyme inhibitor intolerance	HTML, TSV	Image, TSV	BED	83	-3.9	0.0
Ankle-brachial index	HTML, TSV	Image, TSV	BED	18	-2.4	0.0
Ankle injury	HTML, TSV,	Image, TSV	BED	140	-7.8	-3.7
Ankylosing spondylitis	HTML, TSV,	Image, TSV	BED	227	-6.4	-2.2
Anorexia nervosa	HTML, TSV	Image, TSV	BED	127	-4.5	-0.4
Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa)	HTML, TSV	Image, TSV	BED	11	-3.2	0.0
Anorexia nervosa or obsessive-compulsive disorder	HTML, TSV,	Image, TSV	BED	32	-6.4	-2.3
Anterior cruciate ligament rupture	HTML, TSV	Image, TSV	BED	38	-3.7	0.0
Anthropometric traits	HTML, TSV	Image, TSV	BED	80	0.0	0.0
Anthropometric traits (multi-trait analysis)	HTML, TSV	Image, TSV	BED	56	-2.7	0.0
Antibody level in response to infection	HTML, TSV	Image, TSV	BED	45	-2.2	0.0
Antibody status in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	47	-3.5	0.0
Anticoagulant levels	HTML, TSV	Image, TSV	BED	35	-3.7	0.0
Antidepressant treatment resistance (> 2 drugs prescribed)	HTML, TSV	Image, TSV	BED	10	-2.9	0.0
Antidepressant treatment resistance (number of drugs prescribed)	HTML, TSV	Image, TSV	BED	25	-3.4	-0.1
Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age	HTML, TSV	Image, TSV	BED	21	-3.2	0.0
Antineutrophil cytoplasmic antibody-associated vasculitis	HTML, TSV	Image, TSV	BED	47	-5.1	-0.9
antipsychotic drug dosage in schizophrenia or schizoaffective disorder	HTML, TSV	Image, TSV	BED	98	-4.6	-0.4
Antipsychotic drug-induced QTc interval change in schizophrenia	HTML, TSV	Image, TSV	BED	75	-1.9	0.0
Antipsychotic drug-induced QTc interval prolongation	HTML, TSV	Image, TSV	BED	33	-5.1	-1.4
Antipsychotic drug-induced weight gain	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Anti-saccade error rate in psychotic disorders	HTML, TSV	Image, TSV	BED	2	-2.6	0.0
Anti-saccade response	HTML, TSV	Image, TSV	BED	257	-5.1	-0.9
Anti-thyroid drug induced agranulocytosis	HTML, TSV	Image, TSV	BED	2	-4.3	-0.1
Antitragus size	HTML, TSV	Image, TSV	BED	3	-2.9	0.0
Anxiety and major depressive disorder	HTML, TSV,	Image, TSV	BED	32	-6.6	-2.7
Anxiety disorder	HTML, TSV	Image, TSV	BED	43	-4.5	-0.5
Anxiety in major depressive disorder	HTML, TSV	Image, TSV	BED	29	-4.0	0.0
Anxiety/tension (special factor of neuroticism)	HTML, TSV	Image, TSV	BED	75	-3.9	0.0
Aortic root size	HTML, TSV	Image, TSV	BED	86	-4.4	-0.4
Aortic stiffness	HTML, TSV	Image, TSV	BED	21	-2.6	0.0
Aortic valve stenosis	HTML, TSV	Image, TSV	BED	32	-4.1	0.0
Apolipoprotein A1 levels	HTML, TSV,	Image, TSV	BED	1115	-9.1	-5.0
Appendicitis	HTML, TSV	Image, TSV	BED	7	-2.6	0.0
Appendicular lean mass	HTML, TSV	Image, TSV	BED	1241	-4.0	-0.2
Area under the curve of insulin levels	HTML, TSV	Image, TSV	BED	2	-5.3	-1.2
Arterial stiffness	HTML, TSV	Image, TSV	BED	8	-4.5	-0.3
Arthritis (juvenile idiopathic)	HTML, TSV	Image, TSV	BED	65	-4.5	-0.3
Asparaginase hypersensitivity in acute lymphoblastic leukemia	HTML, TSV	Image, TSV	BED	6	-3.9	0.0
Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time)	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Aspartate aminotransferase levels	HTML, TSV,	Image, TSV	BED	596	-7.8	-3.6
Aspartate aminotransferase levels in excessive alcohol consumption	HTML, TSV	Image, TSV	BED	45	-2.9	0.0
Aspartate aminotransferase levels in low alcohol consumption	HTML, TSV	Image, TSV	BED	73	-3.3	0.0
Asperger disorder	HTML, TSV	Image, TSV	BED	43	-3.0	0.0
Asthma	HTML, TSV,	Image, TSV	BED	1841	-26.4	-22.3
Asthma and hay fever	HTML, TSV,	Image, TSV	BED	139	-9.6	-5.5
Asthma (bronchodilator response)	HTML, TSV	Image, TSV	BED	11	-3.5	0.0
Asthma (childhood onset)	HTML, TSV,	Image, TSV	BED	907	-12.6	-8.4
Asthma-chronic obstructive pulmonary disease overlap syndrome	HTML, TSV	Image, TSV	BED	9	-2.3	0.0
Asthma (corticosteroid response)	HTML, TSV	Image, TSV	BED	16	-3.0	0.0
Asthma exacerbations in inhaled corticosteroid treatment	HTML, TSV	Image, TSV	BED	51	-4.5	-0.4
Asthma (moderate or severe)	HTML, TSV	Image, TSV	BED	136	-5.7	-1.8
Asthma or allergic disease (pleiotropy)	HTML, TSV	Image, TSV	BED	157	-5.2	-1.0
Asthma or chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	13	-4.7	-0.5
Asthma (sex interaction)	HTML, TSV	Image, TSV	BED	9	-2.8	0.0
Asthma (toluene diisocyanate-induced)	HTML, TSV	Image, TSV	BED	32	-3.2	0.0
Asymmetrical dimethylarginine levels	HTML, TSV	Image, TSV	BED	40	-2.8	0.0
Atazanavir levels	HTML, TSV	Image, TSV	BED	6	-4.6	-0.9
Atopic dermatitis	HTML, TSV,	Image, TSV	BED	224	-10.5	-6.3
Atopic march	HTML, TSV,	Image, TSV	BED	80	-6.8	-2.6
Atopy	HTML, TSV	Image, TSV	BED	16	-4.1	0.0
Atrial fibrillation	HTML, TSV,	Image, TSV	BED	1041	-6.4	-2.2
Atrial fibrillation/atrial flutter	HTML, TSV	Image, TSV	BED	37	-3.3	0.0
Atrioventricular conduction	HTML, TSV	Image, TSV	BED	15	-2.8	0.0
Atrioventricular septal defects in Down syndrome	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Attention deficit hyperactivity disorder	HTML, TSV	Image, TSV	BED	642	-4.7	-0.8
Attention deficit hyperactivity disorder and conduct disorder	HTML, TSV	Image, TSV	BED	105	-4.4	-0.3
Attention deficit hyperactivity disorder (combined symptoms)	HTML, TSV	Image, TSV	BED	30	0.0	0.0
Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)	HTML, TSV	Image, TSV	BED	83	-3.3	0.0
Attention deficit hyperactivity disorder (inattention symptoms)	HTML, TSV	Image, TSV	BED	106	-3.0	0.0
Attention deficit hyperactivity disorder motor coordination	HTML, TSV	Image, TSV	BED	2	-1.4	0.0
Attention deficit hyperactivity disorder or amygdala volume (pleiotropy)	HTML, TSV	Image, TSV	BED	7	-2.1	0.0
Attention deficit hyperactivity disorder or cannabis use	HTML, TSV	Image, TSV	BED	178	-4.8	-1.0
Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy)	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Attention deficit hyperactivity disorder or intracranial volume (pleiotropy)	HTML, TSV	Image, TSV	BED	8	-2.1	0.0
Attention deficit hyperactivity disorder symptom score	HTML, TSV	Image, TSV	BED	23	-3.1	0.0
Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction)	HTML, TSV	Image, TSV	BED	29	-2.5	0.0
Attention deficit hyperactivity disorder (time to onset)	HTML, TSV	Image, TSV	BED	34	-4.2	-0.0
Attention function in attention deficit hyperactive disorder	HTML, TSV	Image, TSV	BED	158	-5.7	-1.5
Autism	HTML, TSV	Image, TSV	BED	31	-3.5	0.0
Autism and educational attainment (MTAG)	HTML, TSV	Image, TSV	BED	14	-5.3	-1.3
Autism and major depressive disorder (MTAG)	HTML, TSV	Image, TSV	BED	12	-3.8	0.0
Autism spectrum disorder	HTML, TSV	Image, TSV	BED	241	-4.5	-0.3
Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	HTML, TSV	Image, TSV	BED	450	-3.9	0.0
Autism spectrum disorder or schizophrenia	HTML, TSV,	Image, TSV	BED	552	-6.1	-2.0
Autism spectrum disorder-related traits	HTML, TSV	Image, TSV	BED	21	-3.6	-0.1
Autoimmune hepatitis type-1	HTML, TSV	Image, TSV	BED	7	-5.0	-0.8
Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis)	HTML, TSV	Image, TSV	BED	24	-3.4	0.0
Autoimmune traits	HTML, TSV	Image, TSV	BED	330	0.0	0.0
Automobile speeding propensity	HTML, TSV	Image, TSV	BED	201	-4.6	-0.8
Axial length	HTML, TSV	Image, TSV	BED	62	-4.7	-0.5
Axial length or spherical error (univariate decomposition analysis)	HTML, TSV	Image, TSV	BED	23	-4.2	-0.0
B6 vitamer levels (multivariate analysis)	HTML, TSV	Image, TSV	BED	7	-5.0	-0.8
Bacteremia	HTML, TSV	Image, TSV	BED	43	-4.1	0.0
Bacterial meningitis	HTML, TSV	Image, TSV	BED	115	-2.6	0.0
Balding	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
Balding type 1	HTML, TSV,	Image, TSV	BED	2080	-10.4	-6.2
Barrett's esophagus	HTML, TSV	Image, TSV	BED	32	-3.2	0.0
Barrett's esophagus or Esophageal adenocarcinoma	HTML, TSV	Image, TSV	BED	29	-5.4	-1.3
Barrett's esophagus x pack-years of smoking exposure interaction	HTML, TSV	Image, TSV	BED	11	-4.8	-0.8
Basal cell carcinoma	HTML, TSV	Image, TSV	BED	270	-4.7	-0.8
Basal ganglia growth	HTML, TSV	Image, TSV	BED	4	-1.7	0.0
Basal metabolic rate	HTML, TSV	Image, TSV	BED	60	-5.0	-1.0
Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Basophil percentage of granulocytes	HTML, TSV,	Image, TSV	BED	130	-16.2	-12.1
Basophil percentage of white cells	HTML, TSV,	Image, TSV	BED	427	-17.3	-13.3
B cell acute lymphoblastic leukaemia (abnormal cytogenetics)	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
B cell acute lymphoblastic leukaemia (hyperdiploid negative)	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
B cell acute lymphoblastic leukaemia in adulthood	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
B cell acute lymphoblastic leukaemia in young adulthood	HTML, TSV	Image, TSV	BED	2	0.0	0.0
B cell acute lymphoblastic leukaemia (normal cytogenetics)	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative)	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)	HTML, TSV	Image, TSV	BED	16	-3.7	0.0
B cell non-Hodgkin lymphoma	HTML, TSV	Image, TSV	BED	10	-4.0	-0.1
Beard thickness	HTML, TSV	Image, TSV	BED	52	-3.8	-0.4
Behavioral disturbance or psychiatric symptoms and prion disease	HTML, TSV	Image, TSV	BED	18	-3.1	0.0
Behavioral disturbance or psychiatric symptoms in prion disease	HTML, TSV	Image, TSV	BED	9	-4.8	-0.8
Behavioural changes in frontotemporal lobe dementia	HTML, TSV	Image, TSV	BED	6	-2.7	0.0
Behavioural disinhibition (generation interaction)	HTML, TSV	Image, TSV	BED	81	-3.2	0.0
Behcet's disease	HTML, TSV	Image, TSV	BED	38	-5.4	-1.2
Benign prostatic hyperplasia and lower urinary tract symptoms	HTML, TSV	Image, TSV	BED	116	-5.0	-0.8
Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded)	HTML, TSV	Image, TSV	BED	109	-5.1	-0.9
Benign prostatic hyperplasia and/or lower urinary tract symptoms	HTML, TSV	Image, TSV	BED	3	-2.0	0.0
β2-Glycoprotein I (β2-GPI) plasma levels	HTML, TSV	Image, TSV	BED	35	-2.9	0.0
beta-nerve growth factor levels	HTML, TSV	Image, TSV	BED	59	-2.9	0.0
Beta thalassemia/hemoglobin E disease	HTML, TSV	Image, TSV	BED	18	-5.0	-0.8
Biliary atresia	HTML, TSV	Image, TSV	BED	32	-4.6	-0.6
Bilirubin levels	HTML, TSV	Image, TSV	BED	98	-4.7	-0.6
Binge eating behaviour and bipolar disorder	HTML, TSV	Image, TSV	BED	46	-2.2	0.0
Binge eating behaviour in bipolar disorder	HTML, TSV	Image, TSV	BED	6	-4.6	-0.4
Biochemical measures	HTML, TSV	Image, TSV	BED	155	-3.2	0.0
Biomedical quantitative traits	HTML, TSV	Image, TSV	BED	92	0.0	0.0
Bipolar disorder	HTML, TSV	Image, TSV	BED	1229	-4.4	-0.5
Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder	HTML, TSV	Image, TSV	BED	7	-4.5	-0.6
Bipolar disorder (age of onset and psychotic symptoms)	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Bipolar disorder and eating disorder	HTML, TSV	Image, TSV	BED	14	-4.3	-0.1
Bipolar disorder and schizophrenia	HTML, TSV	Image, TSV	BED	705	-5.0	-0.9
Bipolar disorder (body mass index interaction)	HTML, TSV,	Image, TSV	BED	278	-7.0	-2.8
Bipolar disorder (early onset)	HTML, TSV	Image, TSV	BED	4	-3.5	0.0
Bipolar disorder (inflammation and infection response interaction)	HTML, TSV	Image, TSV	BED	32	-4.2	0.0
Bipolar disorder lithium response (categorical) or schizophrenia	HTML, TSV	Image, TSV	BED	23	-3.4	0.0
Bipolar disorder lithium response (continuous) or schizophrenia	HTML, TSV	Image, TSV	BED	2	-2.4	0.0
Bipolar disorder or attention deficit hyperactivity disorder	HTML, TSV,	Image, TSV	BED	40	-6.2	-2.0
Bipolar disorder or major depressive disorder	HTML, TSV,	Image, TSV	BED	596	-6.5	-2.3
Bipolar disorder with mood-incongruent psychosis	HTML, TSV	Image, TSV	BED	68	-3.8	0.0
Bipolar I disorder	HTML, TSV	Image, TSV	BED	250	-4.4	-0.2
Birth weight	HTML, TSV	Image, TSV	BED	868	-5.2	-1.5
Bitter taste perception	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Bitter taste perception (multivariate analysis)	HTML, TSV	Image, TSV	BED	5	-4.5	-0.6
Black vs. blond hair color	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Black vs. red hair color	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Bladder cancer	HTML, TSV,	Image, TSV	BED	124	-34.3	-30.1
Bladder cancer (smoking interaction)	HTML, TSV	Image, TSV	BED	19	-3.7	0.0
Blond vs. brown/black hair color	HTML, TSV,	Image, TSV	BED	883	-9.4	-5.2
Blond vs. brown hair color	HTML, TSV	Image, TSV	BED	54	-6.1	-1.9
Blond vs non-blond hair color	HTML, TSV	Image, TSV	BED	60	0.0	0.0
Blood and toenail selenium levels	HTML, TSV	Image, TSV	BED	7	-2.5	0.0
Blood glucose levels	HTML, TSV	Image, TSV	BED	44	-4.0	0.0
Blood metabolite levels	HTML, TSV,	Image, TSV	BED	200	-9.3	-5.1
Blood metabolite ratios	HTML, TSV	Image, TSV	BED	59	-3.8	0.0
Blood osmolality (transformed sodium)	HTML, TSV	Image, TSV	BED	122	-4.1	0.0
Blood pressure	HTML, TSV	Image, TSV	BED	445	-3.2	0.0
Blood pressure (age interaction)	HTML, TSV	Image, TSV	BED	8	-2.8	0.0
Blood pressure (anthropometric measures interaction)	HTML, TSV	Image, TSV	BED	24	-3.6	0.0
Blood pressure measurement (cold pressor test)	HTML, TSV	Image, TSV	BED	11	-3.1	0.0
Blood pressure measurement (high sodium and potassium intervention)	HTML, TSV	Image, TSV	BED	54	-4.2	0.0
Blood pressure measurement (high sodium intervention)	HTML, TSV	Image, TSV	BED	26	-3.3	0.0
Blood pressure measurement (low sodium intervention)	HTML, TSV	Image, TSV	BED	32	-4.1	-0.0
Blood pressure (smoking interaction)	HTML, TSV	Image, TSV	BED	132	-3.4	0.0
Blood pressure traits (multi-trait analysis)	HTML, TSV	Image, TSV	BED	40	-4.3	-0.2
Blood protein levels	HTML, TSV,	Image, TSV	BED	3780	-14.6	-10.5
Blood sugar levels	HTML, TSV	Image, TSV	BED	75	-4.8	-0.8
Blood trace element (Cu levels)	HTML, TSV	Image, TSV	BED	21	-2.4	0.0
Blood trace element (Se levels)	HTML, TSV	Image, TSV	BED	49	-5.1	-1.0
Blood trace element (Zn levels)	HTML, TSV	Image, TSV	BED	36	-2.5	0.0
Blood urea nitrogen levels	HTML, TSV,	Image, TSV	BED	675	-9.4	-5.2
BMI (adjusted for smoking behaviour)	HTML, TSV	Image, TSV	BED	422	-5.3	-1.1
BMI in non-smokers	HTML, TSV	Image, TSV	BED	299	-4.7	-0.5
BMI in smokers	HTML, TSV	Image, TSV	BED	183	-5.9	-1.7
BMI (smoking interaction)	HTML, TSV,	Image, TSV	BED	62	-8.7	-4.5
Body fat distribution (arm fat ratio)	HTML, TSV	Image, TSV	BED	164	-4.2	-0.6
Body fat distribution (leg fat ratio)	HTML, TSV	Image, TSV	BED	229	-4.5	-0.4
Body fat distribution (trunk fat ratio)	HTML, TSV	Image, TSV	BED	214	-4.2	-0.2
Body fat mass	HTML, TSV	Image, TSV	BED	186	-5.0	-0.9
Body fat percentage	HTML, TSV	Image, TSV	BED	499	-4.1	0.0
Body mass in chronic obstructive pulmonary disease	HTML, TSV,	Image, TSV	BED	30	-7.9	-3.7
Body mass index	HTML, TSV,	Image, TSV	BED	12558	-15.6	-11.4
Body mass index (adult)	HTML, TSV	Image, TSV	BED	146	-4.2	-0.1
Body mass index (age <50)	HTML, TSV,	Image, TSV	BED	118	-7.8	-3.7
Body mass index (age>50)	HTML, TSV	Image, TSV	BED	134	-4.0	-0.2
Body mass index (age interaction)	HTML, TSV	Image, TSV	BED	38	-5.8	-1.9
Body mass index (alcohol intake interaction)	HTML, TSV	Image, TSV	BED	6	-3.5	0.0
Body mass index and cholesterol (psychopharmacological treatment)	HTML, TSV	Image, TSV	BED	25	-3.2	0.0
Body mass index and waist-hip ratio (pleiotropy)	HTML, TSV	Image, TSV	BED	34	-5.6	-1.8
Body mass index (change over time)	HTML, TSV	Image, TSV	BED	34	-2.9	0.0
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	19	-4.3	-0.2
Body mass index (change over time) in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	29	-5.0	-0.8
Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	8	-4.0	-0.4
Body mass index (change over time) in lung cancer	HTML, TSV	Image, TSV	BED	12	-2.6	0.0
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	12	-4.4	-0.3
Body mass index (dietary energy interaction)	HTML, TSV	Image, TSV	BED	5	-1.6	0.0
Body mass index (education interaction)	HTML, TSV	Image, TSV	BED	51	-3.3	0.0
Body mass index (ever vs never smoking interaction)	HTML, TSV	Image, TSV	BED	17	-2.8	0.0
Body mass index in asthmatics	HTML, TSV	Image, TSV	BED	27	-5.2	-1.0
Body mass index in non-asthmatics	HTML, TSV	Image, TSV	BED	39	-4.8	-0.6
Body mass index in physically active individuals	HTML, TSV	Image, TSV	BED	381	-4.2	-0.2
Body mass index in physically inactive individuals	HTML, TSV,	Image, TSV	BED	229	-7.6	-3.5
Body mass index (joint analysis main effects and physical activity interaction)	HTML, TSV	Image, TSV	BED	433	-5.8	-1.6
Body mass index (joint analysis main effects and smoking interaction)	HTML, TSV,	Image, TSV	BED	484	-6.2	-2.1
Body mass index (physical activity interaction)	HTML, TSV	Image, TSV	BED	10	-3.1	0.0
Body mass index (recreational physical activity interaction)	HTML, TSV,	Image, TSV	BED	24	-7.6	-3.4
Body mass index (smoking years interaction)	HTML, TSV	Image, TSV	BED	43	-2.3	0.0
Body mass index (SNP x SNP interaction)	HTML, TSV	Image, TSV	BED	72	-4.9	-0.7
Body mass index variance	HTML, TSV	Image, TSV	BED	146	-4.3	-0.1
Body mass index x age interaction	HTML, TSV	Image, TSV	BED	59	-4.2	-0.0
Body mass index x sex x age interaction (4df test)	HTML, TSV,	Image, TSV	BED	161	-7.2	-3.0
Bone erosion in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	1	-4.3	-0.7
Bone fracture in osteoporosis	HTML, TSV	Image, TSV	BED	22	-3.7	0.0
Bone mineral accretion in asthma (oral corticosteroid dose interaction)	HTML, TSV	Image, TSV	BED	29	-1.9	0.0
Bone mineral density	HTML, TSV,	Image, TSV	BED	237	-6.7	-2.5
Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia	HTML, TSV	Image, TSV	BED	4	-2.5	0.0
Bone mineral density (femoral neck)	HTML, TSV	Image, TSV	BED	3	-4.4	-0.6
Bone mineral density (femoral neck) in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	11	-4.9	-0.7
Bone mineral density (hip)	HTML, TSV	Image, TSV	BED	284	-4.5	-0.6
Bone mineral density (hip) and age at menarche	HTML, TSV	Image, TSV	BED	36	-5.2	-1.2
Bone mineral density (lumbar spine) in inflammatory bowel disease	HTML, TSV,	Image, TSV	BED	36	-10.7	-6.5
Bone mineral density (paediatric, lower limb)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Bone mineral density (paediatric, skull)	HTML, TSV	Image, TSV	BED	32	-3.8	0.0
Bone mineral density (paediatric, total body less head)	HTML, TSV	Image, TSV	BED	66	-3.8	-0.2
Bone mineral density (paediatric, upper limb)	HTML, TSV	Image, TSV	BED	80	-5.7	-1.6
Bone mineral density (spine)	HTML, TSV	Image, TSV	BED	121	-4.8	-1.2
Bone mineral density (spine) and age at menarche	HTML, TSV	Image, TSV	BED	20	-5.7	-1.6
Bone mineral density (total hip)	HTML, TSV	Image, TSV	BED	121	-4.6	-0.7
Bone mineral density (Ward's triangle area)	HTML, TSV	Image, TSV	BED	88	-2.7	0.0
Bone mineral density (wrist)	HTML, TSV	Image, TSV	BED	28	-2.8	0.0
Bone mineral density x blood lead interaction in current smokers (1df test)	HTML, TSV	Image, TSV	BED	1	-2.4	0.0
Bone mineral density x blood lead interaction in current smokers (2df test)	HTML, TSV	Image, TSV	BED	5	-4.7	-0.8
Bone properties (heel)	HTML, TSV	Image, TSV	BED	67	-3.6	0.0
Bone ultrasound measurement (broadband ultrasound attenuation)	HTML, TSV,	Image, TSV	BED	77	-6.6	-2.4
Bone ultrasound measurement (velocity of sound)	HTML, TSV	Image, TSV	BED	61	-3.7	0.0
Borderline personality disorder	HTML, TSV	Image, TSV	BED	33	-3.6	0.0
Bortezomib-induced peripheral neuropathy in multiple myeloma	HTML, TSV	Image, TSV	BED	23	-1.8	0.0
Brain connectivity	HTML, TSV	Image, TSV	BED	68	-3.2	0.0
Brain cytoarchitecture	HTML, TSV	Image, TSV	BED	10	-2.5	0.0
Brain glucose metabolism (fluorodeoxyglucose uptake)	HTML, TSV	Image, TSV	BED	15	-3.4	0.0
Brain imaging	HTML, TSV,	Image, TSV	BED	39	-6.9	-2.7
Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction)	HTML, TSV	Image, TSV	BED	64	-3.7	0.0
Brain imaging measurements	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
Brain lesion load	HTML, TSV	Image, TSV	BED	14	-3.4	0.0
Brain structure	HTML, TSV	Image, TSV	BED	66	-4.0	0.0
Brain structure (hippocampal volume)	HTML, TSV	Image, TSV	BED	21	-3.9	0.0
Brain structure (temporal lobe volume)	HTML, TSV	Image, TSV	BED	42	-3.0	0.0
Brain volume in infants (cerebrospinal fluid)	HTML, TSV	Image, TSV	BED	14	-3.0	0.0
Brain volume in infants (grey matter)	HTML, TSV	Image, TSV	BED	48	-3.3	0.0
Brain volume in infants (intracranial brain volume)	HTML, TSV	Image, TSV	BED	3	-3.1	0.0
Brain volume in infants (white matter)	HTML, TSV	Image, TSV	BED	7	-2.2	0.0
Branched-chain amino acid levels (Isoleucine)	HTML, TSV	Image, TSV	BED	30	-4.8	-0.6
BRCA1/2-negative high-risk breast cancer	HTML, TSV	Image, TSV	BED	52	-3.6	0.0
Breast cancer	HTML, TSV,	Image, TSV	BED	2939	-13.3	-9.1
Breast cancer and/or colorectal cancer	HTML, TSV	Image, TSV	BED	16	-5.0	-1.3
Breast cancer (early onset)	HTML, TSV	Image, TSV	BED	46	-4.6	-0.4
Breast cancer (estrogen-receptor negative)	HTML, TSV,	Image, TSV	BED	273	-8.5	-4.4
Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)	HTML, TSV,	Image, TSV	BED	17	-7.6	-3.5
Breast cancer (estrogen-receptor positive)	HTML, TSV	Image, TSV	BED	19	-5.8	-1.6
Breast cancer-free interval (treatment with aromatase inhibitor)	HTML, TSV	Image, TSV	BED	4	-4.1	0.0
Breast Cancer in BRCA1 mutation carriers	HTML, TSV,	Image, TSV	BED	47	-7.1	-3.0
Breast cancer in BRCA2 mutation carriers	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
Breast cancer in childhood cancer survivors	HTML, TSV	Image, TSV	BED	6	-2.5	0.0
Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy	HTML, TSV	Image, TSV	BED	27	-4.1	-0.3
Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy	HTML, TSV	Image, TSV	BED	4	-2.6	0.0
Breast cancer (male)	HTML, TSV,	Image, TSV	BED	58	-16.3	-12.1
Breast cancer (menopausal hormone therapy interaction)	HTML, TSV	Image, TSV	BED	5	-3.2	0.0
Breast cancer (progesterone-receptor positive)	HTML, TSV,	Image, TSV	BED	7	-6.3	-2.1
Breast cancer (prognosis)	HTML, TSV	Image, TSV	BED	18	-5.4	-1.6
Breast cancer specific mortality in breast cancer	HTML, TSV	Image, TSV	BED	49	-2.9	0.0
Breast cancer specific mortality in estrogen receptor negative breast cancer	HTML, TSV	Image, TSV	BED	53	-4.7	-0.6
Breast cancer specific mortality in estrogen receptor positive breast cancer	HTML, TSV	Image, TSV	BED	63	-4.6	-0.4
Breast cancer (survival)	HTML, TSV	Image, TSV	BED	19	-4.0	0.0
Breastfeeding duration	HTML, TSV	Image, TSV	BED	9	-2.9	0.0
Breast milk fatty acid composition (infant genotype effect)	HTML, TSV	Image, TSV	BED	31	-3.4	0.0
Breast milk fatty acid composition (maternal genotype effect)	HTML, TSV	Image, TSV	BED	34	-3.3	0.0
Breast size	HTML, TSV	Image, TSV	BED	230	-5.5	-1.3
Broad depression or bipolar disorder	HTML, TSV	Image, TSV	BED	1	-3.3	0.0
Broad depression or major depressive disorder (self-reported)	HTML, TSV	Image, TSV	BED	26	-2.1	0.0
Broad depression or schizophrenia	HTML, TSV	Image, TSV	BED	64	-3.0	0.0
Bronchial neuroendocrine tumor	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Bronchodilator response in asthma	HTML, TSV	Image, TSV	BED	5	-2.6	0.0
Bronchodilator response in asthma (inhaled corticosteroid treatment interaction)	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Bronchopulmonary dysplasia	HTML, TSV	Image, TSV	BED	70	-2.9	0.0
Bronchopulmonary dysplasia in preterm infants	HTML, TSV	Image, TSV	BED	43	-3.3	0.0
Brooding (response to stress)	HTML, TSV	Image, TSV	BED	12	-4.3	-0.5
Brown vs. black hair color	HTML, TSV,	Image, TSV	BED	163	-6.5	-2.3
Brown vs. non-brown hair color	HTML, TSV	Image, TSV	BED	60	-5.9	-1.7
Brugada syndrome	HTML, TSV	Image, TSV	BED	2	-5.4	-1.2
Bulimia nervosa	HTML, TSV	Image, TSV	BED	130	-3.7	0.0
Caffeine consumption	HTML, TSV	Image, TSV	BED	24	-3.3	0.0
Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)	HTML, TSV	Image, TSV	BED	15	-4.2	0.0
Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)	HTML, TSV	Image, TSV	BED	2	-3.3	-0.2
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)	HTML, TSV	Image, TSV	BED	30	-5.0	-1.1
Calcific aortic valve stenosis	HTML, TSV	Image, TSV	BED	104	-4.2	-0.1
Calcium levels	HTML, TSV	Image, TSV	BED	249	-4.3	-0.1
Callous-unemotional behaviour	HTML, TSV	Image, TSV	BED	11	-2.8	0.0
Cancer	HTML, TSV	Image, TSV	BED	37	-2.8	0.0
Cancer (pleiotropy)	HTML, TSV,	Image, TSV	BED	450	-6.0	-2.2
Cannabis dependence	HTML, TSV	Image, TSV	BED	114	-2.8	0.0
Cannabis dependence symptom count	HTML, TSV	Image, TSV	BED	173	-3.7	0.0
Cannabis use	HTML, TSV	Image, TSV	BED	49	-3.4	0.0
Cannabis use (age at onset)	HTML, TSV	Image, TSV	BED	43	-1.5	0.0
Cannabis use (initiation)	HTML, TSV	Image, TSV	BED	104	-4.7	-0.5
Capecitabine sensitivity	HTML, TSV	Image, TSV	BED	68	-3.5	0.0
Carboplatin disposition in epthelial ovarian cancer	HTML, TSV	Image, TSV	BED	157	-2.4	0.0
Cardiac hypertrophy	HTML, TSV	Image, TSV	BED	125	-3.5	0.0
Cardiac muscle measurement	HTML, TSV	Image, TSV	BED	71	-4.9	-0.7
Cardiac structure and function	HTML, TSV	Image, TSV	BED	26	-3.3	0.0
Cardiac Troponin-T levels	HTML, TSV	Image, TSV	BED	165	-2.9	0.0
Cardiometabolic and hematological traits	HTML, TSV	Image, TSV	BED	73	-2.3	0.0
Cardiovascular disease	HTML, TSV	Image, TSV	BED	1229	-4.4	-0.5
Cardiovascular disease in hypertension (calcium channel blocker interaction)	HTML, TSV	Image, TSV	BED	6	-4.8	-0.6
Cardiovascular disease risk factors	HTML, TSV	Image, TSV	BED	23	-4.7	-0.7
Cardiovascular event in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	6	-4.2	0.0
Cardiovascular heart disease in diabetics	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Cardiovascular risk factors	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Cardiovascular risk factors (age interaction)	HTML, TSV	Image, TSV	BED	7	-2.3	0.0
Carotenoid and tocopherol levels	HTML, TSV	Image, TSV	BED	12	-4.4	-0.5
Carotenoid levels (alpha-carotene)	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Carotid artery intima media thickness (sex interaction)	HTML, TSV	Image, TSV	BED	68	-3.6	0.0
Carotid atherosclerosis in HIV infection	HTML, TSV	Image, TSV	BED	8	-4.2	-1.1
Carotid intima media thickness	HTML, TSV	Image, TSV	BED	54	-4.4	-0.7
Carotid intima media thickness in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	3	-1.7	0.0
Carotid plaque burden	HTML, TSV	Image, TSV	BED	77	-4.2	-0.3
Carotid plaque burden (smoking interaction)	HTML, TSV	Image, TSV	BED	11	-3.6	0.0
Carotid plaques in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	17	-5.1	-0.9
Carotid plaque	HTML, TSV	Image, TSV	BED	19	-4.2	-0.1
Carpal tunnel syndrome	HTML, TSV	Image, TSV	BED	98	-3.6	0.0
Caudate activity during reward	HTML, TSV	Image, TSV	BED	180	-5.0	-1.0
Caudate nucleus volume	HTML, TSV,	Image, TSV	BED	108	-6.5	-2.3
Caudate volume in trauma-exposed individuals	HTML, TSV	Image, TSV	BED	39	-4.7	-1.0
Celiac disease	HTML, TSV,	Image, TSV	BED	413	-23.0	-18.9
Celiac disease or Rheumatoid arthritis	HTML, TSV,	Image, TSV	BED	137	-7.3	-3.1
Cellular adhesion molecule (red blood cell fatty acid level interaction)	HTML, TSV	Image, TSV	BED	3	-2.0	0.0
Cellular nuclear factor (erythroid-derived 2)-like 2 levels	HTML, TSV	Image, TSV	BED	25	-4.1	0.0
Central corneal thickness	HTML, TSV,	Image, TSV	BED	525	-6.9	-2.7
Cephalic index	HTML, TSV	Image, TSV	BED	74	-5.7	-1.9
Cerebellum growth	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Cerebral amyloid angiopathy	HTML, TSV	Image, TSV	BED	55	-2.6	0.0
Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging)	HTML, TSV	Image, TSV	BED	123	-5.1	-1.0
Cerebral amyloid deposition (PET imaging)	HTML, TSV	Image, TSV	BED	102	-3.1	0.0
Cerebral cortical growth	HTML, TSV,	Image, TSV	BED	25	-7.2	-3.2
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia	HTML, TSV	Image, TSV	BED	19	-2.9	0.0
Cerebrospinal AB1-42 levels in mild cognitive impairment	HTML, TSV	Image, TSV	BED	3	-3.4	0.0
Cerebrospinal AB1-42 levels in normal cognition	HTML, TSV,	Image, TSV	BED	74	-7.4	-3.2
Cerebrospinal fluid AB1-42 levels	HTML, TSV	Image, TSV	BED	145	-5.4	-1.5
Cerebrospinal fluid beta-site APP cleaving enzyme levels	HTML, TSV	Image, TSV	BED	67	-2.5	0.0
Cerebrospinal fluid biomarker levels	HTML, TSV	Image, TSV	BED	59	-3.6	0.0
Cerebrospinal fluid clusterin levels	HTML, TSV	Image, TSV	BED	64	-4.8	-0.7
Cerebrospinal fluid clusterin levels in APOEe4+ carriers	HTML, TSV	Image, TSV	BED	11	-4.2	0.0
Cerebrospinal fluid p-Tau181p:AB1-42 ratio	HTML, TSV	Image, TSV	BED	19	-5.1	-1.0
Cerebrospinal fluid p-tau levels	HTML, TSV	Image, TSV	BED	6	-2.2	0.0
Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia	HTML, TSV	Image, TSV	BED	5	-4.0	-0.3
Cerebrospinal fluid p-tau levels in mild cognitive impairment	HTML, TSV	Image, TSV	BED	9	-3.7	0.0
Cerebrospinal fluid p-tau levels in normal cognition	HTML, TSV	Image, TSV	BED	10	-1.8	0.0
Cerebrospinal fluid pyridoxal phosphate levels	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Cerebrospinal fluid ?-synuclein levels	HTML, TSV	Image, TSV	BED	41	-4.8	-0.8
Cerebrospinal fluid t-tau:AB1-42 ratio	HTML, TSV	Image, TSV	BED	192	-4.0	0.0
Cerebrospinal fluid t-tau levels	HTML, TSV	Image, TSV	BED	80	-3.3	0.0
Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
Cerebrospinal fluid t-tau levels in mild cognitive impairment	HTML, TSV	Image, TSV	BED	4	-2.7	0.0
Cerebrospinal fluid t-tau levels in normal cognition	HTML, TSV	Image, TSV	BED	8	-4.0	0.0
Cerebrospinal P-tau181p levels	HTML, TSV	Image, TSV	BED	74	-4.0	-0.1
Cerebrospinal T-tau levels	HTML, TSV	Image, TSV	BED	102	-4.3	-0.5
Cervical artery dissection	HTML, TSV	Image, TSV	BED	17	-3.2	0.0
Cervical cancer	HTML, TSV	Image, TSV	BED	161	-4.4	-0.4
Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	66	-5.9	-1.7
Change in glucose in response to thiazide diuretic treatment in hypertension	HTML, TSV	Image, TSV	BED	19	-4.3	-0.5
Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide)	HTML, TSV	Image, TSV	BED	3	-2.4	0.0
Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer	HTML, TSV	Image, TSV	BED	28	-3.8	-0.0
Cheek morphology (partial least square model)	HTML, TSV	Image, TSV	BED	1	-4.2	-1.4
Chemerin levels	HTML, TSV	Image, TSV	BED	50	-3.9	-0.2
Chickenpox	HTML, TSV	Image, TSV	BED	93	-3.8	0.0
Childhood absence epilepsy	HTML, TSV	Image, TSV	BED	42	-3.4	0.0
Childhood and early adolescence aggressive behavior	HTML, TSV	Image, TSV	BED	14	-2.4	0.0
Childhood body mass index	HTML, TSV	Image, TSV	BED	328	-3.0	0.0
Childhood dental caries in permanent teeth	HTML, TSV	Image, TSV	BED	1	-3.1	0.0
Childhood ear infection	HTML, TSV,	Image, TSV	BED	446	-9.6	-5.4
Childhood onset systemic lupus erythematosus	HTML, TSV	Image, TSV	BED	3	-4.3	-0.4
Childhood steroid-sensitive nephrotic syndrome	HTML, TSV,	Image, TSV	BED	63	-6.8	-2.7
Chin dimples	HTML, TSV	Image, TSV	BED	416	-3.9	-0.2
Chloride levels	HTML, TSV	Image, TSV	BED	94	-3.7	0.0
Cholangiocarcinoma in primary sclerosing cholangitis (time to event)	HTML, TSV	Image, TSV	BED	10	-5.2	-1.1
Cholesterol	HTML, TSV,	Image, TSV	BED	24	-6.2	-2.3
Cholesterol efflux capacity	HTML, TSV	Image, TSV	BED	7	-2.0	0.0
Cholesterol efflux capacity (ABCA-1 dependent assay)	HTML, TSV	Image, TSV	BED	6	-3.7	0.0
Cholesterol efflux capacity (BHK stimulated assay)	HTML, TSV	Image, TSV	BED	4	-4.1	-0.4
Cholesterol efflux capacity (cAMP stimulated assay)	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Cholesterol ester levels in large LDL	HTML, TSV	Image, TSV	BED	4	-3.0	0.0
Cholesterol ester levels in medium LDL	HTML, TSV	Image, TSV	BED	5	-2.9	0.0
Cholesterol ester levels in very large HDL	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Cholesterol, total	HTML, TSV,	Image, TSV	BED	215	-8.0	-3.8
Cholesteryl ester transfer protein levels	HTML, TSV	Image, TSV	BED	6	-2.0	0.0
Chronic back pain	HTML, TSV,	Image, TSV	BED	6	-8.8	-4.6
Chronic bronchitis and chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	43	-3.3	0.0
Chronic central serous retinopathy	HTML, TSV	Image, TSV	BED	5	-4.3	-0.3
Chronic hepatitis B infection	HTML, TSV	Image, TSV	BED	12	-4.9	-0.9
Chronic hepatitis C infection	HTML, TSV	Image, TSV	BED	6	-2.6	0.0
Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)	HTML, TSV,	Image, TSV	BED	1001	-26.6	-22.5
Chronic kidney disease	HTML, TSV	Image, TSV	BED	318	-5.4	-1.2
Chronic kidney disease and serum creatinine levels	HTML, TSV,	Image, TSV	BED	56	-8.0	-3.9
Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes	HTML, TSV	Image, TSV	BED	14	-4.3	-0.4
Chronic kidney disease in diabetes	HTML, TSV	Image, TSV	BED	6	-2.3	0.0
Chronic kidney disease in type 2 diabetes	HTML, TSV	Image, TSV	BED	22	-4.5	-0.6
Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Chronic lymphocytic leukemia	HTML, TSV,	Image, TSV	BED	162	-13.4	-9.3
Chronic mucus hypersecretion	HTML, TSV	Image, TSV	BED	6	-2.9	0.0
Chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	629	-4.5	-0.9
Chronic obstructive pulmonary disease (moderate to severe)	HTML, TSV	Image, TSV	BED	64	-3.0	0.0
Chronic obstructive pulmonary disease or coronary artery disease (pleiotropy)	HTML, TSV	Image, TSV	BED	26	-4.6	-0.4
Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	HTML, TSV	Image, TSV	BED	81	-3.2	0.0
Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	HTML, TSV,	Image, TSV	BED	121	-7.4	-3.2
Chronic obstructive pulmonary disease-related biomarkers	HTML, TSV	Image, TSV	BED	58	-5.0	-0.8
Chronic obstructive pulmonary disease (severe)	HTML, TSV	Image, TSV	BED	39	-3.6	0.0
Chronic periodontitis	HTML, TSV	Image, TSV	BED	8	-4.0	-0.1
Chronic periodontitis (mean interproximal clinical attachment level)	HTML, TSV	Image, TSV	BED	35	-4.7	-0.5
Chronic rhinosinusitis	HTML, TSV	Image, TSV	BED	29	-2.3	0.0
Chronic rhinosinusitis with nasal polyps	HTML, TSV	Image, TSV	BED	2	-3.2	0.0
Chronic sinus infection	HTML, TSV	Image, TSV	BED	73	-2.4	0.0
Chronic venous disease	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Chronotype	HTML, TSV,	Image, TSV	BED	2500	-7.3	-3.6
Cigarettes smoked per day (MTAG)	HTML, TSV	Image, TSV	BED	351	-3.1	0.0
Cingulate cortical amyloid beta load	HTML, TSV	Image, TSV	BED	8	-4.5	-0.3
Circulating chemerin levels	HTML, TSV	Image, TSV	BED	16	-4.2	-0.2
Circulating chromogranin peptide levels	HTML, TSV,	Image, TSV	BED	29	-7.7	-3.5
Circulating fibroblast growth factor 23 levels	HTML, TSV	Image, TSV	BED	102	-4.2	-0.3
circulating leptin levels	HTML, TSV,	Image, TSV	BED	71	-5.9	-2.3
circulating leptin levels adjusted for BMI	HTML, TSV,	Image, TSV	BED	35	-7.2	-3.4
Circulating myeloperoxidase levels (plasma)	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Circulating myeloperoxidase levels (serum)	HTML, TSV,	Image, TSV	BED	17	-6.7	-2.5
Circulating odd-numbered chain saturated fatty acid levels (C15:0)	HTML, TSV	Image, TSV	BED	26	-3.0	0.0
Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0)	HTML, TSV	Image, TSV	BED	18	-2.8	0.0
Circulating odd-numbered chain saturated fatty acid levels (C17:0)	HTML, TSV	Image, TSV	BED	27	-3.1	0.0
Circulating odd-numbered chain saturated fatty acid levels (C19:0)	HTML, TSV,	Image, TSV	BED	66	-7.5	-3.3
Circulating odd-numbered chain saturated fatty acid levels (C23:0)	HTML, TSV	Image, TSV	BED	35	-4.6	-0.5
Circulating phylloquinone levels	HTML, TSV	Image, TSV	BED	6	-5.7	-1.5
Cisplatin-induced ototoxicity	HTML, TSV	Image, TSV	BED	53	-2.8	0.0
Classic bladder exstrophy	HTML, TSV	Image, TSV	BED	119	-2.7	0.0
Cleft lip	HTML, TSV	Image, TSV	BED	10	-2.7	0.0
Cleft lip with or without cleft palate	HTML, TSV,	Image, TSV	BED	90	-6.7	-2.5
Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction)	HTML, TSV,	Image, TSV	BED	2	-7.1	-2.9
Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction)	HTML, TSV	Image, TSV	BED	6	-2.8	0.0
Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)	HTML, TSV	Image, TSV	BED	37	-3.8	0.0
Cleft palate	HTML, TSV	Image, TSV	BED	74	-2.2	0.0
Clinical laboratory measurements	HTML, TSV	Image, TSV	BED	41	-3.5	0.0
Clopidogrel active metabolite levels	HTML, TSV	Image, TSV	BED	50	-5.9	-1.8
Clostridium difficile infection in multiple myeloma	HTML, TSV	Image, TSV	BED	102	-3.8	0.0
Clozapine-induced agranulocytosis	HTML, TSV	Image, TSV	BED	154	-4.2	-0.0
Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	HTML, TSV	Image, TSV	BED	23	-3.5	0.0
Clozapine-induced cytotoxicity	HTML, TSV	Image, TSV	BED	50	-4.6	-0.8
Cluster headache	HTML, TSV	Image, TSV	BED	6	-4.7	-0.7
Cocaine dependence	HTML, TSV	Image, TSV	BED	92	-4.0	0.0
Coenzyme Q10 levels	HTML, TSV	Image, TSV	BED	51	-2.4	0.0
Coffee consumption	HTML, TSV	Image, TSV	BED	395	-4.6	-0.6
Coffee consumption (cups per day)	HTML, TSV	Image, TSV	BED	77	-4.8	-0.6
Cognitive ability	HTML, TSV,	Image, TSV	BED	341	-9.1	-5.2
Cognitive ability (MTAG)	HTML, TSV,	Image, TSV	BED	488	-8.3	-4.1
Cognitive decline (age-related)	HTML, TSV,	Image, TSV	BED	135	-6.3	-2.1
Cognitive decline rate in late mild cognitive impairment	HTML, TSV	Image, TSV	BED	184	-3.1	0.0
Cognitive empathy	HTML, TSV	Image, TSV	BED	358	-3.0	0.0
Cognitive flexibility	HTML, TSV	Image, TSV	BED	6	-3.1	0.0
Cognitive function	HTML, TSV,	Image, TSV	BED	384	-6.9	-2.7
Cognitive impairment test score	HTML, TSV,	Image, TSV	BED	64	-7.1	-3.0
Cognitive performance	HTML, TSV	Image, TSV	BED	1478	-4.9	-1.0
Cognitive performance (MTAG)	HTML, TSV	Image, TSV	BED	2651	-6.1	-2.0
Cognitive test performance	HTML, TSV	Image, TSV	BED	143	-5.5	-1.6
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement	HTML, TSV	Image, TSV	BED	16	-5.4	-1.2
Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications	HTML, TSV	Image, TSV	BED	2	-1.7	0.0
Cold sores	HTML, TSV,	Image, TSV	BED	119	-16.8	-12.6
Colon cancer	HTML, TSV	Image, TSV	BED	71	0.0	0.0
Colonoscopy-negative controls vs population controls	HTML, TSV	Image, TSV	BED	571	-3.6	0.0
Colorectal adenoma (advanced)	HTML, TSV	Image, TSV	BED	59	-3.0	0.0
Colorectal cancer	HTML, TSV,	Image, TSV	BED	1296	-6.5	-2.4
Colorectal cancer (alcohol consumption interaction)	HTML, TSV	Image, TSV	BED	2	-2.9	0.0
Colorectal cancer (aspirin and/or NSAID use interaction)	HTML, TSV	Image, TSV	BED	18	-5.4	-1.3
Colorectal cancer (calcium intake interaction)	HTML, TSV	Image, TSV	BED	12	-2.6	0.0
Colorectal cancer (diet interaction)	HTML, TSV	Image, TSV	BED	66	-6.0	-1.9
Colorectal cancer (oestrogen-progestogen hormone therapy interaction)	HTML, TSV,	Image, TSV	BED	3	-6.7	-2.5
Colorectal or endometrial cancer	HTML, TSV	Image, TSV	BED	161	-2.7	0.0
Common carotid intima-media thickness	HTML, TSV	Image, TSV	BED	51	-1.7	0.0
Common carotid intima-media thickness in HIV infection	HTML, TSV	Image, TSV	BED	44	-5.0	-0.9
Common carotid intima-media thickness in HIV negative individuals	HTML, TSV	Image, TSV	BED	28	-3.1	0.0
Common traits (Other)	HTML, TSV,	Image, TSV	BED	46	-6.5	-2.4
Complete remission in asthma	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Conduct disorder	HTML, TSV	Image, TSV	BED	126	-3.6	0.0
Conduct disorder (maternal expressed emotions interaction)	HTML, TSV	Image, TSV	BED	56	-2.5	0.0
Conduct disorder (symptom count)	HTML, TSV	Image, TSV	BED	157	-3.2	0.0
Congenital heart disease (inherited effect)	HTML, TSV	Image, TSV	BED	56	-3.4	0.0
Congenital heart disease (maternal effect)	HTML, TSV	Image, TSV	BED	53	-3.3	0.0
Congenital heart malformation	HTML, TSV	Image, TSV	BED	19	-3.1	0.0
Congenital left-sided heart lesions	HTML, TSV	Image, TSV	BED	3	-3.2	0.0
Congenital left-sided heart lesions (maternal effect)	HTML, TSV	Image, TSV	BED	9	-2.4	0.0
Conotruncal heart defects	HTML, TSV	Image, TSV	BED	44	-4.3	-0.3
Conotruncal heart defects (inherited effects)	HTML, TSV	Image, TSV	BED	45	-2.8	0.0
Conotruncal heart defects (maternal effects)	HTML, TSV	Image, TSV	BED	64	-3.1	0.0
Contrast sensitivity	HTML, TSV	Image, TSV	BED	4	-1.9	0.0
Corneal astigmatism	HTML, TSV	Image, TSV	BED	222	-2.6	0.0
Corneal curvature	HTML, TSV	Image, TSV	BED	337	-3.8	0.0
Corneal structure	HTML, TSV	Image, TSV	BED	187	-5.1	-1.5
Coronary artery aneurysm in Kawasaki disease	HTML, TSV,	Image, TSV	BED	66	-8.2	-4.1
Coronary artery calcification	HTML, TSV	Image, TSV	BED	249	-4.6	-0.4
Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	HTML, TSV	Image, TSV	BED	415	-3.1	0.0
Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	HTML, TSV	Image, TSV	BED	339	-3.3	0.0
Coronary artery calcified atherosclerotic plaque score in type 2 diabetes	HTML, TSV	Image, TSV	BED	138	-3.0	0.0
Coronary artery disease	HTML, TSV,	Image, TSV	BED	2014	-7.8	-3.6
Coronary artery disease and triglyceride levels (multivariate analysis)	HTML, TSV	Image, TSV	BED	4	-2.7	0.0
Coronary artery disease in type 1 diabetes	HTML, TSV	Image, TSV	BED	56	-2.1	0.0
Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	HTML, TSV	Image, TSV	BED	159	-5.9	-1.8
Coronary artery disease or ischemic stroke	HTML, TSV	Image, TSV	BED	12	-3.7	0.0
Coronary artery disease or large artery stroke	HTML, TSV	Image, TSV	BED	11	-3.8	0.0
Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction)	HTML, TSV	Image, TSV	BED	73	-3.6	-0.5
Coronary heart disease	HTML, TSV	Image, TSV	BED	263	-3.2	0.0
Coronary restenosis	HTML, TSV	Image, TSV	BED	2	-3.5	0.0
Corrected insulin response adjusted for insulin sensitivity index	HTML, TSV	Image, TSV	BED	17	-3.7	0.0
Corrected insulin response	HTML, TSV	Image, TSV	BED	17	-3.7	0.0
Cortical amyloid beta load	HTML, TSV	Image, TSV	BED	97	-3.0	0.0
Cortical brain region measurements (area, volume and thickness)	HTML, TSV	Image, TSV	BED	12	-2.6	0.0
Cortical thickness	HTML, TSV	Image, TSV	BED	127	-2.5	0.0
Corticobasal degeneration	HTML, TSV	Image, TSV	BED	7	-4.6	-0.5
Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L)	HTML, TSV	Image, TSV	BED	8	-5.0	-0.8
Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L)	HTML, TSV	Image, TSV	BED	8	-5.0	-0.8
Cortisol levels (saliva)	HTML, TSV	Image, TSV	BED	40	-4.5	-0.3
Cotinine glucuronidation	HTML, TSV	Image, TSV	BED	31	-3.7	0.0
Cough in response to angiotensin-converting enzyme inhibitor drugs	HTML, TSV	Image, TSV	BED	62	-3.9	-0.1
C-peptide levels in type I diabetes	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
Cranial base width	HTML, TSV	Image, TSV	BED	5	-4.8	-0.7
Craniofacial microsomia	HTML, TSV	Image, TSV	BED	28	-3.9	0.0
C-reactive protein	HTML, TSV	Image, TSV	BED	61	-3.2	0.0
C-reactive protein and white blood cell count	HTML, TSV	Image, TSV	BED	35	-2.6	0.0
C-reactive protein levels	HTML, TSV,	Image, TSV	BED	2003	-7.8	-3.6
C-reactive protein levels in ischemic stroke	HTML, TSV	Image, TSV	BED	15	-3.6	0.0
C-reactive protein levels or HDL-cholesterol levels (pleiotropy)	HTML, TSV	Image, TSV	BED	74	0.0	0.0
C-reactive protein levels or LDL-cholesterol levels (pleiotropy)	HTML, TSV	Image, TSV	BED	66	-4.9	-1.2
C-reactive protein levels or total cholesterol levels (pleiotropy)	HTML, TSV	Image, TSV	BED	69	-4.6	-0.7
C-reactive protein levels or triglyceride levels (pleiotropy)	HTML, TSV	Image, TSV	BED	79	-3.7	-0.0
Creatine kinase levels	HTML, TSV	Image, TSV	BED	110	-5.5	-1.6
Creatinine levels	HTML, TSV	Image, TSV	BED	323	-3.4	0.0
Creatinine levels in ischemic stroke	HTML, TSV	Image, TSV	BED	19	-4.3	-1.0
Creutzfeldt-Jakob disease	HTML, TSV	Image, TSV	BED	14	-2.9	0.0
Creutzfeldt-Jakob disease (sporadic)	HTML, TSV	Image, TSV	BED	3	-3.1	0.0
Creutzfeldt-Jakob disease (variant)	HTML, TSV	Image, TSV	BED	18	-3.5	0.0
Crohn's disease	HTML, TSV,	Image, TSV	BED	1321	-27.1	-22.9
Crohn's disease and celiac disease	HTML, TSV	Image, TSV	BED	13	-3.0	0.0
Crohn's disease and sarcoidosis (combined)	HTML, TSV	Image, TSV	BED	9	-5.0	-0.8
Crohn's disease (indolent vs progressive)	HTML, TSV	Image, TSV	BED	69	-3.7	0.0
Crohn's disease (need for surgery)	HTML, TSV	Image, TSV	BED	28	-2.5	0.0
Crohn's disease-related phenotypes	HTML, TSV	Image, TSV	BED	31	-2.8	0.0
Crohn's disease (time to first abdominal surgery)	HTML, TSV	Image, TSV	BED	37	-5.9	-1.7
Crohn's disease (time to progression)	HTML, TSV	Image, TSV	BED	75	-5.9	-1.7
Crohn's disease (time to surgery)	HTML, TSV	Image, TSV	BED	7	-2.8	0.0
CSF tryptophan concentration in tuberculous meningitis	HTML, TSV	Image, TSV	BED	40	-4.9	-0.8
CTACK levels	HTML, TSV	Image, TSV	BED	143	-4.4	-0.9
Current cigarettes per day in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	26	-2.7	0.0
Cutaneous malignant melanoma	HTML, TSV,	Image, TSV	BED	189	-6.5	-2.3
Cutaneous nevi	HTML, TSV	Image, TSV	BED	4	-2.5	0.0
Cutaneous squamous cell carcinoma	HTML, TSV	Image, TSV	BED	39	-5.7	-1.5
Cystic fibrosis severity	HTML, TSV	Image, TSV	BED	49	-5.3	-1.2
Cytomegalovirus antibody response	HTML, TSV	Image, TSV	BED	19	-5.6	-1.5
Daytime nap	HTML, TSV	Image, TSV	BED	17	-3.8	-0.0
Daytime sleepiness	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Daytime sleep phenotypes	HTML, TSV	Image, TSV	BED	386	-3.6	0.0
D-dimer levels	HTML, TSV	Image, TSV	BED	49	-2.4	0.0
DDT metabolite (p,p'-DDE levels)	HTML, TSV	Image, TSV	BED	5	-5.4	-1.2
Decline in glucose metabolism in posterior cingulate cortex	HTML, TSV	Image, TSV	BED	5	-3.1	0.0
Deep ovarian and/or rectovaginal disease with dense adhesions	HTML, TSV,	Image, TSV	BED	68	-6.8	-2.9
Dehydroepiandrosterone sulphate levels	HTML, TSV	Image, TSV	BED	37	-5.1	-1.0
Delayed reward discounting	HTML, TSV	Image, TSV	BED	72	-3.2	0.0
Deliberate self-harm	HTML, TSV,	Image, TSV	BED	181	-6.2	-2.0
Delta-5 desaturase activity	HTML, TSV	Image, TSV	BED	25	-2.7	0.0
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement	HTML, TSV	Image, TSV	BED	12	-5.4	-1.2
Delta-6 desaturase activity	HTML, TSV,	Image, TSV	BED	14	-6.5	-2.3
Dementia and core Alzheimer's disease neuropathologic changes	HTML, TSV	Image, TSV	BED	74	-4.2	0.0
Dementia with Lewy bodies	HTML, TSV	Image, TSV	BED	38	0.0	0.0
Dengue shock syndrome	HTML, TSV	Image, TSV	BED	14	-3.0	0.0
Dental caries	HTML, TSV	Image, TSV	BED	334	-4.2	-0.3
Dentate gyrus granule cell layer volume	HTML, TSV	Image, TSV	BED	14	-4.0	0.0
Dentate gyrus granule cell layer volume (corrected for total hippocampal volume)	HTML, TSV	Image, TSV	BED	1	-3.1	0.0
Dentate gyrus molecular layer volume	HTML, TSV	Image, TSV	BED	18	-3.6	0.0
Depressed affect	HTML, TSV	Image, TSV	BED	639	-3.8	0.0
Depression	HTML, TSV	Image, TSV	BED	1078	-4.3	-0.4
Depression and alcohol dependence	HTML, TSV	Image, TSV	BED	3	-2.6	0.0
Depression (broad)	HTML, TSV	Image, TSV	BED	648	-5.3	-1.2
Depression in response to interferon-based therapy in chronic hepatitis C	HTML, TSV	Image, TSV	BED	15	-4.0	0.0
Depression in smokers	HTML, TSV	Image, TSV	BED	104	-5.1	-0.9
Depression (quantitative trait)	HTML, TSV	Image, TSV	BED	89	-4.9	-1.1
Depressive and manic episodes in bipolar disorder	HTML, TSV	Image, TSV	BED	55	-2.5	0.0
Depressive episodes in bipolar disorder	HTML, TSV	Image, TSV	BED	69	-3.3	0.0
Depressive symptom improvement	HTML, TSV	Image, TSV	BED	28	-6.1	-1.9
Depressive symptom measurement or major depressive disorder	HTML, TSV	Image, TSV	BED	9	-1.9	0.0
Depressive symptoms	HTML, TSV,	Image, TSV	BED	1821	-7.4	-3.3
Depressive symptoms (MTAG)	HTML, TSV	Image, TSV	BED	710	-4.5	-0.6
Depressive symptoms (SSRI exposure interaction)	HTML, TSV	Image, TSV	BED	28	-3.0	0.0
Depressive symptoms (stressful life events interaction)	HTML, TSV	Image, TSV	BED	9	-2.7	0.0
Depressive symptoms x dependent stressful life events interaction (1df test)	HTML, TSV	Image, TSV	BED	53	-5.3	-1.2
Depressive symptoms x dependent stressful life events interaction (2df test)	HTML, TSV	Image, TSV	BED	52	-4.9	-0.8
Depressive symptoms x independent stressful life events interaction (1df test)	HTML, TSV	Image, TSV	BED	30	-4.3	-0.5
Depressive symptoms x independent stressful life events interaction (2df test)	HTML, TSV	Image, TSV	BED	24	-3.7	0.0
Dermatomyositis or juvenile dermatomyositis	HTML, TSV	Image, TSV	BED	2	-3.3	0.0
Developmental dysplasia of the hip	HTML, TSV	Image, TSV	BED	8	-2.2	0.0
Developmental language disorder	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Developmental language disorder (linguistic errors)	HTML, TSV	Image, TSV	BED	6	-4.4	-0.8
Diabetes (gestational)	HTML, TSV	Image, TSV	BED	78	-5.2	-1.0
Diabetes (incident)	HTML, TSV	Image, TSV	BED	26	-2.2	0.0
Diabetes in response to antihypertensive drug treatment (treatment strategy interaction)	HTML, TSV	Image, TSV	BED	1	-3.3	0.0
Diabetes mellitus	HTML, TSV	Image, TSV	BED	14	-2.1	0.0
Diabetes related insulin traits	HTML, TSV	Image, TSV	BED	5	-2.8	0.0
Diabetic kidney disease	HTML, TSV	Image, TSV	BED	239	-2.8	0.0
Diabetic kidney disease in diabetes (ESRD vs. no ESRD)	HTML, TSV	Image, TSV	BED	1	-3.0	0.0
Diabetic kidney disease in type 2 diabetes	HTML, TSV	Image, TSV	BED	13	-5.0	-1.1
Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD)	HTML, TSV	Image, TSV	BED	17	-2.8	0.0
Diabetic macular edema in type 2 diabetes	HTML, TSV	Image, TSV	BED	2	-1.4	0.0
Diabetic nephropathy in type 1 diabetes	HTML, TSV	Image, TSV	BED	10	-5.0	-0.8
Diabetic retinopathy	HTML, TSV	Image, TSV	BED	127	-4.1	0.0
Diabetic retinopathy (all NPDR and PDR)	HTML, TSV	Image, TSV	BED	72	-2.7	0.0
Diabetic retinopathy (moderate NPDR and PDR)	HTML, TSV	Image, TSV	BED	34	-4.9	-0.7
Dialysis-related mortality	HTML, TSV	Image, TSV	BED	80	0.0	0.0
Diarrhoea-associated Entamoeba histolytica infection	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Diarrhoea in darapladib-treated cardiovascular disease (time to event)	HTML, TSV	Image, TSV	BED	4	-3.3	-1.0
diarrhoeal disease at age 1 with doctor diagnosis	HTML, TSV	Image, TSV	BED	1	-2.4	0.0
diarrhoeal disease at age 2	HTML, TSV	Image, TSV	BED	2	-2.9	0.0
Diastolic blood pressure	HTML, TSV,	Image, TSV	BED	2913	-17.3	-13.1
Diastolic blood pressure (alcohol consumption interaction)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Diastolic blood pressure (cigarette smoking interaction)	HTML, TSV	Image, TSV	BED	155	-2.5	0.0
Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Diastolic blood pressure night-to-day ratio in hypertension	HTML, TSV	Image, TSV	BED	19	-3.8	0.0
Diastolic blood pressure response to hydrochlorothiazide in hypertension	HTML, TSV	Image, TSV	BED	25	-3.3	0.0
Diastolic blood pressure x alcohol consumption interaction (2df test)	HTML, TSV,	Image, TSV	BED	343	-6.6	-2.4
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	HTML, TSV,	Image, TSV	BED	114	-8.5	-4.4
Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test)	HTML, TSV	Image, TSV	BED	83	-3.0	0.0
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	HTML, TSV	Image, TSV	BED	265	-3.7	0.0
Diastolic blood pressure x smoking status (ever vs never) interaction (1df test)	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test)	HTML, TSV	Image, TSV	BED	182	-4.0	-0.4
Diastolic blood pressure x sodium interaction (1df test)	HTML, TSV	Image, TSV	BED	13	-3.5	0.0
Diastolic blood pressure x sodium interaction (2df test)	HTML, TSV	Image, TSV	BED	4	-4.6	-0.7
Dietary macronutrient intake	HTML, TSV	Image, TSV	BED	45	-5.4	-1.5
Differentiated thyroid cancer	HTML, TSV	Image, TSV	BED	71	-4.1	0.0
Diffuse cutaneous systemic sclerosis	HTML, TSV	Image, TSV	BED	7	-3.2	0.0
Diffuse large B cell lymphoma	HTML, TSV	Image, TSV	BED	12	-3.1	0.0
Diffusing capacity of carbon monoxide	HTML, TSV	Image, TSV	BED	246	-4.5	-0.4
Diffusing capacity of the lung for carbon monoxide traits	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)	HTML, TSV	Image, TSV	BED	55	-4.9	-0.7
Digit length ratio	HTML, TSV,	Image, TSV	BED	51	-8.5	-4.3
Digit length ratio (left hand)	HTML, TSV,	Image, TSV	BED	51	-8.5	-4.3
Digit length ratio (right hand)	HTML, TSV,	Image, TSV	BED	43	-8.7	-4.5
Diisocyanate-induced asthma	HTML, TSV	Image, TSV	BED	557	-3.4	0.0
Disc degeneration (lumbar)	HTML, TSV	Image, TSV	BED	86	-3.8	0.0
Discordance in emotional problems in monozygotic twins	HTML, TSV	Image, TSV	BED	28	-3.8	-1.0
Disease-free survival in breast cancer	HTML, TSV	Image, TSV	BED	13	-5.0	-1.1
Disease progression in age-related macular degeneration	HTML, TSV	Image, TSV	BED	55	-3.2	0.0
Disease progression to choroidal neovascularization form in age-related macular degeneration	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Disrupted circadian rhythm (low relative amplitude of rest-activity cycles)	HTML, TSV	Image, TSV	BED	8	-2.6	0.0
Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia	HTML, TSV	Image, TSV	BED	21	-3.5	0.0
Diverticular disease	HTML, TSV	Image, TSV	BED	540	-3.1	0.0
DNA methylation (parent-of-origin)	HTML, TSV	Image, TSV	BED	51	-3.2	0.0
DNA methylation (variation)	HTML, TSV	Image, TSV	BED	42	-2.8	0.0
DNA methylation variation (age effect)	HTML, TSV	Image, TSV	BED	1778	-4.2	-0.1
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer	HTML, TSV	Image, TSV	BED	35	-2.7	0.0
Double-edged eyelids	HTML, TSV	Image, TSV	BED	25	-2.2	0.0
Drinking behavior	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Drug experimentation measurement	HTML, TSV	Image, TSV	BED	7	-3.2	0.0
Drug-induced cholestatic/mixed liver injury	HTML, TSV	Image, TSV	BED	5	-2.0	0.0
Drug-induced liver injury	HTML, TSV	Image, TSV	BED	7	-2.0	0.0
Drug-induced liver injury (anti-tuberculosis drugs)	HTML, TSV	Image, TSV	BED	21	-3.5	0.0
Drug-induced liver injury (diclofenac)	HTML, TSV	Image, TSV	BED	51	-1.8	0.0
Drug-induced liver injury (flucloxacillin)	HTML, TSV	Image, TSV	BED	18	-4.2	-0.3
Drug-induced liver injury (fluoroquinolones)	HTML, TSV	Image, TSV	BED	11	-2.5	0.0
Drug-induced liver injury (nitrofurantoin)	HTML, TSV	Image, TSV	BED	41	-2.2	0.0
Drug-induced liver injury (nonsteroidal anti-inflammatory drugs)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Drug-induced liver injury (statins)	HTML, TSV	Image, TSV	BED	26	-3.3	0.0
Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)	HTML, TSV	Image, TSV	BED	22	-5.3	-1.2
Duloxetine response in major depressive disorder ( change in symptom score)	HTML, TSV	Image, TSV	BED	11	-2.7	0.0
Duodenal ulcer	HTML, TSV	Image, TSV	BED	3	-3.2	0.0
Dupuytren's disease	HTML, TSV	Image, TSV	BED	170	-3.1	0.0
Dysmenorrheic pain	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Dysmenorrheic pain severity	HTML, TSV	Image, TSV	BED	27	-4.1	0.0
Dysphagia	HTML, TSV	Image, TSV	BED	39	-1.9	0.0
Early age at menarche	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Early childhood aggressive behavior	HTML, TSV	Image, TSV	BED	7	-2.8	0.0
Early diabetic kidney disease in diabetes	HTML, TSV	Image, TSV	BED	11	-5.4	-1.5
Early onset atrial fibrillation	HTML, TSV	Image, TSV	BED	64	-5.6	-1.5
Ear morphology	HTML, TSV	Image, TSV	BED	16	-5.2	-1.4
Ease of getting up in the morning	HTML, TSV	Image, TSV	BED	325	-3.0	0.0
Eating disorder in bipolar disorder	HTML, TSV	Image, TSV	BED	6	-2.4	0.0
Eating disorders	HTML, TSV	Image, TSV	BED	70	-3.7	0.0
Eating disorders (purging via substances)	HTML, TSV	Image, TSV	BED	69	-3.7	0.0
Echocardiographic traits	HTML, TSV	Image, TSV	BED	24	-2.3	0.0
Economic and political preferences	HTML, TSV	Image, TSV	BED	102	-3.9	-0.2
Economic and political preferences (environmentalism)	HTML, TSV	Image, TSV	BED	73	-3.0	0.0
Economic and political preferences (fairness)	HTML, TSV	Image, TSV	BED	54	-2.9	0.0
Economic and political preferences (feminism/equality)	HTML, TSV	Image, TSV	BED	84	-3.3	0.0
Economic and political preferences (immigration/crime)	HTML, TSV	Image, TSV	BED	15	-3.1	0.0
Economic and political preferences (time)	HTML, TSV	Image, TSV	BED	20	-4.7	-0.8
Eczema	HTML, TSV,	Image, TSV	BED	689	-15.3	-11.3
Educational attainment	HTML, TSV	Image, TSV	BED	444	-5.0	-0.8
Educational attainment (college completion)	HTML, TSV	Image, TSV	BED	97	-5.0	-0.9
Educational attainment (MTAG)	HTML, TSV,	Image, TSV	BED	6438	-12.0	-7.9
Educational attainment (years of education)	HTML, TSV,	Image, TSV	BED	8259	-13.2	-9.0
EGFR mutation-positive lung adenocarcinoma	HTML, TSV	Image, TSV	BED	11	-3.2	0.0
Egg allergy	HTML, TSV	Image, TSV	BED	6	0.0	0.0
Egg allergy (maternal genetic effects)	HTML, TSV	Image, TSV	BED	44	-4.8	-0.7
Egg allergy (parent-of-origin effect)	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Ejection fraction	HTML, TSV	Image, TSV	BED	13	-5.6	-1.4
Ejection fraction in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	134	-3.8	0.0
Electrocardiographic conduction measures	HTML, TSV	Image, TSV	BED	30	-2.6	0.0
Electrocardiographic traits	HTML, TSV	Image, TSV	BED	402	-4.4	-0.5
Electrodermal activity	HTML, TSV	Image, TSV	BED	115	-6.1	-1.9
Electroencephalogram traits	HTML, TSV,	Image, TSV	BED	170	-7.3	-3.1
Electroencephalographic traits in alcoholism	HTML, TSV	Image, TSV	BED	25	-3.4	0.0
Elevated fasting plasma glucose	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Elevated serum carcinoembryonic antigen levels	HTML, TSV	Image, TSV	BED	4	-2.6	0.0
Emotional dysregulation	HTML, TSV	Image, TSV	BED	4	-2.1	0.0
Empathy quotient	HTML, TSV	Image, TSV	BED	34	-2.3	0.0
Emphysema distribution in smoking	HTML, TSV	Image, TSV	BED	32	-3.4	0.0
Emphysema imaging phenotypes	HTML, TSV	Image, TSV	BED	129	-2.7	0.0
Emphysema-related traits	HTML, TSV	Image, TSV	BED	22	-2.3	0.0
Endometrial cancer	HTML, TSV	Image, TSV	BED	121	-4.6	-0.4
Endometrial cancer (endometrioid histology)	HTML, TSV	Image, TSV	BED	81	-4.6	-0.4
Endometrial cancer (Non-endometrioid histology)	HTML, TSV	Image, TSV	BED	9	-1.2	0.0
Endometrial endometrioid carcinoma	HTML, TSV	Image, TSV	BED	6	-2.8	0.0
Endometrioid ovarian cancer	HTML, TSV	Image, TSV	BED	1	-2.8	0.0
Endometriosis	HTML, TSV,	Image, TSV	BED	397	-6.7	-2.5
Endometriosis or endometrial cancer (pleiotropy)	HTML, TSV	Image, TSV	BED	9	-3.4	0.0
End-stage coagulation	HTML, TSV	Image, TSV	BED	40	-4.2	-0.0
End-stage renal disease	HTML, TSV	Image, TSV	BED	49	-3.4	0.0
End stage renal disease in APOL1 risk genotype-negative individuals	HTML, TSV,	Image, TSV	BED	44	-6.2	-2.0
End-stage renal disease in Type 1 diabetics	HTML, TSV	Image, TSV	BED	7	-3.3	0.0
End-stage renal disease in type 2 diabetes	HTML, TSV	Image, TSV	BED	4	0.0	0.0
End stage renal disease x APOL1 genotype interaction	HTML, TSV	Image, TSV	BED	16	-2.3	0.0
Energy expenditure (24h)	HTML, TSV	Image, TSV	BED	16	-2.9	0.0
Energy expenditure	HTML, TSV	Image, TSV	BED	32	-2.5	0.0
Energy intake	HTML, TSV	Image, TSV	BED	6	-4.1	-0.3
Enteric fever	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Entorhinal cortical thickness	HTML, TSV	Image, TSV	BED	43	-3.5	0.0
Entorhinal cortical thickness (Alzheimer's disease interaction)	HTML, TSV	Image, TSV	BED	1	-3.0	0.0
Entorhinal cortical volume	HTML, TSV	Image, TSV	BED	16	-2.9	0.0
Eosinophil counts	HTML, TSV,	Image, TSV	BED	3463	-69.8	-65.6
Eosinophilic esophagitis	HTML, TSV	Image, TSV	BED	84	-3.5	0.0
Eosinophilic esophagitis (pediatric)	HTML, TSV	Image, TSV	BED	55	-3.4	0.0
Eosinophil percentage of granulocytes	HTML, TSV,	Image, TSV	BED	467	-13.8	-9.6
Eosinophil percentage of white cells	HTML, TSV,	Image, TSV	BED	1911	-42.4	-38.2
Eotaxin levels	HTML, TSV	Image, TSV	BED	118	-3.1	0.0
Epilepsy	HTML, TSV	Image, TSV	BED	75	0.0	0.0
Epilepsy and lamotrigine-induced maculopapular eruptions	HTML, TSV	Image, TSV	BED	202	-5.3	-1.1
Epilepsy (remission after treatment)	HTML, TSV	Image, TSV	BED	24	-5.5	-1.3
Epirubicin-induced leukopenia	HTML, TSV	Image, TSV	BED	6	-3.6	0.0
Epithelial ovarian cancer	HTML, TSV,	Image, TSV	BED	375	-6.8	-2.9
Epstein-Barr virus copy number in lymphoblastoid cell lines	HTML, TSV	Image, TSV	BED	157	-2.9	0.0
Epstein-Barr virus immune response (EBNA-1)	HTML, TSV	Image, TSV	BED	12	-5.7	-1.5
Epstein Barr virus nuclear antigen 1 IgG levels	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis	HTML, TSV	Image, TSV	BED	10	-3.1	0.0
Erectile dysfunction	HTML, TSV	Image, TSV	BED	109	-4.7	-0.6
Erectile dysfunction and prostate cancer treatment	HTML, TSV	Image, TSV	BED	74	-5.9	-1.7
Erectile dysfunction in type 1 diabetes	HTML, TSV	Image, TSV	BED	5	-2.0	0.0
Erosive tooth wear (severe vs none or mild)	HTML, TSV	Image, TSV	BED	100	-5.7	-1.5
Erosive tooth wear (severe vs non-severe)	HTML, TSV	Image, TSV	BED	351	-5.2	-1.2
Erythema nodosum in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	22	-4.5	-0.3
Erythrocyte cadmium concentration	HTML, TSV	Image, TSV	BED	43	-3.4	0.0
Erythrocyte cadmium concentration in never smokers	HTML, TSV	Image, TSV	BED	4	-2.7	0.0
E-selectin levels	HTML, TSV	Image, TSV	BED	42	-4.4	-0.7
Esophageal adenocarcinoma	HTML, TSV	Image, TSV	BED	21	-3.8	0.0
Esophageal adenocarcinoma x gastroesophageal reflux disease interaction	HTML, TSV	Image, TSV	BED	28	-3.4	0.0
Esophageal adenocarcinoma x pack-years of smoking exposure interaction	HTML, TSV	Image, TSV	BED	1	-2.0	0.0
Esophageal adenocarcinoma x smoking interaction	HTML, TSV,	Image, TSV	BED	60	-6.9	-2.7
Esophageal cancer	HTML, TSV	Image, TSV	BED	43	0.0	0.0
Esophageal cancer (alcohol interaction)	HTML, TSV	Image, TSV	BED	19	-3.8	0.0
Esophageal squamous cell carcinoma	HTML, TSV	Image, TSV	BED	15	-4.5	-0.3
Essential tremor	HTML, TSV	Image, TSV	BED	61	-4.3	-0.1
Esterified cholesterol levels	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Estimated glomerular filtration rate	HTML, TSV,	Image, TSV	BED	1718	-6.0	-2.2
Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect)	HTML, TSV	Image, TSV	BED	18	-2.9	0.0
Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect)	HTML, TSV	Image, TSV	BED	10	-2.5	0.0
Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect)	HTML, TSV	Image, TSV	BED	35	-3.4	0.0
Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect)	HTML, TSV	Image, TSV	BED	55	-3.2	0.0
Estimated glomerular filtration rate change in renal transplantation (donor effect)	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Estimated glomerular filtration rate change in renal transplantation (recipient effect)	HTML, TSV	Image, TSV	BED	46	-4.0	0.0
Estimated glomerular filtration rate in coronary artery disease and impaired kidney function	HTML, TSV	Image, TSV	BED	3	-2.6	0.0
Estradiol levels	HTML, TSV	Image, TSV	BED	84	-3.8	0.0
Estradiol plasma levels (breast cancer)	HTML, TSV	Image, TSV	BED	72	-2.2	0.0
Estrogen receptor status in HER2 negative breast cancer	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer	HTML, TSV	Image, TSV	BED	43	-4.4	-0.4
Estrone levels	HTML, TSV,	Image, TSV	BED	4	-6.2	-2.1
Eudaimonic well-being	HTML, TSV	Image, TSV	BED	50	-4.3	-0.2
Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy	HTML, TSV	Image, TSV	BED	4	-3.3	0.0
Ewing sarcoma	HTML, TSV	Image, TSV	BED	16	-4.4	-0.3
Excessive daytime sleepiness	HTML, TSV	Image, TSV	BED	24	-5.3	-1.1
Excessive hairiness	HTML, TSV,	Image, TSV	BED	20	-8.7	-4.5
Excessive sweating	HTML, TSV	Image, TSV	BED	9	-2.9	0.0
Executive function in ADHD	HTML, TSV,	Image, TSV	BED	17	-10.0	-5.8
Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder	HTML, TSV	Image, TSV	BED	8	-5.6	-1.6
Exercise treadmill test traits	HTML, TSV	Image, TSV	BED	5	-2.8	0.0
Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	14	-3.2	0.0
Exhaled nitric oxide levels	HTML, TSV	Image, TSV	BED	41	-4.1	0.0
Exhaled nitric oxide output	HTML, TSV	Image, TSV	BED	33	-2.4	0.0
Experiencing mood swings	HTML, TSV	Image, TSV	BED	266	-3.6	0.0
Exploratory eye movement dysfunction in schizophrenia (cognitive search score)	HTML, TSV	Image, TSV	BED	33	-3.0	0.0
Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Exploratory eye movement dysfunction in schizophrenia (number of eye fixations)	HTML, TSV	Image, TSV	BED	81	-3.2	0.0
Exploratory eye movement dysfunction in schizophrenia (responsive search score)	HTML, TSV	Image, TSV	BED	42	-4.5	-0.3
Exploratory eye movement dysfunction in schizophrenia (total eye scanning length)	HTML, TSV	Image, TSV	BED	82	-2.9	0.0
Expressive vocabulary in infants	HTML, TSV	Image, TSV	BED	75	-2.9	0.0
Extraversion	HTML, TSV	Image, TSV	BED	28	-4.0	0.0
Extremely high intelligence	HTML, TSV	Image, TSV	BED	175	-3.2	0.0
Exudative age-related macular degeneration	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Eyebrow thickness	HTML, TSV	Image, TSV	BED	43	-4.5	-0.4
Eye color	HTML, TSV	Image, TSV	BED	34	-3.4	0.0
Eye color (brightness)	HTML, TSV	Image, TSV	BED	8	-4.7	-0.8
Eye color (saturation)	HTML, TSV	Image, TSV	BED	19	-3.9	-0.0
Eye length	HTML, TSV,	Image, TSV	BED	14	-7.0	-2.8
Eye morphology	HTML, TSV	Image, TSV	BED	79	-3.9	0.0
Eye movement (horizontal position gain)	HTML, TSV	Image, TSV	BED	20	-5.8	-1.6
Eye movement in schizophrenia (horizontal position gain)	HTML, TSV	Image, TSV	BED	52	-4.1	0.0
Facial depth	HTML, TSV	Image, TSV	BED	6	-3.2	0.0
Facial emotion recognition	HTML, TSV	Image, TSV	BED	18	-4.9	-0.7
Facial emotion recognition (angry faces)	HTML, TSV	Image, TSV	BED	40	-3.0	0.0
Facial emotion recognition (fearful faces)	HTML, TSV	Image, TSV	BED	5	-5.0	-1.0
Facial emotion recognition (happy faces)	HTML, TSV	Image, TSV	BED	1	-2.8	0.0
Facial emotion recognition (sad faces)	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
Facial morphology	HTML, TSV	Image, TSV	BED	199	-3.6	0.0
Facial morphology (factor 10, width of nasal floor)	HTML, TSV	Image, TSV	BED	39	-4.6	-0.5
Facial morphology (factor 11, projection of the nose)	HTML, TSV	Image, TSV	BED	81	-5.3	-1.1
Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)	HTML, TSV	Image, TSV	BED	33	-3.8	0.0
Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)	HTML, TSV,	Image, TSV	BED	35	-7.0	-2.8
Facial morphology (factor 14, intercanthal width)	HTML, TSV	Image, TSV	BED	56	-3.6	0.0
Facial morphology (factor 15, philtrum width)	HTML, TSV	Image, TSV	BED	36	-3.8	0.0
Facial morphology (factor 16)	HTML, TSV	Image, TSV	BED	38	-3.5	0.0
Facial morphology (factor 17, height of vermillion upper lip)	HTML, TSV	Image, TSV	BED	48	-4.7	-0.5
Facial morphology (factor 18)	HTML, TSV	Image, TSV	BED	50	-4.0	-0.1
Facial morphology (factor 19)	HTML, TSV	Image, TSV	BED	145	-2.8	0.0
Facial morphology (factor 1, breadth of lateral portion of upper face)	HTML, TSV	Image, TSV	BED	52	-3.8	0.0
Facial morphology (factor 20)	HTML, TSV	Image, TSV	BED	71	-5.8	-1.6
Facial morphology (factor 21, depth of nasal alae)	HTML, TSV	Image, TSV	BED	42	-4.2	-0.4
Facial morphology (factor 22)	HTML, TSV	Image, TSV	BED	61	-2.6	0.0
Facial morphology (factor 23)	HTML, TSV	Image, TSV	BED	33	0.0	0.0
Facial morphology (factor 2, vertical position of orbits relative to midface)	HTML, TSV	Image, TSV	BED	34	-3.0	0.0
Facial morphology (factor 3, length of philtrum)	HTML, TSV	Image, TSV	BED	15	-2.3	0.0
Facial morphology (factor 4, facial height related to vertical position of gnathion)	HTML, TSV,	Image, TSV	BED	24	-8.8	-4.6
Facial morphology (factor 5, width of mouth relative to central midface)	HTML, TSV	Image, TSV	BED	58	-4.7	-0.6
Facial morphology (factor 6, height of vermillion lower lip)	HTML, TSV	Image, TSV	BED	41	-2.6	0.0
Facial morphology (factor 7, width of cartilaginous portion of nose)	HTML, TSV	Image, TSV	BED	47	-3.5	0.0
Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)	HTML, TSV	Image, TSV	BED	48	-3.2	0.0
Facial morphology (factor 9, facial height related to vertical position of nasion)	HTML, TSV	Image, TSV	BED	40	-3.0	0.0
facial morphology traits (multivariate analysis)	HTML, TSV	Image, TSV	BED	17	-4.2	-0.3
Facial pigmentation	HTML, TSV	Image, TSV	BED	1	-2.5	0.0
Facial wrinkles	HTML, TSV	Image, TSV	BED	25	-4.0	0.0
Factor VII	HTML, TSV	Image, TSV	BED	15	-3.4	0.0
Factor VII activity	HTML, TSV	Image, TSV	BED	32	-2.2	0.0
Factor VIII levels	HTML, TSV,	Image, TSV	BED	39	-6.7	-2.6
Familial hepatitis B virus-related hepatocellular carcinoma	HTML, TSV	Image, TSV	BED	31	-4.5	-0.4
Familial lung adenocarcinoma	HTML, TSV	Image, TSV	BED	73	-5.2	-1.0
Familial lung cancer	HTML, TSV	Image, TSV	BED	12	-2.3	0.0
Familial squamous cell lung carcinoma	HTML, TSV	Image, TSV	BED	199	-5.7	-1.5
Family history of Alzheimer's disease	HTML, TSV,	Image, TSV	BED	110	-14.5	-10.3
Fast beta electroencephalogram	HTML, TSV	Image, TSV	BED	29	-5.0	-0.8
Fasting blood glucose	HTML, TSV	Image, TSV	BED	219	-3.9	0.0
Fasting blood glucose adjusted for BMI	HTML, TSV	Image, TSV	BED	9	-4.2	-0.2
Fasting blood glucose (BMI interaction)	HTML, TSV	Image, TSV	BED	158	-4.3	-0.1
Fasting blood insulin	HTML, TSV	Image, TSV	BED	105	-4.5	-0.4
Fasting blood insulin (BMI interaction)	HTML, TSV	Image, TSV	BED	125	-4.1	0.0
Fasting glucose in pregnancy (gestational week 14-16)	HTML, TSV	Image, TSV	BED	2	-2.7	0.0
Fasting insulin (dietary factor interaction)	HTML, TSV	Image, TSV	BED	96	-4.2	-0.4
Fasting plasma glucose	HTML, TSV	Image, TSV	BED	154	-5.0	-1.0
Fasting plasma glucose (childhood)	HTML, TSV	Image, TSV	BED	3	0.0	0.0
Fat body mass	HTML, TSV	Image, TSV	BED	15	-2.6	0.0
Fat distribution (HIV)	HTML, TSV	Image, TSV	BED	25	-4.8	-0.6
Fat-free mass	HTML, TSV,	Image, TSV	BED	790	-7.7	-3.6
Fatty acid desaturase activity (adipose tissue)	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Fatty acid desaturase activity (serum)	HTML, TSV	Image, TSV	BED	2	-5.0	-0.9
F-cell distribution	HTML, TSV,	Image, TSV	BED	23	-6.5	-2.3
F-cell distribution in sickle cell anaemia	HTML, TSV	Image, TSV	BED	54	-2.1	0.0
Fear of medical pain (dental)	HTML, TSV	Image, TSV	BED	3	-2.9	0.0
Fear of minor pain	HTML, TSV	Image, TSV	BED	15	-2.6	0.0
Fear of pain	HTML, TSV	Image, TSV	BED	3	-2.6	0.0
Fear of severe pain	HTML, TSV	Image, TSV	BED	12	-3.4	0.0
Febrile seizures (MMR vaccine-related)	HTML, TSV	Image, TSV	BED	11	-2.6	0.0
Feeling fed-up	HTML, TSV,	Image, TSV	BED	237	-10.7	-6.6
Feeling guilty	HTML, TSV,	Image, TSV	BED	139	-46.4	-42.3
Feeling hurt	HTML, TSV	Image, TSV	BED	248	-3.5	0.0
Feeling lonely	HTML, TSV	Image, TSV	BED	41	-4.6	-0.5
Feeling miserable	HTML, TSV	Image, TSV	BED	274	-3.1	0.0
Feeling nervous	HTML, TSV	Image, TSV	BED	155	-2.7	0.0
Feeling tense	HTML, TSV	Image, TSV	BED	153	-4.9	-0.9
Feeling worry	HTML, TSV	Image, TSV	BED	308	-5.3	-1.2
Femoral neck bone geometry	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Femoral neck bone geometry and menarche (age at onset)	HTML, TSV	Image, TSV	BED	21	-4.7	-0.5
Femoral neck bone mineral density	HTML, TSV	Image, TSV	BED	455	-4.4	-0.3
Femoral neck length	HTML, TSV	Image, TSV	BED	18	-4.0	0.0
Fetal hemoglobin levels	HTML, TSV	Image, TSV	BED	26	-3.7	0.0
Fetal hemoglobin levels in sickle cell anemia	HTML, TSV	Image, TSV	BED	6	-3.7	0.0
FEV1	HTML, TSV,	Image, TSV	BED	1179	-8.8	-4.6
Fibrinogen	HTML, TSV	Image, TSV	BED	16	-4.8	-0.7
Fibrinogen levels	HTML, TSV,	Image, TSV	BED	114	-6.4	-2.3
Fibroblast growth factor basic levels	HTML, TSV	Image, TSV	BED	66	-3.1	0.0
Focal epilepsy (with hippocampal sclerosis)	HTML, TSV	Image, TSV	BED	14	-3.6	0.0
Folate pathway vitamin levels	HTML, TSV	Image, TSV	BED	23	-1.9	0.0
Folding of antihelix	HTML, TSV	Image, TSV	BED	27	-4.1	-0.1
Follicular lymphoma	HTML, TSV,	Image, TSV	BED	45	-8.4	-4.2
Food addiction	HTML, TSV	Image, TSV	BED	84	-6.1	-1.9
Food allergy	HTML, TSV	Image, TSV	BED	27	-5.5	-1.3
Food allergy (maternal genetic effects)	HTML, TSV	Image, TSV	BED	70	-3.3	0.0
Food allergy (parent-of-origin effect)	HTML, TSV	Image, TSV	BED	3	-5.9	-1.8
Food antigen IgG levels	HTML, TSV	Image, TSV	BED	19	-2.5	0.0
Foot ulcer and neuropathy in diabetes	HTML, TSV	Image, TSV	BED	88	-3.8	0.0
Forced expiratory volume in 1 second (occupational environmental exposures interaction)	HTML, TSV	Image, TSV	BED	77	-3.1	0.0
Forearm bone mineral density	HTML, TSV	Image, TSV	BED	3	-5.1	-1.2
Forehead morphology	HTML, TSV	Image, TSV	BED	8	-2.0	0.0
Formal thought disorder in schizophrenia	HTML, TSV	Image, TSV	BED	38	-3.8	-0.0
Fractional excretion of metabolites in chronic kidney disease	HTML, TSV	Image, TSV	BED	4	-2.4	0.0
Fractional excretion of uric acid	HTML, TSV	Image, TSV	BED	3	-4.8	-0.6
Fractional exhaled nitric oxide (childhood)	HTML, TSV	Image, TSV	BED	81	-3.8	0.0
Fractional exhaled nitric oxide levels	HTML, TSV	Image, TSV	BED	46	-4.6	-0.5
Fractional shortening	HTML, TSV	Image, TSV	BED	16	-5.3	-1.1
Fractures	HTML, TSV	Image, TSV	BED	146	-4.4	-0.2
Fractures (vertebral)	HTML, TSV	Image, TSV	BED	8	-4.1	-0.1
Freckles	HTML, TSV	Image, TSV	BED	17	-4.1	-0.0
Free cholesterol levels	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Free cholesterol levels in large LDL	HTML, TSV	Image, TSV	BED	2	-3.3	0.0
Free cholesterol levels in medium HDL	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Free thyroxine concentration	HTML, TSV	Image, TSV	BED	109	-3.4	0.0
Frontotemporal dementia	HTML, TSV	Image, TSV	BED	33	-6.0	-1.8
Frontotemporal dementia (age at onset)	HTML, TSV	Image, TSV	BED	8	-4.7	-0.5
Frontotemporal dementia with GRN mutation	HTML, TSV	Image, TSV	BED	63	-2.5	0.0
Frontotemporal dementia with GRN mutation (age at onset)	HTML, TSV	Image, TSV	BED	11	-4.1	0.0
Fructosamine levels	HTML, TSV	Image, TSV	BED	22	-4.4	-0.5
Fuchs's corneal dystrophy	HTML, TSV	Image, TSV	BED	13	-4.7	-0.5
Full scale intelligence quotient (cesarean section interaction)	HTML, TSV	Image, TSV	BED	10	-3.5	0.0
Fulminant type 1 diabetes	HTML, TSV	Image, TSV	BED	4	-2.4	0.0
Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	HTML, TSV	Image, TSV	BED	26	-2.5	0.0
Gait rhythm	HTML, TSV,	Image, TSV	BED	19	-7.2	-3.3
Gait speed in old age	HTML, TSV	Image, TSV	BED	156	-3.9	0.0
Gait variability	HTML, TSV	Image, TSV	BED	1	-2.3	0.0
Gallbladder cancer	HTML, TSV	Image, TSV	BED	66	-2.5	0.0
Gallstone disease	HTML, TSV	Image, TSV	BED	57	-3.7	0.0
Gambling	HTML, TSV	Image, TSV	BED	8	-3.6	0.0
Gamma glutamyl transferase levels	HTML, TSV,	Image, TSV	BED	182	-12.6	-8.5
Gamma glutamyl transferase levels in excessive alcohol consumption	HTML, TSV	Image, TSV	BED	31	-5.3	-1.1
Gamma glutamyl transferase levels in low alcohol consumption	HTML, TSV	Image, TSV	BED	56	-4.5	-0.3
Gamma glutamyl transpeptidase	HTML, TSV	Image, TSV	BED	4	-5.0	-0.9
Gastric cancer	HTML, TSV	Image, TSV	BED	35	-3.0	0.0
Gastric parietal cell autoantibody levels in type 1 diabetes	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Gastritis	HTML, TSV	Image, TSV	BED	53	-5.1	-1.0
Gastroesophageal reflux disease	HTML, TSV	Image, TSV	BED	142	-5.6	-1.4
Gaucher disease severity	HTML, TSV	Image, TSV	BED	7	-3.7	0.0
Gemcitabine-induced early high-grade neutropenia in pancreatic cancer	HTML, TSV	Image, TSV	BED	60	0.0	0.0
Gene methylation in lung tissue	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
General cognitive ability	HTML, TSV,	Image, TSV	BED	4713	-13.0	-8.9
General factor of neuroticism	HTML, TSV	Image, TSV	BED	850	-5.1	-0.9
General glucose level in pregnancy (gestational week 30-32)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Generalized epilepsy	HTML, TSV	Image, TSV	BED	162	-3.9	0.0
General risk tolerance (MTAG)	HTML, TSV,	Image, TSV	BED	1762	-6.5	-2.4
Gestational age at birth (child effect)	HTML, TSV	Image, TSV	BED	33	-4.9	-0.7
Gestational age at birth in labor-initiated deliveries (child effect)	HTML, TSV	Image, TSV	BED	52	-3.5	0.0
Gestational age at birth in labor-initiated deliveries (maternal effect)	HTML, TSV	Image, TSV	BED	9	-2.9	0.0
Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	HTML, TSV	Image, TSV	BED	19	-4.4	-0.2
Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect)	HTML, TSV	Image, TSV	BED	39	-4.6	-0.5
Gestational age at birth (maternal effect)	HTML, TSV	Image, TSV	BED	45	-3.5	0.0
Giant cell arteritis	HTML, TSV,	Image, TSV	BED	19	-7.1	-2.9
GIP levels in response to oral glucose tolerance test (120 minutes)	HTML, TSV	Image, TSV	BED	10	-6.1	-1.9
Glaucoma	HTML, TSV,	Image, TSV	BED	372	-8.1	-3.9
Glaucoma (high intraocular pressure)	HTML, TSV	Image, TSV	BED	9	-3.2	0.0
Glaucoma (low intraocular pressure)	HTML, TSV	Image, TSV	BED	14	-2.9	0.0
Glaucoma (primary angle closure)	HTML, TSV	Image, TSV	BED	32	-5.4	-1.2
Glaucoma (primary open-angle)	HTML, TSV	Image, TSV	BED	343	-4.1	-0.4
Glioblastoma	HTML, TSV	Image, TSV	BED	35	-4.3	-0.4
Glioblastoma (age-stratified)	HTML, TSV	Image, TSV	BED	25	-4.9	-0.9
Glioma	HTML, TSV	Image, TSV	BED	105	-5.8	-1.8
Glioma (high-grade)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Global electrical heterogeneity phenotypes	HTML, TSV	Image, TSV	BED	62	-5.7	-1.6
Glomerular filtration rate	HTML, TSV	Image, TSV	BED	322	-3.4	0.0
Glomerular filtration rate change in heart transplantation	HTML, TSV	Image, TSV	BED	13	-3.1	0.0
Glomerular filtration rate (creatinine)	HTML, TSV	Image, TSV	BED	383	-3.6	0.0
Glomerular filtration rate in chronic kidney disease	HTML, TSV	Image, TSV	BED	89	-3.6	0.0
Glomerular filtration rate in diabetes	HTML, TSV	Image, TSV	BED	14	-3.7	0.0
Glomerular filtration rate in non diabetics (creatinine)	HTML, TSV	Image, TSV	BED	147	-4.1	0.0
Glomerular filtration rate in type 2 diabetes	HTML, TSV	Image, TSV	BED	27	-3.1	0.0
GLP-1 levels in response to oral glucose tolerance test (fasting)	HTML, TSV,	Image, TSV	BED	2	-7.2	-3.0
Glucagon levels in response to oral glucose tolerance test (120 minutes)	HTML, TSV	Image, TSV	BED	63	-3.8	0.0
Glucagon levels in response to oral glucose tolerance test (fasting)	HTML, TSV	Image, TSV	BED	107	-4.6	-0.5
Glucocorticoid-induced osteonecrosis	HTML, TSV	Image, TSV	BED	42	-3.6	0.0
Glucocorticoid-induced osteonecrosis (age 10 years and older)	HTML, TSV	Image, TSV	BED	24	-2.8	0.0
Glucocorticoid-induced osteonecrosis (time dependent analysis)	HTML, TSV	Image, TSV	BED	7	-2.4	0.0
Glucose homeostasis traits	HTML, TSV	Image, TSV	BED	245	-3.8	0.0
Glycated hemoglobin levels	HTML, TSV,	Image, TSV	BED	393	-6.2	-2.0
Glycated hemoglobin levels in type 1 diabetes	HTML, TSV	Image, TSV	BED	10	-2.1	0.0
Glycemic traits	HTML, TSV	Image, TSV	BED	9	-4.6	-0.4
Glycemic traits (multi-trait analysis)	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Glycemic traits (pregnancy)	HTML, TSV	Image, TSV	BED	10	-5.3	-1.1
Glycerophospholipid levels	HTML, TSV	Image, TSV	BED	42	-5.5	-1.6
Glycine levels	HTML, TSV	Image, TSV	BED	115	-4.1	0.0
Gout	HTML, TSV	Image, TSV	BED	197	-4.2	-0.3
Gout in chronic kidney disease	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Gout vs. Hyperuricemia	HTML, TSV	Image, TSV	BED	36	-2.3	0.0
Granulocyte-colony stimulating factor levels	HTML, TSV	Image, TSV	BED	53	-3.8	0.0
Granulocyte count	HTML, TSV	Image, TSV	BED	391	0.0	0.0
Granulocyte percentage of myeloid white cells	HTML, TSV,	Image, TSV	BED	523	-33.2	-29.0
Graves' disease	HTML, TSV	Image, TSV	BED	87	-5.2	-1.3
Gray matter volume (schizophrenia interaction)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Growth differentiation factor-15 levels	HTML, TSV	Image, TSV	BED	7	-3.8	0.0
Growth-regulated protein alpha levels	HTML, TSV,	Image, TSV	BED	129	-6.7	-2.5
Gut microbiome composition (summer)	HTML, TSV	Image, TSV	BED	256	-2.6	0.0
Gut microbiome composition (summer and winter)	HTML, TSV	Image, TSV	BED	94	-3.1	0.0
Gut microbiome composition (winter)	HTML, TSV	Image, TSV	BED	168	-3.2	0.0
Gut microbiota (bacterial taxa)	HTML, TSV	Image, TSV	BED	424	-4.9	-0.8
Gut microbiota (beta diversity)	HTML, TSV	Image, TSV	BED	207	0.0	0.0
Gut microbiota (functional units)	HTML, TSV	Image, TSV	BED	166	-2.4	0.0
Hair color	HTML, TSV,	Image, TSV	BED	2037	-7.1	-2.9
Hair greying	HTML, TSV	Image, TSV	BED	24	-3.2	0.0
Hair morphology	HTML, TSV	Image, TSV	BED	22	-4.7	-0.5
Hair morphology traits	HTML, TSV	Image, TSV	BED	3	-4.1	-0.1
Hair shape	HTML, TSV	Image, TSV	BED	21	-3.4	0.0
Handedness	HTML, TSV	Image, TSV	BED	15	-2.1	0.0
Handedness (Left-handed vs. non-left-handed)	HTML, TSV	Image, TSV	BED	5	-2.8	0.0
Hand grip strength	HTML, TSV	Image, TSV	BED	505	-3.8	0.0
Hashimoto thyroiditis	HTML, TSV	Image, TSV	BED	1	-1.5	0.0
Hashimoto thyroiditis versus Graves' disease	HTML, TSV	Image, TSV	BED	9	-1.6	0.0
HATA volume	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
HbA2 levels	HTML, TSV	Image, TSV	BED	18	-5.3	-1.3
HDL cholesterol	HTML, TSV,	Image, TSV	BED	797	-9.4	-5.3
HDL cholesterol and triglyceride levels	HTML, TSV	Image, TSV	BED	68	-4.9	-0.8
HDL cholesterol and triglyceride levels (pleiotropy)	HTML, TSV	Image, TSV	BED	11	-2.2	0.0
HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	HTML, TSV	Image, TSV	BED	59	-4.3	-0.2
HDL Cholesterol in HIV-infection	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
HDL cholesterol levels	HTML, TSV,	Image, TSV	BED	1818	-11.1	-6.9
HDL Cholesterol - Triglycerides (HDLC-TG)	HTML, TSV	Image, TSV	BED	33	-5.1	-0.9
HDL cholesterol x physical activity interaction (2df test)	HTML, TSV	Image, TSV	BED	103	-5.1	-1.1
Headache	HTML, TSV	Image, TSV	BED	111	-4.2	-0.0
Head circumference (infant)	HTML, TSV	Image, TSV	BED	11	-2.4	0.0
Healthspan	HTML, TSV	Image, TSV	BED	38	-3.6	0.0
Hearing function	HTML, TSV	Image, TSV	BED	8	-3.8	0.0
Hearing impairment	HTML, TSV	Image, TSV	BED	1	-3.3	0.0
Heart failure	HTML, TSV	Image, TSV	BED	219	-5.4	-1.5
Heart rate	HTML, TSV	Image, TSV	BED	262	-4.6	-0.6
Heart rate increase in response to exercise	HTML, TSV	Image, TSV	BED	30	-6.0	-1.8
Heart rate response to beta blockers	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
Heart rate response to beta blockers (atenolol add-on therapy)	HTML, TSV	Image, TSV	BED	105	-2.6	0.0
Heart rate response to beta blockers (atenolol monotherapy)	HTML, TSV	Image, TSV	BED	142	-3.7	0.0
Heart rate response to exercise	HTML, TSV	Image, TSV	BED	90	-4.5	-0.4
Heart rate response to recovery post exercise (10 sec)	HTML, TSV,	Image, TSV	BED	23	-6.3	-2.2
Heart rate response to recovery post exercise (20 sec)	HTML, TSV	Image, TSV	BED	42	-5.5	-1.4
Heart rate response to recovery post exercise (30 sec)	HTML, TSV	Image, TSV	BED	44	-5.5	-1.3
Heart rate response to recovery post exercise (40 sec)	HTML, TSV	Image, TSV	BED	28	-6.1	-1.9
Heart rate response to recovery post exercise (50 sec)	HTML, TSV	Image, TSV	BED	50	-5.4	-1.4
Heart rate response to recovery post exercise	HTML, TSV,	Image, TSV	BED	197	-30.9	-26.8
Heart rate variability traits	HTML, TSV	Image, TSV	BED	79	-3.9	0.0
Heart rate variability traits (pvRSA/HF)	HTML, TSV	Image, TSV	BED	48	-5.4	-1.2
Heart rate variability traits (RMSSD)	HTML, TSV	Image, TSV	BED	42	-5.5	-1.4
Heart rate variability traits (SDNN)	HTML, TSV	Image, TSV	BED	65	-5.0	-0.8
Heavy vaginal discharge	HTML, TSV	Image, TSV	BED	9	-5.8	-1.8
Hedonic well-being	HTML, TSV	Image, TSV	BED	13	-1.9	0.0
Heel bone mineral density	HTML, TSV,	Image, TSV	BED	8357	-19.9	-15.8
Height	HTML, TSV,	Image, TSV	BED	11689	-14.5	-10.8
Height adjusted BMI	HTML, TSV,	Image, TSV	BED	23	-7.1	-3.1
Helix rolling	HTML, TSV	Image, TSV	BED	8	-3.5	0.0
Helping behaviour (self reported)	HTML, TSV	Image, TSV	BED	11	-3.9	0.0
Hematocrit	HTML, TSV,	Image, TSV	BED	2442	-8.7	-4.6
Hematological and biochemical traits	HTML, TSV	Image, TSV	BED	81	0.0	0.0
Hematological parameters	HTML, TSV,	Image, TSV	BED	12	-6.7	-2.6
Hematology traits	HTML, TSV	Image, TSV	BED	30	-5.2	-1.2
Hematoma volume in lobar spontaneous intracerebral hemorrhage	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Hemoglobin	HTML, TSV,	Image, TSV	BED	1459	-8.2	-4.1
Hemoglobin A1c levels	HTML, TSV,	Image, TSV	BED	168	-6.3	-2.1
Hemoglobin A2 levels in sickle cell anemia	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Hemoglobin concentration	HTML, TSV,	Image, TSV	BED	1882	-9.7	-5.5
Hemoglobin levels	HTML, TSV	Image, TSV	BED	669	-5.2	-1.1
Hemostatic factors and hematological phenotypes	HTML, TSV	Image, TSV	BED	160	-4.8	-0.6
Hen's egg allergy	HTML, TSV	Image, TSV	BED	1	-1.6	0.0
Hepatic lipid content in extreme obesity	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
Hepatitis	HTML, TSV	Image, TSV	BED	25	-3.4	0.0
Hepatitis A	HTML, TSV	Image, TSV	BED	67	-6.0	-1.8
Hepatitis B	HTML, TSV	Image, TSV	BED	152	-3.3	0.0
Hepatitis B surface antigen seroclearance in chronic hepatitis B infection	HTML, TSV	Image, TSV	BED	6	-5.1	-1.1
Hepatitis B vaccine response	HTML, TSV	Image, TSV	BED	12	-5.7	-1.5
Hepatitis C induced liver cirrhosis	HTML, TSV	Image, TSV	BED	3	-3.1	-0.1
Hepatitis C induced liver fibrosis	HTML, TSV	Image, TSV	BED	6	-3.1	0.0
Hepatitis C (spontaneous viral clearance)	HTML, TSV	Image, TSV	BED	10	-5.2	-1.0
Hepatocellular carcinoma	HTML, TSV	Image, TSV	BED	25	-2.2	0.0
Hepatocellular carcinoma in hepatitis B infection	HTML, TSV	Image, TSV	BED	18	-4.4	-0.5
Hepatocellular carcinoma in hepatitis C infection	HTML, TSV	Image, TSV	BED	10	-5.2	-1.0
Hepatocyte growth factor levels	HTML, TSV	Image, TSV	BED	82	-3.7	0.0
Hepcidin/ferritin ratio	HTML, TSV	Image, TSV	BED	305	-4.7	-0.6
Hepcidin levels	HTML, TSV	Image, TSV	BED	71	-3.4	0.0
Hepcidin/transferrin saturation ratio	HTML, TSV	Image, TSV	BED	11	-3.2	0.0
HER2 status in breast cancer	HTML, TSV	Image, TSV	BED	11	-2.8	0.0
Heroin dependence	HTML, TSV	Image, TSV	BED	110	-5.5	-1.5
Heschl's gyrus morphology	HTML, TSV	Image, TSV	BED	192	-4.0	0.0
High altitude adaptation	HTML, TSV	Image, TSV	BED	14	-4.9	-1.3
High density lipoprotein cholesterol levels	HTML, TSV,	Image, TSV	BED	1041	-8.2	-4.1
Highest math class taken	HTML, TSV	Image, TSV	BED	1805	-4.7	-0.5
Highest math class taken (MTAG)	HTML, TSV,	Image, TSV	BED	5508	-16.4	-12.5
High fetal hemoglobin in sickle cell disease	HTML, TSV	Image, TSV	BED	10	-3.0	0.0
High-grade serous ovarian cancer	HTML, TSV	Image, TSV	BED	32	-2.7	0.0
High IL-1beta levels in gingival crevicular fluid	HTML, TSV,	Image, TSV	BED	118	-12.8	-8.6
High light scatter reticulocyte count	HTML, TSV,	Image, TSV	BED	1559	-24.2	-20.0
High light scatter reticulocyte percentage of red cells	HTML, TSV,	Image, TSV	BED	1473	-32.5	-28.3
Hip bone size	HTML, TSV	Image, TSV	BED	144	-5.6	-1.5
Hip circumference	HTML, TSV	Image, TSV	BED	601	-4.8	-0.6
Hip circumference adjusted for BMI	HTML, TSV	Image, TSV	BED	531	-4.8	-0.7
Hip circumference (psychosocial stress interaction)	HTML, TSV	Image, TSV	BED	13	-2.5	0.0
Hip geometry	HTML, TSV	Image, TSV	BED	146	-3.1	0.0
Hip minimal joint space width	HTML, TSV	Image, TSV	BED	61	-5.1	-0.9
Hippocampal atrophy	HTML, TSV	Image, TSV	BED	161	-4.0	-0.1
Hippocampal sclerosis	HTML, TSV	Image, TSV	BED	32	-4.3	-0.1
Hippocampal subfield CA1 volume	HTML, TSV	Image, TSV	BED	13	-2.9	0.0
Hippocampal subfield CA1 volume (corrected for total hippocampal volume)	HTML, TSV	Image, TSV	BED	1	-3.1	0.0
Hippocampal subfield CA3 volume	HTML, TSV	Image, TSV	BED	13	-2.9	0.0
Hippocampal subfield CA4 volume	HTML, TSV	Image, TSV	BED	14	-4.0	0.0
Hippocampal tail volume	HTML, TSV	Image, TSV	BED	54	-2.2	0.0
Hippocampal tail volume (corrected for total hippocampal volume)	HTML, TSV	Image, TSV	BED	39	-3.3	0.0
Hippocampal volume	HTML, TSV	Image, TSV	BED	175	-2.8	0.0
Hippocampal volume in Alzheimer's disease dementia	HTML, TSV	Image, TSV	BED	21	-2.3	0.0
Hippocampal volume in mild cognitive impairment	HTML, TSV	Image, TSV	BED	23	-3.8	0.0
Hippocampal volume in normal cognition	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Hip shape (DXA scan)	HTML, TSV	Image, TSV	BED	153	-4.3	-0.2
Hirschsprung disease	HTML, TSV	Image, TSV	BED	55	-3.7	0.0
HIV-1 control	HTML, TSV	Image, TSV	BED	135	-3.4	0.0
HIV-1 progression	HTML, TSV	Image, TSV	BED	12	-2.0	0.0
HIV-1 susceptibility	HTML, TSV	Image, TSV	BED	42	-4.5	-0.3
HIV-1 viral setpoint	HTML, TSV	Image, TSV	BED	186	-3.0	0.0
HIV-associated dementia	HTML, TSV	Image, TSV	BED	34	-2.6	0.0
HIV-associated neurocognitive disorder	HTML, TSV	Image, TSV	BED	2	-1.9	0.0
HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)	HTML, TSV	Image, TSV	BED	10	-4.4	-0.2
HIV-associated neurocognitive disorder (mild neurocognitive disorder)	HTML, TSV	Image, TSV	BED	49	-4.3	-0.6
HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)	HTML, TSV	Image, TSV	BED	16	-2.8	0.0
Hoarding	HTML, TSV	Image, TSV	BED	30	-2.7	0.0
Hodgkin's lymphoma	HTML, TSV,	Image, TSV	BED	140	-11.7	-7.5
Homeostasis model assessment of beta-cell function	HTML, TSV	Image, TSV	BED	8	-2.5	0.0
Homeostasis model assessment of beta-cell function (dietary factor interaction)	HTML, TSV	Image, TSV	BED	25	-2.9	0.0
Homeostasis model assessment of insulin resistance	HTML, TSV	Image, TSV	BED	4	-3.4	0.0
Homeostasis model assessment of insulin resistance (dietary factor interaction)	HTML, TSV	Image, TSV	BED	96	-4.2	-0.4
Hormone measurements	HTML, TSV	Image, TSV	BED	21	-4.8	-0.6
Household income	HTML, TSV	Image, TSV	BED	162	-3.4	0.0
HPV seropositivity	HTML, TSV	Image, TSV	BED	15	-4.6	-0.7
Huntington's disease progression	HTML, TSV	Image, TSV	BED	32	-2.2	0.0
Hyperactive-impulsive symptoms	HTML, TSV	Image, TSV	BED	42	-2.6	0.0
Hyperemesis gravidarum	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Hyperopia	HTML, TSV	Image, TSV	BED	21	-4.3	-0.5
Hypersomnia during a major depressive episode in bipolar disorder	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Hypersomnia (HLA-DQB1*06:02 negative)	HTML, TSV	Image, TSV	BED	13	-2.5	0.0
Hypertension	HTML, TSV	Image, TSV	BED	679	-4.9	-0.7
Hypertension risk in short sleep duration	HTML, TSV	Image, TSV	BED	5	-3.3	0.0
Hyperthyroidism	HTML, TSV	Image, TSV	BED	55	-4.4	-0.2
Hypertriglyceridemia	HTML, TSV	Image, TSV	BED	47	-3.5	0.0
Hypospadias	HTML, TSV	Image, TSV	BED	105	-5.2	-1.2
Hypothyroidism	HTML, TSV,	Image, TSV	BED	597	-10.3	-6.2
Idiopathic dilated cardiomyopathy	HTML, TSV,	Image, TSV	BED	357	-26.7	-22.5
Idiopathic inflammatory myopathy	HTML, TSV	Image, TSV	BED	2	-2.7	-0.0
Idiopathic intracranial hypertension	HTML, TSV	Image, TSV	BED	64	-3.5	0.0
Idiopathic membranous nephropathy	HTML, TSV	Image, TSV	BED	3	-3.9	-0.2
Idiopathic osteonecrosis of the femoral head	HTML, TSV	Image, TSV	BED	49	-3.8	0.0
Idiopathic pulmonary fibrosis	HTML, TSV	Image, TSV	BED	49	-5.4	-1.3
IgA levels	HTML, TSV	Image, TSV	BED	14	-2.7	0.0
IgA nephropathy	HTML, TSV,	Image, TSV	BED	38	-8.1	-3.9
IgE grass sensitization	HTML, TSV	Image, TSV	BED	63	-4.2	-0.2
IgE levels	HTML, TSV	Image, TSV	BED	3	-4.5	-0.5
IgE levels in asthmatics	HTML, TSV	Image, TSV	BED	15	-3.2	0.0
IgE levels in asthmatics (D.f. specific)	HTML, TSV	Image, TSV	BED	22	-3.5	0.0
IgE levels in asthmatics (D.p. specific)	HTML, TSV	Image, TSV	BED	33	-4.4	-0.2
IgG1 response to Plasmodium falciparum antigen (GLURP)	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
IgG digalactosylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	18	-3.3	0.0
IgG disialylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
IgG fucosylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	18	-3.3	0.0
IgG galactosylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	20	-3.2	0.0
IgG glycosylation	HTML, TSV	Image, TSV	BED	1498	-3.4	0.0
IgG glycosylation patterns	HTML, TSV,	Image, TSV	BED	99	-7.1	-2.9
IgG levels	HTML, TSV	Image, TSV	BED	20	-3.7	0.0
IgG monogalactosylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	18	-3.3	0.0
IgG monosialylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	18	-3.3	0.0
IgG N-glycosylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	39	-5.3	-1.1
IgG sialylation phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	18	-3.3	0.0
IgM levels	HTML, TSV	Image, TSV	BED	26	-5.6	-1.4
Ileal carcinoids	HTML, TSV	Image, TSV	BED	51	-4.7	-0.6
Illicit drug use	HTML, TSV,	Image, TSV	BED	31	-7.5	-3.4
Immature fraction of reticulocytes	HTML, TSV,	Image, TSV	BED	958	-22.1	-17.9
Immune reponse to smallpox (secreted IFN-alpha)	HTML, TSV	Image, TSV	BED	76	-3.2	0.0
Immune reponse to smallpox (secreted IL-10)	HTML, TSV	Image, TSV	BED	67	-3.3	0.0
Immune reponse to smallpox (secreted IL-12p40)	HTML, TSV	Image, TSV	BED	65	-3.7	0.0
Immune reponse to smallpox (secreted IL-1beta)	HTML, TSV	Image, TSV	BED	20	-4.9	-0.8
Immune reponse to smallpox (secreted IL-2)	HTML, TSV	Image, TSV	BED	77	-5.9	-1.8
Immune reponse to smallpox (secreted TNF-alpha)	HTML, TSV	Image, TSV	BED	29	-3.0	0.0
Immune response to anthrax vaccine	HTML, TSV	Image, TSV	BED	17	-2.2	0.0
Immune response to measles-mumps-rubella vaccine	HTML, TSV	Image, TSV	BED	82	-2.2	0.0
Immune response to smallpox vaccine (IL-6)	HTML, TSV	Image, TSV	BED	317	-3.3	0.0
Immunoglobulin A	HTML, TSV	Image, TSV	BED	33	-3.5	0.0
Immunoglobulin A vasculitis	HTML, TSV	Image, TSV	BED	110	-3.6	0.0
Immunoglobulin G index levels in multiple sclerosis	HTML, TSV	Image, TSV	BED	8	-4.7	-1.4
Immunoglobulin light chain (AL) amyloidosis	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Immunoglobulin light chain (AL) amyloidosis (heart and kidney involvement)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Immunoglobulin light chain (AL) amyloidosis (liver involvement)	HTML, TSV	Image, TSV	BED	9	-1.9	0.0
Immunoglobulin measurement (zinc sulfate turbidity test)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Impulsivity	HTML, TSV	Image, TSV	BED	3	-2.0	0.0
Impulsivity (attentional)	HTML, TSV	Image, TSV	BED	7	-2.2	0.0
Impulsivity (motor)	HTML, TSV	Image, TSV	BED	9	-3.6	0.0
Impulsivity (non-planning)	HTML, TSV	Image, TSV	BED	7	-2.0	0.0
Inattentive symptoms	HTML, TSV	Image, TSV	BED	83	-2.7	0.0
Incident atrial fibrillation	HTML, TSV	Image, TSV	BED	61	-5.7	-1.5
Incident coronary heart disease	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Incident myocardial infarction	HTML, TSV	Image, TSV	BED	16	-1.7	0.0
Incremental insulin	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Infant, child and juvenile death in continuous marriage (proportion of children died <15 years)	HTML, TSV	Image, TSV	BED	23	-3.2	0.0
Infant, child and juvenile death (proportion of children died <15 years)	HTML, TSV	Image, TSV	BED	4	-2.2	0.0
Infantile hypertrophic pyloric stenosis	HTML, TSV	Image, TSV	BED	22	-3.0	0.0
Infant length	HTML, TSV	Image, TSV	BED	60	-6.1	-2.0
Inflammatory biomarkers	HTML, TSV	Image, TSV	BED	76	-2.9	0.0
Inflammatory bowel disease	HTML, TSV,	Image, TSV	BED	1080	-23.6	-19.4
Inflammatory bowel disease (early onset)	HTML, TSV,	Image, TSV	BED	6	-8.7	-4.5
Inflammatory skin disease	HTML, TSV	Image, TSV	BED	283	-4.0	-0.2
Influenza A (H1N1) infection	HTML, TSV	Image, TSV	BED	16	-2.5	0.0
Influenza A (H1N1) severity	HTML, TSV	Image, TSV	BED	41	-3.7	0.0
Information processing speed	HTML, TSV	Image, TSV	BED	145	-4.2	-0.1
Inguinal hernia	HTML, TSV	Image, TSV	BED	54	0.0	0.0
Inhibitory control	HTML, TSV	Image, TSV	BED	34	-4.6	-0.4
Initial alcohol sensitivity	HTML, TSV	Image, TSV	BED	158	-3.3	0.0
Initial pursuit acceleration	HTML, TSV	Image, TSV	BED	160	-3.0	0.0
Initial pursuit acceleration in psychotic disorders	HTML, TSV	Image, TSV	BED	78	0.0	0.0
Insomnia	HTML, TSV,	Image, TSV	BED	2218	-6.6	-2.5
Insomnia (caffeine-induced)	HTML, TSV	Image, TSV	BED	40	-3.1	0.0
Insomnia complaints	HTML, TSV	Image, TSV	BED	5	-3.9	-0.2
Insomnia complaints (continuous)	HTML, TSV	Image, TSV	BED	3	-4.9	-1.2
Insomnia complaints (dichotomous)	HTML, TSV	Image, TSV	BED	3	-4.9	-1.2
Insomnia symptoms (never/rarely vs. sometimes/usually)	HTML, TSV	Image, TSV	BED	234	-3.3	0.0
Insomnia symptoms (never/rarely vs. usually)	HTML, TSV	Image, TSV	BED	268	-2.8	0.0
Insulin disposition index	HTML, TSV	Image, TSV	BED	16	-3.8	-0.0
Insulin levels adjusted for BMI	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Insulin levels in response to oral glucose tolerance test (fasting)	HTML, TSV	Image, TSV	BED	10	-3.5	0.0
Insulin levels	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Insulin-like growth factors	HTML, TSV	Image, TSV	BED	13	-4.0	0.0
Insulin resistance/response	HTML, TSV	Image, TSV	BED	15	-4.7	-0.5
Insulin secretion rate	HTML, TSV	Image, TSV	BED	31	-4.3	-0.2
Insulin sensitivity index	HTML, TSV	Image, TSV	BED	8	-4.0	-0.1
Intelligence	HTML, TSV,	Image, TSV	BED	2556	-8.1	-3.9
Intelligence (childhood)	HTML, TSV	Image, TSV	BED	12	-3.4	-0.1
Intelligence (MTAG)	HTML, TSV,	Image, TSV	BED	2219	-8.7	-4.5
Interferon alpha levels in systemic lupus erythematosus	HTML, TSV	Image, TSV	BED	41	-3.6	0.0
Interferon gamma-induced protein 10 levels	HTML, TSV	Image, TSV	BED	133	-4.4	-0.3
Interferon gamma levels	HTML, TSV	Image, TSV	BED	54	-5.5	-1.8
Interleukin-10 levels	HTML, TSV	Image, TSV	BED	101	-3.6	0.0
Interleukin-12p70 levels	HTML, TSV	Image, TSV	BED	92	-4.5	-0.6
Interleukin-13 levels	HTML, TSV	Image, TSV	BED	48	-4.9	-0.7
Interleukin-16 levels	HTML, TSV	Image, TSV	BED	46	-5.2	-1.4
Interleukin-17 levels	HTML, TSV	Image, TSV	BED	79	-3.4	0.0
Interleukin-18 levels	HTML, TSV	Image, TSV	BED	183	-2.6	0.0
Interleukin-1-beta levels	HTML, TSV	Image, TSV	BED	19	-2.5	0.0
Interleukin-1-receptor antagonist levels	HTML, TSV	Image, TSV	BED	32	-3.5	0.0
Interleukin-2 levels	HTML, TSV	Image, TSV	BED	89	-3.2	0.0
Interleukin-2 receptor antagonist levels	HTML, TSV	Image, TSV	BED	96	-4.2	-0.1
Interleukin-4 levels	HTML, TSV	Image, TSV	BED	69	-4.6	-0.4
Interleukin-5 levels	HTML, TSV	Image, TSV	BED	29	-2.8	0.0
Interleukin-6 levels	HTML, TSV,	Image, TSV	BED	148	-15.6	-11.4
Interleukin-6 (red blood cell fatty acid level interaction)	HTML, TSV	Image, TSV	BED	47	-4.1	0.0
Interleukin-7 levels	HTML, TSV,	Image, TSV	BED	105	-22.7	-18.5
Interleukin-8 levels	HTML, TSV,	Image, TSV	BED	70	-7.5	-3.3
Interleukin-9 levels	HTML, TSV	Image, TSV	BED	40	-3.6	0.0
Interstitial lung disease	HTML, TSV	Image, TSV	BED	18	-2.4	0.0
Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)	HTML, TSV	Image, TSV	BED	37	-4.5	-0.4
Intracranial aneurysm	HTML, TSV	Image, TSV	BED	289	-5.8	-1.6
Intracranial volume	HTML, TSV	Image, TSV	BED	82	-5.1	-1.0
Intra-individual response time variability (selective attention)	HTML, TSV,	Image, TSV	BED	17	-7.0	-2.8
Intraocular pressure	HTML, TSV,	Image, TSV	BED	1958	-6.2	-2.0
Intrinsic epigenetic age acceleration	HTML, TSV	Image, TSV	BED	17	-3.9	0.0
Invasive epithelial ovarian cancer	HTML, TSV	Image, TSV	BED	20	-3.1	0.0
Iris characteristics	HTML, TSV	Image, TSV	BED	12	-3.7	0.0
Iris color (a* coordinate)	HTML, TSV	Image, TSV	BED	196	-3.8	0.0
Iris color (b* coordinate)	HTML, TSV	Image, TSV	BED	155	-4.5	-0.9
Iris color (L* coordinate)	HTML, TSV	Image, TSV	BED	158	-5.0	-0.8
Iris heterochromicity	HTML, TSV	Image, TSV	BED	165	-4.0	0.0
Iron deficiency	HTML, TSV	Image, TSV	BED	5	-4.5	-0.4
Iron status biomarkers	HTML, TSV	Image, TSV	BED	80	-5.7	-1.6
Iron status biomarkers (ferritin levels)	HTML, TSV,	Image, TSV	BED	22	-6.7	-2.8
Iron status biomarkers (iron levels)	HTML, TSV	Image, TSV	BED	39	-3.5	0.0
Iron status biomarkers (total iron binding capacity)	HTML, TSV	Image, TSV	BED	22	-4.2	-0.3
Iron status biomarkers (transferrin levels)	HTML, TSV,	Image, TSV	BED	20	-8.5	-4.3
Iron status biomarkers (transferrin saturation)	HTML, TSV,	Image, TSV	BED	29	-6.2	-2.1
Irritable bowel syndrome	HTML, TSV	Image, TSV	BED	184	-3.2	0.0
Irritable mood	HTML, TSV	Image, TSV	BED	330	-3.3	0.0
Ischemic stroke	HTML, TSV	Image, TSV	BED	171	-4.4	-0.6
Ischemic stroke (cardioembolic)	HTML, TSV	Image, TSV	BED	101	-6.0	-1.8
Ischemic stroke (large artery atherosclerosis)	HTML, TSV,	Image, TSV	BED	32	-6.3	-2.1
Ischemic stroke (small-vessel)	HTML, TSV	Image, TSV	BED	26	-4.1	-0.3
Ischemic stroke (undetermined subtype)	HTML, TSV	Image, TSV	BED	2	-5.0	-1.2
Isovolumetric relaxation time	HTML, TSV	Image, TSV	BED	55	-2.3	0.0
Itch intensity from mosquito bite	HTML, TSV	Image, TSV	BED	593	-5.0	-0.9
Itch intensity from mosquito bite adjusted by bite size	HTML, TSV	Image, TSV	BED	864	-4.5	-0.3
Job-related exhaustion	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Job-related exhaustion in shift workers	HTML, TSV	Image, TSV	BED	1	-2.0	0.0
Joint damage progression in ACPA-negative rheumatoid arthritis	HTML, TSV	Image, TSV	BED	2	-1.9	0.0
Joint mobility (Beighton score)	HTML, TSV,	Image, TSV	BED	63	-7.1	-2.9
JT interval (sulfonylurea treatment interaction)	HTML, TSV	Image, TSV	BED	151	-4.1	-0.0
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular)	HTML, TSV	Image, TSV	BED	72	-4.3	-0.5
Juvenile osteochondritis dissecans	HTML, TSV	Image, TSV	BED	24	-2.3	0.0
Kashin-Beck disease	HTML, TSV	Image, TSV	BED	13	-2.7	0.0
Kawasaki disease	HTML, TSV,	Image, TSV	BED	144	-10.7	-6.8
Keloid	HTML, TSV	Image, TSV	BED	11	-2.3	0.0
Kidney disease (early stage) in type 1 diabetes	HTML, TSV	Image, TSV	BED	7	-3.3	0.0
Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes	HTML, TSV	Image, TSV	BED	7	-2.1	0.0
Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes	HTML, TSV	Image, TSV	BED	2	-1.6	0.0
Kidney disease (late stage) in type 1 diabetes	HTML, TSV	Image, TSV	BED	3	-3.9	0.0
Kidney function decline traits	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Kidney stones	HTML, TSV	Image, TSV	BED	38	-5.1	-1.0
Knee osteoarthritis	HTML, TSV	Image, TSV	BED	52	-3.3	0.0
Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis	HTML, TSV	Image, TSV	BED	3	-3.7	0.0
Lack of perseverance	HTML, TSV	Image, TSV	BED	6	-2.2	0.0
Lack of premeditation	HTML, TSV	Image, TSV	BED	12	-2.8	0.0
Lactate dehydrogenase levels	HTML, TSV,	Image, TSV	BED	53	-6.9	-2.9
Language impairment in frontotemporal lobe dementia	HTML, TSV	Image, TSV	BED	8	-2.5	0.0
Language performance in older adults (adjusted for episodic memory)	HTML, TSV	Image, TSV	BED	4	-3.4	0.0
Lapatinib-induced hepatotoxicity	HTML, TSV	Image, TSV	BED	21	-5.2	-1.1
Large artery stroke	HTML, TSV	Image, TSV	BED	46	-3.1	0.0
Large B-cell lymphoma	HTML, TSV	Image, TSV	BED	8	-5.7	-1.5
Large HDL particle concentration	HTML, TSV	Image, TSV	BED	14	-5.7	-1.6
Large LDL particle concentration	HTML, TSV	Image, TSV	BED	4	-3.0	0.0
Laryngeal squamous cell carcinoma	HTML, TSV	Image, TSV	BED	8	-4.6	-0.4
Late diabetic kidney disease in type 2 diabetes	HTML, TSV	Image, TSV	BED	13	-3.6	0.0
Latent autoimmune diabetes	HTML, TSV	Image, TSV	BED	3	-2.9	0.0
Late-onset Alzheimer's disease	HTML, TSV	Image, TSV	BED	258	-3.1	0.0
Late-onset myasthenia gravis	HTML, TSV	Image, TSV	BED	20	-2.8	0.0
Laterality in neovascular age-related macular degeneration	HTML, TSV	Image, TSV	BED	28	-3.2	0.0
Lateral ventricular volume in normal aging	HTML, TSV	Image, TSV	BED	24	-3.1	0.0
LDL cholesterol	HTML, TSV,	Image, TSV	BED	353	-7.4	-3.2
LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	HTML, TSV	Image, TSV	BED	6	-2.6	0.0
LDL cholesterol levels	HTML, TSV,	Image, TSV	BED	628	-16.5	-12.3
LDL cholesterol x physical activity interaction (1df test)	HTML, TSV	Image, TSV	BED	1	-2.3	0.0
LDL cholesterol x physical activity interaction (2df test)	HTML, TSV,	Image, TSV	BED	65	-9.4	-5.2
LDL peak particle diameter (total fat intake interaction)	HTML, TSV	Image, TSV	BED	130	-2.8	0.0
Lead levels in blood	HTML, TSV	Image, TSV	BED	76	-4.5	-0.5
Lean body mass	HTML, TSV	Image, TSV	BED	144	-3.9	-0.2
Left atrial antero-posterior diameter	HTML, TSV	Image, TSV	BED	48	-3.0	0.0
Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction)	HTML, TSV	Image, TSV	BED	3	-2.3	0.0
Left superior temporal gyrus thickness (schizophrenia interaction)	HTML, TSV	Image, TSV	BED	34	-2.9	0.0
Left ventricle diastolic internal dimension	HTML, TSV	Image, TSV	BED	15	-5.4	-1.2
Left ventricle systolic dysfunction	HTML, TSV	Image, TSV	BED	43	-5.7	-1.6
Left ventricle wall thickness	HTML, TSV,	Image, TSV	BED	95	-6.4	-2.2
Left ventricular function change in anthracycline treatment	HTML, TSV	Image, TSV	BED	12	-3.1	0.0
Left ventricular internal dimension in diastole	HTML, TSV	Image, TSV	BED	20	-5.0	-0.8
Left ventricular internal dimension in systole	HTML, TSV	Image, TSV	BED	20	-5.0	-0.8
Left ventricular mass	HTML, TSV	Image, TSV	BED	24	-4.7	-0.7
Left ventricular obstructive tract defect (inherited effect)	HTML, TSV	Image, TSV	BED	76	-4.0	-0.0
Left ventricular obstructive tract defect (maternal effect)	HTML, TSV	Image, TSV	BED	42	-2.3	0.0
Leishmaniasis (visceral)	HTML, TSV	Image, TSV	BED	2	-3.0	0.0
Leisure-time exercise behaviour	HTML, TSV	Image, TSV	BED	8	-2.7	0.0
Leisure-time exercise behaviour (age-stratified)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Length of menstrual cycle	HTML, TSV	Image, TSV	BED	4	-4.0	-0.1
Lentiform nucleus volume	HTML, TSV	Image, TSV	BED	23	-3.5	0.0
Leprosy	HTML, TSV,	Image, TSV	BED	156	-7.9	-3.8
Lewy body disease	HTML, TSV	Image, TSV	BED	74	-4.4	-0.2
Life satisfaction	HTML, TSV	Image, TSV	BED	944	-3.5	0.0
Lifespan	HTML, TSV	Image, TSV	BED	2	-3.8	0.0
Life threatening arrhythmia	HTML, TSV,	Image, TSV	BED	16	-6.7	-2.6
Lifetime average cigarettes per day in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	74	-2.9	0.0
Light vs. dark hair color	HTML, TSV	Image, TSV	BED	60	-5.9	-1.7
Limited cutaneous systemic scleroderma	HTML, TSV	Image, TSV	BED	24	-2.6	0.0
Lipid metabolism phenotypes	HTML, TSV	Image, TSV	BED	67	-4.4	-0.7
Lipid traits	HTML, TSV	Image, TSV	BED	50	-5.4	-1.3
Lipid traits (pleiotropy) (HIPO component 1)	HTML, TSV	Image, TSV	BED	35	-5.0	-1.2
Lipid traits (pleiotropy) (HIPO component 2)	HTML, TSV	Image, TSV	BED	2	-4.5	-0.5
Lip morphology	HTML, TSV	Image, TSV	BED	2	-2.9	0.0
Lipoprotein (a) - cholesterol levels	HTML, TSV	Image, TSV	BED	15	-2.1	0.0
Lipoprotein (a) levels	HTML, TSV	Image, TSV	BED	101	-5.0	-1.1
Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms	HTML, TSV	Image, TSV	BED	19	-3.2	0.0
Lipoprotein-associated phospholipase A2 activity and mass	HTML, TSV,	Image, TSV	BED	20	-8.7	-4.5
Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	HTML, TSV	Image, TSV	BED	8	-3.2	0.0
Lipoprotein phospholipase A2 activity in cardiovascular disease	HTML, TSV	Image, TSV	BED	65	-5.5	-1.3
Liver disease severity in Alagille syndrome	HTML, TSV	Image, TSV	BED	5	-3.5	0.0
Liver enzyme levels	HTML, TSV	Image, TSV	BED	10	-2.4	0.0
Liver enzyme levels (alanine transaminase)	HTML, TSV	Image, TSV	BED	90	-3.1	0.0
Liver enzyme levels (alkaline phosphatase)	HTML, TSV	Image, TSV	BED	21	-4.6	-0.7
Liver enzyme levels (aspartate transaminase)	HTML, TSV	Image, TSV	BED	56	-2.9	0.0
Liver enzyme levels (gamma-glutamyl transferase)	HTML, TSV	Image, TSV	BED	74	-4.5	-0.3
Liver fibrosis in pediatric non-alcoholic fatty acid liver disease	HTML, TSV	Image, TSV	BED	2	-4.9	-0.7
Liver fibrosis severity in HIV/hepatitis C co-infection	HTML, TSV	Image, TSV	BED	51	-2.7	0.0
Liver injury in anti-tuberculosis drug treatment	HTML, TSV	Image, TSV	BED	15	-3.0	0.0
Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis	HTML, TSV	Image, TSV	BED	38	-4.4	-0.3
Liver transplant-free survival in primary sclerosing cholangitis (time to event)	HTML, TSV	Image, TSV	BED	80	-5.2	-1.1
Lobe attachment	HTML, TSV	Image, TSV	BED	7	-4.1	0.0
Lobe attachment (rater scored)	HTML, TSV	Image, TSV	BED	25	-4.8	-0.7
Lobe attachment (rater-scored or self-reported)	HTML, TSV,	Image, TSV	BED	860	-8.3	-4.2
Lobe size	HTML, TSV	Image, TSV	BED	17	-5.2	-1.2
Lobular breast cancer (menopausal hormone therapy interaction)	HTML, TSV	Image, TSV	BED	5	-5.0	-1.0
Local histogram emphysema pattern	HTML, TSV	Image, TSV	BED	29	-2.4	0.0
Logical memory (delayed recall)	HTML, TSV	Image, TSV	BED	8	-2.2	0.0
Logical memory (delayed recall) in Alzheimer's disease dementia	HTML, TSV,	Image, TSV	BED	5	-9.1	-4.9
Logical memory (delayed recall) in mild cognitive impairment	HTML, TSV	Image, TSV	BED	9	-4.1	-0.2
Logical memory (delayed recall) in normal cognition	HTML, TSV	Image, TSV	BED	49	-3.0	0.0
Logical memory (immediate recall)	HTML, TSV	Image, TSV	BED	8	-2.2	0.0
Logical memory (immediate recall) in Alzheimer's disease dementia	HTML, TSV	Image, TSV	BED	16	-2.7	0.0
Logical memory (immediate recall) in mild cognitive impairment	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Logical memory (immediate recall) in normal cognition	HTML, TSV	Image, TSV	BED	18	-3.1	0.0
Loneliness	HTML, TSV	Image, TSV	BED	244	-4.7	-0.5
Loneliness (linear analysis)	HTML, TSV,	Image, TSV	BED	125	-7.2	-3.0
Loneliness (MTAG)	HTML, TSV	Image, TSV	BED	171	-5.4	-1.3
Loneliness (multivariate analysis)	HTML, TSV	Image, TSV	BED	190	-6.1	-1.9
Longevity	HTML, TSV,	Image, TSV	BED	643	-8.3	-4.1
Longevity (85 years and older)	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Longevity (90 years and older)	HTML, TSV	Image, TSV	BED	58	-3.2	0.0
Longitudinal alcohol consumption	HTML, TSV	Image, TSV	BED	34	-3.3	0.0
Longitudinal change in brain amyloid plaque burden	HTML, TSV	Image, TSV	BED	38	-4.1	-0.3
Long-term memory (delayed word recall task)	HTML, TSV	Image, TSV	BED	3	-2.4	0.0
Low density lipoprotein cholesterol levels	HTML, TSV,	Image, TSV	BED	923	-12.3	-8.2
Lower body strength	HTML, TSV	Image, TSV	BED	27	-3.0	0.0
Lower facial height	HTML, TSV	Image, TSV	BED	46	-3.2	0.0
Low-grade serous and serous borderline ovarian cancer	HTML, TSV	Image, TSV	BED	20	-4.4	-0.3
Low-grade serous ovarian cancer	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Low high density lipoprotein cholesterol levels	HTML, TSV	Image, TSV	BED	77	-3.9	0.0
Low tan response	HTML, TSV	Image, TSV	BED	120	-5.2	-1.2
Low vWF levels	HTML, TSV	Image, TSV	BED	19	-3.7	0.0
Low white blood cell count (conditioned on rs2814778)	HTML, TSV	Image, TSV	BED	23	-4.6	-0.4
Lp (a) levels	HTML, TSV	Image, TSV	BED	31	-2.7	0.0
Lumbar spine bone mineral density	HTML, TSV,	Image, TSV	BED	306	-12.0	-7.8
Lumbar spine bone mineral density (integral)	HTML, TSV	Image, TSV	BED	104	-4.5	-0.9
Lumbar spine bone mineral density (trabecular)	HTML, TSV	Image, TSV	BED	56	-4.0	0.0
Lung adenocarcinoma	HTML, TSV,	Image, TSV	BED	279	-12.5	-8.8
Lung cancer	HTML, TSV,	Image, TSV	BED	468	-6.2	-2.0
Lung cancer (asbestos exposure interaction)	HTML, TSV	Image, TSV	BED	1	-2.8	0.0
Lung Cancer (DNA repair capacity)	HTML, TSV	Image, TSV	BED	3	-2.7	0.0
Lung cancer in ever smokers	HTML, TSV	Image, TSV	BED	223	-5.4	-1.2
Lung cancer in never smokers	HTML, TSV	Image, TSV	BED	123	-5.1	-1.0
Lung cancer (smoking interaction)	HTML, TSV,	Image, TSV	BED	24	-5.9	-2.0
Lung cancer x radon exposure interaction (1df)	HTML, TSV	Image, TSV	BED	40	-6.0	-1.8
Lung disease severity in cystic fibrosis	HTML, TSV,	Image, TSV	BED	52	-6.2	-2.0
Lung function (FEV1)	HTML, TSV	Image, TSV	BED	357	-5.1	-1.0
Lung function (FEV1/FVC)	HTML, TSV,	Image, TSV	BED	4103	-13.9	-9.8
Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction)	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Lung function (FEV1) in asthma (dust mite allergen exposure interaction)	HTML, TSV	Image, TSV	BED	59	-2.5	0.0
Lung function (forced expiratory flow during mid-portion (25 and 75) of forced vital capacity)	HTML, TSV	Image, TSV	BED	17	-4.9	-0.8
Lung function (forced expiratory volume in 1 second)	HTML, TSV	Image, TSV	BED	26	-2.2	0.0
Lung function (forced vital capacity)	HTML, TSV	Image, TSV	BED	18	-2.0	0.0
Lung function (FVC)	HTML, TSV,	Image, TSV	BED	3756	-6.5	-2.3
Lung function (maximal voluntary ventilation)	HTML, TSV	Image, TSV	BED	7	-2.7	0.0
Lupus nephritis in systemic lupus erythematosus	HTML, TSV	Image, TSV	BED	76	-2.9	0.0
Luteinizing hormone levels in polycystic ovary syndrome	HTML, TSV	Image, TSV	BED	11	-2.3	0.0
Lymphocyte counts	HTML, TSV,	Image, TSV	BED	2805	-34.3	-30.1
Lymphocyte percentage of white cells	HTML, TSV,	Image, TSV	BED	1462	-27.1	-22.9
Lymphoma	HTML, TSV	Image, TSV	BED	24	-4.1	-0.6
Macrophage colony stimulating factor levels	HTML, TSV	Image, TSV	BED	127	-5.8	-1.6
Macrophage inflammatory protein 1a levels	HTML, TSV	Image, TSV	BED	65	-3.0	0.0
Macrophage inflammatory protein 1b levels	HTML, TSV	Image, TSV	BED	110	-3.6	-0.1
Macrophage Migration Inhibitory Factor levels	HTML, TSV	Image, TSV	BED	40	-4.9	-0.9
Macular telangiectasia type 2	HTML, TSV	Image, TSV	BED	3	-3.4	0.0
Macular thickness	HTML, TSV	Image, TSV	BED	571	-6.0	-1.8
Magnesium levels	HTML, TSV	Image, TSV	BED	118	-4.2	-0.0
Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction)	HTML, TSV	Image, TSV	BED	5	-1.9	0.0
Major coronary event in darapladib-treated cardiovascular disease (time to event)	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Major depression and alcohol dependence	HTML, TSV	Image, TSV	BED	318	-5.6	-1.4
Major depressive disorder	HTML, TSV,	Image, TSV	BED	1405	-6.9	-2.7
Major depressive disorder (broad)	HTML, TSV	Image, TSV	BED	81	-3.2	0.0
Major depressive disorder (ICD-10 coded)	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Major depressive disorder (probable)	HTML, TSV	Image, TSV	BED	55	-5.3	-1.1
Major depressive disorder (stressful life events interaction)	HTML, TSV	Image, TSV	BED	21	-2.1	0.0
Major depressive disorder (unexposed to adversity)	HTML, TSV	Image, TSV	BED	16	-3.5	0.0
Malaria	HTML, TSV	Image, TSV	BED	212	-3.8	-0.5
Male fertility	HTML, TSV	Image, TSV	BED	31	-2.7	0.0
Male infertility	HTML, TSV	Image, TSV	BED	36	-4.0	-0.1
Male-pattern baldness	HTML, TSV,	Image, TSV	BED	4032	-10.7	-6.5
Male sexual orientation	HTML, TSV	Image, TSV	BED	11	-4.0	0.0
Mammographic density	HTML, TSV	Image, TSV	BED	26	-3.2	0.0
Mammographic density (dense area)	HTML, TSV	Image, TSV	BED	91	-3.2	0.0
Mammographic density (non-dense area)	HTML, TSV	Image, TSV	BED	33	-3.9	-0.1
Marginal zone lymphoma	HTML, TSV	Image, TSV	BED	2	-2.4	0.0
Maternal history of Alzheimer's disease	HTML, TSV	Image, TSV	BED	6	-3.0	0.0
Mathematical ability	HTML, TSV	Image, TSV	BED	51	-5.2	-1.0
Matrix metalloproteinase levels	HTML, TSV	Image, TSV	BED	57	-4.2	0.0
Maximal oxygen uptake response	HTML, TSV	Image, TSV	BED	12	-3.7	0.0
Maximum cranial length	HTML, TSV	Image, TSV	BED	29	-2.6	0.0
Maximum cranial width	HTML, TSV	Image, TSV	BED	36	-4.9	-0.9
Mean arterial pressure	HTML, TSV	Image, TSV	BED	605	-4.8	-0.6
Mean arterial pressure (alcohol consumption interaction)	HTML, TSV	Image, TSV	BED	20	-3.8	0.0
Mean arterial pressure x alcohol consumption interaction (2df test)	HTML, TSV,	Image, TSV	BED	261	-7.1	-2.9
Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test)	HTML, TSV,	Image, TSV	BED	99	-8.8	-4.6
Mean corpuscular hemoglobin	HTML, TSV,	Image, TSV	BED	3097	-64.2	-60.0
Mean corpuscular hemoglobin concentration	HTML, TSV,	Image, TSV	BED	789	-24.1	-19.9
Mean corpuscular volume	HTML, TSV,	Image, TSV	BED	2304	-62.4	-58.3
Mean diameter of HDL particles	HTML, TSV	Image, TSV	BED	12	-6.1	-2.0
Mean forced vital capacity from 2 exams	HTML, TSV	Image, TSV	BED	15	-3.9	0.0
Mean platelet volume	HTML, TSV,	Image, TSV	BED	2257	-35.7	-31.5
Measles	HTML, TSV	Image, TSV	BED	102	-5.1	-0.9
Meconium ileus in cystic fibrosis	HTML, TSV	Image, TSV	BED	25	-4.0	0.0
Medication adherence in chronic diseases	HTML, TSV	Image, TSV	BED	24	-2.5	0.0
Medium HDL particle concentration	HTML, TSV	Image, TSV	BED	12	-6.1	-2.0
Medium LDL particle concentration	HTML, TSV	Image, TSV	BED	5	-2.9	0.0
Melanoma	HTML, TSV	Image, TSV	BED	226	-5.6	-1.4
Membranous nephropathy	HTML, TSV	Image, TSV	BED	9	-4.7	-0.8
Memory dysfunction in frontotemporal lobe dementia	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Memory performance	HTML, TSV,	Image, TSV	BED	5	-7.2	-3.1
Menarche (age at onset)	HTML, TSV	Image, TSV	BED	2176	-4.8	-0.7
Menarche and menopause (age at onset)	HTML, TSV	Image, TSV	BED	15	-2.4	0.0
Meningococcal disease	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Menopause (age at onset)	HTML, TSV	Image, TSV	BED	170	-3.5	0.0
Menstruation quality of life impact (acne)	HTML, TSV	Image, TSV	BED	4	-2.2	0.0
Menstruation quality of life impact (aggressiveness)	HTML, TSV	Image, TSV	BED	52	-3.4	0.0
Menstruation quality of life impact (bowel movement)	HTML, TSV	Image, TSV	BED	24	-3.5	0.0
Menstruation quality of life impact (depression)	HTML, TSV	Image, TSV	BED	23	-3.3	0.0
Menstruation quality of life impact (dysmenorrhea)	HTML, TSV	Image, TSV	BED	42	-3.3	0.0
Menstruation quality of life impact (edema)	HTML, TSV,	Image, TSV	BED	5	-8.8	-4.6
Menstruation quality of life impact (fever)	HTML, TSV,	Image, TSV	BED	21	-6.7	-2.5
Menstruation quality of life impact (headache)	HTML, TSV	Image, TSV	BED	14	-4.5	-0.3
Menstruation quality of life impact (increased appetite)	HTML, TSV	Image, TSV	BED	10	-3.6	0.0
Menstruation quality of life impact (joint pain)	HTML, TSV	Image, TSV	BED	2	-2.7	0.0
Menstruation quality of life impact (loss of concentration)	HTML, TSV	Image, TSV	BED	101	-3.2	0.0
Menstruation quality of life impact (nervousness)	HTML, TSV	Image, TSV	BED	23	-3.9	0.0
Menstruation quality of life impact (pressure in breast)	HTML, TSV	Image, TSV	BED	11	-2.1	0.0
Menstruation quality of life impact (sleepiness)	HTML, TSV	Image, TSV	BED	5	-1.8	0.0
Menstruation quality of life impact (stiff neck)	HTML, TSV	Image, TSV	BED	35	-2.3	0.0
Mental composite score	HTML, TSV	Image, TSV	BED	23	-4.3	-0.2
Mental development (prenatal lead exposure interaction)	HTML, TSV	Image, TSV	BED	4	-2.1	0.0
Metabolic coherence (transcriptomic)	HTML, TSV	Image, TSV	BED	10	-4.0	0.0
Metabolic syndrome	HTML, TSV	Image, TSV	BED	345	-5.1	-1.0
Metabolic syndrome (bivariate traits)	HTML, TSV	Image, TSV	BED	40	-3.8	0.0
Metabolic syndrome (multivariate analysis)	HTML, TSV	Image, TSV	BED	32	-3.1	0.0
Metabolic traits	HTML, TSV	Image, TSV	BED	85	-3.7	0.0
Metabolite levels	HTML, TSV,	Image, TSV	BED	8216	-8.8	-4.6
Metabolite levels (5-HIAA/ MHPG Ratio)	HTML, TSV	Image, TSV	BED	12	-4.9	-0.7
Metabolite levels (5-HIAA)	HTML, TSV,	Image, TSV	BED	62	-8.9	-4.7
Metabolite levels (Dihydroxy docosatrienoic acid)	HTML, TSV	Image, TSV	BED	125	-4.2	-0.1
Metabolite levels (HVA-5-HIAA Factor score)	HTML, TSV	Image, TSV	BED	37	-4.0	0.0
Metabolite levels (HVA/5-HIAA ratio)	HTML, TSV	Image, TSV	BED	69	-4.0	0.0
Metabolite levels (HVA/MHPG ratio)	HTML, TSV	Image, TSV	BED	81	-3.0	0.0
Metabolite levels (HVA)	HTML, TSV	Image, TSV	BED	15	-5.1	-0.9
Metabolite levels (lipid measures)	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Metabolite levels (lipoprotein measures)	HTML, TSV,	Image, TSV	BED	101	-6.4	-2.2
Metabolite levels (MHPG)	HTML, TSV	Image, TSV	BED	67	-3.2	0.0
Metabolite levels (Pyroglutamine)	HTML, TSV	Image, TSV	BED	106	-3.1	0.0
Metabolite levels (small molecules and protein measures)	HTML, TSV	Image, TSV	BED	19	-3.4	0.0
Metabolite levels (X-11787)	HTML, TSV	Image, TSV	BED	206	-2.6	0.0
Metastasis at diagnosis in osteosarcoma	HTML, TSV	Image, TSV	BED	6	-2.8	0.0
Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event)	HTML, TSV	Image, TSV	BED	124	-4.3	-0.1
Methadone dose in opioid dependence	HTML, TSV	Image, TSV	BED	178	-2.8	0.0
Methotrexate-induced interstitial lung disease in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	23	-3.6	0.0
Methotrexate phramacokinetics (acute lymphoblastic leukemia)	HTML, TSV,	Image, TSV	BED	53	-6.6	-2.5
Microalbuminuria	HTML, TSV,	Image, TSV	BED	129	-7.8	-3.6
Middle childhood and early adolescence aggressive behavior	HTML, TSV	Image, TSV	BED	36	-3.4	0.0
middle facial morphology traits (quantitative measurement)	HTML, TSV	Image, TSV	BED	11	-4.8	-1.0
Midgestational circulating levels of organochlorine pesticides	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Midgestational circulating levels of PBDEs	HTML, TSV	Image, TSV	BED	6	-1.3	0.0
Midgestational circulating levels of PBDEs (fetal genetic effect)	HTML, TSV	Image, TSV	BED	24	-3.4	0.0
Midgestational circulating levels of PCBs	HTML, TSV	Image, TSV	BED	155	-5.3	-1.1
Midgestational circulating levels of PCBs (fetal genetic effect)	HTML, TSV	Image, TSV	BED	9	-4.0	0.0
Midgestational cytokine/chemokine levels (fetal genetic effect)	HTML, TSV	Image, TSV	BED	4	-2.4	0.0
Midgestational cytokine/chemokine levels (maternal genetic effect)	HTML, TSV	Image, TSV	BED	25	-2.5	0.0
Migraine	HTML, TSV	Image, TSV	BED	692	-2.9	0.0
Migraine - clinic-based	HTML, TSV	Image, TSV	BED	211	-4.1	0.0
Migraine with aura	HTML, TSV,	Image, TSV	BED	138	-8.4	-4.2
Migraine without aura	HTML, TSV	Image, TSV	BED	245	-4.5	-0.3
Mild influenza (H1N1) infection	HTML, TSV	Image, TSV	BED	89	-4.1	0.0
Milk allergy	HTML, TSV	Image, TSV	BED	12	-2.7	0.0
Mitochondrial DNA copy number	HTML, TSV	Image, TSV	BED	17	-1.9	0.0
Mitochondrial DNA copy number (white blood cells)	HTML, TSV	Image, TSV	BED	4	-2.1	0.0
Mitochondrial DNA levels	HTML, TSV	Image, TSV	BED	101	-3.9	0.0
Mitral valve prolapse	HTML, TSV	Image, TSV	BED	106	-3.8	0.0
Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection	HTML, TSV	Image, TSV	BED	12	-5.7	-1.5
Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event)	HTML, TSV	Image, TSV	BED	10	-3.5	0.0
Moderate to vigorous physical activity levels	HTML, TSV,	Image, TSV	BED	127	-9.4	-5.2
Modic changes	HTML, TSV	Image, TSV	BED	39	-2.9	0.0
Modified Stumvoll Insulin Sensitivity Index (BMI interaction)	HTML, TSV	Image, TSV	BED	48	-2.3	0.0
Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI)	HTML, TSV	Image, TSV	BED	4	-2.7	0.0
Molar-incisor hypomineralization	HTML, TSV	Image, TSV	BED	28	-4.9	-0.8
Monobrow	HTML, TSV	Image, TSV	BED	202	-3.5	0.0
Monobrow thickness	HTML, TSV	Image, TSV	BED	30	-2.3	0.0
Monocyte chemoattractant protein-1 levels	HTML, TSV,	Image, TSV	BED	115	-6.6	-2.4
Monocyte chemoattractant protein-3 levels	HTML, TSV	Image, TSV	BED	33	-2.8	0.0
Monocyte count	HTML, TSV,	Image, TSV	BED	3732	-71.3	-67.2
Monocyte early outgrowth colony forming units	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Monocyte-lymphocyte ratio	HTML, TSV	Image, TSV	BED	7	-5.5	-1.4
Monocyte percentage of white cells	HTML, TSV,	Image, TSV	BED	1805	-57.1	-53.0
Monokine induced by gamma interferon levels	HTML, TSV	Image, TSV	BED	99	-3.9	0.0
Mononucleosis	HTML, TSV	Image, TSV	BED	83	-4.9	-0.7
Mood disorder and prion disease	HTML, TSV	Image, TSV	BED	23	-4.3	-0.1
Mood disorder in prion disease	HTML, TSV	Image, TSV	BED	16	-2.9	0.0
Mood instability	HTML, TSV	Image, TSV	BED	330	-5.2	-1.3
Morbidity-free survival	HTML, TSV	Image, TSV	BED	53	-3.3	0.0
Morning person	HTML, TSV,	Image, TSV	BED	2156	-22.6	-18.5
Morning vs. evening chronotype	HTML, TSV,	Image, TSV	BED	507	-14.0	-9.8
Mortality in heart failure	HTML, TSV	Image, TSV	BED	74	-3.7	0.0
Mortality in sepsis	HTML, TSV	Image, TSV	BED	31	-4.3	-0.8
Mosquito bite size	HTML, TSV,	Image, TSV	BED	464	-7.1	-3.2
Motion sickness	HTML, TSV	Image, TSV	BED	205	-3.1	0.0
Motor composite score	HTML, TSV	Image, TSV	BED	51	-4.5	-0.3
Mouth morphology (principal component model)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Moyamoya disease	HTML, TSV	Image, TSV	BED	144	-5.4	-1.2
Mucinous adenocarcinoma in colorectal cancer	HTML, TSV	Image, TSV	BED	34	-3.8	0.0
Mucinous ovarian carcinoma	HTML, TSV	Image, TSV	BED	5	-3.0	0.0
Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	HTML, TSV	Image, TSV	BED	8	-3.9	0.0
Multiple keratinocyte cancers	HTML, TSV,	Image, TSV	BED	72	-41.3	-37.1
Multiple myeloma	HTML, TSV	Image, TSV	BED	137	-4.1	-0.4
Multiple myeloma and monoclonal gammopathy	HTML, TSV	Image, TSV	BED	14	-3.2	0.0
Multiple myeloma (hyperdiploidy)	HTML, TSV	Image, TSV	BED	33	-4.7	-0.5
Multiple myeloma (IgH translocation)	HTML, TSV	Image, TSV	BED	106	-5.3	-1.1
Multiple sclerosis	HTML, TSV,	Image, TSV	BED	1633	-40.4	-36.3
Multiple sclerosis (age of onset)	HTML, TSV	Image, TSV	BED	49	-3.0	0.0
Multiple sclerosis and C-reactive protein levels (pleiotropy)	HTML, TSV	Image, TSV	BED	5	-2.8	0.0
Multiple sclerosis and HDL levels (pleiotropy)	HTML, TSV	Image, TSV	BED	23	-3.6	0.0
Multiple sclerosis and LDL levels (pleiotropy)	HTML, TSV	Image, TSV	BED	12	-2.9	0.0
Multiple sclerosis and systolic blood pressure (pleiotropy)	HTML, TSV	Image, TSV	BED	10	0.0	0.0
Multiple sclerosis and triglyceride levels (pleiotropy)	HTML, TSV,	Image, TSV	BED	32	-10.1	-5.9
Multiple sclerosis and type 2 diabetes (pleiotropy)	HTML, TSV	Image, TSV	BED	5	-3.0	0.0
Multiple sclerosis--Brain Glutamate Levels	HTML, TSV	Image, TSV	BED	18	-3.4	0.0
Multiple sclerosis (OCB status)	HTML, TSV,	Image, TSV	BED	28	-9.5	-5.4
Multiple sclerosis (severity)	HTML, TSV	Image, TSV	BED	104	-5.7	-1.5
Multiple system atrophy	HTML, TSV	Image, TSV	BED	60	-3.5	0.0
Multiple system atrophy (pathologically confirmed)	HTML, TSV	Image, TSV	BED	4	-4.1	-0.2
Mumps	HTML, TSV	Image, TSV	BED	99	-5.4	-1.2
Musician's dystonia	HTML, TSV	Image, TSV	BED	2	-2.4	0.0
Myasthenia gravis	HTML, TSV	Image, TSV	BED	34	-5.3	-1.1
Myeloid white cell count	HTML, TSV,	Image, TSV	BED	414	-11.9	-7.7
Myeloproliferative neoplasms	HTML, TSV	Image, TSV	BED	121	-5.6	-1.4
Myocardial infarction	HTML, TSV	Image, TSV	BED	138	-4.4	-0.6
Myocardial infarction (early onset)	HTML, TSV	Image, TSV	BED	27	-3.9	-0.2
Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction)	HTML, TSV	Image, TSV	BED	8	-2.8	0.0
Myocardial infarction in darapladib-treated cardiovascular disease (time to event)	HTML, TSV	Image, TSV	BED	11	-2.7	0.0
Myocardial infarction in hypertension (calcium channel blocker interaction)	HTML, TSV	Image, TSV	BED	5	-3.9	-0.1
Myopia	HTML, TSV	Image, TSV	BED	138	-4.7	-0.6
Myopia (age of diagnosis)	HTML, TSV	Image, TSV	BED	297	-5.3	-1.1
Myopia (pathological)	HTML, TSV,	Image, TSV	BED	601	-11.5	-7.3
Myopia (severe)	HTML, TSV	Image, TSV	BED	20	-2.4	0.0
Myringotomy	HTML, TSV	Image, TSV	BED	57	-4.5	-0.3
Narcolepsy	HTML, TSV	Image, TSV	BED	42	-5.5	-1.5
Narcolepsy (age of onset)	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Narcolepsy (onset before 2009 H1N1 influenza pandemic)	HTML, TSV	Image, TSV	BED	4	-5.8	-1.8
Narcolepsy with cataplexy	HTML, TSV	Image, TSV	BED	40	-5.6	-1.6
Narrowest width of the femoral neck	HTML, TSV	Image, TSV	BED	5	-4.9	-1.1
Nasal polyps	HTML, TSV	Image, TSV	BED	32	-3.3	0.0
Nasopharyngeal carcinoma	HTML, TSV	Image, TSV	BED	32	-4.2	-0.0
Natriuretic peptide levels	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Negative urgency	HTML, TSV	Image, TSV	BED	6	-4.2	0.0
Neonatal cytokine/chemokine levels (fetal genetic effect)	HTML, TSV	Image, TSV	BED	38	-4.3	-0.1
Neonatal cytokine/chemokine levels (maternal genetic effect)	HTML, TSV	Image, TSV	BED	17	-3.6	0.0
Neonatal lupus	HTML, TSV	Image, TSV	BED	49	-1.6	0.0
Nephrolithiasis	HTML, TSV	Image, TSV	BED	2	-3.0	0.0
Nephropathy	HTML, TSV	Image, TSV	BED	17	-5.5	-1.3
Nephrotic syndrome (acquired)	HTML, TSV	Image, TSV	BED	28	-2.9	0.0
Neuranatomic and neurocognitive phenotypes	HTML, TSV	Image, TSV	BED	30	-3.6	0.0
Neuritic plaques or cerebral amyloid angiopathy (pleiotropy)	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy)	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Neuritic plaques or neurofibrillary tangles (pleiotropy)	HTML, TSV	Image, TSV	BED	7	-2.8	0.0
Neuritic plaque	HTML, TSV	Image, TSV	BED	81	-3.5	0.0
Neuroblastoma	HTML, TSV	Image, TSV	BED	5	0.0	0.0
Neurociticism	HTML, TSV	Image, TSV	BED	636	-4.0	0.0
Neurocognitive impairment in HIV-1 infection (continuous)	HTML, TSV	Image, TSV	BED	67	-5.2	-1.6
Neurocognitive impairment in HIV-1 infection (dichotomous)	HTML, TSV	Image, TSV	BED	12	-2.4	0.0
Neurofibrillary tangles	HTML, TSV	Image, TSV	BED	173	-4.4	-0.6
Neuromyelitis optica	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Neuromyelitis optica (AQP4-IgG-positive)	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Neuropathic pain in head and neck cancer	HTML, TSV	Image, TSV	BED	6	-4.2	-0.1
Neuropathic pain in type 2 diabetes	HTML, TSV	Image, TSV	BED	65	-3.3	0.0
Neuroticism	HTML, TSV,	Image, TSV	BED	3707	-7.1	-3.2
Neuroticism (age interaction)	HTML, TSV	Image, TSV	BED	34	-3.8	-0.2
Neuroticism (MTAG)	HTML, TSV	Image, TSV	BED	298	-3.7	0.0
Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies)	HTML, TSV	Image, TSV	BED	12	-5.7	-1.5
Neutrophil count	HTML, TSV,	Image, TSV	BED	2173	-30.4	-26.2
Neutrophil level response to clozapine in treatment-resistant schizophrenia	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Neutrophil percentage of granulocytes	HTML, TSV,	Image, TSV	BED	453	-16.4	-12.2
Neutrophil percentage of white cells	HTML, TSV,	Image, TSV	BED	1206	-28.1	-24.0
Nevirapine-induced rash	HTML, TSV	Image, TSV	BED	5	-5.5	-1.3
Nevus count	HTML, TSV	Image, TSV	BED	28	-3.2	0.0
Nevus count or cutaneous melanoma	HTML, TSV,	Image, TSV	BED	200	-6.7	-2.5
N-glycan levels	HTML, TSV,	Image, TSV	BED	135	-8.5	-4.3
Nicotine dependence	HTML, TSV,	Image, TSV	BED	85	-6.4	-2.5
Nicotine dependence and major depression (severity of comorbidity)	HTML, TSV	Image, TSV	BED	201	-5.2	-1.0
Nicotine dependence symptom count	HTML, TSV	Image, TSV	BED	562	-3.6	0.0
Nicotine use	HTML, TSV	Image, TSV	BED	8	-1.8	0.0
Nicotine withdrawal	HTML, TSV	Image, TSV	BED	26	-3.1	0.0
Nicotine withdrawal symptom count	HTML, TSV	Image, TSV	BED	39	-3.9	0.0
Night sleep phenotypes	HTML, TSV	Image, TSV	BED	615	-4.6	-0.5
Nodular sclerosis Hodgkin lymphoma	HTML, TSV,	Image, TSV	BED	59	-10.3	-6.1
Non-albumin protein levels	HTML, TSV,	Image, TSV	BED	183	-7.1	-2.9
Nonalcoholic fatty liver disease	HTML, TSV	Image, TSV	BED	79	-5.8	-1.6
Non-alcoholic fatty liver disease histology (AST)	HTML, TSV	Image, TSV	BED	47	-2.7	0.0
Non-alcoholic fatty liver disease histology (lobular)	HTML, TSV	Image, TSV	BED	46	-4.0	0.0
Non-alcoholic fatty liver disease histology (other)	HTML, TSV	Image, TSV	BED	85	-4.6	-0.8
Nonalcoholic steatohepatitis-derived hepatocellular carcinoma	HTML, TSV	Image, TSV	BED	1	-2.5	0.0
Non-cardia gastric cancer	HTML, TSV	Image, TSV	BED	55	-4.6	-0.5
Non-glioblastoma glioma	HTML, TSV	Image, TSV	BED	38	-6.0	-1.8
Non-melanoma skin cancer	HTML, TSV	Image, TSV	BED	325	-5.8	-1.8
Non-obstructive azoospermia	HTML, TSV,	Image, TSV	BED	48	-18.6	-14.4
Non-response to antidepressants and depression	HTML, TSV	Image, TSV	BED	2	-3.0	0.0
Non-response to bupropion and depression	HTML, TSV,	Image, TSV	BED	52	-8.3	-4.1
Non-response to citalopram or escitalopram and depression	HTML, TSV	Image, TSV	BED	4	0.0	0.0
Non-response to selective serotonin reuptake inhibitors and depression	HTML, TSV	Image, TSV	BED	2	-2.9	0.0
Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Non-small cell lung cancer	HTML, TSV,	Image, TSV	BED	77	-7.4	-3.2
Non-small cell lung cancer (survival)	HTML, TSV	Image, TSV	BED	28	-3.0	0.0
Non-substance related behavioral disinhibition	HTML, TSV	Image, TSV	BED	57	-4.3	-0.2
Nonsyndromic cleft lip with cleft palate	HTML, TSV,	Image, TSV	BED	215	-6.9	-2.7
Nonsyndromic cleft lip with or without cleft palate	HTML, TSV,	Image, TSV	BED	60	-14.2	-10.0
Nonsyndromic cleft lip with or without cleft palate x sex interaction (2df test)	HTML, TSV	Image, TSV	BED	37	-6.0	-1.8
Nontyphoidal Salmonella bacteraemia	HTML, TSV	Image, TSV	BED	2	-2.0	0.0
Non-word reading	HTML, TSV	Image, TSV	BED	153	-3.9	0.0
Non-word repetition	HTML, TSV	Image, TSV	BED	13	-2.4	0.0
Normal body mass index vs. thin	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Normal facial asymmetry (angle of deformation score)	HTML, TSV	Image, TSV	BED	3	-1.5	0.0
Normal facial asymmetry (angle of surface orientation score)	HTML, TSV	Image, TSV	BED	7	-2.6	0.0
Normal facial asymmetry (deformation magnitude)	HTML, TSV	Image, TSV	BED	5	-4.4	-0.2
Normalized brain volume	HTML, TSV,	Image, TSV	BED	3	-6.6	-2.4
Nose length	HTML, TSV	Image, TSV	BED	2	-2.0	0.0
Nose morphology	HTML, TSV	Image, TSV	BED	233	-5.2	-1.2
Nose size	HTML, TSV,	Image, TSV	BED	166	-7.2	-3.0
N-terminal pro B-type natriuretic peptide levels	HTML, TSV	Image, TSV	BED	6	-3.5	-0.4
Nucleus accumbens volume in trauma-exposed individuals	HTML, TSV	Image, TSV	BED	13	-3.9	0.0
Number of children	HTML, TSV	Image, TSV	BED	34	-2.4	0.0
Number of children (6+ vs. 0 or 1)	HTML, TSV	Image, TSV	BED	64	-2.5	0.0
Number of children ever born	HTML, TSV	Image, TSV	BED	25	-3.4	0.0
Number of common colds	HTML, TSV	Image, TSV	BED	52	-3.9	0.0
Number of pregnancies	HTML, TSV	Image, TSV	BED	88	-2.4	0.0
Number of sexual partners	HTML, TSV	Image, TSV	BED	728	-4.3	-0.1
Number of stillbirths in continuous marriage	HTML, TSV	Image, TSV	BED	4	-3.8	0.0
Number of twin births	HTML, TSV	Image, TSV	BED	7	-3.0	0.0
Obese vs. thin	HTML, TSV	Image, TSV	BED	57	-4.1	-0.0
Obesity	HTML, TSV	Image, TSV	BED	367	-3.5	0.0
Obesity (early onset extreme)	HTML, TSV	Image, TSV	BED	164	-4.6	-0.8
Obesity (extreme)	HTML, TSV	Image, TSV	BED	292	-3.7	0.0
Obesity in adult survivors of childhood cancer exposed to cranial radiation	HTML, TSV	Image, TSV	BED	7	-2.1	0.0
Obesity-related traits	HTML, TSV	Image, TSV	BED	3280	-3.8	0.0
Obesity without metabolic disease	HTML, TSV	Image, TSV	BED	130	-4.5	-0.3
Objective response to lithium treatment	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Objective response to lithium treatment in bipolar disorder	HTML, TSV	Image, TSV	BED	3	-2.2	0.0
Obsessive-compulsive disorder	HTML, TSV	Image, TSV	BED	157	-2.9	0.0
Obsessive-compulsive disorder or autism spectrum disorder	HTML, TSV	Image, TSV	BED	50	-3.8	0.0
Obsessive-compulsive disorder x sex interaction	HTML, TSV	Image, TSV	BED	6	-6.0	-1.8
Obsessive-compulsive symptoms	HTML, TSV	Image, TSV	BED	61	-3.4	0.0
Obstetric antiphospholipid syndrome	HTML, TSV	Image, TSV	BED	23	-3.4	0.0
Obstructive sleep apnea	HTML, TSV	Image, TSV	BED	23	-2.4	0.0
Obstructive sleep apnea (average oxygen saturation during sleep)	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Obstructive sleep apnea during REM sleep (apnea hypopnea index)	HTML, TSV	Image, TSV	BED	8	-4.0	0.0
Obstructive sleep apnea trait (apnea hypopnea index)	HTML, TSV	Image, TSV	BED	112	-5.2	-1.2
Obstructive sleep apnea trait (average respiratory event duration)	HTML, TSV	Image, TSV	BED	37	-3.6	0.0
Offspring birth weight	HTML, TSV	Image, TSV	BED	418	-5.7	-1.6
Oleic acid (18:1n-9) levels	HTML, TSV	Image, TSV	BED	12	-2.7	0.0
Oligoclonal band status in multiple sclerosis	HTML, TSV	Image, TSV	BED	5	0.0	0.0
Open-angle glaucoma and optic cup area	HTML, TSV	Image, TSV	BED	3	-2.8	0.0
Open-angle glaucoma and vertical cup-disc ratio	HTML, TSV,	Image, TSV	BED	26	-6.8	-2.6
Opioid dependence	HTML, TSV	Image, TSV	BED	26	-3.5	0.0
Opioid requirements during laparoscopic-assisted colectomy	HTML, TSV	Image, TSV	BED	2	-1.7	0.0
Opioid sensitivity	HTML, TSV	Image, TSV	BED	14	-4.8	-0.6
Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	HTML, TSV	Image, TSV	BED	48	-3.5	0.0
Optic cup area	HTML, TSV	Image, TSV	BED	267	-4.8	-0.7
Optic disc area	HTML, TSV	Image, TSV	BED	198	-5.5	-1.5
Optic disc parameters	HTML, TSV	Image, TSV	BED	19	-3.1	0.0
Optic nerve measurement (cup area)	HTML, TSV	Image, TSV	BED	101	-4.4	-0.4
Optic nerve measurement (cup-to-disc ratio)	HTML, TSV	Image, TSV	BED	90	-4.4	-0.4
Optic nerve measurement (disc area)	HTML, TSV	Image, TSV	BED	21	-5.0	-1.1
Optic nerve measurement (rim area)	HTML, TSV	Image, TSV	BED	37	-2.2	0.0
Oral cavity and pharyngeal cancer	HTML, TSV	Image, TSV	BED	13	-3.0	0.0
Oral cavity cancer	HTML, TSV	Image, TSV	BED	8	-2.2	0.0
Orofacial clefts	HTML, TSV	Image, TSV	BED	183	-5.8	-1.6
Orofacial clefts (maternal alcohol consumption interaction)	HTML, TSV	Image, TSV	BED	2	-3.9	0.0
Oropharynx cancer	HTML, TSV	Image, TSV	BED	64	-3.0	0.0
Orthostatic hypotension	HTML, TSV	Image, TSV	BED	89	0.0	0.0
Ossification of the posterior longitudinal ligament of the spine	HTML, TSV	Image, TSV	BED	80	-5.0	-1.2
Osteoarthritis	HTML, TSV	Image, TSV	BED	145	-4.2	-0.4
Osteoarthritis biomarkers	HTML, TSV	Image, TSV	BED	13	-2.8	0.0
Osteoarthritis (hip)	HTML, TSV,	Image, TSV	BED	89	-6.4	-2.2
Osteoarthritis (hospital diagnosed)	HTML, TSV	Image, TSV	BED	3	-2.0	0.0
Osteoarthritis of the hip (hospital diagnosed)	HTML, TSV	Image, TSV	BED	36	-3.5	0.0
Osteoarthritis of the hip or knee	HTML, TSV	Image, TSV	BED	114	-4.4	-0.8
Osteoarthritis of the hip or knee (hospital diagnosed)	HTML, TSV	Image, TSV	BED	6	-2.3	0.0
Osteoarthritis of the hip (with total joint replacement)	HTML, TSV	Image, TSV	BED	16	-3.3	0.0
Osteoarthritis of the knee (hospital diagnosed)	HTML, TSV	Image, TSV	BED	8	-2.0	0.0
Osteoarthritis of the knee (with total joint replacement)	HTML, TSV	Image, TSV	BED	18	-5.4	-1.3
Osteoarthritis (self-reported)	HTML, TSV	Image, TSV	BED	75	-2.8	0.0
Osteolysis in total hip arthroplasty	HTML, TSV	Image, TSV	BED	23	-5.5	-1.3
Osteolysis in total hip arthroplasty (time to prosthesis revision)	HTML, TSV	Image, TSV	BED	25	-2.4	0.0
Osteoporosis	HTML, TSV	Image, TSV	BED	14	-4.3	-0.1
Osteoporosis-related phenotypes	HTML, TSV	Image, TSV	BED	11	-5.8	-1.6
Osteoprotegerin levels	HTML, TSV	Image, TSV	BED	34	-3.2	0.0
Osteosarcoma	HTML, TSV	Image, TSV	BED	6	-3.3	0.0
Other erythrocyte phenotypes	HTML, TSV	Image, TSV	BED	10	-5.4	-1.2
Otitis media	HTML, TSV	Image, TSV	BED	2	-4.4	-0.2
Otitis media (chronic)	HTML, TSV	Image, TSV	BED	1	-2.3	0.0
Otitis media (chronic/recurrent)	HTML, TSV	Image, TSV	BED	12	-3.4	0.0
Otitis media (recurrent)	HTML, TSV	Image, TSV	BED	2	-2.6	0.0
Otosclerosis	HTML, TSV	Image, TSV	BED	10	-2.0	0.0
Ovarian cancer	HTML, TSV	Image, TSV	BED	176	-3.7	0.0
Ovarian cancer in BRCA1 mutation carriers	HTML, TSV,	Image, TSV	BED	16	-6.7	-2.5
Ovarian cancer in BRCA2 mutation carriers	HTML, TSV	Image, TSV	BED	6	-4.2	-0.1
Ovarian disease with few adhesions	HTML, TSV	Image, TSV	BED	12	-2.8	0.0
Ovarian reserve	HTML, TSV	Image, TSV	BED	64	-5.5	-1.3
Overall survival in osteosarcoma	HTML, TSV	Image, TSV	BED	60	-3.7	0.0
Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin	HTML, TSV	Image, TSV	BED	52	-3.0	0.0
Overweight status	HTML, TSV	Image, TSV	BED	29	-5.5	-1.5
Paclitaxel disposition in epithelial ovarian cancer	HTML, TSV	Image, TSV	BED	157	-3.5	0.0
Paclitaxel-induced cytotoxicity	HTML, TSV	Image, TSV	BED	35	-4.1	0.0
Paclitaxel-induced neuropathy	HTML, TSV	Image, TSV	BED	51	-4.3	-0.5
Paget's disease	HTML, TSV	Image, TSV	BED	27	-5.3	-1.5
Pain	HTML, TSV	Image, TSV	BED	27	-3.5	0.0
Pain medicine use during menstruation	HTML, TSV	Image, TSV	BED	27	-5.0	-0.8
Pallidum volume in trauma-exposed individuals	HTML, TSV	Image, TSV	BED	4	-2.6	0.0
Palmitic acid (16:0) levels	HTML, TSV	Image, TSV	BED	83	-3.5	0.0
Palmitoleic acid (16:1n-7) levels	HTML, TSV	Image, TSV	BED	55	-2.7	0.0
Pancreatic cancer	HTML, TSV	Image, TSV	BED	209	-4.6	-0.6
Pancreatic ductal adenocarcinoma	HTML, TSV	Image, TSV	BED	24	-4.8	-1.2
Pancreatitis	HTML, TSV	Image, TSV	BED	23	-3.8	-0.0
Paneth cell defects in Crohn's disease	HTML, TSV	Image, TSV	BED	37	-3.9	-0.0
Panic disorder	HTML, TSV	Image, TSV	BED	94	-3.6	0.0
Papillary thyroid cancer	HTML, TSV	Image, TSV	BED	45	-4.3	-0.3
Parasitemia in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	120	-2.5	0.0
Parental extreme longevity (95 years and older)	HTML, TSV	Image, TSV	BED	163	-4.0	-0.0
Parental lifespan	HTML, TSV	Image, TSV	BED	57	-3.7	0.0
Parental longevity (at least one long-lived parent)	HTML, TSV	Image, TSV	BED	6	-4.0	0.0
Parental longevity (both parents in top 10)	HTML, TSV	Image, TSV	BED	11	-4.4	-0.4
Parental longevity (combined parental age at death)	HTML, TSV	Image, TSV	BED	108	-4.3	-0.1
Parental longevity (combined parental attained age, Martingale residuals)	HTML, TSV	Image, TSV	BED	112	-4.4	-0.2
Parental longevity (father's age at death)	HTML, TSV	Image, TSV	BED	76	-4.9	-0.9
Parental longevity (father's attained age)	HTML, TSV	Image, TSV	BED	24	-3.5	0.0
Parental longevity (mother's age at death)	HTML, TSV	Image, TSV	BED	175	-3.0	0.0
Parent of origin effect on language impairment (paternal)	HTML, TSV	Image, TSV	BED	23	-3.1	0.0
Parkinson disease and lewy body pathology	HTML, TSV,	Image, TSV	BED	64	-9.9	-5.7
Parkinsonism in frontotemporal lobe dementia	HTML, TSV	Image, TSV	BED	11	-3.4	0.0
Parkinson's disease	HTML, TSV	Image, TSV	BED	510	-4.8	-0.6
Parkinson's disease (age of onset)	HTML, TSV	Image, TSV	BED	7	-2.9	0.0
Parkinson's disease (familial, age at onset)	HTML, TSV	Image, TSV	BED	6	-4.0	0.0
Parkinson's disease (motor and cognition)	HTML, TSV,	Image, TSV	BED	14	-6.6	-2.4
Parkinson's disease (pesticide exposure interaction)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Partial epilepsies	HTML, TSV	Image, TSV	BED	23	-2.7	0.0
Paternal history of Alzheimer's disease	HTML, TSV	Image, TSV	BED	6	-3.0	0.0
Pathological gambling	HTML, TSV,	Image, TSV	BED	5	-6.3	-2.1
PCA3 expression level	HTML, TSV	Image, TSV	BED	11	-5.0	-0.8
Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma	HTML, TSV	Image, TSV	BED	4	-3.6	0.0
Peak creatinine levels in vancomycin therapy	HTML, TSV	Image, TSV	BED	6	-2.4	0.0
Peak expiratory flow	HTML, TSV,	Image, TSV	BED	719	-8.3	-4.1
Peak insulin response	HTML, TSV	Image, TSV	BED	107	-4.3	-0.2
Peak velocity of the mitral A-wave	HTML, TSV	Image, TSV	BED	4	-5.0	-0.8
Peanut allergy	HTML, TSV	Image, TSV	BED	33	-4.0	-0.1
Peanut allergy (maternal genetic effects)	HTML, TSV	Image, TSV	BED	1	-4.7	-1.0
Peanut allergy (parent-of-origin effect)	HTML, TSV	Image, TSV	BED	10	-5.1	-1.0
Pediatric areal bone mineral density (concordant skeletal phenotype)	HTML, TSV	Image, TSV	BED	1	-2.1	0.0
Pediatric areal bone mineral density (radius)	HTML, TSV	Image, TSV	BED	85	-3.7	-0.0
Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype)	HTML, TSV	Image, TSV	BED	29	-5.1	-0.9
Pediatric autoimmune diseases	HTML, TSV	Image, TSV	BED	80	-5.9	-1.7
Pediatric bone mineral content (femoral neck)	HTML, TSV	Image, TSV	BED	50	-4.2	-0.1
Pediatric bone mineral content (hip)	HTML, TSV	Image, TSV	BED	79	-4.1	-0.2
Pediatric bone mineral content (radius)	HTML, TSV,	Image, TSV	BED	67	-6.9	-2.7
Pediatric bone mineral content (spine)	HTML, TSV	Image, TSV	BED	73	-4.0	0.0
Pediatric bone mineral density (femoral neck)	HTML, TSV	Image, TSV	BED	43	-4.0	-0.1
Pediatric bone mineral density (hip)	HTML, TSV	Image, TSV	BED	45	-2.7	0.0
Pediatric bone mineral density (spine)	HTML, TSV	Image, TSV	BED	63	-4.7	-0.5
Pediatric non-alcoholic fatty liver disease activity score	HTML, TSV	Image, TSV	BED	30	-2.1	0.0
Pediatric nonalcoholic steatohepatitis	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia	HTML, TSV	Image, TSV	BED	7	-2.0	0.0
Pelvic organ prolapse	HTML, TSV	Image, TSV	BED	132	-4.0	0.0
Pelvic organ prolapse (moderate/severe)	HTML, TSV	Image, TSV	BED	95	-4.3	-0.2
Pemphigus foliaceus	HTML, TSV	Image, TSV	BED	7	-3.4	0.0
Pemphigus vulgaris	HTML, TSV	Image, TSV	BED	24	-2.6	0.0
Perceived unattractiveness to mosquitoes	HTML, TSV	Image, TSV	BED	155	-5.3	-1.1
Percentage gas trapping	HTML, TSV	Image, TSV	BED	96	-5.3	-1.1
Percent glycated albumin	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Percent mammographic density	HTML, TSV,	Image, TSV	BED	58	-6.8	-2.6
Perceptual rivalry (voluntary modulation strength)	HTML, TSV	Image, TSV	BED	3	-5.7	-1.6
Pericardial adipose tissue adjusted for height and weight	HTML, TSV	Image, TSV	BED	44	-2.7	0.0
Pericardial fat	HTML, TSV	Image, TSV	BED	42	-2.8	0.0
Periodontal microbiota	HTML, TSV	Image, TSV	BED	61	-3.6	0.0
Periodontitis	HTML, TSV	Image, TSV	BED	77	-4.6	-0.4
Periodontitis (CDC/AAP)	HTML, TSV	Image, TSV	BED	44	-2.9	0.0
Periodontitis (DPAL)	HTML, TSV,	Image, TSV	BED	74	-6.0	-2.1
Periodontitis (Mean PAL)	HTML, TSV	Image, TSV	BED	80	-3.4	0.0
Periodontitis (PAL4Q3)	HTML, TSV	Image, TSV	BED	47	-2.9	0.0
Peripheral arterial disease (traffic-related air pollution interaction)	HTML, TSV	Image, TSV	BED	611	-2.7	0.0
Peripheral artery disease	HTML, TSV	Image, TSV	BED	84	-3.2	0.0
Permanent tooth development	HTML, TSV	Image, TSV	BED	6	-2.7	0.0
Personality dimensions	HTML, TSV	Image, TSV	BED	71	-3.9	-0.2
Personality traits in bipolar disorder	HTML, TSV	Image, TSV	BED	14	-3.1	0.0
Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio)	HTML, TSV	Image, TSV	BED	16	-5.0	-0.8
Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	HTML, TSV,	Image, TSV	BED	18	-6.2	-2.1
Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio)	HTML, TSV	Image, TSV	BED	12	-2.2	0.0
Philtrum width	HTML, TSV,	Image, TSV	BED	85	-7.3	-3.2
Phoneme awareness	HTML, TSV	Image, TSV	BED	82	-3.9	0.0
Phospholipid levels in large HDL	HTML, TSV	Image, TSV	BED	14	-5.7	-1.6
Phospholipid levels in medium HDL	HTML, TSV	Image, TSV	BED	14	-5.7	-1.6
Phospholipid levels (plasma)	HTML, TSV	Image, TSV	BED	27	-4.3	-0.2
Phosphorus levels	HTML, TSV	Image, TSV	BED	42	-3.7	0.0
Photic sneeze reflex	HTML, TSV	Image, TSV	BED	444	-4.4	-0.2
Physical activity (moderate intensity activity duration)	HTML, TSV	Image, TSV	BED	23	-4.2	-0.3
Physical activity (overall physical activity time)	HTML, TSV,	Image, TSV	BED	121	-8.0	-3.8
Phytosterol levels	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Pit-and-Fissure caries	HTML, TSV	Image, TSV	BED	61	-2.7	0.0
Placebo response in major depressive disorder ( change in symptom score)	HTML, TSV	Image, TSV	BED	45	-3.1	0.0
Placental abruption	HTML, TSV	Image, TSV	BED	17	-2.3	0.0
Plantar warts	HTML, TSV	Image, TSV	BED	82	0.0	0.0
Plasma amyloid beta peptide concentrations (ABx-40)	HTML, TSV	Image, TSV	BED	33	-5.5	-1.4
Plasma amyloid beta peptide concentrations (ABx-42)	HTML, TSV	Image, TSV	BED	40	-4.4	-0.3
Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer	HTML, TSV,	Image, TSV	BED	36	-7.2	-3.1
Plasma androstenedione levels in resected early stage-receptor positive breast cancer	HTML, TSV	Image, TSV	BED	3	-3.1	0.0
Plasma clozapine levels in treatment-resistant schizophrenia	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Plasma clusterin levels	HTML, TSV	Image, TSV	BED	177	-3.0	0.0
Plasma cystastin c levels in acute coronary syndrome	HTML, TSV	Image, TSV	BED	12	-4.3	-0.1
Plasma factor VII activating protease levels	HTML, TSV,	Image, TSV	BED	163	-61.1	-56.9
Plasma free amino acid levels	HTML, TSV	Image, TSV	BED	80	-3.5	0.0
Plasma free amino acid levels (adjusted for one other PFAA)	HTML, TSV	Image, TSV	BED	16	-2.5	0.0
Plasma free amino acid levels (adjusted for twenty other PFAAs)	HTML, TSV	Image, TSV	BED	58	-3.8	0.0
Plasma homocysteine levels	HTML, TSV	Image, TSV	BED	12	-4.5	-0.4
Plasma homocysteine levels (post-methionine load test)	HTML, TSV	Image, TSV	BED	3	0.0	0.0
Plasma kynurenine levels in major depressive disorder	HTML, TSV	Image, TSV	BED	8	-1.8	0.0
Plasma kynurenine to tryptophan ratio in major depressive disorder	HTML, TSV	Image, TSV	BED	6	-1.3	0.0
Plasma neurofilament light levels	HTML, TSV	Image, TSV	BED	8	-2.5	0.0
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid)	HTML, TSV	Image, TSV	BED	36	-5.5	-1.3
Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid)	HTML, TSV	Image, TSV	BED	38	-3.0	0.0
Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid)	HTML, TSV	Image, TSV	BED	84	-2.9	0.0
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid)	HTML, TSV,	Image, TSV	BED	23	-14.0	-9.9
Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid)	HTML, TSV	Image, TSV	BED	4	-4.0	0.0
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	HTML, TSV	Image, TSV	BED	108	-3.4	0.0
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	HTML, TSV	Image, TSV	BED	65	-4.8	-0.7
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	HTML, TSV	Image, TSV	BED	90	-5.4	-1.2
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	HTML, TSV	Image, TSV	BED	38	-3.0	0.0
Plasma parathyroid hormone levels	HTML, TSV	Image, TSV	BED	78	0.0	0.0
Plasma plasminogen levels	HTML, TSV	Image, TSV	BED	5	-4.0	-0.0
Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease	HTML, TSV	Image, TSV	BED	46	-3.4	0.0
Plasma pyridoxic acid to pyridoxal phosphate ratio	HTML, TSV	Image, TSV	BED	5	-5.5	-1.3
Plasma renin activity levels	HTML, TSV	Image, TSV	BED	38	-4.2	-0.0
Plasma thyroid-stimulating hormone levels	HTML, TSV	Image, TSV	BED	112	-2.8	0.0
Plasma trimethylamine N-oxide levels	HTML, TSV	Image, TSV	BED	12	-3.1	0.0
Plasma trimethyllysine levels	HTML, TSV	Image, TSV	BED	22	-5.0	-0.8
Plasma t-tau levels	HTML, TSV	Image, TSV	BED	17	-3.5	0.0
Plasminogen activator inhibitor type 1 levels (PAI-1)	HTML, TSV,	Image, TSV	BED	8	-6.4	-2.2
Platelet aggregation	HTML, TSV	Image, TSV	BED	49	-5.5	-1.3
Platelet count	HTML, TSV,	Image, TSV	BED	3732	-30.1	-26.2
Plateletcrit	HTML, TSV,	Image, TSV	BED	2223	-21.2	-17.0
Platelet-derived growth factor BB levels	HTML, TSV	Image, TSV	BED	176	-3.8	0.0
Platelet distribution width	HTML, TSV,	Image, TSV	BED	1698	-21.6	-17.5
Platelet thrombus formation	HTML, TSV,	Image, TSV	BED	18	-9.1	-5.0
Platinum-induced myelosuppression in non-small cell lung cancer	HTML, TSV	Image, TSV	BED	10	-2.5	0.0
Pneumococcal bacteremia	HTML, TSV,	Image, TSV	BED	21	-6.3	-2.3
Pneumoconiosis in silica exposure	HTML, TSV	Image, TSV	BED	4	-2.5	0.0
Pneumonia	HTML, TSV	Image, TSV	BED	155	-3.2	0.0
Political ideology	HTML, TSV,	Image, TSV	BED	58	-8.3	-4.1
Polychlorinated biphenyl levels	HTML, TSV,	Image, TSV	BED	137	-6.6	-2.4
Polycystic ovary syndrome	HTML, TSV	Image, TSV	BED	188	-3.8	-0.2
Polymyositis	HTML, TSV	Image, TSV	BED	13	-2.5	0.0
Poor prognosis in Crohn's disease	HTML, TSV	Image, TSV	BED	6	-3.4	0.0
Positive affect	HTML, TSV,	Image, TSV	BED	1110	-8.1	-3.9
Positive urgency	HTML, TSV	Image, TSV	BED	81	-4.3	-0.3
Possible neuropathic pain in post total joint replacement surgery for osteoarthritis	HTML, TSV	Image, TSV	BED	42	-5.4	-1.2
Post bronchodilator FEV1	HTML, TSV	Image, TSV	BED	819	-4.8	-0.9
Post bronchodilator FEV1/FVC ratio	HTML, TSV	Image, TSV	BED	1151	-3.2	0.0
Post bronchodilator FEV1/FVC ratio in COPD	HTML, TSV	Image, TSV	BED	322	-3.0	0.0
Post bronchodilator FEV1/FVC ratio in smoking	HTML, TSV	Image, TSV	BED	7	-2.7	0.0
Post bronchodilator FEV1 in COPD	HTML, TSV	Image, TSV	BED	197	-4.2	0.0
Post bronchodilator percent predicted FEV1 in smoking	HTML, TSV,	Image, TSV	BED	22	-6.7	-2.5
Postburn hypertrophic scarring severity	HTML, TSV	Image, TSV	BED	3	-1.7	0.0
Postburn scar height	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Postburn scar pliability	HTML, TSV	Image, TSV	BED	47	-4.3	-0.1
Posterior cortical atrophy and Alzheimer's disease	HTML, TSV	Image, TSV	BED	99	-3.3	0.0
Postoperative atrial fibrillation in coronary artery bypass grafting surgery	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Postoperative survival time in hepatocellular carcinoma	HTML, TSV	Image, TSV	BED	27	-4.1	-0.3
Postprandial triglyceride response to high fat diet meal	HTML, TSV	Image, TSV	BED	21	-3.6	0.0
Post-traumatic stress disorder	HTML, TSV	Image, TSV	BED	205	-4.0	0.0
Post-traumatic stress disorder (asjusted for relatedness)	HTML, TSV	Image, TSV	BED	32	-3.2	0.0
Potassium levels	HTML, TSV	Image, TSV	BED	26	-5.4	-1.5
Pre bronchodilator FEV1/FVC ratio	HTML, TSV	Image, TSV	BED	39	-2.9	0.0
Pre bronchodilator FEV1/FVC ratio in never-smokers	HTML, TSV	Image, TSV	BED	39	-3.7	0.0
Preeclampsia	HTML, TSV	Image, TSV	BED	53	-5.4	-1.2
Premature menopause in childhood cancer survivors	HTML, TSV	Image, TSV	BED	31	-4.6	-0.5
Premature ovarian failure	HTML, TSV	Image, TSV	BED	9	-2.8	0.0
Preschool internalizing problems	HTML, TSV	Image, TSV	BED	32	-3.3	0.0
Presence of antiphospholipid antibodies	HTML, TSV	Image, TSV	BED	142	-3.2	0.0
Preterm birth (maternal effect)	HTML, TSV	Image, TSV	BED	31	-4.0	-0.2
Pre-treatment pain in head and neck squamous cell carcinoma	HTML, TSV	Image, TSV	BED	35	-3.7	0.0
Prevalent atrial fibrillation	HTML, TSV	Image, TSV	BED	68	-5.6	-1.4
Prevalent type 2 diabetes	HTML, TSV	Image, TSV	BED	50	-4.8	-0.6
Primary biliary cholangitis	HTML, TSV,	Image, TSV	BED	206	-11.0	-6.8
Primary biliary cirrhosis	HTML, TSV,	Image, TSV	BED	89	-8.8	-4.7
Primary sclerosing cholangitis	HTML, TSV,	Image, TSV	BED	126	-7.6	-3.7
Primary tooth development (number of teeth)	HTML, TSV	Image, TSV	BED	38	-3.6	0.0
Primary tooth development (time to first tooth eruption)	HTML, TSV,	Image, TSV	BED	27	-6.5	-2.5
Primary vesicoureteric reflux	HTML, TSV	Image, TSV	BED	4	-3.5	0.0
PR interval	HTML, TSV,	Image, TSV	BED	1072	-13.2	-9.1
PR interval in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	285	-2.4	0.0
Prion diseases	HTML, TSV	Image, TSV	BED	116	-4.2	-0.1
Problematic alcohol use in trauma-exposed individuals	HTML, TSV	Image, TSV	BED	14	-4.4	-0.5
Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)	HTML, TSV	Image, TSV	BED	8	-3.8	0.0
Progression free survival in metastatic colorectal cancer (chemotherapy interaction)	HTML, TSV	Image, TSV	BED	1	-2.0	0.0
Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Progressive supranuclear palsy	HTML, TSV	Image, TSV	BED	20	-3.8	0.0
Proinsulin levels	HTML, TSV	Image, TSV	BED	73	-3.1	0.0
Proliferative diabetic retinopathy in type 2 diabetes	HTML, TSV	Image, TSV	BED	3	-4.5	-0.4
Proliferative diabetic retinopathy (vs no DR)	HTML, TSV	Image, TSV	BED	98	-4.6	-0.6
Proliferative diabetic retinopathy (vs NPDR and no DR)	HTML, TSV	Image, TSV	BED	94	-4.3	-0.1
Prostate cancer	HTML, TSV,	Image, TSV	BED	1433	-19.4	-15.2
Prostate cancer (advanced)	HTML, TSV,	Image, TSV	BED	91	-8.6	-4.4
Prostate cancer aggressiveness	HTML, TSV	Image, TSV	BED	3	-3.4	0.0
Prostate cancer (early onset)	HTML, TSV,	Image, TSV	BED	65	-6.7	-2.7
Prostate cancer (survival)	HTML, TSV	Image, TSV	BED	14	-3.5	0.0
Prostate-specific antigen levels	HTML, TSV,	Image, TSV	BED	121	-6.6	-2.4
Prostate-specific antigen levels (conditioned on lead SNPs)	HTML, TSV	Image, TSV	BED	51	-5.1	-1.2
Protein C levels	HTML, TSV	Image, TSV	BED	5	-1.5	0.0
Protein quantitative trait loci	HTML, TSV	Image, TSV	BED	195	-4.1	-0.3
Proteinuria and chronic kidney disease	HTML, TSV	Image, TSV	BED	7	0.0	0.0
Proteinuria in chronic kidney disease	HTML, TSV	Image, TSV	BED	6	-2.3	0.0
Prothrombin fragments F1+2 levels in ischemic stroke	HTML, TSV	Image, TSV	BED	9	-4.7	-0.8
Prothrombin time	HTML, TSV	Image, TSV	BED	41	-3.2	0.0
PR segment	HTML, TSV	Image, TSV	BED	20	-3.9	-0.1
Prudent dietary pattern	HTML, TSV	Image, TSV	BED	88	-3.2	0.0
Psoriasis	HTML, TSV,	Image, TSV	BED	402	-8.2	-4.1
Psoriasis vulgaris	HTML, TSV	Image, TSV	BED	190	-4.2	-0.3
Psoriatic arthritis	HTML, TSV	Image, TSV	BED	23	-3.6	-0.5
Psychiatric diseases (pleiotropy) (HIPO component 1)	HTML, TSV	Image, TSV	BED	10	-2.9	0.0
Psychological distress	HTML, TSV	Image, TSV	BED	41	-2.4	0.0
Psychosis and Alzheimer's disease	HTML, TSV	Image, TSV	BED	85	-3.5	0.0
Psychosis (atypical)	HTML, TSV,	Image, TSV	BED	26	-6.2	-2.1
Psychosis in Alzheimer's disease	HTML, TSV	Image, TSV	BED	45	-6.0	-1.8
Psychosis proneness (hypomanic personality scale)	HTML, TSV	Image, TSV	BED	7	-2.3	0.0
Psychosis proneness (hypomanic personality scale and perceptual aberration scale)	HTML, TSV	Image, TSV	BED	3	-2.7	0.0
Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale)	HTML, TSV	Image, TSV	BED	13	-2.7	0.0
Psychosis proneness (hypomanic personality scale and revised social anhedonia scale)	HTML, TSV	Image, TSV	BED	21	-3.8	0.0
Psychosis proneness (perceptual aberration scale and revised social anhedonia scale)	HTML, TSV	Image, TSV	BED	9	-2.8	0.0
Psychosis proneness (revised physical anhedonia scale)	HTML, TSV	Image, TSV	BED	3	-2.4	0.0
Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale)	HTML, TSV	Image, TSV	BED	9	-2.8	0.0
Psychosis proneness (revised social anhedonia scale)	HTML, TSV	Image, TSV	BED	9	-2.8	0.0
Psychotic symptoms in prion disease	HTML, TSV	Image, TSV	BED	26	-3.9	0.0
Pubertal anthropometrics	HTML, TSV,	Image, TSV	BED	136	-6.3	-2.1
Pulmonary arterial hypertension	HTML, TSV	Image, TSV	BED	7	-2.7	0.0
Pulmonary arterial hypertension (without BMPR2 mutations)	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Pulmonary emphysema	HTML, TSV	Image, TSV	BED	4	-1.6	0.0
Pulmonary function	HTML, TSV	Image, TSV	BED	215	-5.2	-1.1
Pulmonary function decline	HTML, TSV	Image, TSV	BED	91	-3.8	0.0
Pulmonary function in asthmatics	HTML, TSV	Image, TSV	BED	40	-5.1	-1.2
Pulmonary function (smoking interaction)	HTML, TSV	Image, TSV	BED	205	-3.2	0.0
Pulse pressure	HTML, TSV,	Image, TSV	BED	2572	-11.5	-7.4
Pulse pressure (alcohol consumption interaction)	HTML, TSV	Image, TSV	BED	7	-2.3	0.0
Pulse pressure in young-onset hypertension	HTML, TSV	Image, TSV	BED	15	-3.9	-0.2
Pulse pressure x alcohol consumption interaction (2df test)	HTML, TSV	Image, TSV	BED	159	-6.0	-1.9
Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test)	HTML, TSV	Image, TSV	BED	20	-4.5	-0.7
Pursuit maintenance gain	HTML, TSV	Image, TSV	BED	306	-2.7	0.0
Pursuit maintenance gain in psychotic disorders	HTML, TSV	Image, TSV	BED	16	-2.5	0.0
Putamen volume	HTML, TSV	Image, TSV	BED	127	-3.6	0.0
P wave duration	HTML, TSV	Image, TSV	BED	43	-5.1	-1.1
P wave terminal force	HTML, TSV	Image, TSV	BED	35	-5.3	-1.1
Pyoderma gangrenosum in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	13	-2.8	0.0
Pyridoxal 5'-phosphate levels	HTML, TSV	Image, TSV	BED	3	-1.4	0.0
QRS complex (12-leadsum)	HTML, TSV	Image, TSV	BED	116	-5.2	-1.0
QRS complex (Cornell)	HTML, TSV	Image, TSV	BED	107	-3.9	0.0
QRS complex (Sokolow-Lyon)	HTML, TSV	Image, TSV	BED	54	-3.6	0.0
QRS duration	HTML, TSV	Image, TSV	BED	428	-3.4	0.0
QRS duration in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	81	-3.4	0.0
QRS interval (sulfonylurea treatment interaction)	HTML, TSV	Image, TSV	BED	107	-3.7	0.0
QT interval	HTML, TSV	Image, TSV	BED	693	-5.0	-1.2
QT interval (ambient particulate matter interaction)	HTML, TSV	Image, TSV	BED	87	-5.1	-1.1
QT interval (drug interaction)	HTML, TSV	Image, TSV	BED	60	-3.4	0.0
QT interval in Tripanosoma cruzi seropositivity	HTML, TSV	Image, TSV	BED	53	-3.3	0.0
QT interval (sulfonylurea treatment interaction)	HTML, TSV	Image, TSV	BED	57	-2.7	0.0
Quantitative traits	HTML, TSV	Image, TSV	BED	139	-3.6	0.0
Radiation response	HTML, TSV	Image, TSV	BED	24	-3.0	0.0
RANTES levels	HTML, TSV	Image, TSV	BED	103	-4.0	-0.1
Rapid automised naming of digits	HTML, TSV	Image, TSV	BED	87	-4.0	0.0
Rapid automised naming of letters	HTML, TSV	Image, TSV	BED	154	-4.3	-0.2
Rapid automised naming of pictures	HTML, TSV	Image, TSV	BED	67	-5.1	-1.2
Rate of cognitive decline in mild cognitive impairment (time interaction)	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Reaction time	HTML, TSV,	Image, TSV	BED	2122	-24.2	-20.1
Reading ability (multivariate)	HTML, TSV	Image, TSV	BED	123	-3.7	0.0
Reading and spelling	HTML, TSV	Image, TSV	BED	39	-2.4	0.0
Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy)	HTML, TSV	Image, TSV	BED	10	-4.7	-0.6
Reading disability or specific language impairment (pleiotropy)	HTML, TSV	Image, TSV	BED	81	-3.6	0.0
Reasoning	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
Recalcitrant atopic dermatitis	HTML, TSV,	Image, TSV	BED	65	-6.6	-2.7
Recombination measurement	HTML, TSV	Image, TSV	BED	10	-1.4	0.0
Recurrent major depressive disorder	HTML, TSV	Image, TSV	BED	83	-3.3	0.0
Red blood cell count	HTML, TSV,	Image, TSV	BED	4518	-21.0	-16.8
Red blood cell density in sickle cell anemia	HTML, TSV	Image, TSV	BED	29	-3.9	-0.1
Red blood cell fatty acid levels	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Red blood cell traits	HTML, TSV,	Image, TSV	BED	165	-9.8	-5.6
Red cell distribution width	HTML, TSV,	Image, TSV	BED	2185	-48.1	-43.9
Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A	HTML, TSV	Image, TSV	BED	2	-1.6	0.0
Red vs. brown/black hair color	HTML, TSV,	Image, TSV	BED	59	-7.1	-3.0
Red wine liking	HTML, TSV	Image, TSV	BED	12	-3.9	0.0
Reflection (response to stress)	HTML, TSV	Image, TSV	BED	45	-3.7	0.0
Refractive astigmatism	HTML, TSV	Image, TSV	BED	260	-4.5	-0.4
Refractive error	HTML, TSV	Image, TSV	BED	2356	-4.4	-0.5
Refractory celiac disease type II	HTML, TSV	Image, TSV	BED	6	-2.7	0.0
Regular attendance at a gym or sports club	HTML, TSV	Image, TSV	BED	14	-2.2	0.0
Regular attendance at a pub or social club	HTML, TSV	Image, TSV	BED	92	-2.8	0.0
Regular attendance at a religious group	HTML, TSV	Image, TSV	BED	96	-2.7	0.0
Relapse in multiple sclerosis	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Relative amplitude of rest-activity cycles	HTML, TSV	Image, TSV	BED	20	-4.0	0.0
Relative hand skill	HTML, TSV,	Image, TSV	BED	26	-6.4	-2.3
Relative hand skill in reading disability	HTML, TSV	Image, TSV	BED	29	-3.2	0.0
Relative wall thickness	HTML, TSV	Image, TSV	BED	13	-5.6	-1.4
Remission after SSRI treatment in major depression	HTML, TSV	Image, TSV	BED	5	-2.9	0.0
Remission after SSRI treatment in MDD or neuroticism	HTML, TSV	Image, TSV	BED	11	-2.8	0.0
Remission after SSRI treatment in MDD or openness	HTML, TSV	Image, TSV	BED	2	-3.1	-0.1
Renal cell carcinoma	HTML, TSV,	Image, TSV	BED	124	-6.3	-2.1
Renal function and chronic kidney disease	HTML, TSV	Image, TSV	BED	26	-3.9	-0.1
Renal function-related traits (BUN)	HTML, TSV	Image, TSV	BED	66	-5.0	-0.8
Renal function-related traits (eGRFcrea)	HTML, TSV	Image, TSV	BED	86	-5.1	-0.9
Renal function-related traits (sCR)	HTML, TSV	Image, TSV	BED	49	-3.0	0.0
Renal function-related traits (urea)	HTML, TSV	Image, TSV	BED	8	-2.9	0.0
Renal overload gout	HTML, TSV	Image, TSV	BED	21	-4.5	-0.4
Renal sinus fat	HTML, TSV	Image, TSV	BED	22	-2.2	0.0
Renal transplant outcome	HTML, TSV	Image, TSV	BED	6	-3.2	0.0
Renal underexcretion gout	HTML, TSV	Image, TSV	BED	8	-2.9	0.0
Residual cognition	HTML, TSV	Image, TSV	BED	40	-4.9	-0.7
Resistance to antihypertensive treatment in hypertension	HTML, TSV	Image, TSV	BED	119	-5.6	-1.6
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous)	HTML, TSV	Image, TSV	BED	3	-3.5	0.0
Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (dichotomous)	HTML, TSV	Image, TSV	BED	18	-3.8	0.0
Resistant hypertension	HTML, TSV	Image, TSV	BED	27	-5.8	-1.6
Resistin levels	HTML, TSV,	Image, TSV	BED	64	-9.3	-5.3
Respiratory diseases	HTML, TSV,	Image, TSV	BED	340	-10.3	-6.2
Response to abacavir-containing treatment in HIV-1 infection (virologic failure)	HTML, TSV	Image, TSV	BED	61	-4.6	-0.4
Response to acetaminophen (hepatotoxicity)	HTML, TSV,	Image, TSV	BED	34	-13.6	-9.4
Response to alcohol consumption (flushing response)	HTML, TSV	Image, TSV	BED	5	-3.1	0.0
Response to amphetamines	HTML, TSV	Image, TSV	BED	343	-3.1	0.0
Response to angiotensin II receptor blocker therapy	HTML, TSV	Image, TSV	BED	103	-3.6	0.0
Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)	HTML, TSV	Image, TSV	BED	16	-4.8	-0.6
Response to antidepressants	HTML, TSV	Image, TSV	BED	53	-4.0	-0.2
Response to antidepressants and depression	HTML, TSV	Image, TSV	BED	2	-2.4	0.0
Response to antidepressants in depression	HTML, TSV	Image, TSV	BED	8	-2.8	0.0
Response to antidepressants (symptom improvement)	HTML, TSV	Image, TSV	BED	154	-4.7	-0.6
Response to antidepressants (symptom remission)	HTML, TSV	Image, TSV	BED	35	-3.5	0.0
Response to antidepressant treatment (citalopram)	HTML, TSV,	Image, TSV	BED	23	-6.9	-2.7
Response to anti-depressant treatment in major depressive disorder	HTML, TSV	Image, TSV	BED	52	-4.3	-0.2
Response to antineoplastic agents	HTML, TSV	Image, TSV	BED	48	-5.6	-1.5
Response to antipsychotic therapy (extrapyramidal side effects)	HTML, TSV	Image, TSV	BED	107	-2.5	0.0
Response to antipsychotic treatment	HTML, TSV	Image, TSV	BED	390	-3.6	0.0
Response to antipsychotic treatment in schizophrenia	HTML, TSV	Image, TSV	BED	36	-4.7	-0.8
Response to antipsychotic treatment in schizophrenia (reasoning)	HTML, TSV	Image, TSV	BED	36	-2.9	0.0
Response to antipsychotic treatment in schizophrenia (working memory)	HTML, TSV	Image, TSV	BED	48	-2.5	0.0
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy)	HTML, TSV	Image, TSV	BED	32	-3.7	0.0
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy)	HTML, TSV	Image, TSV	BED	93	-2.6	0.0
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy)	HTML, TSV	Image, TSV	BED	33	-4.0	0.0
Response to anti-TNF alpha therapy in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	8	-2.3	0.0
Response to anti-TNF therapy in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	22	-4.6	-0.4
Response to aripiprazole in schizophrenia	HTML, TSV	Image, TSV	BED	15	-3.8	0.0
Response to bleomycin (chromatid breaks)	HTML, TSV	Image, TSV	BED	4	-5.0	-0.8
Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)	HTML, TSV	Image, TSV	BED	65	-4.3	-0.2
Response to bupropion and depression	HTML, TSV	Image, TSV	BED	10	-3.3	0.0
Response to bupropion in depression	HTML, TSV	Image, TSV	BED	12	-3.6	0.0
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)	HTML, TSV	Image, TSV	BED	20	-5.1	-1.1
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)	HTML, TSV	Image, TSV	BED	4	-5.0	-0.8
Response to carboplatin in ovarian cancer (MTT IC50)	HTML, TSV	Image, TSV	BED	63	-3.0	0.0
Response to chemotherapy in breast cancer (hypertension) (bevacizumab)	HTML, TSV	Image, TSV	BED	13	-3.1	0.0
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)	HTML, TSV	Image, TSV	BED	39	-2.7	0.0
Response to cholinesterase inhibitors in Alzheimer's disease	HTML, TSV	Image, TSV	BED	15	-3.2	0.0
Response to citalopram or escitalopram and depression	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Response to citalopram or escitalopram in depression	HTML, TSV	Image, TSV	BED	15	-2.8	0.0
Response to citalopram treatment	HTML, TSV	Image, TSV	BED	67	-4.1	0.0
Response to cognitive-behavioural therapy in anxiety disorder	HTML, TSV	Image, TSV	BED	123	-4.1	0.0
Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	HTML, TSV	Image, TSV	BED	29	-3.0	0.0
Response to cytadine analogues (cytosine arabinoside)	HTML, TSV	Image, TSV	BED	43	-3.7	0.0
Response to cytidine analogues (gemcitabine)	HTML, TSV	Image, TSV	BED	22	-4.6	-0.4
Response to Dalcetrapib treatment in acute coronary syndrome	HTML, TSV	Image, TSV	BED	4	-3.0	0.0
Response to efavirenz-containing treatment in HIV 1 infection (virologic failure)	HTML, TSV	Image, TSV	BED	186	-5.0	-0.8
Response to exercise (triglyceride level interaction)	HTML, TSV	Image, TSV	BED	20	-3.1	0.0
Response to fenofibrate	HTML, TSV	Image, TSV	BED	10	-5.2	-1.2
Response to fenofibrate (adiponectin levels)	HTML, TSV	Image, TSV	BED	38	-4.2	-0.1
Response to fenofibrate (HDL cholesterol levels)	HTML, TSV	Image, TSV	BED	6	-2.0	0.0
Response to fenofibrate (total cholesterol levels)	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Response to fenofibrate (triglyceride levels)	HTML, TSV	Image, TSV	BED	11	-2.8	0.0
Response to gemcitabine in pancreatic cancer	HTML, TSV	Image, TSV	BED	11	-1.8	0.0
Response to haloperidol in schizophrenia	HTML, TSV	Image, TSV	BED	32	-2.2	0.0
Response to hepatitis B vaccine	HTML, TSV	Image, TSV	BED	39	-4.4	-0.3
Response to hepatitis C treatment	HTML, TSV	Image, TSV	BED	19	-4.1	-0.2
Response to Homoharringtonine (cytotoxicity)	HTML, TSV	Image, TSV	BED	32	-3.6	0.0
Response to iloperidone treatment (QT prolongation)	HTML, TSV	Image, TSV	BED	12	-1.4	0.0
Response to inhaled corticosteroid treatment in asthma (change in FEV1)	HTML, TSV	Image, TSV	BED	63	-4.3	-0.2
Response to inhaled glucocorticoid treatment in asthma (change in FEV1)	HTML, TSV	Image, TSV	BED	9	-2.2	0.0
Response to interferon beta in multiple sclerosis	HTML, TSV	Image, TSV	BED	25	-2.2	0.0
Response to interferon beta therapy	HTML, TSV	Image, TSV	BED	5	-3.9	-0.2
Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer	HTML, TSV	Image, TSV	BED	14	-4.0	0.0
Response to irinotecan in non-small-cell lung cancer	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Response to ketamine in bipolar disorder or major depression (antidepressant effects)	HTML, TSV	Image, TSV	BED	11	-2.4	0.0
Response to ketamine in bipolar disorder or major depression (dissociation effects)	HTML, TSV,	Image, TSV	BED	34	-7.1	-3.0
Response to ketogenic dietary therapies in epilepsy	HTML, TSV,	Image, TSV	BED	7	-6.3	-2.1
Response to lithium treatment in bipolar disorder	HTML, TSV	Image, TSV	BED	22	-2.2	0.0
Response to long-chain n-3 polyunsaturated fatty acid supplementation (change in triglyceride levels)	HTML, TSV	Image, TSV	BED	47	-4.7	-0.5
Response to long-term oxygen therapy in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	43	-3.4	0.0
Response to lurasidone in schizophrenia	HTML, TSV	Image, TSV	BED	43	-5.1	-0.9
Response to mepolizumab in severe asthma	HTML, TSV	Image, TSV	BED	55	-5.1	-1.1
Response to metformin (IC50)	HTML, TSV	Image, TSV	BED	50	-3.3	0.0
Response to methotrexate in juvenile idiopathic arthritis	HTML, TSV	Image, TSV	BED	105	-5.0	-0.8
Response to methotrexate in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	HTML, TSV	Image, TSV	BED	6	-3.9	-0.0
Response to montelukast in asthma (change in FEV1)	HTML, TSV	Image, TSV	BED	11	-2.5	0.0
Response to mTOR inhibitor (everolimus)	HTML, TSV	Image, TSV	BED	45	-3.7	0.0
Response to mTOR inhibitor (rapamycin)	HTML, TSV	Image, TSV	BED	36	-6.1	-2.0
Response to olanzapine in schizophrenia	HTML, TSV	Image, TSV	BED	32	-5.9	-2.0
Response to opioid analgesics in cancer (pain decrease)	HTML, TSV	Image, TSV	BED	5	0.0	0.0
Response to paliperidone in schizophrenia (CGI-S score)	HTML, TSV	Image, TSV	BED	94	-5.4	-1.2
Response to paliperidone in schizophrenia (Multivariate)	HTML, TSV	Image, TSV	BED	62	-3.1	0.0
Response to paliperidone in schizophrenia (negative Marder score)	HTML, TSV	Image, TSV	BED	192	-2.9	0.0
Response to paliperidone in schizophrenia (PANSS score)	HTML, TSV	Image, TSV	BED	109	-5.6	-1.4
Response to paliperidone in schizophrenia (positive Marder score)	HTML, TSV	Image, TSV	BED	163	-5.6	-1.7
Response to perphenazine in schizophrenia	HTML, TSV	Image, TSV	BED	24	-4.8	-0.8
Response to platinum-based agents	HTML, TSV	Image, TSV	BED	78	-5.1	-1.0
Response to platinum-based chemotherapy (carboplatin)	HTML, TSV	Image, TSV	BED	101	-3.1	0.0
Response to platinum-based chemotherapy (cisplatin)	HTML, TSV	Image, TSV	BED	86	-5.9	-1.8
Response to platinum-based chemotherapy in non-small-cell lung cancer	HTML, TSV	Image, TSV	BED	8	-3.7	0.0
Response to platinum-based neoadjuvant chemotherapy in cervical cancer	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels)	HTML, TSV	Image, TSV	BED	14	-2.5	0.0
Response to quetiapine in schizophrenia	HTML, TSV	Image, TSV	BED	16	-5.3	-1.4
Response to radiotherapy in cancer (late toxicity)	HTML, TSV	Image, TSV	BED	97	-4.7	-0.5
Response to radiotherapy in prostate cancer (overall toxicity)	HTML, TSV	Image, TSV	BED	25	-2.7	0.0
Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)	HTML, TSV	Image, TSV	BED	3	-3.4	0.0
Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	HTML, TSV	Image, TSV	BED	20	-5.7	-1.7
Response to ranibizumab in age-related macular degeneration (exudative)	HTML, TSV	Image, TSV	BED	3	-4.3	-0.9
Response to risperidone in schizophrenia	HTML, TSV	Image, TSV	BED	2	-5.0	-1.3
Response to selective serotonin reuptake inhibitors and depression	HTML, TSV	Image, TSV	BED	55	-5.2	-1.2
Response to selective serotonin reuptake inhibitors in depression	HTML, TSV	Image, TSV	BED	20	-4.7	-0.7
Response to serotonin reuptake inhibitors in major depressive disorder	HTML, TSV	Image, TSV	BED	83	-2.4	0.0
Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	HTML, TSV	Image, TSV	BED	33	-4.5	-0.3
Response to serotonin reuptake inhibitors in non-psychotic unipolar depression	HTML, TSV	Image, TSV	BED	53	-4.0	0.0
Response to simvastatin treatment (PCSK9 protein level change)	HTML, TSV	Image, TSV	BED	22	-2.7	0.0
Response to SSRI in MDD or openness	HTML, TSV	Image, TSV	BED	11	-3.4	0.0
Response to SSRI (symptom remission)	HTML, TSV	Image, TSV	BED	17	-3.2	-0.1
Response to statins (HDL cholesterol change)	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Response to statins (LDL cholesterol change)	HTML, TSV	Image, TSV	BED	46	-5.4	-1.3
Response to statin therapy	HTML, TSV	Image, TSV	BED	197	-4.0	0.0
Response to tamoxifen in breast cancer	HTML, TSV	Image, TSV	BED	8	-4.4	-0.2
Response to taxane treatment (docetaxel)	HTML, TSV,	Image, TSV	BED	78	-6.3	-2.2
Response to taxane treatment (placlitaxel)	HTML, TSV	Image, TSV	BED	25	-2.9	0.0
Response to temozolomide	HTML, TSV	Image, TSV	BED	27	-4.0	0.0
Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine)	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Response to TNF-alpha inhibitors in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	63	-3.4	0.0
Response to TNF antagonist treatment	HTML, TSV	Image, TSV	BED	83	-4.4	-0.4
Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score)	HTML, TSV	Image, TSV	BED	3	-3.8	0.0
Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score)	HTML, TSV	Image, TSV	BED	2	-5.6	-1.4
Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count)	HTML, TSV,	Image, TSV	BED	120	-16.7	-12.6
Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count)	HTML, TSV	Image, TSV	BED	61	-4.3	-0.3
Response to tocilizumab in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	147	-4.7	-1.0
Response to treatment for acute lymphoblastic leukemia	HTML, TSV	Image, TSV	BED	100	-4.7	-0.5
Response to zileuton treatment in asthma (FEV1 change interaction)	HTML, TSV	Image, TSV	BED	63	-3.3	0.0
Response to ziprazidone in schizophrenia	HTML, TSV	Image, TSV	BED	12	-2.7	0.0
Resting heart rate	HTML, TSV,	Image, TSV	BED	462	-24.9	-20.7
Resting metabolic rate	HTML, TSV	Image, TSV	BED	13	-3.9	-0.6
Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry)	HTML, TSV	Image, TSV	BED	2	-1.4	0.0
Resting-state electroencephalogram vigilance	HTML, TSV	Image, TSV	BED	101	-2.9	0.0
Restless legs syndrome	HTML, TSV	Image, TSV	BED	133	-2.9	0.0
Reticulocyte count	HTML, TSV,	Image, TSV	BED	1508	-20.9	-16.8
Reticulocyte fraction of red cells	HTML, TSV,	Image, TSV	BED	1473	-30.4	-26.2
Retinal arteriolar caliber	HTML, TSV	Image, TSV	BED	14	-5.2	-1.0
Retinal vascular caliber	HTML, TSV	Image, TSV	BED	7	-4.2	-0.6
Retinopathy in non-diabetics	HTML, TSV	Image, TSV	BED	11	-5.3	-1.1
Rheumatic fever	HTML, TSV	Image, TSV	BED	60	-4.5	-0.5
Rheumatic heart disease	HTML, TSV,	Image, TSV	BED	17	-6.9	-2.9
Rheumatoid arthritis	HTML, TSV,	Image, TSV	BED	884	-20.2	-16.0
Rheumatoid arthritis (ACPA-negative)	HTML, TSV	Image, TSV	BED	28	-3.4	0.0
Rheumatoid arthritis (ACPA-positive)	HTML, TSV,	Image, TSV	BED	192	-8.6	-4.4
Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive)	HTML, TSV	Image, TSV	BED	30	-3.7	0.0
Rheumatoid factor seropositivity in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	7	-3.3	0.0
Right lateral prefrontal cortical growth	HTML, TSV,	Image, TSV	BED	104	-6.3	-2.1
Risk-taking tendency (4-domain principal component model)	HTML, TSV	Image, TSV	BED	503	-4.7	-0.5
Risky sexual behaviors (alcohol dependence interaction)	HTML, TSV	Image, TSV	BED	38	-3.8	0.0
Risky sexual behaviors in alcohol dependence	HTML, TSV	Image, TSV	BED	36	-4.6	-0.7
Rosacea symptom severity	HTML, TSV	Image, TSV	BED	203	-4.4	-0.3
Rotator cuff tears	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
RR interval (heart rate)	HTML, TSV	Image, TSV	BED	148	-4.3	-0.4
Rubella	HTML, TSV	Image, TSV	BED	93	-3.6	0.0
Rumination (response to stress)	HTML, TSV	Image, TSV	BED	45	-2.5	0.0
Sagittal craniosynostosis	HTML, TSV	Image, TSV	BED	10	-3.3	0.0
Sarcoidosis	HTML, TSV	Image, TSV	BED	5	-3.8	0.0
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)	HTML, TSV	Image, TSV	BED	3	-3.9	-0.2
Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations)	HTML, TSV	Image, TSV	BED	7	-2.5	0.0
Sasang constitutional medicine type (So-Eum)	HTML, TSV,	Image, TSV	BED	30	-7.9	-3.7
Scalp hair shape	HTML, TSV	Image, TSV	BED	26	-2.1	0.0
Scarlet fever	HTML, TSV	Image, TSV	BED	153	-4.4	-0.2
Schizophrenia	HTML, TSV,	Image, TSV	BED	4483	-9.7	-5.5
Schizophrenia (age at onset)	HTML, TSV	Image, TSV	BED	94	-4.3	-0.6
Schizophrenia, bipolar disorder and depression (combined)	HTML, TSV	Image, TSV	BED	12	-4.8	-0.6
Schizophrenia (cytomegalovirus infection interaction)	HTML, TSV	Image, TSV	BED	20	-5.4	-1.2
Schizophrenia (inflammation and infection response interaction)	HTML, TSV	Image, TSV	BED	14	-3.8	0.0
Schizophrenia (negative symptoms)	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Schizophrenia or bipolar disorder	HTML, TSV	Image, TSV	BED	6	-2.9	0.0
Schizophrenia, schizoaffective disorder or bipolar disorder	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Schizophrenia (treatment resistant)	HTML, TSV	Image, TSV	BED	39	-5.2	-1.0
Schizophrenia vs type 2 diabetes	HTML, TSV	Image, TSV	BED	38	0.0	0.0
Sciatica caused by lumbar disc herniation (treated with microdiscectomy)	HTML, TSV,	Image, TSV	BED	4	-9.5	-5.3
Sclerosing cholangitis and ulcerative colitis (combined)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Seasonality	HTML, TSV	Image, TSV	BED	42	-3.2	0.0
Seasonality and depression	HTML, TSV	Image, TSV	BED	67	-4.2	0.0
Seborrheic dermatitis	HTML, TSV	Image, TSV	BED	43	-3.4	0.0
Sedentary behaviour duration	HTML, TSV	Image, TSV	BED	25	-5.1	-1.1
Select biomarker traits	HTML, TSV	Image, TSV	BED	144	0.0	0.0
Selective IgA deficiency	HTML, TSV,	Image, TSV	BED	192	-7.3	-3.3
Self-employment	HTML, TSV	Image, TSV	BED	3	-4.6	-0.4
Self-rated health	HTML, TSV	Image, TSV	BED	60	-3.3	0.0
Self-reported allergy	HTML, TSV,	Image, TSV	BED	230	-9.3	-5.4
Self-reported childhood asthma in adult smokers	HTML, TSV	Image, TSV	BED	14	-3.9	0.0
Self-reported math ability	HTML, TSV	Image, TSV	BED	2468	-5.9	-1.7
Self-reported math ability (MTAG)	HTML, TSV,	Image, TSV	BED	3731	-7.5	-3.3
Self-reported risk-taking behaviour	HTML, TSV	Image, TSV	BED	218	-4.4	-0.2
Self-reported tiredness	HTML, TSV	Image, TSV	BED	4	-4.6	-0.4
Sensation seeking	HTML, TSV	Image, TSV	BED	14	-2.6	0.0
Sense of smell	HTML, TSV,	Image, TSV	BED	55	-8.6	-4.4
Sensory disturbances after bilateral sagittal split ramus osteotomy	HTML, TSV	Image, TSV	BED	6	-2.8	0.0
Sepsis from pneumonia (survival)	HTML, TSV	Image, TSV	BED	4	-3.3	0.0
Sepsis in extremely premature infants	HTML, TSV	Image, TSV	BED	9	-3.0	0.0
Sero-negative rheumatoid arthritis	HTML, TSV	Image, TSV	BED	7	-4.2	-0.6
Serous borderline ovarian cancer	HTML, TSV	Image, TSV	BED	2	-2.7	0.0
Serous invasive ovarian cancer	HTML, TSV	Image, TSV	BED	18	-3.2	0.0
Serum 25-Hydroxyvitamin D levels	HTML, TSV,	Image, TSV	BED	734	-7.6	-3.5
Serum albumin level	HTML, TSV	Image, TSV	BED	75	-3.8	0.0
Serum alkaline phosphatase levels	HTML, TSV,	Image, TSV	BED	534	-9.2	-5.0
Serum bilirubin levels in metabolic syndrome	HTML, TSV	Image, TSV	BED	24	-3.9	0.0
Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome	HTML, TSV	Image, TSV	BED	96	-2.5	0.0
Serum bilirubin levels x sex interaction in metabolic syndrome	HTML, TSV	Image, TSV	BED	81	0.0	0.0
Serum creatinine levels	HTML, TSV	Image, TSV	BED	10	-2.2	0.0
Serum dimethylarginine levels (asymmetric/symetric ratio)	HTML, TSV	Image, TSV	BED	64	-3.1	0.0
Serum folate levels	HTML, TSV	Image, TSV	BED	52	-4.7	-0.5
Serum galactose-deficient IgA1 levels	HTML, TSV	Image, TSV	BED	10	-2.6	0.0
Serum lycopene concentrations	HTML, TSV	Image, TSV	BED	12	-2.9	0.0
Serum metabolite concentrations in chronic kidney disease	HTML, TSV	Image, TSV	BED	73	-3.5	-0.2
Serum metabolite levels	HTML, TSV	Image, TSV	BED	395	-3.3	0.0
Serum metabolite ratios in chronic kidney disease	HTML, TSV	Image, TSV	BED	23	-4.0	0.0
Serum parathyroid hormone levels	HTML, TSV,	Image, TSV	BED	9	-8.2	-4.1
Serum prostate-specific antigen levels	HTML, TSV	Image, TSV	BED	8	-4.1	0.0
Serum protein levels (sST2)	HTML, TSV	Image, TSV	BED	7	-2.1	0.0
Serum selenium levels	HTML, TSV	Image, TSV	BED	7	-4.0	0.0
Serum sulfate level	HTML, TSV	Image, TSV	BED	65	-4.9	-1.0
Serum tamsulosin hydrochloride concentration	HTML, TSV	Image, TSV	BED	28	-1.5	0.0
Serum thyroid-stimulating hormone levels	HTML, TSV	Image, TSV	BED	151	-5.7	-1.5
Serum total cholesterol levels	HTML, TSV	Image, TSV	BED	20	-2.4	0.0
Serum total protein level	HTML, TSV	Image, TSV	BED	132	-5.2	-1.3
Serum urate levels in chronic kidney disease	HTML, TSV	Image, TSV	BED	4	-2.0	0.0
Serum urea levels	HTML, TSV	Image, TSV	BED	20	-6.2	-2.0
Serum uric acid levels	HTML, TSV,	Image, TSV	BED	329	-6.6	-2.6
Serum uric acid levels in response to allopurinol in gout	HTML, TSV	Image, TSV	BED	50	-2.5	0.0
Serum VEGFR2 concentration	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Serum vitamin D-binding protein levels	HTML, TSV	Image, TSV	BED	10	-3.0	0.0
Severe aortic features in Marfan syndrome	HTML, TSV	Image, TSV	BED	19	-5.5	-1.6
Severe depressive disorders in coronary artery disease	HTML, TSV	Image, TSV	BED	5	-1.7	0.0
Severe diabetic retinopathy in type 2 diabetes	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Severe gingival inflammation	HTML, TSV	Image, TSV	BED	14	-2.0	0.0
Severe influenza A (H1N1) infection	HTML, TSV	Image, TSV	BED	171	-5.0	-0.9
Severe malaria	HTML, TSV	Image, TSV	BED	45	-3.1	0.0
Severe malaria (adjusted for sickle cell variant rs334)	HTML, TSV	Image, TSV	BED	43	-2.0	0.0
Severe progression in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	3	-3.7	0.0
Severe skin toxicity response to cetuximab in colorectal cancer	HTML, TSV	Image, TSV	BED	50	-4.2	-0.1
Severity of facial solar lentigines	HTML, TSV	Image, TSV	BED	14	-3.4	0.0
Severity of nausea and vomiting of pregnancy	HTML, TSV,	Image, TSV	BED	36	-16.3	-12.1
Sex hormone-binding globulin levels	HTML, TSV,	Image, TSV	BED	1936	-16.4	-12.2
Sex hormone levels	HTML, TSV	Image, TSV	BED	28	-2.7	0.0
Sexual dimorphism in anthropometric traits	HTML, TSV	Image, TSV	BED	89	-2.9	0.0
Sexual dysfunction (female)	HTML, TSV	Image, TSV	BED	32	-5.3	-1.4
Sexual dysfunction (SSRI/SNRI-related)	HTML, TSV	Image, TSV	BED	66	-5.5	-1.3
Shingles	HTML, TSV	Image, TSV	BED	155	-4.1	-0.1
Short-term memory (digit-span task)	HTML, TSV	Image, TSV	BED	26	-3.3	0.0
Short-term memory (visuospatial task)	HTML, TSV	Image, TSV	BED	17	-1.8	0.0
Sickle cell anemia (haemolysis)	HTML, TSV	Image, TSV	BED	13	-2.8	0.0
Sight-threatening diabetic retinopathy in type 2 diabetes	HTML, TSV	Image, TSV	BED	6	-4.1	-0.2
Sitting height ratio	HTML, TSV	Image, TSV	BED	169	-4.6	-0.7
Sjogren's syndrome	HTML, TSV	Image, TSV	BED	71	-3.7	0.0
Skin aging (microtopography measurement)	HTML, TSV	Image, TSV	BED	23	-4.4	-0.2
Skin and soft tissue Staphylococcus aureus infection	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Skin colour saturation	HTML, TSV	Image, TSV	BED	3	-4.1	-0.1
Skin fluorescence in type 1 diabetes	HTML, TSV	Image, TSV	BED	3	-2.2	0.0
Skin, hair and eye pigmentation (multivariate analysis)	HTML, TSV	Image, TSV	BED	38	-4.0	-0.1
Skin pigmentation	HTML, TSV	Image, TSV	BED	66	-4.3	-0.1
Skin pigmentation traits	HTML, TSV	Image, TSV	BED	3	-4.1	-0.1
Sleep depth	HTML, TSV	Image, TSV	BED	16	-3.9	0.0
Sleep duration	HTML, TSV	Image, TSV	BED	894	-4.4	-0.2
Sleep duration (long sleep)	HTML, TSV,	Image, TSV	BED	39	-6.3	-2.1
Sleep duration (oversleepers vs undersleepers)	HTML, TSV	Image, TSV	BED	27	-5.7	-1.5
Sleep duration (short sleep)	HTML, TSV	Image, TSV	BED	119	-3.5	0.0
Sleep latency	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Sleep quality	HTML, TSV	Image, TSV	BED	7	-2.7	0.0
Sleep-related phenotypes	HTML, TSV	Image, TSV	BED	29	-2.8	0.0
Sleep time	HTML, TSV	Image, TSV	BED	10	-4.3	-0.1
Sleep traits (multi-trait analysis)	HTML, TSV	Image, TSV	BED	37	-5.0	-0.8
Small-cell lung cancer (survival)	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Small cell lung carcinoma	HTML, TSV	Image, TSV	BED	127	-2.4	0.0
Small intestine neuroendocrine tumor	HTML, TSV	Image, TSV	BED	30	-6.2	-2.0
Small LDL particle concentration	HTML, TSV	Image, TSV	BED	8	-3.1	0.0
Small vessel stroke	HTML, TSV	Image, TSV	BED	18	-3.0	0.0
Smoking behavior	HTML, TSV	Image, TSV	BED	255	-3.3	0.0
Smoking behaviour (cigarettes smoked per day)	HTML, TSV,	Image, TSV	BED	272	-7.5	-3.4
Smoking behaviour (maximum cigarettes in a 24 hour period)	HTML, TSV	Image, TSV	BED	93	-3.6	0.0
Smoking cessation	HTML, TSV	Image, TSV	BED	132	-4.4	-0.2
Smoking cessation in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	22	-3.5	0.0
Smoking cessation (MTAG)	HTML, TSV,	Image, TSV	BED	489	-12.0	-7.9
Smoking initiation	HTML, TSV	Image, TSV	BED	356	-3.9	0.0
Smoking initiation (ever regular vs never regular) (MTAG)	HTML, TSV,	Image, TSV	BED	4007	-10.8	-6.7
Smoking initiation (ever regular vs never regular)	HTML, TSV,	Image, TSV	BED	2851	-9.8	-5.6
Smoking quantity	HTML, TSV	Image, TSV	BED	28	-4.8	-0.6
Smoking status	HTML, TSV	Image, TSV	BED	1140	-4.7	-0.7
Smoking status (current vs former)	HTML, TSV	Image, TSV	BED	1	-2.8	0.0
Smoking status (ever vs never smokers)	HTML, TSV,	Image, TSV	BED	1852	-6.5	-2.6
Smoking status (heavy vs light)	HTML, TSV	Image, TSV	BED	31	-2.3	0.0
Smooth-surface caries	HTML, TSV	Image, TSV	BED	183	-4.3	-0.1
Snoring	HTML, TSV	Image, TSV	BED	410	-5.4	-1.4
Social autistic-like traits	HTML, TSV	Image, TSV	BED	22	-5.5	-1.3
Social communication problems	HTML, TSV	Image, TSV	BED	73	-4.4	-0.3
Social science traits (pleiotropy) (HIPO component 1)	HTML, TSV	Image, TSV	BED	50	-2.9	0.0
Sodium levels	HTML, TSV	Image, TSV	BED	39	-3.7	0.0
Soluble E-selectin levels	HTML, TSV	Image, TSV	BED	7	0.0	0.0
Soluble ICAM-1	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Soluble interleukin-2 receptor subunit alpha	HTML, TSV,	Image, TSV	BED	46	-10.0	-5.8
Soluble levels of adhesion molecules	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Speech perception in dyslexia	HTML, TSV	Image, TSV	BED	5	-4.9	-0.7
Sperm motility	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
S-phenylmercapturic acid levels in smokers	HTML, TSV	Image, TSV	BED	8	-4.8	-0.6
Spherical equivalent	HTML, TSV	Image, TSV	BED	1024	-3.6	0.0
Spherical equivalent (joint analysis main effects and education interaction)	HTML, TSV	Image, TSV	BED	73	-4.6	-0.4
Spherical equivalent or myopia (age of diagnosis)	HTML, TSV	Image, TSV	BED	706	-3.2	0.0
Sphingolipid levels	HTML, TSV	Image, TSV	BED	25	-3.7	0.0
Spine bone size	HTML, TSV	Image, TSV	BED	9	-3.8	0.0
Spontaneous dizygotic twinning	HTML, TSV	Image, TSV	BED	20	-6.1	-2.0
Spontaneous preterm birth (maternal effect)	HTML, TSV	Image, TSV	BED	13	-3.2	0.0
Spontaneous preterm birth (preterm birth)	HTML, TSV	Image, TSV	BED	53	-4.1	0.0
Spontaneous preterm birth (preterm delivery)	HTML, TSV	Image, TSV	BED	3	-1.6	0.0
Sporadic neuroblastoma	HTML, TSV	Image, TSV	BED	22	-4.0	-0.3
Sporadic pituitary adenoma	HTML, TSV	Image, TSV	BED	11	-5.4	-1.2
Squamous cell carcinoma	HTML, TSV	Image, TSV	BED	59	-2.4	0.0
Squamous cell lung carcinoma	HTML, TSV	Image, TSV	BED	150	-5.7	-1.7
Staphylococcus aureus infection	HTML, TSV,	Image, TSV	BED	21	-9.3	-5.5
Staphylococcus aureus nasal carriage (intermittent)	HTML, TSV	Image, TSV	BED	65	-4.3	-0.2
Staphylococcus aureus nasal carriage (persistent)	HTML, TSV	Image, TSV	BED	34	-4.5	-0.8
Stearic acid (18:0) levels	HTML, TSV	Image, TSV	BED	27	0.0	0.0
Stem cell factor levels	HTML, TSV	Image, TSV	BED	116	-6.1	-2.0
Stem cell growth factor beta levels	HTML, TSV	Image, TSV	BED	110	-3.2	0.0
Stimulated C-peptide levels in type I diabetes	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
Strenuous sports or other exercises	HTML, TSV,	Image, TSV	BED	29	-6.4	-2.5
Strep throat	HTML, TSV,	Image, TSV	BED	98	-15.0	-11.2
Stroke	HTML, TSV	Image, TSV	BED	285	-4.7	-0.8
Stroke (ischemic)	HTML, TSV	Image, TSV	BED	70	-5.5	-1.3
Stroke (pediatric)	HTML, TSV	Image, TSV	BED	22	-4.4	-0.7
Stromal-cell-derived factor 1 alpha levels	HTML, TSV	Image, TSV	BED	75	-4.3	-0.4
Subclinical atherosclerosis traits (other)	HTML, TSV,	Image, TSV	BED	22	-7.0	-2.9
Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan)	HTML, TSV	Image, TSV	BED	6	-2.9	0.0
Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan)	HTML, TSV	Image, TSV	BED	4	-3.6	0.0
Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan)	HTML, TSV	Image, TSV	BED	1	-3.5	-0.2
Subcortical brain region volumes	HTML, TSV	Image, TSV	BED	125	-3.8	0.0
Subcutaneous adipose tissue	HTML, TSV	Image, TSV	BED	246	-5.2	-1.0
Subcutaneous adipose tissue attenuation (Hounsfield unit scale)	HTML, TSV	Image, TSV	BED	7	-3.6	0.0
Subcutaneous adipose tissue (sex interaction)	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Subiculum volume	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Subiculum volume (corrected for total hippocampal volume)	HTML, TSV	Image, TSV	BED	15	-2.3	0.0
Subjective response to lithium treatment	HTML, TSV	Image, TSV	BED	8	-3.6	0.0
Subjective response to lithium treatment in bipolar disorder	HTML, TSV,	Image, TSV	BED	17	-5.9	-2.0
Subjective well-being	HTML, TSV	Image, TSV	BED	411	-4.6	-0.5
Subjective well-being (MTAG)	HTML, TSV	Image, TSV	BED	242	-5.0	-1.0
Substance dependence	HTML, TSV	Image, TSV	BED	7	-3.2	0.0
Substance use disorder	HTML, TSV	Image, TSV	BED	16	-2.8	0.0
Sudden cardiac arrest	HTML, TSV	Image, TSV	BED	174	-4.5	-0.3
Suffering from nerves	HTML, TSV	Image, TSV	BED	29	-5.1	-1.0
Suicidal ideation	HTML, TSV	Image, TSV	BED	135	-5.2	-1.2
Suicidality	HTML, TSV	Image, TSV	BED	23	-2.3	0.0
Suicidality (suicidal ideation/attempts)	HTML, TSV	Image, TSV	BED	2	-2.4	0.0
Suicide	HTML, TSV	Image, TSV	BED	22	-3.2	0.0
Suicide attempts	HTML, TSV	Image, TSV	BED	191	-3.0	0.0
Suicide attempt severity	HTML, TSV	Image, TSV	BED	5	-1.6	0.0
Suicide attempts in bipolar disorder	HTML, TSV	Image, TSV	BED	49	-3.3	0.0
Suicide attempts in depression or bipolar disorder	HTML, TSV	Image, TSV	BED	3	-4.1	0.0
Suicide attempts in major depressive disorder	HTML, TSV	Image, TSV	BED	17	-3.8	-0.2
Suicide ideation score in major depressive disorder	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Suicide in bipolar disorder	HTML, TSV	Image, TSV	BED	48	-2.4	0.0
Suicide risk	HTML, TSV	Image, TSV	BED	9	-3.9	-0.3
Sulfasalazine-induced agranulocytosis	HTML, TSV	Image, TSV	BED	65	-5.2	-1.0
Sum basophil neutrophil counts	HTML, TSV,	Image, TSV	BED	383	-12.2	-8.0
Sum eosinophil basophil counts	HTML, TSV,	Image, TSV	BED	623	-12.9	-8.7
Sum neutrophil eosinophil counts	HTML, TSV,	Image, TSV	BED	390	-11.9	-7.8
Sunburns	HTML, TSV	Image, TSV	BED	307	-4.6	-0.4
Superior crus of antihelix expression	HTML, TSV	Image, TSV	BED	16	-4.2	-0.4
Superior frontal gyrus grey matter volume	HTML, TSV	Image, TSV	BED	76	-3.1	0.0
Supraventricular ectopy	HTML, TSV	Image, TSV	BED	29	-2.4	0.0
Surgical necrotising enterocolitis in extremely premature birth	HTML, TSV	Image, TSV	BED	69	-2.5	0.0
Survival in breast cancer (estrogen-receptor positive)	HTML, TSV	Image, TSV	BED	26	0.0	0.0
Survival in colon cancer	HTML, TSV	Image, TSV	BED	33	-5.5	-1.4
Survival in colorectal cancer (non-distant metastatic)	HTML, TSV	Image, TSV	BED	6	-4.1	-0.1
Survival in colorectal cancer	HTML, TSV	Image, TSV	BED	7	-2.5	0.0
Survival in endocrine treated breast cancer (estrogen-receptor positive)	HTML, TSV	Image, TSV	BED	10	-2.3	0.0
Survival in head and neck cancer	HTML, TSV	Image, TSV	BED	19	-2.2	0.0
Survival in microsatellite instability low/stable colorectal cancer	HTML, TSV	Image, TSV	BED	113	-5.3	-1.1
Survival in pancreatic cancer	HTML, TSV	Image, TSV	BED	100	-2.2	0.0
Survival in rectal cancer	HTML, TSV	Image, TSV	BED	131	-4.9	-0.7
Survival in sporadic amyotrophic lateral sclerosis	HTML, TSV	Image, TSV	BED	40	-4.9	-1.0
Susceptibility to persistent hepatitis B virus infection	HTML, TSV	Image, TSV	BED	10	-3.1	0.0
Symmetrical dimethylarginine levels	HTML, TSV	Image, TSV	BED	94	-2.8	0.0
Systemic juvenile idiopathic arthritis	HTML, TSV	Image, TSV	BED	137	-4.4	-0.2
Systemic lupus erythematosus	HTML, TSV,	Image, TSV	BED	1740	-33.3	-29.1
Systemic lupus erythematosus and Systemic sclerosis	HTML, TSV,	Image, TSV	BED	99	-6.2	-2.1
Systemic lupus erythematosus or rheumatoid arthritis	HTML, TSV,	Image, TSV	BED	27	-6.6	-2.4
Systemic sclerosis	HTML, TSV	Image, TSV	BED	158	-5.1	-1.3
Systemic sclerosis (anti-centromere-positive)	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Systemic sclerosis (anti-topoisomerase-positive)	HTML, TSV	Image, TSV	BED	3	-3.1	0.0
Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies)	HTML, TSV	Image, TSV	BED	51	-4.3	-0.3
Systolic blood pressure	HTML, TSV,	Image, TSV	BED	5752	-12.0	-7.9
Systolic blood pressure (alcohol consumption interaction)	HTML, TSV	Image, TSV	BED	9	-2.8	0.0
Systolic blood pressure change trajectories	HTML, TSV	Image, TSV	BED	2	-5.5	-1.3
Systolic blood pressure (cigarette smoking interaction)	HTML, TSV	Image, TSV	BED	208	-2.8	0.0
Systolic blood pressure (dietary potassium intake interaction)	HTML, TSV	Image, TSV	BED	13	-4.2	-0.1
Systolic blood pressure in sickle cell anemia	HTML, TSV	Image, TSV	BED	13	-3.2	0.0
Systolic blood pressure night-to-day ratio in hypertension	HTML, TSV	Image, TSV	BED	3	-1.5	0.0
Systolic blood pressure response to hydrochlorothiazide in hypertension	HTML, TSV	Image, TSV	BED	120	-6.2	-2.0
Systolic blood pressure x alcohol consumption interaction (2df test)	HTML, TSV,	Image, TSV	BED	317	-6.8	-2.6
Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test)	HTML, TSV,	Image, TSV	BED	123	-8.4	-4.2
Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)	HTML, TSV	Image, TSV	BED	10	-3.8	0.0
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	HTML, TSV	Image, TSV	BED	194	-3.8	-0.2
Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	HTML, TSV	Image, TSV	BED	173	-4.2	-0.4
Systolic blood pressure x sodium interaction (1df test)	HTML, TSV	Image, TSV	BED	8	-4.2	-0.2
Takayasu arteritis	HTML, TSV,	Image, TSV	BED	125	-7.2	-3.0
Takotsubo syndrome	HTML, TSV	Image, TSV	BED	37	-5.5	-1.3
Tandem gait	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Tanning	HTML, TSV	Image, TSV	BED	43	-2.8	0.0
Tardive dyskinesia	HTML, TSV	Image, TSV	BED	3	-1.7	0.0
Taxane-induced peripheral neuropathy in breast cancer	HTML, TSV	Image, TSV	BED	19	-2.7	0.0
TB-LM or TBLH-BMD (pleiotropy)	HTML, TSV	Image, TSV	BED	55	-4.2	-0.3
Telomere length	HTML, TSV,	Image, TSV	BED	269	-6.2	-2.1
Temperament (bipolar disorder)	HTML, TSV,	Image, TSV	BED	67	-8.1	-3.9
Temperament	HTML, TSV	Image, TSV	BED	114	-5.5	-1.3
Temporomandibular joint disorder	HTML, TSV	Image, TSV	BED	10	-2.7	0.0
Tenofovir clearance in HIV infection	HTML, TSV	Image, TSV	BED	146	-4.4	-0.2
Testicular cancer	HTML, TSV,	Image, TSV	BED	44	-7.7	-3.5
Testicular germ cell cancer	HTML, TSV	Image, TSV	BED	3	-5.0	-0.9
Testicular germ cell tumor	HTML, TSV,	Image, TSV	BED	115	-6.4	-2.2
Testosterone levels	HTML, TSV	Image, TSV	BED	37	-5.9	-1.7
Testosterone levels in polycystic ovary syndrome	HTML, TSV	Image, TSV	BED	50	-5.3	-1.4
Tetralogy of Fallot	HTML, TSV	Image, TSV	BED	15	-3.3	0.0
Theory of mind score in adolescence (Emotional Triangles Task)	HTML, TSV	Image, TSV	BED	1	-4.0	0.0
Thiazide-induced adverse metabolic effects in hypertensive patients	HTML, TSV	Image, TSV	BED	323	-3.1	0.0
Thionamide-induced agranulocytosis in Graves' disease	HTML, TSV	Image, TSV	BED	16	-6.1	-2.0
Thiopurine-induced alopecia in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Thiopurine-induced digestive symptoms in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	1	-2.0	0.0
Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232)	HTML, TSV	Image, TSV	BED	2	-3.4	0.0
Thiopurine-induced pancreatitis in inflammatory bowel disease	HTML, TSV	Image, TSV	BED	4	-2.2	0.0
Thiopurine S-methyltransferase activity	HTML, TSV	Image, TSV	BED	10	-4.3	-0.6
Thoracic-to-hip circumference ratio	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Thrombin-activatable fibrinolysis inhibitor activation peptide	HTML, TSV	Image, TSV	BED	10	-3.3	0.0
Thrombin-activatable fibrinolysis inhibitor levels	HTML, TSV	Image, TSV	BED	1	-2.8	0.0
Thrombin-antithrombin complex levels in ischemic stroke	HTML, TSV	Image, TSV	BED	43	-3.1	0.0
Thrombin generation potential phenotypes	HTML, TSV	Image, TSV	BED	5	-3.5	0.0
Thrombocytopenia in coronary artery bypass surgery	HTML, TSV	Image, TSV	BED	16	-2.5	0.0
Thrombomodulin levels in ischemic stroke	HTML, TSV	Image, TSV	BED	20	-4.5	-0.3
Thrombosis	HTML, TSV	Image, TSV	BED	15	-4.2	-0.1
Thyroid cancer	HTML, TSV	Image, TSV	BED	37	-5.1	-1.0
Thyroid cancer (Papillary, radiation-related)	HTML, TSV	Image, TSV	BED	17	-3.3	0.0
Thyroid function	HTML, TSV	Image, TSV	BED	41	-2.9	0.0
Thyroid hormone levels	HTML, TSV,	Image, TSV	BED	202	-6.5	-2.4
Thyroid nodules	HTML, TSV	Image, TSV	BED	5	-2.2	0.0
Thyroid peroxidase antibody levels	HTML, TSV	Image, TSV	BED	12	-5.4	-1.2
Thyroid peroxidase antibody positivity	HTML, TSV,	Image, TSV	BED	71	-14.0	-9.9
Thyroid stimulating hormone levels	HTML, TSV,	Image, TSV	BED	450	-8.4	-4.6
Thyroid volume	HTML, TSV	Image, TSV	BED	14	-2.9	0.0
Thyrotoxic hypokalemic periodic paralysis	HTML, TSV,	Image, TSV	BED	53	-6.9	-2.7
Thyroxine levels	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor	HTML, TSV	Image, TSV	BED	2	-3.4	0.0
Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction)	HTML, TSV	Image, TSV	BED	240	-5.4	-1.2
Toenail selenium levels	HTML, TSV	Image, TSV	BED	91	-2.9	0.0
Tonometry	HTML, TSV	Image, TSV	BED	29	-4.5	-0.3
Tonsillectomy	HTML, TSV	Image, TSV	BED	419	-4.5	-0.6
Tooth agenesis	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Tooth agenesis (mandibular second premolars)	HTML, TSV	Image, TSV	BED	2	-2.9	0.0
Tooth agenesis (mandibular third molar)	HTML, TSV	Image, TSV	BED	23	-3.5	0.0
Tooth agenesis (maxillary lateral incisors)	HTML, TSV	Image, TSV	BED	27	-5.6	-1.4
Total bilirubin levels	HTML, TSV,	Image, TSV	BED	16	-9.4	-5.2
Total bilirubin levels in HIV-1 infection	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Total body bone mineral density	HTML, TSV	Image, TSV	BED	699	-5.0	-0.8
Total body bone mineral density (age 0-15)	HTML, TSV	Image, TSV	BED	30	-5.5	-1.3
Total body bone mineral density (age 30-45)	HTML, TSV	Image, TSV	BED	57	-5.6	-1.5
Total body bone mineral density (age 45-60)	HTML, TSV	Image, TSV	BED	73	-5.3	-1.1
Total body bone mineral density (age over 60)	HTML, TSV	Image, TSV	BED	120	-4.7	-0.5
Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	HTML, TSV	Image, TSV	BED	37	-2.3	0.0
Total cholesterol levels	HTML, TSV,	Image, TSV	BED	814	-10.4	-6.3
Total cholesterol levels in HDL	HTML, TSV	Image, TSV	BED	9	-5.1	-0.9
Total cholesterol levels in large HDL	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Total cholesterol levels in large LDL	HTML, TSV	Image, TSV	BED	4	-3.0	0.0
Total cholesterol levels in LDL	HTML, TSV	Image, TSV	BED	6	-3.5	0.0
Total cholesterol levels in medium LDL	HTML, TSV	Image, TSV	BED	5	-2.9	0.0
Total cholesterol levels in small LDL	HTML, TSV	Image, TSV	BED	8	-3.1	0.0
Total glycated albumin levels	HTML, TSV	Image, TSV	BED	24	-4.3	-0.3
Total hippocampal volume	HTML, TSV	Image, TSV	BED	12	-4.2	-0.0
Total mean fractional anisotropy measurement in first episode schizophrenia	HTML, TSV	Image, TSV	BED	7	-3.8	0.0
Total triglycerides levels	HTML, TSV	Image, TSV	BED	1	-3.2	0.0
Total ventricular volume	HTML, TSV	Image, TSV	BED	37	-4.1	-0.1
Total ventricular volume (Alzheimer's disease interaction)	HTML, TSV	Image, TSV	BED	32	-3.9	0.0
Tourette's syndrome or obsessive-compulsive disorder	HTML, TSV	Image, TSV	BED	14	-1.7	0.0
Tourette syndrome	HTML, TSV	Image, TSV	BED	84	-4.2	-0.2
Tragus size	HTML, TSV	Image, TSV	BED	5	-4.0	-0.0
TRAIL levels	HTML, TSV	Image, TSV	BED	124	-3.5	0.0
Trans-epidermal water loss	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Trans fatty acid levels	HTML, TSV	Image, TSV	BED	233	-4.3	-0.4
Treatment resistant depression	HTML, TSV	Image, TSV	BED	7	-3.0	0.0
Treatment response for severe sepsis	HTML, TSV	Image, TSV	BED	22	-4.3	-0.3
Trichloroethylene-induced hypersensitivity syndrome	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes	HTML, TSV	Image, TSV	BED	31	-3.3	0.0
Triglyceride levels	HTML, TSV,	Image, TSV	BED	1954	-23.9	-19.7
Triglyceride levels in small VLDL	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Triglycerides	HTML, TSV,	Image, TSV	BED	969	-8.1	-4.0
Triglycerides-Blood Pressure (TG-BP)	HTML, TSV	Image, TSV	BED	28	-5.5	-1.3
Triglycerides x physical activity interaction (2df test)	HTML, TSV	Image, TSV	BED	36	-4.0	-0.1
Triglyceride to HDL cholesterol ratio	HTML, TSV	Image, TSV	BED	3	-2.6	0.0
Triiodothyronine levels	HTML, TSV,	Image, TSV	BED	8	-6.5	-3.0
Triiodothyronine levels and thyroxine levels	HTML, TSV	Image, TSV	BED	15	0.0	0.0
Triiodothyronine/thyroxine ratio	HTML, TSV	Image, TSV	BED	5	-2.5	0.0
Triptolide cytotoxicity	HTML, TSV	Image, TSV	BED	68	-5.1	-1.2
Tuberculosis	HTML, TSV	Image, TSV	BED	288	-3.3	0.0
Tumor biomarkers	HTML, TSV	Image, TSV	BED	3	-4.2	-0.3
Tumor necrosis factor alpha levels	HTML, TSV	Image, TSV	BED	66	-4.8	-0.7
Tumor necrosis factor beta levels	HTML, TSV	Image, TSV	BED	16	-2.2	0.0
Tumor necrosis factor receptor II (red blood cell fatty acid level interaction)	HTML, TSV	Image, TSV	BED	2	-1.3	0.0
Two-hour glucose challenge	HTML, TSV,	Image, TSV	BED	37	-6.2	-2.0
Two-hour glucose in pregnancy (gestational week 30-32)	HTML, TSV	Image, TSV	BED	18	-4.9	-0.8
Type 1 diabetes	HTML, TSV,	Image, TSV	BED	389	-9.9	-5.8
Type 1 diabetes and autoimmune thyroid diseases	HTML, TSV	Image, TSV	BED	21	-4.7	-1.1
Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event)	HTML, TSV	Image, TSV	BED	6	-2.1	0.0
Type 1 diabetes in high risk HLA genotype individuals (time to event)	HTML, TSV	Image, TSV	BED	22	-2.8	0.0
Type 1 diabetes nephropathy	HTML, TSV	Image, TSV	BED	17	-4.9	-0.7
Type 2 diabetes	HTML, TSV	Image, TSV	BED	5195	-5.5	-1.3
Type 2 diabetes (adjusted for BMI)	HTML, TSV	Image, TSV	BED	72	-4.8	-0.9
Type 2 diabetes (age of onset)	HTML, TSV	Image, TSV	BED	77	-2.3	0.0
Type 2 diabetes (dietary heme iron intake interaction)	HTML, TSV	Image, TSV	BED	4	-2.3	0.0
Type 2 diabetes nephropathy	HTML, TSV,	Image, TSV	BED	32	-6.2	-2.3
Type 2 diabetes nephropathy including microalbuminuria	HTML, TSV,	Image, TSV	BED	41	-7.7	-3.7
Type 2 diabetes (young onset) and obesity	HTML, TSV	Image, TSV	BED	3	-5.4	-1.5
Ulcerative colitis	HTML, TSV,	Image, TSV	BED	829	-10.6	-6.4
Ulcerative colitis or Crohn's disease	HTML, TSV	Image, TSV	BED	19	-3.6	0.0
Ulna and radius bone mineral density	HTML, TSV	Image, TSV	BED	15	-5.5	-1.4
Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic)	HTML, TSV	Image, TSV	BED	1	-2.4	0.0
Underweight status	HTML, TSV	Image, TSV	BED	5	0.0	0.0
Upper eyelid morphology	HTML, TSV	Image, TSV	BED	52	-3.3	0.0
Upper eyelid sagging severity	HTML, TSV,	Image, TSV	BED	116	-7.2	-3.1
Urate levels	HTML, TSV,	Image, TSV	BED	1639	-9.3	-5.2
Urate levels (BMI interaction)	HTML, TSV,	Image, TSV	BED	225	-6.9	-2.7
Urate levels in lean individuals	HTML, TSV	Image, TSV	BED	48	-2.7	0.0
Urate levels in obese individuals	HTML, TSV	Image, TSV	BED	142	-4.9	-0.7
Urate levels in overweight individuals	HTML, TSV	Image, TSV	BED	133	-4.7	-0.7
Urea levels	HTML, TSV	Image, TSV	BED	45	-4.6	-0.8
Urgency urinary incontinence	HTML, TSV	Image, TSV	BED	7	-1.7	0.0
Uric acid levels	HTML, TSV	Image, TSV	BED	279	-3.0	0.0
Urinary 1,3-butadiene metabolite levels in smokers	HTML, TSV	Image, TSV	BED	2	-2.9	0.0
Urinary albumin excretion	HTML, TSV	Image, TSV	BED	137	0.0	0.0
Urinary albumin excretion (no hypertensive medication)	HTML, TSV	Image, TSV	BED	45	-3.8	0.0
Urinary albumin excretion rate in type 1 diabetes	HTML, TSV	Image, TSV	BED	6	-2.9	0.0
Urinary albumin-to-creatinine ratio	HTML, TSV	Image, TSV	BED	309	-5.0	-1.0
Urinary albumin-to-creatinine ratio in diabetes	HTML, TSV	Image, TSV	BED	58	-6.0	-1.8
Urinary albumin-to-creatinine ratio in non-diabetics	HTML, TSV	Image, TSV	BED	6	-2.9	0.0
Urinary bladder cancer	HTML, TSV	Image, TSV	BED	10	-3.5	0.0
Urinary electrolytes (magnesium/calcium ratio)	HTML, TSV	Image, TSV	BED	8	-2.9	0.0
Urinary magnesium-to-creatinine ratio	HTML, TSV	Image, TSV	BED	8	-4.0	0.0
Urinary metabolites	HTML, TSV	Image, TSV	BED	13	-4.1	-0.2
Urinary metabolites (H-NMR features)	HTML, TSV	Image, TSV	BED	9	-3.1	0.0
Urinary tract infection frequency	HTML, TSV,	Image, TSV	BED	107	-6.2	-2.3
Urinary uric acid to urinary creatinine ratio	HTML, TSV	Image, TSV	BED	29	-3.7	0.0
Urinary uromodulin levels	HTML, TSV	Image, TSV	BED	6	-1.8	0.0
Uterine fibroid number (single vs multiple)	HTML, TSV	Image, TSV	BED	43	-3.6	0.0
Uterine fibroids	HTML, TSV	Image, TSV	BED	363	-5.1	-1.3
Uterine fibroid size (maximum dimension)	HTML, TSV	Image, TSV	BED	2	-1.5	0.0
Uterine fibroid size (maximum volume)	HTML, TSV	Image, TSV	BED	11	-3.2	0.0
Uveal melanoma	HTML, TSV	Image, TSV	BED	43	-5.8	-1.7
Vaccenic acid (18:1n-7) levels	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Vaccine-related adverse events	HTML, TSV	Image, TSV	BED	2	-2.0	0.0
Vaginal discharge (itching)	HTML, TSV	Image, TSV	BED	7	-2.6	0.0
Vaginal discharge (metrorrhagia)	HTML, TSV	Image, TSV	BED	2	-2.7	0.0
Vaginal discharge (smell)	HTML, TSV	Image, TSV	BED	49	-5.8	-1.6
Varicose veins	HTML, TSV	Image, TSV	BED	104	-5.6	-1.6
Vascular brain injury	HTML, TSV	Image, TSV	BED	19	-3.1	0.0
Vascular endothelial growth factor levels	HTML, TSV	Image, TSV	BED	111	-4.0	0.0
Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase	HTML, TSV	Image, TSV	BED	1	-2.5	0.0
Vaspin levels	HTML, TSV	Image, TSV	BED	5	-2.9	0.0
Vein graft stenosis in coronary artery bypass grafting	HTML, TSV	Image, TSV	BED	20	-4.3	-0.5
Velopharyngeal dysfunction	HTML, TSV	Image, TSV	BED	315	-5.7	-1.5
Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks)	HTML, TSV	Image, TSV	BED	20	-5.4	-1.3
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks)	HTML, TSV	Image, TSV	BED	8	-3.7	0.0
Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks)	HTML, TSV	Image, TSV	BED	5	-2.3	0.0
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks)	HTML, TSV	Image, TSV	BED	1	-2.1	0.0
Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks)	HTML, TSV	Image, TSV	BED	39	-4.0	0.0
Venous thromboembolism	HTML, TSV	Image, TSV	BED	311	-3.4	0.0
Venous thromboembolism adjusted for sickle cell variant rs77121243-T	HTML, TSV	Image, TSV	BED	256	-2.9	0.0
Ventricular ectopy	HTML, TSV	Image, TSV	BED	4	-2.4	0.0
Ventricular ectopy or supraventricular ectopy (pleiotropy)	HTML, TSV	Image, TSV	BED	16	-2.7	0.0
Verbal declarative memory	HTML, TSV	Image, TSV	BED	143	-6.0	-1.8
Verbal intelligence quotient (cesarean section interaction)	HTML, TSV,	Image, TSV	BED	15	-7.5	-3.3
Verbal memory	HTML, TSV	Image, TSV	BED	5	-1.6	0.0
Verbal memory performance (delayed recall level)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Verbal memory performance (immediate recall change)	HTML, TSV	Image, TSV	BED	19	-4.1	0.0
Verbal memory performance (immediate recall level)	HTML, TSV	Image, TSV	BED	73	-5.8	-1.9
Verbal memory performance (residualized delayed recall change)	HTML, TSV	Image, TSV	BED	13	-3.0	0.0
Verbal memory performance (residualized delayed recall level)	HTML, TSV	Image, TSV	BED	12	-4.7	-0.6
Verbal-numerical reasoning	HTML, TSV	Image, TSV	BED	36	-2.4	0.0
Vertical cup-disc ratio	HTML, TSV	Image, TSV	BED	306	-5.3	-1.4
Very long-chain saturated fatty acid levels (fatty acid 20:0)	HTML, TSV	Image, TSV	BED	53	-3.3	0.0
Very long-chain saturated fatty acid levels (fatty acid 22:0)	HTML, TSV	Image, TSV	BED	59	-3.0	0.0
Very long-chain saturated fatty acid levels (fatty acid 24:0)	HTML, TSV	Image, TSV	BED	13	-4.4	-0.3
Very low density lipoprotein cholesterol levels	HTML, TSV	Image, TSV	BED	2	-2.6	0.0
Vestibular neuritis	HTML, TSV	Image, TSV	BED	3	-0.9	0.0
Vigorous physical activity	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	HTML, TSV	Image, TSV	BED	21	-2.2	0.0
Viral capsid antigen IgG seropositivity	HTML, TSV	Image, TSV	BED	7	-2.2	0.0
Virologic severity in Herpes simplex virus type 2 infection	HTML, TSV	Image, TSV	BED	22	-3.3	0.0
Visceral adipose tissue	HTML, TSV	Image, TSV	BED	32	-3.5	0.0
Visceral adipose tissue adjusted for BMI	HTML, TSV	Image, TSV	BED	204	-5.3	-1.1
Visceral adipose tissue attenuation (Hounslow unit scale)	HTML, TSV	Image, TSV	BED	7	-3.6	0.0
Visceral adipose tissue/subcutaneous adipose tissue ratio	HTML, TSV	Image, TSV	BED	155	-3.6	0.0
Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI	HTML, TSV	Image, TSV	BED	14	-5.1	-0.9
visceral adipose tissue/total adipose tissue ratio	HTML, TSV	Image, TSV	BED	16	-2.5	0.0
Visceral fat	HTML, TSV	Image, TSV	BED	295	-3.2	0.0
Visual memory	HTML, TSV	Image, TSV	BED	3	-4.2	-0.2
Vitamin B12 levels	HTML, TSV	Image, TSV	BED	64	-3.5	0.0
Vitamin B levels in ischemic stroke	HTML, TSV	Image, TSV	BED	11	-3.2	0.0
Vitamin D levels	HTML, TSV	Image, TSV	BED	93	-5.1	-1.2
Vitamin D levels (dietary vitamin D intake interaction)	HTML, TSV	Image, TSV	BED	2	-6.0	-2.0
Vitamin E levels	HTML, TSV,	Image, TSV	BED	15	-9.6	-5.4
Vitiligo	HTML, TSV	Image, TSV	BED	86	-5.3	-1.4
Vitiligo (early onset)	HTML, TSV,	Image, TSV	BED	4	-7.6	-3.4
Vitiligo (late onset)	HTML, TSV	Image, TSV	BED	3	-5.0	-1.1
Vogt-Koyanagi-Harada syndrome	HTML, TSV	Image, TSV	BED	41	-4.9	-0.7
Volumetric brain MRI	HTML, TSV	Image, TSV	BED	52	-3.8	0.0
Voxel-wise structural brain imaging measurements	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
vWF and FVIII levels	HTML, TSV	Image, TSV	BED	68	-4.5	-0.6
vWF levels	HTML, TSV	Image, TSV	BED	39	-5.4	-1.5
vWF levels in ischaemic stroke and hyperhomocysteinaemia	HTML, TSV	Image, TSV	BED	3	-3.2	0.0
Waist circumference	HTML, TSV	Image, TSV	BED	868	-4.3	-0.1
Waist circumference adjusted for BMI (adjusted for smoking behaviour)	HTML, TSV,	Image, TSV	BED	419	-6.3	-2.1
Waist circumference adjusted for BMI in active individuals	HTML, TSV,	Image, TSV	BED	415	-6.1	-2.0
Waist circumference adjusted for BMI in inactive individuals	HTML, TSV	Image, TSV	BED	68	-5.4	-1.2
Waist circumference adjusted for BMI in non-smokers	HTML, TSV,	Image, TSV	BED	325	-6.3	-2.1
Waist circumference adjusted for BMI in smokers	HTML, TSV	Image, TSV	BED	12	-4.0	-0.0
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	HTML, TSV	Image, TSV	BED	444	-5.9	-1.9
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction)	HTML, TSV,	Image, TSV	BED	418	-6.3	-2.1
Waist circumference adjusted for BMI (smoking interaction)	HTML, TSV	Image, TSV	BED	3	-2.7	0.0
Waist circumference adjusted for body mass index	HTML, TSV,	Image, TSV	BED	4615	-9.0	-4.9
Waist circumference and related phenotypes	HTML, TSV	Image, TSV	BED	33	-5.0	-0.8
Waist-hip ratio	HTML, TSV,	Image, TSV	BED	4030	-9.4	-5.2
Waist-to-hip circumference ratio (alcohol intake interaction)	HTML, TSV	Image, TSV	BED	31	-5.9	-1.7
Waist-to-hip circumference ratio (dietary energy interaction)	HTML, TSV	Image, TSV	BED	3	-2.2	0.0
Waist-to-hip circumference ratio (ever vs never smoking interaction)	HTML, TSV	Image, TSV	BED	39	-2.6	0.0
Waist-to-hip circumference ratio (recreational physical activity interaction)	HTML, TSV	Image, TSV	BED	17	-4.4	-0.2
Waist-to-hip circumference ratio (smoking years interaction)	HTML, TSV	Image, TSV	BED	27	-2.4	0.0
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour)	HTML, TSV,	Image, TSV	BED	404	-8.1	-3.9
Waist-to-hip ratio adjusted for BMI (age <50)	HTML, TSV	Image, TSV	BED	104	-5.6	-1.5
Waist-to-hip ratio adjusted for BMI (age >50)	HTML, TSV,	Image, TSV	BED	128	-6.7	-2.5
Waist-to-hip ratio adjusted for BMI in active individuals	HTML, TSV,	Image, TSV	BED	328	-6.8	-2.9
Waist-to-hip ratio adjusted for BMI in inactive individuals	HTML, TSV	Image, TSV	BED	83	-5.7	-1.8
Waist-to-hip ratio adjusted for BMI in non-smokers	HTML, TSV,	Image, TSV	BED	168	-7.9	-3.8
Waist-to-hip ratio adjusted for BMI in smokers	HTML, TSV	Image, TSV	BED	21	-4.2	-0.0
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	HTML, TSV,	Image, TSV	BED	371	-6.4	-2.5
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction)	HTML, TSV,	Image, TSV	BED	165	-8.0	-3.8
Waist-to-hip ratio adjusted for BMI	HTML, TSV,	Image, TSV	BED	4650	-19.2	-15.0
Waist-to-hip ratio adjusted for BMI x sex interaction	HTML, TSV	Image, TSV	BED	177	-4.4	-0.4
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	HTML, TSV,	Image, TSV	BED	448	-7.7	-3.5
Waist-to-hip ratio adjusted for body mass index	HTML, TSV,	Image, TSV	BED	568	-6.8	-2.6
Waldenstrom macroglobulinemia / lymphoplasmacytic lymphoma	HTML, TSV	Image, TSV	BED	3	-1.3	0.0
Warfarin maintenance dose	HTML, TSV	Image, TSV	BED	62	-3.4	0.0
Wegener's granulomatosis	HTML, TSV	Image, TSV	BED	38	-4.6	-0.4
Weight	HTML, TSV	Image, TSV	BED	588	-4.9	-1.0
Weight loss (gastric bypass surgery)	HTML, TSV	Image, TSV	BED	15	-1.9	0.0
Well-being spectrum (multivariate analysis)	HTML, TSV,	Image, TSV	BED	1422	-6.1	-2.0
Western dietary pattern	HTML, TSV	Image, TSV	BED	54	-3.0	0.0
White blood cell count	HTML, TSV,	Image, TSV	BED	4512	-38.7	-34.6
White blood cell count (basophil)	HTML, TSV,	Image, TSV	BED	181	-17.4	-13.2
White blood cell count (eosinophil)	HTML, TSV	Image, TSV	BED	17	-3.7	0.0
White blood cell count (lymphocyte)	HTML, TSV	Image, TSV	BED	1	-2.5	0.0
White blood cell count (monocyte)	HTML, TSV,	Image, TSV	BED	7	-6.4	-2.3
White blood cell count (neutrophil)	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
White blood cell types	HTML, TSV	Image, TSV	BED	40	0.0	0.0
White matter growth	HTML, TSV	Image, TSV	BED	14	-2.9	0.0
White matter hyperintensities in ischemic stroke	HTML, TSV	Image, TSV	BED	8	-2.0	0.0
White matter hyperintensity burden	HTML, TSV	Image, TSV	BED	106	-3.0	0.0
White matter hyperintensity volume	HTML, TSV	Image, TSV	BED	32	-3.9	0.0
White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy	HTML, TSV	Image, TSV	BED	19	-3.6	0.0
White matter integrity	HTML, TSV	Image, TSV	BED	77	-4.1	-0.2
White matter integrity (bipolar disorder risk interaction)	HTML, TSV	Image, TSV	BED	22	-2.5	0.0
White matter integrity (fractional anisotropy)	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
White matter integrity (mean diffusivity)	HTML, TSV	Image, TSV	BED	6	-4.0	-0.3
White matter lesion progression	HTML, TSV	Image, TSV	BED	11	-2.3	0.0
White matter lesion progression (adjusted for white matter lesion burden at baseline)	HTML, TSV	Image, TSV	BED	26	-4.3	-0.1
White matter microstructure (global fractional anisotropy)	HTML, TSV	Image, TSV	BED	66	-4.1	0.0
White matter microstructure in first episode schizophrenia (left posterior cingulate cortex)	HTML, TSV	Image, TSV	BED	3	-5.2	-1.0
White matter microstructure in first episode schizophrenia (right anterior cingulate cortex)	HTML, TSV	Image, TSV	BED	3	-4.5	-0.5
White wine liking	HTML, TSV,	Image, TSV	BED	3	-6.2	-2.1
Whole-brain volume	HTML, TSV,	Image, TSV	BED	28	-6.4	-2.2
Whole-brain volume (Alzheimer's disease interaction)	HTML, TSV	Image, TSV	BED	22	-4.5	-0.3
Wilms tumor	HTML, TSV,	Image, TSV	BED	27	-8.7	-4.5
Word reading	HTML, TSV	Image, TSV	BED	103	-2.6	0.0
Word spelling	HTML, TSV,	Image, TSV	BED	93	-7.7	-3.5
Working memory	HTML, TSV,	Image, TSV	BED	71	-6.0	-2.1
World class endurance athleticism	HTML, TSV	Image, TSV	BED	35	-4.6	-0.5
Worry	HTML, TSV	Image, TSV	BED	657	-4.2	-0.4
Worry too long after an embarrassing experience	HTML, TSV	Image, TSV	BED	41	-2.3	0.0
Worry/vulnerability (special factor of neuroticism)	HTML, TSV	Image, TSV	BED	46	-3.9	0.0
Yang-deficiency constitution	HTML, TSV	Image, TSV	BED	8	-3.7	0.0
Yeast infection	HTML, TSV	Image, TSV	BED	106	-3.9	0.0
Yu-Zhi constitution type in type 2 diabetes	HTML, TSV	Image, TSV	BED	42	-4.4	-0.5
Albuminuria	HTML, TSV	Image, TSV	BED	14	-5.3	-1.1
Alzheimer's disease or fasting glucose levels (pleiotropy)	HTML, TSV	Image, TSV	BED	41	-3.5	0.0
Alzheimer's disease or HDL levels (pleiotropy)	HTML, TSV,	Image, TSV	BED	31	-6.6	-2.4
Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis	HTML, TSV	Image, TSV	BED	39	-3.5	0.0
Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis	HTML, TSV	Image, TSV	BED	44	-2.6	0.0
Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis	HTML, TSV	Image, TSV	BED	17	-3.2	0.0
Anti-Toxoplasma gondii IgG seropositivity	HTML, TSV	Image, TSV	BED	15	-5.4	-1.2
Asthma (adult onset)	HTML, TSV,	Image, TSV	BED	331	-10.8	-6.7
Asthma onset (childhood vs adult)	HTML, TSV,	Image, TSV	BED	253	-10.5	-6.3
Carbamazepine-induced hyponatremia in epilepsy	HTML, TSV	Image, TSV	BED	25	-3.0	0.0
Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy	HTML, TSV	Image, TSV	BED	9	-1.8	0.0
Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy	HTML, TSV	Image, TSV	BED	16	-3.8	0.0
Colorectal cancer or advanced adenoma	HTML, TSV,	Image, TSV	BED	499	-6.3	-2.2
Emotional lability in attention deficit hyperactivity disorder	HTML, TSV	Image, TSV	BED	10	-2.2	0.0
Facial attractiveness (female raters)	HTML, TSV	Image, TSV	BED	15	-5.6	-1.4
Facial attractiveness (male raters)	HTML, TSV	Image, TSV	BED	15	0.0	0.0
Frontal fibrosing alopecia	HTML, TSV	Image, TSV	BED	114	-4.7	-0.6
Homeostasis model assessment of insulin resistance in less-fat diet	HTML, TSV	Image, TSV	BED	3	-2.5	0.0
Homeostasis model assessment of insulin resistance in more-fat diet	HTML, TSV	Image, TSV	BED	4	-3.4	0.0
Homeostasis model assessment of insulin resistance x saturated fatty acids interaction	HTML, TSV	Image, TSV	BED	3	-2.5	0.0
Hyperglycemia in higher physical activity	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Hyperinsulinemia in lower physical activity	HTML, TSV	Image, TSV	BED	6	-1.7	0.0
Hyperinsulinemia in obesity	HTML, TSV	Image, TSV	BED	28	-3.2	0.0
Hyperinsulinemia x BMI interaction	HTML, TSV	Image, TSV	BED	1	-1.3	0.0
Hyperinsulinemia x physical activity interaction	HTML, TSV	Image, TSV	BED	6	-1.7	0.0
Incident chronic kidney disease	HTML, TSV	Image, TSV	BED	12	-2.4	0.0
Latent naming speed	HTML, TSV	Image, TSV	BED	12	-4.3	-0.1
Low HDL-cholesterol levels	HTML, TSV	Image, TSV	BED	36	-3.9	0.0
Medication use (adrenergics, inhalants)	HTML, TSV,	Image, TSV	BED	254	-8.0	-3.8
Medication use (agents acting on the renin-angiotensin system)	HTML, TSV	Image, TSV	BED	1024	-5.2	-1.2
Medication use (anilides)	HTML, TSV	Image, TSV	BED	4	-2.2	0.0
Medication use (antidepressants)	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Medication use (antiglaucoma preparations and miotics)	HTML, TSV	Image, TSV	BED	35	-3.3	0.0
Medication use (antihistamines for systemic use)	HTML, TSV,	Image, TSV	BED	86	-7.3	-3.1
Medication use (antihypertensives)	HTML, TSV	Image, TSV	BED	5	-5.1	-0.9
Medication use (anti-inflammatory and antirheumatic products, non-steroids)	HTML, TSV	Image, TSV	BED	29	-4.6	-0.4
Medication use (antimigraine preparations)	HTML, TSV	Image, TSV	BED	131	-3.4	0.0
Medication use (antithrombotic agents)	HTML, TSV	Image, TSV	BED	2	-1.2	0.0
Medication use (beta blocking agents)	HTML, TSV	Image, TSV	BED	256	-3.3	0.0
Medication use (calcium channel blockers)	HTML, TSV	Image, TSV	BED	524	-6.0	-1.8
Medication use (diuretics)	HTML, TSV	Image, TSV	BED	508	-4.9	-0.8
Medication use (drugs affecting bone structure and mineralization)	HTML, TSV	Image, TSV	BED	82	-5.2	-1.0
Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease)	HTML, TSV	Image, TSV	BED	8	-2.4	0.0
Medication use (drugs used in diabetes)	HTML, TSV	Image, TSV	BED	286	-3.8	-0.1
Medication use (glucocorticoids)	HTML, TSV,	Image, TSV	BED	88	-8.1	-3.9
Medication use (HMG CoA reductase inhibitors)	HTML, TSV,	Image, TSV	BED	290	-8.8	-4.6
Medication use (salicylic acid and derivatives)	HTML, TSV	Image, TSV	BED	4	-2.5	0.0
Medication use (thyroid preparations)	HTML, TSV,	Image, TSV	BED	447	-10.9	-6.9
Medication use (vasodilators used in cardiac diseases)	HTML, TSV	Image, TSV	BED	1	-3.5	-0.1
Monoclonal gammopathy of undetermined significance	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
Mouth ulcers	HTML, TSV,	Image, TSV	BED	203	-13.9	-9.7
Oxcarbazepine-induced hyponatremia in epilepsy	HTML, TSV	Image, TSV	BED	2	-1.3	0.0
Primary central nervous system lymphoma	HTML, TSV,	Image, TSV	BED	6	-6.4	-2.2
Psychological resilience (outcome-based)	HTML, TSV	Image, TSV	BED	25	-3.6	0.0
Psychological resilience (outcome-based) in high deployment stress exposure	HTML, TSV,	Image, TSV	BED	22	-7.7	-3.6
Psychological resilience (self-assessed)	HTML, TSV	Image, TSV	BED	19	-2.4	0.0
Rapid alternating stimulus test for letters/numbers	HTML, TSV	Image, TSV	BED	15	-3.2	0.0
Rapid automised naming and rapid alternating stimulus test performance	HTML, TSV	Image, TSV	BED	15	-3.2	0.0
Right-sided colonic diverticulosis	HTML, TSV	Image, TSV	BED	12	-2.9	0.0
Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy	HTML, TSV	Image, TSV	BED	28	-3.4	0.0
Skin reflectance (Melanin index)	HTML, TSV	Image, TSV	BED	193	-2.7	0.0
Sleep (number of episodes)	HTML, TSV	Image, TSV	BED	12	-1.8	0.0
Sodium levels in epilepsy	HTML, TSV	Image, TSV	BED	4	-2.7	0.0
Tinnitus in cisplatin-treated testicular cancer	HTML, TSV	Image, TSV	BED	17	-2.2	0.0
Trunk fat mass adjusted for trunk lean mass	HTML, TSV	Image, TSV	BED	26	-4.8	-0.7
Type 2 diabetes and end-stage kidney disease	HTML, TSV	Image, TSV	BED	24	-2.3	0.0
Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals	HTML, TSV	Image, TSV	BED	10	-3.7	0.0
Urolithiasis	HTML, TSV,	Image, TSV	BED	25	-6.2	-2.1
Accommodative esotropia	HTML, TSV	Image, TSV	BED	55	-1.9	0.0
Airway obstruction (FEV1/FVC<70) in never smokers	HTML, TSV	Image, TSV	BED	9	-2.2	0.0
Alanine aminotransferase levels in non-alcoholic fatty liver disease	HTML, TSV	Image, TSV	BED	91	-3.4	0.0
Alcohol dependence or heroin dependence or methamphetamine dependence	HTML, TSV,	Image, TSV	BED	11	-8.1	-4.0
Alcohol dependence (time spent drinking)	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Alcohol use disorder	HTML, TSV	Image, TSV	BED	358	-3.5	0.0
Alcohol withdrawal symptoms	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Allergic rhinitis x sex interaction	HTML, TSV,	Image, TSV	BED	12	-6.3	-2.1
Alzheimer's disease in hypertension	HTML, TSV	Image, TSV	BED	23	-2.8	0.0
Alzheimer's disease in hypertension-negative individuals	HTML, TSV	Image, TSV	BED	13	-2.4	0.0
Amblyopia	HTML, TSV	Image, TSV	BED	45	-5.9	-1.7
Annualised percent change of cerebrospinal fluid AB1-42 levels	HTML, TSV	Image, TSV	BED	12	-5.2	-1.0
Anti-adalimumab antibody production in response to treatment in Crohn's disease	HTML, TSV	Image, TSV	BED	25	-4.7	-0.5
Anxiety and stress-related disorders	HTML, TSV	Image, TSV	BED	14	-3.6	0.0
Anxiety disorders	HTML, TSV	Image, TSV	BED	1	-3.2	0.0
Arterial stiffness index	HTML, TSV	Image, TSV	BED	91	-6.2	-2.0
Artificially sweetened beverage consumption	HTML, TSV	Image, TSV	BED	13	-3.3	0.0
Aspartate aminotransferase levels in non-alcoholic fatty liver disease	HTML, TSV	Image, TSV	BED	69	-5.7	-1.5
Asthma (age of onset)	HTML, TSV	Image, TSV	BED	63	-3.6	0.0
Atorvastatin-induced myopathy	HTML, TSV	Image, TSV	BED	16	-3.1	0.0
Atypical femoral fracture in phosphonate treatment	HTML, TSV	Image, TSV	BED	60	-5.5	-1.3
Balance difficulty in Charcot-Marie-Tooth disease type 1A	HTML, TSV	Image, TSV	BED	16	-2.5	0.0
Benign prostatic hyperplasia	HTML, TSV	Image, TSV	BED	34	-2.9	0.0
Bipolar II disorder	HTML, TSV,	Image, TSV	BED	26	-6.5	-2.3
Bisphosphonate-associated atypical femoral fracture	HTML, TSV	Image, TSV	BED	53	-3.3	0.0
Bitter alcoholic beverage consumption	HTML, TSV	Image, TSV	BED	305	-3.5	0.0
Bitter beverage consumption	HTML, TSV	Image, TSV	BED	82	-3.5	0.0
Bitter non-alcoholic beverage consumption	HTML, TSV	Image, TSV	BED	67	-3.8	-0.1
Bitter taste perception (6-n-propylthiouracil) in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	11	-3.4	0.0
Bitter taste perception (phenylthiocarbamide) in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	12	-3.1	0.0
Blood cell traits (multivariate analysis)	HTML, TSV	Image, TSV	BED	14	-3.8	0.0
Breakfast cereal skipping frequency	HTML, TSV	Image, TSV	BED	38	-3.8	0.0
Breakfast skipping	HTML, TSV	Image, TSV	BED	38	-3.8	0.0
Candidemia	HTML, TSV	Image, TSV	BED	30	-4.8	-0.8
Cannabis use disorder	HTML, TSV	Image, TSV	BED	15	-2.9	0.0
Cardiac troponin-I levels	HTML, TSV	Image, TSV	BED	10	-4.1	-0.0
Celiac disease and Rheumatoid arthritis	HTML, TSV	Image, TSV	BED	121	0.0	0.0
Cerebral microbleed progression	HTML, TSV	Image, TSV	BED	2	-2.8	0.0
Cerebral microbleeds	HTML, TSV	Image, TSV	BED	8	-4.0	0.0
Cerebrospinal fluid sTREM-2 levels	HTML, TSV	Image, TSV	BED	474	-5.6	-1.4
Change in neurofilament light levels	HTML, TSV	Image, TSV	BED	15	-3.0	0.0
Chronic lymphocytic leukemia or multiple sclerosis	HTML, TSV,	Image, TSV	BED	33	-6.3	-2.2
Chronic lymphocytic leukemia or systemic lupus erythematosus	HTML, TSV	Image, TSV	BED	48	-4.4	-0.5
Chronic mountain sickness	HTML, TSV	Image, TSV	BED	12	-4.7	-0.8
Cognitive ability in schizophrenia	HTML, TSV	Image, TSV	BED	7	-2.1	0.0
Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	HTML, TSV	Image, TSV	BED	1295	-4.0	0.0
Cognitive impairment	HTML, TSV	Image, TSV	BED	36	-4.4	-0.3
Composite immunoglobulin trait (IgA/IgM)	HTML, TSV	Image, TSV	BED	12	-4.4	-0.5
Composite immunoglobulin trait (IgA x IgG)	HTML, TSV	Image, TSV	BED	4	-3.5	-0.0
Composite immunoglobulin trait (IgA x IgG/IgM)	HTML, TSV	Image, TSV	BED	16	-3.8	0.0
Composite immunoglobulin trait (IgA x IgG x IgM)	HTML, TSV	Image, TSV	BED	2	-1.4	0.0
Composite immunoglobulin trait (IgG/IgM)	HTML, TSV	Image, TSV	BED	15	-5.0	-0.9
Corneal endothelial cell density	HTML, TSV	Image, TSV	BED	39	-5.1	-1.2
Corneal endothelial cell shape (percentage of hexagonally shaped cells)	HTML, TSV	Image, TSV	BED	14	-4.0	0.0
Corneal endothelial cell size variation coefficient	HTML, TSV	Image, TSV	BED	61	-4.2	-0.2
Corneal hysteresis	HTML, TSV,	Image, TSV	BED	37	-9.5	-5.5
Corneal resistance factor	HTML, TSV	Image, TSV	BED	18	-3.8	0.0
Decreased sensory function in Charcot-Marie-Tooth disease type 1A	HTML, TSV	Image, TSV	BED	13	-3.2	0.0
Dentures	HTML, TSV	Image, TSV	BED	102	-5.2	-1.1
Diabetic maculopathy in type 2 diabetes	HTML, TSV	Image, TSV	BED	29	-2.4	0.0
Diabetic maculopathy with decreased visual acuity in type 2 diabetes	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Diabetic peripheral neuropathy in type 2 diabetes	HTML, TSV	Image, TSV	BED	7	-3.7	0.0
Diffuse large B-cell lymphoma or multiple sclerosis	HTML, TSV,	Image, TSV	BED	22	-7.0	-2.9
Diffuse large B-cell lymphoma or systemic lupus erythematosus	HTML, TSV	Image, TSV	BED	1	-1.4	0.0
Diverticulitis	HTML, TSV,	Image, TSV	BED	99	-6.4	-2.4
Early spontaneous preterm birth	HTML, TSV	Image, TSV	BED	34	-5.2	-1.2
Emphysema annual change measurement in smokers (adjusted lung density)	HTML, TSV	Image, TSV	BED	161	-3.6	0.0
Emphysema annual change measurement in smokers (percent low attenuation area)	HTML, TSV	Image, TSV	BED	155	-4.5	-0.3
End-stage kidney disease	HTML, TSV	Image, TSV	BED	33	-2.7	0.0
Epigenetic age acceleration in alcohol use disorder	HTML, TSV,	Image, TSV	BED	31	-6.9	-2.8
Esotropia	HTML, TSV,	Image, TSV	BED	2	-6.2	-2.1
Estimated glomerular filtration rate in diabetes	HTML, TSV	Image, TSV	BED	105	-3.6	0.0
Estimated glomerular filtration rate in non-diabetics	HTML, TSV	Image, TSV	BED	259	-4.2	-0.2
Facial morphology traits (63 three-dimensional facial segments)	HTML, TSV	Image, TSV	BED	53	-3.2	0.0
Fagerstr?m test for nicotine dependence	HTML, TSV	Image, TSV	BED	9	-3.2	0.0
Fasting blood proinsulin levels	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Fasting glucose change	HTML, TSV	Image, TSV	BED	28	-4.9	-0.7
Fasting glucose change (long-term)	HTML, TSV,	Image, TSV	BED	49	-6.3	-2.1
Fasting glucose change (short-term)	HTML, TSV,	Image, TSV	BED	34	-7.2	-3.0
Fish intake frequency	HTML, TSV,	Image, TSV	BED	17	-7.0	-2.9
Follicular lymphoma or multiple sclerosis	HTML, TSV	Image, TSV	BED	4	-3.6	0.0
Foot deformity in Charcot-Marie-Tooth disease 1A	HTML, TSV	Image, TSV	BED	9	-5.5	-1.8
Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Geographic atrophy lesion growth rate in age-related macular degeneration	HTML, TSV,	Image, TSV	BED	34	-9.5	-5.5
Glucosuria	HTML, TSV	Image, TSV	BED	38	-3.6	0.0
Glucosuria (mild)	HTML, TSV	Image, TSV	BED	38	-3.6	0.0
Glucosuria (moderate to severe)	HTML, TSV	Image, TSV	BED	38	-3.6	0.0
Glycemic traits (pleiotropy)	HTML, TSV	Image, TSV	BED	32	-2.6	0.0
Grapefruit juice consumption	HTML, TSV	Image, TSV	BED	4	-3.9	0.0
group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP	HTML, TSV	Image, TSV	BED	75	-4.0	0.0
HDL cholesterol levels in current drinkers	HTML, TSV,	Image, TSV	BED	208	-7.6	-3.6
HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	HTML, TSV,	Image, TSV	BED	262	-7.4	-3.3
HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	HTML, TSV,	Image, TSV	BED	251	-7.1	-2.9
Health literacy	HTML, TSV	Image, TSV	BED	58	-2.9	0.0
Hearing loss in Charcot-Marie-Tooth disease 1A	HTML, TSV	Image, TSV	BED	6	-2.1	0.0
Heart rate in heart failure with reduced ejection fraction	HTML, TSV	Image, TSV	BED	307	-3.4	0.0
Heel bone mineral density (MTAG)	HTML, TSV,	Image, TSV	BED	88	-7.0	-2.8
Hematuria	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Hematuria (moderate to severe)	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Infection persistence (>18 months) in genital human papillomavirus 16 infection	HTML, TSV,	Image, TSV	BED	18	-6.7	-2.5
Intake of sweets	HTML, TSV,	Image, TSV	BED	44	-6.4	-2.5
Intake of total sugars	HTML, TSV	Image, TSV	BED	219	-4.1	-0.1
Intertrochanteric region size	HTML, TSV	Image, TSV	BED	61	-4.8	-0.6
Intraocular pressure (Goldman correlated)	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Joint damage in rheumatoid arthritis	HTML, TSV	Image, TSV	BED	82	-4.9	-0.7
Knee pain	HTML, TSV	Image, TSV	BED	16	-2.1	0.0
LDL cholesterol levels in current drinkers	HTML, TSV,	Image, TSV	BED	149	-6.2	-2.1
LDL cholesterol levels in current smokers	HTML, TSV,	Image, TSV	BED	4	-7.5	-3.3
LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	HTML, TSV,	Image, TSV	BED	166	-6.5	-2.3
LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	HTML, TSV,	Image, TSV	BED	161	-6.2	-2.0
LDL cholesterol levels x smoking (current vs non smokers) interaction (1df test)	HTML, TSV,	Image, TSV	BED	4	-7.5	-3.3
LDL cholesterol levels x smoking (current vs non smokers) interaction (2df test)	HTML, TSV,	Image, TSV	BED	4	-7.5	-3.3
Leukocyte telomere length	HTML, TSV	Image, TSV	BED	26	-5.1	-1.3
Liver fibrosis in non-alcoholic fatty acid liver disease	HTML, TSV	Image, TSV	BED	94	-4.2	0.0
Longevity (age >90th survival percentile)	HTML, TSV	Image, TSV	BED	60	-5.1	-0.9
Longevity (age >99th survival percentile)	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Low susceptibility to hepatitis C infection	HTML, TSV	Image, TSV	BED	29	-2.5	0.0
Low urine pH	HTML, TSV	Image, TSV	BED	14	-3.2	0.0
Lung function in heavy smokers (low FEV1 vs high FEV1)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Lung function in never smokers (high FEV1 vs average FEV1)	HTML, TSV	Image, TSV	BED	9	-2.0	0.0
Lung function in never smokers (low FEV1 vs average FEV1)	HTML, TSV	Image, TSV	BED	15	-2.1	0.0
Lung function in never smokers (low FEV1 vs high FEV1)	HTML, TSV	Image, TSV	BED	140	-4.1	0.0
Lung function (low FEV1 vs high FEV1)	HTML, TSV	Image, TSV	BED	107	-4.8	-0.6
Lung function (low FEV1 vs high FEV1) x smoking interaction	HTML, TSV	Image, TSV	BED	8	-4.2	-0.1
Lymphangioleiomyomatosis (sporadic)	HTML, TSV	Image, TSV	BED	25	-3.5	0.0
Marginal zone lymphoma or multiple sclerosis	HTML, TSV	Image, TSV	BED	9	-3.5	0.0
Marginal zone lymphoma or rheumatoid arthritis	HTML, TSV	Image, TSV	BED	13	-2.8	0.0
Marginal zone lymphoma or systemic lupus erythematosus	HTML, TSV	Image, TSV	BED	74	-3.7	0.0
Maximum habitual alcohol consumption	HTML, TSV,	Image, TSV	BED	140	-7.5	-3.3
Meningococcal C functional antibody titers post childhood immunization	HTML, TSV	Image, TSV	BED	12	-2.4	0.0
Mental health study participation (completed survey)	HTML, TSV	Image, TSV	BED	44	-6.0	-1.9
Mental health study participation (provided email address)	HTML, TSV	Image, TSV	BED	46	-3.7	0.0
Mild to moderate chronic kidney disease	HTML, TSV	Image, TSV	BED	17	-2.6	0.0
Moderate-to-late spontaneous preterm birth	HTML, TSV	Image, TSV	BED	57	-4.7	-0.5
Morningness	HTML, TSV	Image, TSV	BED	1538	-4.8	-0.6
Multisite chronic pain	HTML, TSV	Image, TSV	BED	85	-3.3	0.0
Neurological blood protein biomarker levels	HTML, TSV	Image, TSV	BED	106	-4.1	-0.4
Neuropathy in Charcot-Marie-Tooth disease type 1A	HTML, TSV	Image, TSV	BED	3	-3.5	0.0
Non-accommodative esotropia	HTML, TSV	Image, TSV	BED	12	-4.4	-0.4
Non-muscle-invasive bladder cancer tumour size	HTML, TSV	Image, TSV	BED	14	-3.7	0.0
Nonobstructive coronary artery disease	HTML, TSV	Image, TSV	BED	7	-3.1	0.0
Number of alcoholic drinks required to feel an effect (first five times drinking)	HTML, TSV	Image, TSV	BED	1	-3.0	0.0
Number of alcoholic drinks required to feel an effect (long-term average)	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Number of decayed, missing and filled tooth surfaces or use of dentures	HTML, TSV	Image, TSV	BED	102	-5.2	-1.1
Occipital lobe volume	HTML, TSV,	Image, TSV	BED	70	-6.8	-2.6
Opioid overdose severity score	HTML, TSV	Image, TSV	BED	113	-2.7	0.0
Peginterferon alfa-2a treatment response in chronic hepatitis B infection	HTML, TSV,	Image, TSV	BED	57	-7.0	-2.9
Pemphigus	HTML, TSV	Image, TSV	BED	2	-5.0	-1.0
Pepsinogen I/II ratio	HTML, TSV	Image, TSV	BED	65	-2.9	0.0
Perceived intensity of aspartame	HTML, TSV	Image, TSV	BED	47	-2.6	0.0
Perceived intensity of fructose	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Perceived intensity of glucose	HTML, TSV	Image, TSV	BED	26	-4.2	0.0
Perceived intensity of neohesperidin dihydrochalcone	HTML, TSV	Image, TSV	BED	34	-2.8	0.0
Perceived intensity of sucrose	HTML, TSV	Image, TSV	BED	64	-4.9	-0.7
Perceived intensity of sweet substances	HTML, TSV	Image, TSV	BED	12	-1.8	0.0
Perceived sweetness of sucrose	HTML, TSV	Image, TSV	BED	56	-3.0	0.0
Periodontal disease related phenotype (PCT3)	HTML, TSV	Image, TSV	BED	5	-4.1	-0.1
Periodontal disease related phenotype (PCT4)	HTML, TSV	Image, TSV	BED	5	-2.0	0.0
Periodontal disease related phenotype (PCT5)	HTML, TSV	Image, TSV	BED	15	-2.4	0.0
Periodontal disease-related phenotype (Socransky)	HTML, TSV	Image, TSV	BED	111	-2.4	0.0
Phenylephrine infusion rate during anesthesia	HTML, TSV	Image, TSV	BED	45	-3.5	0.0
Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis)	HTML, TSV	Image, TSV	BED	38	-4.1	0.0
Plasma anti-thyroglobulin levels	HTML, TSV	Image, TSV	BED	81	-5.6	-1.4
Plasma anti-thyroid peroxidase levels	HTML, TSV	Image, TSV	BED	117	-3.0	0.0
Plasma factor V levels in venous thrombosis	HTML, TSV	Image, TSV	BED	41	-3.2	0.0
Plasma factor V levels in venous thrombosis (conditioned on rs6027)	HTML, TSV	Image, TSV	BED	68	-2.9	0.0
Platelet reactivity measurement (collagen-epinephrine)	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma	HTML, TSV	Image, TSV	BED	15	-6.1	-2.0
Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma	HTML, TSV,	Image, TSV	BED	50	-7.1	-2.9
Postoperative acute renal failure after cardiac surgery	HTML, TSV	Image, TSV	BED	4	-2.6	0.0
Postoperative atrial fibrillation after cardiac surgery	HTML, TSV	Image, TSV	BED	11	-4.6	-0.6
Postoperative complication after cardiac surgery	HTML, TSV	Image, TSV	BED	6	-4.9	-0.7
Postoperative delirium after cardiac surgery	HTML, TSV	Image, TSV	BED	18	-4.7	-0.5
Postoperative myocardial infarction after cardiac surgery	HTML, TSV	Image, TSV	BED	6	-2.4	0.0
Postoperative stroke after cardiac surgery	HTML, TSV	Image, TSV	BED	69	-4.1	0.0
Post-traumatic stress disorder (re-experiencing symptoms)	HTML, TSV	Image, TSV	BED	53	-4.6	-0.4
Post-traumatic stress disorder symptoms in trauma-exposed soldiers	HTML, TSV	Image, TSV	BED	33	-3.2	0.0
Predicted visceral adipose tissue	HTML, TSV	Image, TSV	BED	1152	-4.0	-0.0
Pre-treatment viral load in HIV-1 infection	HTML, TSV	Image, TSV	BED	236	-2.9	0.0
Proliferative diabetic retinopathy	HTML, TSV	Image, TSV	BED	5	-3.5	0.0
Psychological wellbeing index 12 (lack of enjoying daily life)	HTML, TSV	Image, TSV	BED	7	-2.8	0.0
Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df)	HTML, TSV	Image, TSV	BED	4	-4.8	-1.0
Pure non-grapefruit juice consumption	HTML, TSV,	Image, TSV	BED	31	-7.8	-3.6
Response to allopurinol in gout (change in serum uric acid levels)	HTML, TSV	Image, TSV	BED	7	-4.6	-0.5
Response to cognitive-behavioural therapy in anxiety and major depressive disorders	HTML, TSV	Image, TSV	BED	25	-5.0	-0.8
Response to cognitive-behavioural therapy in major depressive disorder	HTML, TSV	Image, TSV	BED	27	-3.6	0.0
Response to direct-acting antiviral treatment in hepatitis C virus genotype 3	HTML, TSV	Image, TSV	BED	68	-3.9	0.0
Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease	HTML, TSV	Image, TSV	BED	1	-3.2	0.0
Response to interferon treatment in hepatitis C virus genotype 3	HTML, TSV	Image, TSV	BED	32	-4.1	-0.1
Salty taste perception in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	12	-4.3	-0.3
same-sex sexual behaviour	HTML, TSV	Image, TSV	BED	13	-2.0	0.0
Schizoaffective disorder-bipolar type	HTML, TSV	Image, TSV	BED	14	-4.5	-0.9
Scoliosis in Charcot-Marie-Tooth disease 1A	HTML, TSV	Image, TSV	BED	5	-3.9	0.0
Serum platinum levels after completion of cisplatin chemotherapy	HTML, TSV	Image, TSV	BED	94	-3.9	0.0
Simvastatin-induced myopathy	HTML, TSV	Image, TSV	BED	59	-2.9	0.0
Skin pigmentation (conditioned on rs1426654 and rs35397)	HTML, TSV	Image, TSV	BED	21	-3.1	0.0
Smoking status (heavy vs never)	HTML, TSV	Image, TSV	BED	55	-3.1	0.0
Sour taste perception in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	10	-4.9	-0.7
Spontaneous preterm birth without premature rupture of membranes	HTML, TSV	Image, TSV	BED	64	-4.5	-0.3
Spontaneous preterm birth with premature rupture of membranes	HTML, TSV	Image, TSV	BED	25	-3.7	-0.1
Statin-induced myopathy	HTML, TSV	Image, TSV	BED	5	-2.7	0.0
Statin-induced myopathy (severe)	HTML, TSV	Image, TSV	BED	6	-2.6	0.0
Stress sensitivity (neuroticism score x major depressive disorder status interaction)	HTML, TSV,	Image, TSV	BED	117	-16.9	-12.7
Sucrose liking	HTML, TSV	Image, TSV	BED	35	-2.6	0.0
Sugar-sweetened beverage consumption	HTML, TSV,	Image, TSV	BED	23	-7.1	-3.1
Suicide attempts in bipolar disorder or schizophrenia	HTML, TSV	Image, TSV	BED	71	-2.9	0.0
Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia	HTML, TSV	Image, TSV	BED	14	-2.4	0.0
Suicide attempts in schizophrenia	HTML, TSV	Image, TSV	BED	75	-2.6	0.0
Sweet beverage consumption	HTML, TSV,	Image, TSV	BED	34	-7.0	-3.1
Sweet taste perception in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	10	-3.4	0.0
Taste perception (total score including phenylthiocarbamide) in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	34	-3.0	0.0
Tea consumption	HTML, TSV	Image, TSV	BED	237	-2.3	0.0
Thyroglobulin plasma levels	HTML, TSV	Image, TSV	BED	17	-3.5	0.0
Thyrotoxic hypokalemic periodic paralysis and Graves disease	HTML, TSV,	Image, TSV	BED	135	-8.2	-4.0
Thyrotoxic hypokalemic periodic paralysis in Graves disease	HTML, TSV,	Image, TSV	BED	86	-7.0	-2.8
Time to smoke first cigarette in the morning	HTML, TSV	Image, TSV	BED	19	-5.3	-1.2
Total body bone mineral density (MTAG)	HTML, TSV	Image, TSV	BED	117	-5.8	-1.6
Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event)	HTML, TSV	Image, TSV	BED	24	-2.8	0.0
Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event)	HTML, TSV	Image, TSV	BED	33	-3.4	0.0
Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event)	HTML, TSV	Image, TSV	BED	7	-2.7	0.0
Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event)	HTML, TSV	Image, TSV	BED	46	-2.8	0.0
Triglyceride levels in current drinkers	HTML, TSV	Image, TSV	BED	163	-4.5	-0.5
Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	HTML, TSV	Image, TSV	BED	170	-4.4	-0.4
Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	HTML, TSV	Image, TSV	BED	169	-4.4	-0.4
Trochanter size	HTML, TSV	Image, TSV	BED	3	-2.7	0.0
Trunk fat mass	HTML, TSV	Image, TSV	BED	132	-4.7	-0.5
Umami taste perception in obesity with metabolic syndrome	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Urinary potassium excretion	HTML, TSV,	Image, TSV	BED	118	-13.5	-9.4
Urinary sodium excretion	HTML, TSV	Image, TSV	BED	475	-4.9	-0.7
Urine pH measurement	HTML, TSV	Image, TSV	BED	14	-3.2	0.0
Walking difficulty in Charcot-Marie-Tooth disease 1A	HTML, TSV	Image, TSV	BED	3	-3.3	0.0
17-hydroxyprogesterone (17-OHP) levels	HTML, TSV	Image, TSV	BED	12	-4.0	-0.5
Abdominal aortic calcification levels	HTML, TSV	Image, TSV	BED	15	-2.9	0.0
Abstraction and mental flexibility	HTML, TSV	Image, TSV	BED	106	-3.1	0.0
Adult hearing aid use	HTML, TSV	Image, TSV	BED	15	-2.5	0.0
Adult hearing difficulty	HTML, TSV	Image, TSV	BED	17	-3.1	0.0
Adverse response to chemotherapy (amenorrhea) in breast cancer	HTML, TSV	Image, TSV	BED	48	-2.0	0.0
Adverse response to drug	HTML, TSV	Image, TSV	BED	119	-2.8	0.0
Age at adiposity rebound	HTML, TSV,	Image, TSV	BED	23	-7.1	-3.1
Age at suicide	HTML, TSV,	Image, TSV	BED	6	-6.8	-2.8
Age-related cognitive decline (attention/processing speed) (slope of z-scores)	HTML, TSV	Image, TSV	BED	33	-4.3	-0.4
Age-related cognitive decline (executive function) (slope of z-scores)	HTML, TSV	Image, TSV	BED	37	-2.1	0.0
Age-related cognitive decline (global cognition) (slope of z-scores)	HTML, TSV	Image, TSV	BED	80	-4.1	0.0
Age-related cognitive decline (language) (slope of z-scores)	HTML, TSV	Image, TSV	BED	92	-3.6	0.0
Age-related cognitive decline (memory) (slope of z-scores)	HTML, TSV	Image, TSV	BED	73	-4.2	-0.1
Age-related cognitive decline (visuospatial skill) (slope of z-scores)	HTML, TSV	Image, TSV	BED	18	-1.8	0.0
Age-related hearing impairment (high frequency)	HTML, TSV	Image, TSV	BED	10	-3.4	0.0
Age-related hearing impairment (high minus low frequency)	HTML, TSV	Image, TSV	BED	13	-4.8	-0.6
Age-related hearing impairment (low/mid frequency)	HTML, TSV	Image, TSV	BED	23	-2.3	0.0
Alzheimer's disease and/or vascular dementia (clinical subgroup VaD++)	HTML, TSV	Image, TSV	BED	1	-1.5	0.0
Alzheimer's disease (onset between ages 58 and 79)	HTML, TSV	Image, TSV	BED	16	-4.3	-0.1
Amygdala volume	HTML, TSV	Image, TSV	BED	60	-3.9	0.0
Androstenedione levels	HTML, TSV,	Image, TSV	BED	20	-6.7	-2.5
anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	HTML, TSV	Image, TSV	BED	841	-4.7	-0.6
Anti-anoctamin 2 antibody levels	HTML, TSV,	Image, TSV	BED	7	-6.9	-2.7
Antipsychotic drug-induced weight gain in schizophrenia	HTML, TSV	Image, TSV	BED	115	-3.4	0.0
Antisaccade task score	HTML, TSV,	Image, TSV	BED	85	-6.5	-2.3
Anxiety symptoms	HTML, TSV	Image, TSV	BED	33	-2.5	0.0
Asthma and anxiety disorder	HTML, TSV	Image, TSV	BED	13	-5.6	-1.5
Asthma and attention deficit hyperactivity disorder	HTML, TSV,	Image, TSV	BED	14	-6.7	-2.5
Asthma and major depressive disorder	HTML, TSV	Image, TSV	BED	19	-3.4	0.0
Asthma (time to childhood onset) in early life tobacco smoke exposure	HTML, TSV	Image, TSV	BED	5	-2.3	0.0
Asthma (time to childhood onset) x early life tobacco smoke interaction	HTML, TSV	Image, TSV	BED	12	-2.6	0.0
Asthma (time to onset)	HTML, TSV	Image, TSV	BED	64	-5.5	-1.4
Asthma x air pollution interaction (2df)	HTML, TSV	Image, TSV	BED	27	-4.7	-0.8
Asthma x Hispanic interaction (2df)	HTML, TSV	Image, TSV	BED	3	-2.8	0.0
Basal metabolic rate variance	HTML, TSV	Image, TSV	BED	49	-5.2	-1.3
B-cell acute lymphoblastic leukaemia	HTML, TSV	Image, TSV	BED	45	-5.3	-1.2
B-cell acute lymphoblastic leukaemia (ETV6-RUNX1 positive)	HTML, TSV	Image, TSV	BED	1	-1.5	0.0
Bicuspid aortic valve	HTML, TSV	Image, TSV	BED	14	-5.6	-1.4
Bipolar disorder or body mass index	HTML, TSV,	Image, TSV	BED	116	-8.5	-4.3
Bipolar disorder or type 2 diabetes	HTML, TSV	Image, TSV	BED	5	-2.3	0.0
Birth length (MTAG)	HTML, TSV	Image, TSV	BED	99	-3.3	0.0
Birth weight (MTAG)	HTML, TSV	Image, TSV	BED	123	-3.2	0.0
Blood protein levels in cardiovascular risk	HTML, TSV	Image, TSV	BED	95	-4.7	-0.6
BMI at 1.5 years old	HTML, TSV	Image, TSV	BED	9	-6.0	-1.8
BMI at 7 years old	HTML, TSV,	Image, TSV	BED	23	-6.7	-2.6
BMI at 8 months old	HTML, TSV	Image, TSV	BED	9	-6.0	-1.8
BMI at 8 years old	HTML, TSV,	Image, TSV	BED	23	-6.7	-2.6
BMI at adiposity rebound	HTML, TSV	Image, TSV	BED	51	-5.3	-1.1
BMI at birth	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Body fat percentage variance	HTML, TSV,	Image, TSV	BED	34	-7.4	-3.4
Bone mineral content	HTML, TSV	Image, TSV	BED	47	-5.7	-1.7
Brain region volumes	HTML, TSV	Image, TSV	BED	2370	0.0	0.0
Brainstem volume	HTML, TSV	Image, TSV	BED	38	-5.0	-1.1
California verbal learning test score	HTML, TSV	Image, TSV	BED	32	-2.1	0.0
Carotid intima media thickness (maximum)	HTML, TSV	Image, TSV	BED	39	-4.8	-0.6
Carotid intima media thickness (mean)	HTML, TSV	Image, TSV	BED	84	-5.2	-1.4
Carotid intima media thickness (mean-maximum)	HTML, TSV	Image, TSV	BED	44	-3.7	0.0
Caudal anterior-cingulate cortex volume	HTML, TSV	Image, TSV	BED	95	-4.2	-0.0
Caudal middle frontal gyrus volume	HTML, TSV	Image, TSV	BED	43	-4.8	-0.6
CCL24 levels	HTML, TSV	Image, TSV	BED	12	-4.3	-0.2
CD40 ligand levels	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Central retinal arteriolar equivalent	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Central retinal vein equivalent	HTML, TSV	Image, TSV	BED	1	-2.9	0.0
Central serous retinopathy	HTML, TSV	Image, TSV	BED	2	-2.6	0.0
Ceramide levels	HTML, TSV	Image, TSV	BED	13	-4.2	-0.0
Cerebellum cortex volume	HTML, TSV	Image, TSV	BED	82	-5.1	-1.3
Cerebellum white matter volume	HTML, TSV	Image, TSV	BED	28	-3.7	0.0
Cerebral white matter volume	HTML, TSV	Image, TSV	BED	69	-3.0	0.0
Cerebrospinal fluid neurofilament light levels	HTML, TSV	Image, TSV	BED	25	-4.0	0.0
Change in serum metabolite levels	HTML, TSV	Image, TSV	BED	15	-5.4	-1.2
Change in serum metabolite levels (CMS)	HTML, TSV	Image, TSV	BED	15	-5.4	-1.2
Childhood obesity	HTML, TSV	Image, TSV	BED	154	-5.0	-0.8
Cholesteryl ester levels	HTML, TSV	Image, TSV	BED	5	-3.9	0.0
Choroidal melanoma	HTML, TSV	Image, TSV	BED	22	-2.8	0.0
Choroid plexus volume	HTML, TSV	Image, TSV	BED	36	-3.1	0.0
Chromosomal aberration frequency (chromatid type)	HTML, TSV	Image, TSV	BED	69	-2.5	0.0
Chromosomal aberration frequency (chromatid type) in genotoxic compound exposure	HTML, TSV	Image, TSV	BED	10	-2.4	0.0
Chromosomal aberration frequency (chromosome type)	HTML, TSV	Image, TSV	BED	5	-2.2	0.0
Chromosomal aberration frequency (total)	HTML, TSV	Image, TSV	BED	20	-3.0	0.0
Chromosomal aberration frequency (total) in genotoxic compound exposure	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Chronic kidney disease (end stage renal disease vs. normal eGFR) in type 1 diabetes	HTML, TSV	Image, TSV	BED	1	-2.3	0.0
Chronic kidney disease (reduced eGFR or end stage renal disease) in type 1 diabetes	HTML, TSV	Image, TSV	BED	1	-1.6	0.0
Circulating leptin levels in high cardiovascular risk	HTML, TSV	Image, TSV	BED	128	-2.3	0.0
Circulating leptin levels x sex interaction in high cardiovascular risk	HTML, TSV	Image, TSV	BED	9	-5.0	-1.0
Cleft lip with or without cleft palate x maternal periconceptional alcohol use interaction (parent of origin effect)	HTML, TSV	Image, TSV	BED	16	-4.1	0.0
Cleft lip with or without cleft palate x maternal periconceptional smoking interaction (parent of origin effect)	HTML, TSV	Image, TSV	BED	11	-2.5	0.0
Cleft lip with or without cleft palate x maternal periconceptional vitamin use interaction (parent of origin effect)	HTML, TSV	Image, TSV	BED	19	-3.0	0.0
Cognitive performance in schizophrenia or bipolar disorder	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Cognitive performance (processing speed)	HTML, TSV	Image, TSV	BED	77	-3.3	0.0
Corpus callosum anterior volume	HTML, TSV	Image, TSV	BED	3	-3.7	0.0
Corpus callosum central volume	HTML, TSV	Image, TSV	BED	33	-3.8	0.0
Corpus callosum mid-anterior volume	HTML, TSV	Image, TSV	BED	8	-4.3	-0.1
Corpus callosum Mid-posterior volume	HTML, TSV	Image, TSV	BED	16	-2.2	0.0
Corpus callosum posterior volume	HTML, TSV	Image, TSV	BED	54	-5.8	-1.8
Cortex volume	HTML, TSV,	Image, TSV	BED	126	-6.2	-2.1
Cortisol levels (plasma)	HTML, TSV	Image, TSV	BED	3	-4.6	-0.4
Cuneus cortex volume	HTML, TSV	Image, TSV	BED	101	-3.5	0.0
Cytokine levels	HTML, TSV	Image, TSV	BED	45	-4.6	-0.4
Cytokine network levels (multivariate analysis)	HTML, TSV	Image, TSV	BED	47	-4.5	-0.3
Decreased low contrast letter acuity in multiple sclerosis	HTML, TSV	Image, TSV	BED	27	-5.3	-1.4
Degraded stimulus continuous performance test score	HTML, TSV	Image, TSV	BED	78	-3.8	0.0
Dental caries (decayed and filled deciduous teeth)	HTML, TSV	Image, TSV	BED	98	-2.6	0.0
Dental caries (decayed and filled deciduous tooth surfaces)	HTML, TSV	Image, TSV	BED	97	-5.9	-1.7
Dental caries (decayed, missing and filled teeth)	HTML, TSV	Image, TSV	BED	61	-3.8	0.0
Dental caries (decayed, missing and filled tooth surfaces)	HTML, TSV	Image, TSV	BED	13	-5.7	-1.6
Depressive symptom (anhedonia) (binary trait)	HTML, TSV	Image, TSV	BED	2	-3.0	0.0
Depressive symptom (anhedonia) (ordinal trait)	HTML, TSV	Image, TSV	BED	6	-1.5	0.0
Depressive symptom (depressed mood) (binary trait)	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Depressive symptom (depressed mood) (ordinal trait)	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Depressive symptom (fatigue) (ordinal trait)	HTML, TSV	Image, TSV	BED	5	-3.5	0.0
Depressive symptom (sleep problems) (binary trait)	HTML, TSV	Image, TSV	BED	53	-5.0	-1.0
DHEAS levels	HTML, TSV	Image, TSV	BED	17	-5.5	-1.5
Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension	HTML, TSV	Image, TSV	BED	8	-3.4	0.0
Disability (impaired activities of daily living)	HTML, TSV	Image, TSV	BED	9	-2.3	0.0
Disease progression in age-related macular degeneration (adjusted for baseline)	HTML, TSV	Image, TSV	BED	87	-3.4	0.0
Disease severity in uveal melanoma (TNM stage 3 or 4 vs TNM stage 1 or 2)	HTML, TSV	Image, TSV	BED	10	-2.1	0.0
Early cardiac repolarization	HTML, TSV	Image, TSV	BED	25	-5.2	-1.1
Early onset periodontitis x smoking status interaction	HTML, TSV	Image, TSV	BED	18	-3.9	-0.0
Emotional recognition	HTML, TSV	Image, TSV	BED	60	-3.2	0.0
Eosinophilic granulomatosis with polyangiitis	HTML, TSV	Image, TSV	BED	5	-5.3	-1.1
Eosinophilic granulomatosis with polyangiitis (ANCA negative)	HTML, TSV	Image, TSV	BED	2	-2.2	0.0
Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive)	HTML, TSV	Image, TSV	BED	23	-3.3	0.0
Estimated glomerular filtration rate reduction (30)	HTML, TSV	Image, TSV	BED	7	-3.7	0.0
Face memory	HTML, TSV	Image, TSV	BED	16	-5.0	-0.8
Fibrosis improvement in nonalcoholic steatohepatitis	HTML, TSV	Image, TSV	BED	11	-3.2	0.0
Figural/spatial cognitive ability	HTML, TSV	Image, TSV	BED	55	-4.2	-0.5
Fourth ventricle volume	HTML, TSV	Image, TSV	BED	53	-4.1	0.0
Frontal pole volume	HTML, TSV	Image, TSV	BED	47	-3.6	0.0
Fusiform gyrus volume	HTML, TSV	Image, TSV	BED	43	-4.7	-0.6
Glaucoma (multi-trait analysis)	HTML, TSV	Image, TSV	BED	35	-4.9	-0.9
Gut microbiota (alpha diversity)	HTML, TSV	Image, TSV	BED	88	-3.8	0.0
Gut microbiota relative abundance (bacterial taxa)	HTML, TSV	Image, TSV	BED	207	-4.4	-0.5
Handedness (left-handed vs. right-handed)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Hay fever and/or eczema	HTML, TSV,	Image, TSV	BED	474	-17.4	-13.2
HDL cholesterol levels x long total sleep time interaction (2df test)	HTML, TSV	Image, TSV	BED	218	-4.5	-0.3
HDL cholesterol levels x loop diuretics use interaction	HTML, TSV	Image, TSV	BED	21	-3.9	0.0
HDL cholesterol levels x short total sleep time interaction (1df test)	HTML, TSV	Image, TSV	BED	7	-5.2	-1.0
HDL cholesterol levels x short total sleep time interaction (2df test)	HTML, TSV	Image, TSV	BED	262	-4.8	-0.7
HDL cholesterol levels x thiazide or thiazide-like diuretics use interaction	HTML, TSV	Image, TSV	BED	22	-4.1	-0.0
Heavy menstrual bleeding	HTML, TSV	Image, TSV	BED	4	-5.7	-1.5
Heel bone mineral density variance	HTML, TSV	Image, TSV	BED	20	-4.7	-0.5
High chromosomal aberration frequency (chromatid type)	HTML, TSV	Image, TSV	BED	6	-4.0	-0.3
High chromosomal aberration frequency (chromatid type) in genotoxic compound exposure	HTML, TSV	Image, TSV	BED	22	-2.9	0.0
High chromosomal aberration frequency (chromosome type)	HTML, TSV	Image, TSV	BED	22	-3.4	0.0
High chromosomal aberration frequency (total)	HTML, TSV	Image, TSV	BED	29	-3.0	0.0
High fasting blood glucose	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Hip circumference variance	HTML, TSV	Image, TSV	BED	140	-4.3	-0.1
Hippocampal atrophy rate	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
HIV progression (CD4 and viral load)	HTML, TSV	Image, TSV	BED	6	-2.5	0.0
Hospital contact for infections	HTML, TSV	Image, TSV	BED	112	-3.7	0.0
Household income (MTAG)	HTML, TSV	Image, TSV	BED	1645	-5.1	-1.1
Hydrolysed wheat protein allergy	HTML, TSV	Image, TSV	BED	3	-5.0	-1.1
Impaired insulin sensitivity in response to n-3 PUFA supplementation	HTML, TSV	Image, TSV	BED	9	-3.4	0.0
Infant head circumference (MTAG)	HTML, TSV	Image, TSV	BED	39	-5.2	-1.0
Inferior parietal cortex volume	HTML, TSV	Image, TSV	BED	36	-4.5	-0.3
Inferior temporal gyrus volume	HTML, TSV	Image, TSV	BED	92	-4.4	-0.6
Insular cortex volume	HTML, TSV	Image, TSV	BED	131	-4.9	-0.7
Interstitial lung abnormalities	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Intraocular pressure and central corneal thickness (multi-trait analysis)	HTML, TSV	Image, TSV	BED	27	-3.8	0.0
Isthmus-cingulate cortex volume	HTML, TSV	Image, TSV	BED	151	-3.5	0.0
kallikrein-11 levels	HTML, TSV	Image, TSV	BED	6	-3.5	0.0
Keratinocyte cancer (MTAG)	HTML, TSV	Image, TSV	BED	279	-4.7	-0.8
Keratoconus	HTML, TSV	Image, TSV	BED	16	-3.8	0.0
Lactose tolerance test	HTML, TSV,	Image, TSV	BED	54	-7.0	-3.1
Lateral occipital cortex volume	HTML, TSV,	Image, TSV	BED	87	-8.5	-4.4
Lateral orbital frontal cortex volume	HTML, TSV	Image, TSV	BED	90	-4.1	-0.2
Lateral ventricle temporal horn volume	HTML, TSV	Image, TSV	BED	239	-5.6	-1.4
Lateral ventricle volume	HTML, TSV	Image, TSV	BED	59	-2.8	0.0
LDL cholesterol levels x long total sleep time interaction (1df test)	HTML, TSV	Image, TSV	BED	26	-5.7	-1.7
LDL cholesterol levels x long total sleep time interaction (2df test)	HTML, TSV,	Image, TSV	BED	95	-6.4	-2.3
LDL cholesterol levels x loop diuretics use interaction	HTML, TSV	Image, TSV	BED	44	-3.0	0.0
LDL cholesterol levels x short total sleep time interaction (2df test)	HTML, TSV,	Image, TSV	BED	152	-6.8	-2.7
Left ventricular ejection fraction	HTML, TSV	Image, TSV	BED	13	-5.6	-1.4
Letter-number span reordering	HTML, TSV	Image, TSV	BED	42	-2.4	0.0
Lifetime anxiety disorder	HTML, TSV	Image, TSV	BED	54	0.0	0.0
Lifetime smoking index	HTML, TSV	Image, TSV	BED	727	-4.9	-0.7
Lingual gyrus volume	HTML, TSV	Image, TSV	BED	98	-2.9	0.0
Liver disease biomarker	HTML, TSV	Image, TSV	BED	3	-2.5	0.0
Longitudinal brain connectivity change (characteristic path length)	HTML, TSV	Image, TSV	BED	16	-3.9	0.0
Longitudinal brain connectivity change (global efficiency)	HTML, TSV	Image, TSV	BED	8	-2.8	0.0
Longitudinal brain connectivity change (Louvain modularity)	HTML, TSV	Image, TSV	BED	22	-2.8	0.0
Longitudinal brain connectivity change (transitivity)	HTML, TSV	Image, TSV	BED	16	-1.7	0.0
Longitudinal cocaine use	HTML, TSV	Image, TSV	BED	8	-3.2	0.0
Lung function (FEV1/FVC) variance	HTML, TSV	Image, TSV	BED	39	-2.9	0.0
Lysophosphatidylcholine levels	HTML, TSV	Image, TSV	BED	25	-3.5	0.0
Lysophosphatidylethanolamine levels	HTML, TSV	Image, TSV	BED	3	-2.8	0.0
Malate levels	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Maternal nondisjunction of chromosome 21 (MI error vs fathers)	HTML, TSV	Image, TSV	BED	27	-2.9	0.0
Maternal nondisjunction of chromosome 21 (MI error vs MII error)	HTML, TSV	Image, TSV	BED	86	-2.7	0.0
Maternal nondisjunction of chromosome 21 (MII error vs fathers)	HTML, TSV	Image, TSV	BED	11	-4.5	-0.3
Maternal nondisjunction of chromosome 21 (mothers vs fathers)	HTML, TSV	Image, TSV	BED	77	-5.6	-1.7
Maximum retinal arteriolar tortuosity	HTML, TSV	Image, TSV	BED	2	-4.2	-0.2
Maximum retinal venular tortuosity	HTML, TSV	Image, TSV	BED	5	-4.7	-0.7
Medial orbital frontal cortex volume	HTML, TSV	Image, TSV	BED	121	-3.0	0.0
Metabolite risk score for predicting weight gain	HTML, TSV	Image, TSV	BED	10	-2.7	0.0
Microalbuminuria in type 1 diabetes	HTML, TSV	Image, TSV	BED	9	-3.2	-0.3
Middle temporal gyrus volume	HTML, TSV	Image, TSV	BED	65	-3.6	0.0
Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis	HTML, TSV	Image, TSV	BED	11	-2.9	0.0
Mosaic loss of chromosome Y (Y chromosome dosage)	HTML, TSV	Image, TSV	BED	184	-5.5	-1.3
NASH resolution in nonalcoholic steatohepatitis	HTML, TSV	Image, TSV	BED	8	-4.7	-0.5
Niacinamide levels	HTML, TSV	Image, TSV	BED	3	-3.2	0.0
Non-del(5q) myelodysplastic syndromes	HTML, TSV	Image, TSV	BED	39	-3.5	0.0
Non-lobar intracerebral hemorrhage	HTML, TSV,	Image, TSV	BED	7	-6.5	-2.6
Non-lobar intracerebral hemorrhage (MTAG)	HTML, TSV	Image, TSV	BED	129	-5.5	-1.3
Nonsyndromic cleft lip	HTML, TSV	Image, TSV	BED	53	0.0	0.0
Nonsyndromic cleft palate	HTML, TSV	Image, TSV	BED	89	-5.6	-1.5
Nucleus accumbens volume	HTML, TSV	Image, TSV	BED	99	-6.2	-2.0
Numerical cognitive ability	HTML, TSV	Image, TSV	BED	32	-3.4	0.0
Obstructive sleep apnea trait (apnea hypopnea index, change over time)	HTML, TSV	Image, TSV	BED	151	-3.5	0.0
Optic disc size	HTML, TSV	Image, TSV	BED	844	-3.8	0.0
Optic nerve head parameters (multi-trait analysis)	HTML, TSV	Image, TSV	BED	43	-4.8	-0.6
Osteoarthritis of the hand	HTML, TSV	Image, TSV	BED	3	-3.1	0.0
Pallidum volume	HTML, TSV	Image, TSV	BED	106	-4.1	0.0
Paracentral lobule volume	HTML, TSV	Image, TSV	BED	93	-5.1	-1.0
Parahippocampal gyrus volume	HTML, TSV	Image, TSV	BED	85	-3.5	0.0
Parental longevity (father's age at death or father's attained age)	HTML, TSV	Image, TSV	BED	193	0.0	0.0
Parental longevity (mother's age at death or mother's attained age)	HTML, TSV	Image, TSV	BED	92	-2.8	0.0
Parkinson's disease or first degree relation to individual with Parkinson's disease	HTML, TSV	Image, TSV	BED	134	-3.5	0.0
Pars opercularis volume	HTML, TSV	Image, TSV	BED	66	0.0	0.0
Pars orbitalis volume	HTML, TSV	Image, TSV	BED	72	-3.1	0.0
Pars triangularis volume	HTML, TSV	Image, TSV	BED	123	-4.7	-1.0
Pericalcarine cortex volume	HTML, TSV	Image, TSV	BED	7	-2.2	0.0
Peripheral artery disease (borderline)	HTML, TSV	Image, TSV	BED	5	-2.2	0.0
Phosphatidylcholine-ether levels	HTML, TSV	Image, TSV	BED	5	-3.0	0.0
Phosphatidylcholine levels	HTML, TSV	Image, TSV	BED	18	-3.0	0.0
Phosphatidylethanolamine levels	HTML, TSV	Image, TSV	BED	8	-2.3	0.0
Planum temporale asymmetry index	HTML, TSV	Image, TSV	BED	2	-1.6	0.0
Pneumococcal meningitis	HTML, TSV	Image, TSV	BED	5	-1.5	0.0
Pneumococcal meningitis x streptococcus pneumoniae genotype cluster interaction	HTML, TSV	Image, TSV	BED	4	-3.7	0.0
Postcentral gyrus volume	HTML, TSV	Image, TSV	BED	23	-3.8	-0.2
Posterior-cingulate cortex volume	HTML, TSV	Image, TSV	BED	69	-1.9	0.0
Precentral gyrus volume	HTML, TSV	Image, TSV	BED	45	-1.6	0.0
Precuneus cortex volume	HTML, TSV	Image, TSV	BED	121	-4.8	-0.7
Prepulse inhibition of the startle response	HTML, TSV	Image, TSV	BED	104	-3.6	0.0
Presence of epithelioid cells in uveal melanoma	HTML, TSV	Image, TSV	BED	5	-1.6	0.0
Priapism in sickle cell disease	HTML, TSV	Image, TSV	BED	4	-4.4	-0.4
Progesterone levels	HTML, TSV	Image, TSV	BED	90	-3.6	0.0
Pruritus in nonalcoholic steatohepatitis	HTML, TSV	Image, TSV	BED	12	-3.7	0.0
Psychotic experience	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Pyridoxal levels	HTML, TSV	Image, TSV	BED	1	-3.2	0.0
Rate of ventricular enlargement	HTML, TSV	Image, TSV	BED	64	-3.4	0.0
Recurrence of mild malaria attacks	HTML, TSV	Image, TSV	BED	6	-3.8	0.0
Response to adalimumab in hidradenitis suppurativa (abscess and inflammatory nodule count increase)	HTML, TSV,	Image, TSV	BED	12	-6.4	-2.2
Response to (pegylated) interferon in chronic hepatitis B	HTML, TSV	Image, TSV	BED	5	-2.4	0.0
Response to (pegylated) interferon in HBeAg-negative hepatitis B	HTML, TSV	Image, TSV	BED	35	-2.8	0.0
Response to (pegylated) interferon in HBeAG-positive hepatitis B	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Response to placebo treatment in childhood asthma (FVC change)	HTML, TSV	Image, TSV	BED	20	-4.4	-0.5
Retinal arteriole-to-venule ratio	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Retinal venular tortuosity	HTML, TSV	Image, TSV	BED	7	-2.8	0.0
Right planum temporale grey matter volume	HTML, TSV	Image, TSV	BED	1	-3.6	0.0
Rostral anterior cingulate cortex volume	HTML, TSV	Image, TSV	BED	22	-4.1	0.0
Rostral middle frontal gyrus volume	HTML, TSV	Image, TSV	BED	82	-2.2	0.0
Schizophrenia or schizoaffective disorder	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Sensorimotor dexterity	HTML, TSV	Image, TSV	BED	163	-3.7	0.0
Serum cancer antigen 19.9 levels	HTML, TSV	Image, TSV	BED	2	0.0	0.0
Serum carcinoembryonic antigen levels	HTML, TSV	Image, TSV	BED	7	-3.5	0.0
Serum metabolite levels (CMS)	HTML, TSV	Image, TSV	BED	257	-3.2	0.0
Serum oxytocin levels	HTML, TSV	Image, TSV	BED	3	-3.9	0.0
Serum sclerostin levels	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Severe aplastic anemia	HTML, TSV	Image, TSV	BED	88	-4.8	-0.7
Severe bacterial meningitis	HTML, TSV	Image, TSV	BED	8	-4.4	-0.2
Skin aging measurement	HTML, TSV	Image, TSV	BED	14	-3.1	0.0
Smoking behaviour (age at first cigarette)	HTML, TSV	Image, TSV	BED	37	-5.3	-1.1
Smoking behaviour (cigarette pack-years)	HTML, TSV,	Image, TSV	BED	61	-6.3	-2.1
Spatial memory	HTML, TSV	Image, TSV	BED	84	-3.4	0.0
Spatial processing	HTML, TSV	Image, TSV	BED	119	-5.6	-1.9
Sphingomyelin 24:0 levels	HTML, TSV	Image, TSV	BED	11	-2.8	0.0
Sphingomyelin levels	HTML, TSV	Image, TSV	BED	10	-3.2	0.0
Strabismus	HTML, TSV	Image, TSV	BED	33	-3.0	0.0
Stress-related phenotypes (multivariate analysis)	HTML, TSV	Image, TSV	BED	17	-2.4	0.0
Sub-cortical grey matter volume	HTML, TSV	Image, TSV	BED	58	-4.6	-0.6
Subjective response to placebo treatment in childhood asthma (change in cough/wheeze)	HTML, TSV	Image, TSV	BED	27	-4.7	-0.8
Subpleural-predominant interstitial lung abnormalities	HTML, TSV	Image, TSV	BED	11	-3.0	0.0
Subscapular skin fold thickness	HTML, TSV,	Image, TSV	BED	31	-7.8	-3.6
Superior frontal gyrus volume	HTML, TSV	Image, TSV	BED	19	-2.9	0.0
Superior parietal cortex volume	HTML, TSV,	Image, TSV	BED	112	-6.7	-2.8
Superior temporal gyrus volume	HTML, TSV	Image, TSV	BED	43	-5.0	-1.2
Superior temporal sulcus banks volume	HTML, TSV	Image, TSV	BED	94	-2.9	0.0
Supramarginal gyrus volume	HTML, TSV	Image, TSV	BED	107	-3.9	0.0
Systemising	HTML, TSV	Image, TSV	BED	15	-3.2	0.0
Systolic blood pressure response to thiazide and thiazide-like diuretics in hypertension	HTML, TSV	Image, TSV	BED	14	-4.0	0.0
Temporal pole volume	HTML, TSV	Image, TSV	BED	23	-2.4	0.0
Thalamus volume	HTML, TSV	Image, TSV	BED	72	-4.1	-0.0
Third ventricle volume	HTML, TSV	Image, TSV	BED	28	-2.5	0.0
Thoracic aortic calcification levels	HTML, TSV	Image, TSV	BED	3	0.0	0.0
Total grey matter volume	HTML, TSV	Image, TSV	BED	125	-3.1	0.0
Total intracranial volume	HTML, TSV	Image, TSV	BED	148	-4.7	-0.9
Transverse temporal cortex volume	HTML, TSV	Image, TSV	BED	9	-2.4	0.0
Trastuzumab-induced cardiotoxicity in cancer	HTML, TSV	Image, TSV	BED	10	-4.7	-0.5
Triacylglyceride levels	HTML, TSV	Image, TSV	BED	24	-2.3	0.0
Triacylglycerol 56:2 levels	HTML, TSV	Image, TSV	BED	6	-2.7	0.0
Triacylglycerol 56:6 levels	HTML, TSV	Image, TSV	BED	30	-5.7	-1.5
Triglyceride levels x long total sleep time interaction (1df test)	HTML, TSV,	Image, TSV	BED	39	-7.8	-3.7
Triglyceride levels x long total sleep time interaction (2df test)	HTML, TSV,	Image, TSV	BED	121	-6.4	-2.3
Triglyceride levels x loop diuretics use interaction	HTML, TSV	Image, TSV	BED	132	-4.4	-0.2
Triglyceride levels x short total sleep time interaction (2df test)	HTML, TSV	Image, TSV	BED	159	-3.1	0.0
Triglyceride levels x thiazide or thiazide-like diuretics use interaction	HTML, TSV	Image, TSV	BED	24	-2.4	0.0
T wave morphology restitution during exercise	HTML, TSV	Image, TSV	BED	28	-2.8	0.0
T wave morphology restitution during exercise (MTAG)	HTML, TSV	Image, TSV	BED	29	-2.7	0.0
T wave morphology restitution during recovery from exercise	HTML, TSV	Image, TSV	BED	35	-3.2	0.0
T wave morphology restitution during recovery from exercise (MTAG)	HTML, TSV	Image, TSV	BED	35	-3.2	0.0
Tyrosine levels	HTML, TSV	Image, TSV	BED	16	-3.5	0.0
Uric acid elevation in response to thiazide-like diuretic in hypertension	HTML, TSV	Image, TSV	BED	3	-2.1	0.0
Uridine levels	HTML, TSV	Image, TSV	BED	1	-1.9	0.0
Urinary calcium excretion	HTML, TSV	Image, TSV	BED	59	-3.6	0.0
Urinary magnesium excretion	HTML, TSV	Image, TSV	BED	26	-2.6	0.0
Urinary metabolite levels in chronic kidney disease	HTML, TSV,	Image, TSV	BED	83	-13.9	-10.1
Urinary metabolite modules (eigenmetabolites) in chronic kidney disease	HTML, TSV	Image, TSV	BED	26	-3.0	0.0
Urinary uric acid excretion	HTML, TSV	Image, TSV	BED	71	-3.0	0.0
Uterine fibroids and heavy menstrual bleeding	HTML, TSV	Image, TSV	BED	6	-5.3	-1.1
Uveal melanoma (TNM stage 1 or 2)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Uveal melanoma (TNM stage 3 or 4)	HTML, TSV	Image, TSV	BED	27	-2.3	0.0
Uveal melanoma with any chromosomal aberration	HTML, TSV	Image, TSV	BED	64	-4.9	-0.9
Uveal melanoma with chromosome 3 loss	HTML, TSV	Image, TSV	BED	12	-2.9	-0.0
Uveal melanoma with epithelioid cells	HTML, TSV	Image, TSV	BED	16	-5.9	-1.8
vascular endothelial growth factor D levels	HTML, TSV	Image, TSV	BED	4	-3.9	0.0
Ventral diencephalon volume	HTML, TSV	Image, TSV	BED	12	-1.8	0.0
Verbal cognitive ability	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Vertical cup-disc ratio (adjusted for vertical disc diameter)	HTML, TSV,	Image, TSV	BED	474	-6.4	-2.3
Vertical cup-disc ratio (multi-trait analysis)	HTML, TSV,	Image, TSV	BED	597	-7.0	-2.8
Vitamin levels	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Voxel-wise structural brain imaging measurements in Alzheimer's disease	HTML, TSV	Image, TSV	BED	165	-3.3	0.0
Waist circumference variance	HTML, TSV	Image, TSV	BED	84	-4.7	-0.7
White coat effect (clinic diastolic blood pressure minus ambulatory diastolic blood pressure)	HTML, TSV	Image, TSV	BED	33	-6.1	-2.0
White matter microstructure (axial diusivities)	HTML, TSV,	Image, TSV	BED	226	-7.3	-3.2
White matter microstructure (fractional anisotropy)	HTML, TSV	Image, TSV	BED	356	-4.7	-0.5
White matter microstructure (mean diusivities)	HTML, TSV	Image, TSV	BED	310	-5.6	-1.6
White matter microstructure (mode of anisotropy)	HTML, TSV,	Image, TSV	BED	339	-6.3	-2.1
White matter microstructure (radial diusivities)	HTML, TSV,	Image, TSV	BED	402	-6.3	-2.2
Whole brain grey matter density	HTML, TSV	Image, TSV	BED	53	-2.4	0.0
Xanthine levels	HTML, TSV	Image, TSV	BED	9	-3.5	0.0
Accrued duration of remission in mepolizumab-treated eosinophilic granulomatosis with polyangiitis	HTML, TSV	Image, TSV	BED	21	-2.7	0.0
Adult onset asthma and/or BMI	HTML, TSV	Image, TSV	BED	20	-3.5	0.0
Adult onset asthma or type 2 diabetes	HTML, TSV	Image, TSV	BED	10	-3.7	-0.3
Adverse response to inhaled corticosteroid treatment x age interaction in asthma	HTML, TSV,	Image, TSV	BED	43	-6.6	-2.6
Anxiety	HTML, TSV,	Image, TSV	BED	117	-8.1	-3.9
Atopic asthma	HTML, TSV,	Image, TSV	BED	538	-12.0	-7.8
Autoimmune traits (pleiotropy)	HTML, TSV	Image, TSV	BED	114	-5.9	-1.7
Average oral glucocorticoid dose in mepolizumab-treated eosinophilic granulomatosis with polyangiitis	HTML, TSV	Image, TSV	BED	13	-3.0	0.0
Cataracts (operation)	HTML, TSV	Image, TSV	BED	63	-4.1	0.0
Childhood maltreatment	HTML, TSV	Image, TSV	BED	10	-2.8	0.0
Chronic postoperative pain	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Clozapine-induced myocarditis in schizophrenia	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Compulsion score in obsessive compulsive disorder	HTML, TSV	Image, TSV	BED	9	-3.1	0.0
Cotinine and 3'-hydroxycotinine levels in current smokers	HTML, TSV	Image, TSV	BED	8	-1.6	0.0
Cotinine levels in current smokers	HTML, TSV	Image, TSV	BED	3	-2.2	0.0
Creativity	HTML, TSV	Image, TSV	BED	8	-2.4	0.0
Cryptosporidiosis	HTML, TSV	Image, TSV	BED	5	-2.5	0.0
Extranodal natural killer T-cell lymphoma (nasal type)	HTML, TSV	Image, TSV	BED	3	-5.0	-1.1
Fecal incontinence	HTML, TSV	Image, TSV	BED	2	-4.1	-0.5
Follicle stimulating hormone levels	HTML, TSV	Image, TSV	BED	18	-5.0	-0.8
Follicle stimulating hormone levels in polycystic ovary syndrome	HTML, TSV	Image, TSV	BED	103	-5.0	-1.0
Frequency of relapse in mepolizumab-treated eosinophilic granulomatosis with polyangiitis	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Gastrointestinal infection	HTML, TSV	Image, TSV	BED	30	-2.9	0.0
Gynecologic disease	HTML, TSV	Image, TSV	BED	2	-2.3	0.0
Gynecologic disease (multivariate analysis)	HTML, TSV	Image, TSV	BED	12	-2.7	0.0
Hallux valgus	HTML, TSV	Image, TSV	BED	186	-2.7	0.0
HDL cholesterol change in response to niacin in statin-treated individuals	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Head and neck squamous cell carcinoma	HTML, TSV	Image, TSV	BED	9	-4.3	-0.1
Help-seeking from a GP	HTML, TSV	Image, TSV	BED	145	-4.1	0.0
High myopia	HTML, TSV,	Image, TSV	BED	116	-6.8	-3.0
Insulin-related traits (multivariate analysis)	HTML, TSV	Image, TSV	BED	220	-3.3	0.0
Lean mass index	HTML, TSV,	Image, TSV	BED	30	-7.9	-3.7
Left ventricular mass x antihypertensive treatment interaction	HTML, TSV	Image, TSV	BED	20	-4.2	-0.1
Lung function	HTML, TSV	Image, TSV	BED	38	-2.6	0.0
Major depressive disorder in trauma exposed individuals	HTML, TSV	Image, TSV	BED	84	-3.7	0.0
Major depressive disorder in trauma-unexposed individuals	HTML, TSV,	Image, TSV	BED	125	-8.4	-4.3
Major depressive disorder (lifetime)	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Nicotine metabolite ratio in current smokers	HTML, TSV	Image, TSV	BED	15	-5.8	-1.7
Nonatopic asthma	HTML, TSV,	Image, TSV	BED	321	-6.2	-2.5
Nonatopic asthma and/or BMI	HTML, TSV	Image, TSV	BED	41	-3.3	0.0
Nonatopic asthma and/or waist-to-hip ratio adjusted for BMI	HTML, TSV	Image, TSV	BED	1	-3.7	0.0
Nonatopic asthma or type 2 diabetes	HTML, TSV	Image, TSV	BED	2	-1.3	0.0
Obsessive compulsive disorder severity	HTML, TSV	Image, TSV	BED	31	-3.5	-0.0
Ocular sarcoidosis	HTML, TSV	Image, TSV	BED	150	-3.3	0.0
Ocular sarcoidosis in sarcoidosis	HTML, TSV	Image, TSV	BED	23	-3.9	0.0
Opioid exposure	HTML, TSV	Image, TSV	BED	3	-2.7	0.0
Opioid use cessation	HTML, TSV	Image, TSV	BED	30	-3.2	0.0
Opioid use disorder	HTML, TSV	Image, TSV	BED	30	-2.5	0.0
Osteoporosis-related phenotypes (MTAG)	HTML, TSV	Image, TSV	BED	17	-3.1	0.0
Physiological traits	HTML, TSV	Image, TSV	BED	57	-4.2	-0.0
Reading disability	HTML, TSV	Image, TSV	BED	14	-2.8	0.0
Relative wall thickness x antihypertensive treatment interaction	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Retinal detachment or retinal break	HTML, TSV	Image, TSV	BED	72	-5.1	-0.9
Salivary metabolite levels	HTML, TSV	Image, TSV	BED	18	-3.7	0.0
Schizophrenia (MTAG)	HTML, TSV	Image, TSV	BED	613	-4.6	-0.5
Small whole fish consumption	HTML, TSV	Image, TSV	BED	4	-3.2	0.0
Soluble gp130 levels	HTML, TSV	Image, TSV	BED	35	-3.2	0.0
Sphingolipid d18:1/d18:2 ratio	HTML, TSV	Image, TSV	BED	1	-3.5	0.0
Suicidal or self-harm ideation	HTML, TSV	Image, TSV	BED	43	-3.7	0.0
Thyroid autoantibody positivity (anti-thyroglobulin (TgAb) and/or anti-thyroid peroxidase (TPOAb) levels)	HTML, TSV	Image, TSV	BED	13	-4.9	-1.3
Thyroid volume in Hashimoto's thyroiditis	HTML, TSV	Image, TSV	BED	68	-3.2	0.0
Trauma exposure	HTML, TSV	Image, TSV	BED	517	-4.4	-0.3
Trauma exposure in major depressive disorder	HTML, TSV	Image, TSV	BED	54	-5.7	-1.5
Trauma exposure in major depressive disorder-negative individuals	HTML, TSV,	Image, TSV	BED	220	-6.8	-2.8
Weight gain in amisulpride-treated first-episode psychosis	HTML, TSV	Image, TSV	BED	30	-5.1	-0.9
Acute cholecystitis	HTML, TSV	Image, TSV	BED	34	-5.0	-1.0
Adult onset Still's disease	HTML, TSV	Image, TSV	BED	4	-2.4	0.0
Aseptic loosening in total joint arthroplasty	HTML, TSV	Image, TSV	BED	98	-2.5	0.0
Beef consumption	HTML, TSV,	Image, TSV	BED	30	-7.9	-3.7
Brain imaging measurements (variance)	HTML, TSV	Image, TSV	BED	21	-3.7	0.0
Buruli ulcer	HTML, TSV	Image, TSV	BED	9	-3.2	0.0
Cardioembolic stroke (CCS and TOAST classification)	HTML, TSV	Image, TSV	BED	46	-6.1	-1.9
Cardioembolic stroke (CCSc classification)	HTML, TSV	Image, TSV	BED	47	-6.0	-1.9
Cardioembolic stroke (CCS or TOAST classification)	HTML, TSV	Image, TSV	BED	46	-6.1	-1.9
Cardioembolic stroke (CCSp classification)	HTML, TSV	Image, TSV	BED	63	-5.7	-1.5
Cardioembolic stroke (TOAST classification)	HTML, TSV	Image, TSV	BED	46	-6.1	-1.9
Carotid intima media thickness x smoking interaction	HTML, TSV	Image, TSV	BED	103	-3.9	0.0
Ceramide levels (C22:0)	HTML, TSV	Image, TSV	BED	26	-3.3	0.0
Ceramide levels (C24:0)	HTML, TSV	Image, TSV	BED	27	-3.6	0.0
Cerebrospinal fluid immune biomarker levels	HTML, TSV	Image, TSV	BED	36	-2.5	0.0
Cervical cancer (MTAG)	HTML, TSV	Image, TSV	BED	90	-4.8	-1.0
Conjunctival UV autofluorescence (CUVAF)	HTML, TSV	Image, TSV	BED	42	-5.1	-1.0
Cooked vegetable consumption	HTML, TSV	Image, TSV	BED	60	-3.1	0.0
Crohn's disease or systemic sclerosis	HTML, TSV	Image, TSV	BED	2	-3.5	0.0
Driving (hours per day)	HTML, TSV	Image, TSV	BED	23	-4.1	0.0
Endometrial cancer (MTAG)	HTML, TSV	Image, TSV	BED	8	-3.2	0.0
Endometriosis (MTAG)	HTML, TSV	Image, TSV	BED	12	-3.2	0.0
Endometriosis or migraine	HTML, TSV	Image, TSV	BED	234	-3.9	0.0
Fish- and plant-related diet	HTML, TSV	Image, TSV	BED	328	-4.0	-0.0
Fruit consumption	HTML, TSV	Image, TSV	BED	220	-3.3	0.0
Idiopathic downbeat nystagmus	HTML, TSV	Image, TSV	BED	25	-2.5	0.0
Invasive breast cancer	HTML, TSV	Image, TSV	BED	87	-5.5	-1.8
Lamb consumption	HTML, TSV	Image, TSV	BED	243	-3.5	0.0
Large artery stroke (CCS and TOAST classification)	HTML, TSV	Image, TSV	BED	17	-3.5	0.0
Large artery stroke (CCS or TOAST classification)	HTML, TSV	Image, TSV	BED	17	-3.5	0.0
Large artery stroke (CCSp classification)j	HTML, TSV	Image, TSV	BED	17	-3.5	0.0
Large artery stroke (TOAST classification)	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Left ventricular end-systolic volume	HTML, TSV	Image, TSV	BED	3	-4.7	-0.6
Leisure sedentary behaviour (computer use)	HTML, TSV	Image, TSV	BED	302	-4.9	-0.8
Leisure sedentary behaviour (television watching)	HTML, TSV	Image, TSV	BED	565	-3.5	0.0
Meat-related diet	HTML, TSV	Image, TSV	BED	51	-3.1	0.0
Midgestational total 25-hydroxyvitamin D levels (fetal genetic effect)	HTML, TSV	Image, TSV	BED	14	-2.0	0.0
Midgestational total 25-hydroxyvitamin D levels (maternal genetic effect)	HTML, TSV	Image, TSV	BED	11	-3.4	0.0
Neck pain or shoulder pain	HTML, TSV	Image, TSV	BED	9	-1.7	0.0
Neonatal total 25-hydroxyvitamin D levels (fetal genetic effect)	HTML, TSV	Image, TSV	BED	3	-1.5	0.0
Neonatal total 25-hydroxyvitamin D levels (maternal genetic effect)	HTML, TSV	Image, TSV	BED	31	-2.6	0.0
Neuroblastoma or malignant cutaneous melanoma	HTML, TSV	Image, TSV	BED	30	-5.1	-1.2
Non-oily fish consumption	HTML, TSV,	Image, TSV	BED	25	-6.8	-2.9
Oily fish consumption	HTML, TSV	Image, TSV	BED	292	-3.9	0.0
Ovarian cancer (MTAG)	HTML, TSV	Image, TSV	BED	41	-3.7	0.0
Pork consumption	HTML, TSV	Image, TSV	BED	292	-3.9	0.0
Poultry consumption	HTML, TSV	Image, TSV	BED	8	-2.0	0.0
Processed meat consumption	HTML, TSV	Image, TSV	BED	10	-2.9	0.0
Protein level change in low calorie diet obesity intervention	HTML, TSV	Image, TSV	BED	73	-3.7	0.0
Protein levels in obesity	HTML, TSV	Image, TSV	BED	143	-2.8	0.0
Raw vegetable consumption	HTML, TSV	Image, TSV	BED	124	-4.2	-0.1
Sensitivity to environmental stress and adversity	HTML, TSV	Image, TSV	BED	174	-4.1	-0.2
Serum immune biomarker levels	HTML, TSV	Image, TSV	BED	95	-3.3	0.0
Severe COVID-19 infection with respiratory failure (analysis I)	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Severe COVID-19 infection with respiratory failure (analysis II)	HTML, TSV	Image, TSV	BED	2	-3.1	0.0
Small vessel stroke (CCS and TOAST classification)	HTML, TSV	Image, TSV	BED	12	-4.7	-0.6
Spontaneous adipocyte lipolysis	HTML, TSV	Image, TSV	BED	28	-2.1	0.0
Stimulated adipocyte lipolysis	HTML, TSV	Image, TSV	BED	125	-3.2	0.0
Sudden cardiac arrest in coronary artery disease	HTML, TSV	Image, TSV	BED	2	-5.0	-0.9
Time to aseptic loosening in total joint arthroplasty	HTML, TSV	Image, TSV	BED	25	-3.1	0.0
Urinary volume	HTML, TSV	Image, TSV	BED	5	-1.6	0.0
Uterine fibroids (MTAG)	HTML, TSV	Image, TSV	BED	72	-3.4	0.0
White matter hyperintensities	HTML, TSV	Image, TSV	BED	72	-3.9	0.0
Acute ischemic stroke x type 2 diabetes interaction	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Acute respiratory distress syndrome in sepsis	HTML, TSV	Image, TSV	BED	12	-4.5	-0.7
Adipose morphology	HTML, TSV	Image, TSV	BED	92	-5.8	-1.8
Adrenomedullin levels	HTML, TSV	Image, TSV	BED	9	-4.1	0.0
Adult body size	HTML, TSV,	Image, TSV	BED	2331	-10.4	-6.3
Adult diffuse glioma (IDH mutation, 1p/19q codeletion)	HTML, TSV	Image, TSV	BED	2	-3.4	0.0
Adult diffuse glioma (IDH mutation, 1p/19q non-codeleted)	HTML, TSV	Image, TSV	BED	3	-3.6	0.0
Adult diffuse glioma (IDH mutation)	HTML, TSV	Image, TSV	BED	4	-3.1	0.0
Adult diffuse glioma (IDH mutation only)	HTML, TSV	Image, TSV	BED	3	-3.6	0.0
Adult diffuse glioma (IDH wildtype)	HTML, TSV	Image, TSV	BED	1	-1.7	0.0
Adult diffuse triple positive glioma (IDH and TERT mutations, 1p19q codeletion)	HTML, TSV	Image, TSV	BED	5	-3.2	0.0
Age-related hearing impairment (MTAG)	HTML, TSV,	Image, TSV	BED	113	-6.2	-2.4
Age-related macular degeneration (MTAG)	HTML, TSV	Image, TSV	BED	1	0.0	0.0
Aging traits (healthspan, parental lifespan or longevity) (multivariate analysis)	HTML, TSV	Image, TSV	BED	53	-3.4	0.0
Agouti-related protein levels	HTML, TSV	Image, TSV	BED	3	-2.0	0.0
Alanine transaminase levels in high alcohol intake	HTML, TSV	Image, TSV	BED	8	-4.1	-0.4
Allergic disease (asthma, hay fever and/or eczema) (age of onset)	HTML, TSV,	Image, TSV	BED	167	-9.2	-5.0
Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)	HTML, TSV,	Image, TSV	BED	167	-9.2	-5.0
Allergic march (atopic dermatitis to allergic rhinitis)	HTML, TSV	Image, TSV	BED	9	-2.9	0.0
Alpha electroencephalogram power	HTML, TSV	Image, TSV	BED	6	-2.7	0.0
Ambidextrousness	HTML, TSV	Image, TSV	BED	15	-2.0	0.0
Angioedema in response to angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker	HTML, TSV,	Image, TSV	BED	261	-7.6	-3.4
Angiopoietin-1 receptor levels	HTML, TSV	Image, TSV	BED	25	-5.3	-1.3
Anthracycline-induced cardiotoxicity in early breast cancer	HTML, TSV	Image, TSV	BED	10	-3.0	0.0
Anti-chlamydia trachomatis IgG seropositivity	HTML, TSV,	Image, TSV	BED	27	-8.3	-4.1
Anti-drug antibodies in autoimmune disease (time to event)	HTML, TSV,	Image, TSV	BED	12	-7.6	-3.4
Anti-Epstein-Barr virus IgG seropositivity	HTML, TSV	Image, TSV	BED	1	-2.1	0.0
Anti-herpes simplex virus 2 IgG seropositivity	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Anti-herpes simplex virus 6 IE1A IgG seropositivity	HTML, TSV	Image, TSV	BED	1	-3.9	-0.2
Apolipoprotein B levels	HTML, TSV,	Image, TSV	BED	503	-10.7	-6.5
Arterial stiffness (brachial-ankle pulse wave velocity)	HTML, TSV	Image, TSV	BED	1	-3.1	0.0
Arterial stiffness (brachial-femoral pulse wave velocity)	HTML, TSV	Image, TSV	BED	3	-2.2	0.0
Arterial stiffness (carotid-femoral pulse wave velocity)	HTML, TSV	Image, TSV	BED	19	-3.5	0.0
Aspartate aminotransferase platelet ratio index in high alcohol intake	HTML, TSV	Image, TSV	BED	116	-5.6	-1.7
Attention deficit hyperactivity disorder (childhood)	HTML, TSV	Image, TSV	BED	63	-4.1	0.0
Attention deficit hyperactivity disorder (MTAG)	HTML, TSV	Image, TSV	BED	270	-4.3	-0.5
Attention deficit hyperactivity disorder (persistent)	HTML, TSV	Image, TSV	BED	102	-3.4	0.0
Autism spectrum disorder (MTAG)	HTML, TSV	Image, TSV	BED	63	-4.6	-1.0
Autism spectrum disorders (peer interaction)	HTML, TSV	Image, TSV	BED	11	-2.5	0.0
Autism spectrum disorders (repetitive sensory-motor behaviour)	HTML, TSV	Image, TSV	BED	4	-2.2	0.0
Autism spectrum disorders (social interaction)	HTML, TSV	Image, TSV	BED	2	-2.7	0.0
Autoimmune disease and mental disorder	HTML, TSV	Image, TSV	BED	1	-1.6	0.0
Autoimmune thyroid disease	HTML, TSV,	Image, TSV	BED	344	-12.0	-7.8
Basophil count	HTML, TSV,	Image, TSV	BED	615	-23.8	-19.6
Benign childhood epilepsy with centro-temporal spikes	HTML, TSV	Image, TSV	BED	64	-2.0	0.0
Beta 1 electroencephalogram power	HTML, TSV	Image, TSV	BED	9	-3.5	0.0
Beta 2 electroencephalogram power	HTML, TSV	Image, TSV	BED	8	-1.9	0.0
Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)	HTML, TSV	Image, TSV	BED	40	-3.0	0.0
Bioavailable testosterone levels	HTML, TSV	Image, TSV	BED	839	-4.3	-0.2
Bipolar disorder (MTAG)	HTML, TSV	Image, TSV	BED	220	-3.6	0.0
Body size at age 10	HTML, TSV	Image, TSV	BED	1412	-4.5	-0.3
Bone mineral density (hip) and hip bone size	HTML, TSV	Image, TSV	BED	84	-6.2	-2.0
Brain amyloid deposition (PET imaging)	HTML, TSV	Image, TSV	BED	53	-2.9	0.0
Brain morphology (min-P)	HTML, TSV,	Image, TSV	BED	586	-7.5	-3.4
Brain morphology (MOSTest)	HTML, TSV,	Image, TSV	BED	1746	-9.8	-5.6
Breast cancer, ovarian cancer or prostate cancer (pleiotropy)	HTML, TSV,	Image, TSV	BED	105	-14.8	-10.6
Breast cancer somatic mutation signature APOBEC C>G	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Breast cancer somatic mutation signature APOBEC C>T	HTML, TSV	Image, TSV	BED	1	-1.8	0.0
Breslow thickness in cutaneous melanoma	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Caffeine consumption from coffee	HTML, TSV	Image, TSV	BED	65	-5.0	-0.8
Caffeine consumption from coffee or tea	HTML, TSV	Image, TSV	BED	167	-4.5	-0.5
Caffeine consumption from tea	HTML, TSV	Image, TSV	BED	68	-4.5	-0.4
Cancer (pleiotropy)(bidirectional)	HTML, TSV	Image, TSV	BED	71	-4.8	-0.6
Cardiorespiratory fitness (800m run time)	HTML, TSV	Image, TSV	BED	23	-4.4	-0.2
Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Cardiovascular death or myocardial infarction in response to clopidogrel treatment	HTML, TSV	Image, TSV	BED	48	-4.3	-0.2
Carotid plaque maximum area	HTML, TSV	Image, TSV	BED	79	-3.2	0.0
Cataract (time to event)	HTML, TSV	Image, TSV	BED	2	-1.6	0.0
Cathepsin D levels	HTML, TSV	Image, TSV	BED	1	-3.3	0.0
Cathepsin L1 levels	HTML, TSV	Image, TSV	BED	12	-4.6	-0.4
C-C motif chemokine 20 levels	HTML, TSV	Image, TSV	BED	16	-3.7	0.0
C-C motif chemokine 3 levels	HTML, TSV	Image, TSV	BED	4	-5.1	-1.3
C-C motif chemokine 4 levels	HTML, TSV	Image, TSV	BED	20	-4.5	-0.6
CD40 levels	HTML, TSV,	Image, TSV	BED	2	-6.2	-2.0
CDH6 protein levels in plasma	HTML, TSV	Image, TSV	BED	11	-4.2	0.0
Childhood ALL/LBL (acute lymphoblastic leukemia/lymphoblastic lymphoma) treatment-related venous thromboembolism	HTML, TSV,	Image, TSV	BED	49	-6.7	-2.5
Chitinase-3-like protein 1 levels	HTML, TSV	Image, TSV	BED	12	-4.8	-0.6
Chlamydia trachomatis PorB antibody levels	HTML, TSV	Image, TSV	BED	1	-3.1	0.0
Chronic kidney disease x type 2 diabetes interaction	HTML, TSV	Image, TSV	BED	3	-2.5	0.0
Chronotype (sMEQ score)	HTML, TSV,	Image, TSV	BED	18	-6.1	-2.5
Circulating fibroblast growth factor 21 levels	HTML, TSV	Image, TSV	BED	7	-3.0	0.0
Circulating leptin levels or type 2 diabetes	HTML, TSV	Image, TSV	BED	106	-3.3	0.0
Clozapine concentration in schizophrenia	HTML, TSV	Image, TSV	BED	1	-2.7	0.0
Cognitive aspects of educational attainment	HTML, TSV,	Image, TSV	BED	1211	-6.0	-2.1
Cognitive decline in depression	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Colorectal cancer x BMI interaction (2df)	HTML, TSV	Image, TSV	BED	4	-2.9	0.0
Colorectal cancer x fine particulate matter exposure levels interaction	HTML, TSV	Image, TSV	BED	25	-3.0	0.0
Complement factor H binding to malondialdehyde	HTML, TSV	Image, TSV	BED	23	-3.5	0.0
Coronary atherosclerosis (time to event)	HTML, TSV	Image, TSV	BED	4	-4.3	-0.1
Coronary heart disease x type 2 diabetes interaction	HTML, TSV	Image, TSV	BED	7	-3.6	0.0
Cortical surface area	HTML, TSV	Image, TSV	BED	1129	-5.9	-1.8
Cortical surface area (global PC1)	HTML, TSV	Image, TSV	BED	7	-1.7	0.0
Cortical surface area (min-P)	HTML, TSV,	Image, TSV	BED	343	-9.1	-5.0
Cortical surface area (MOSTest)	HTML, TSV,	Image, TSV	BED	638	-10.2	-6.0
Cortical surface area (visual PC2)	HTML, TSV	Image, TSV	BED	234	-4.1	0.0
Cortical thickness (min-P)	HTML, TSV	Image, TSV	BED	156	-4.7	-0.5
Cortical thickness (MOSTest)	HTML, TSV,	Image, TSV	BED	343	-14.4	-10.2
Cutaneous melanoma or hair colour	HTML, TSV	Image, TSV	BED	222	-5.0	-0.9
CV-A6-associated hand, foot, and mouth disease (severe vs mild)	HTML, TSV	Image, TSV	BED	42	-3.8	0.0
CX3CL1 levels	HTML, TSV	Image, TSV	BED	5	-2.3	0.0
C-X-C motif chemokine 16 levels	HTML, TSV,	Image, TSV	BED	44	-6.2	-2.0
C-X-C motif chemokine 1 levels	HTML, TSV	Image, TSV	BED	19	-3.8	-0.1
C-X-C motif chemokine 6 levels	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Cystatin-B levels	HTML, TSV	Image, TSV	BED	6	-4.4	-0.2
Cytomegalovirus pp28 antibody levels	HTML, TSV,	Image, TSV	BED	3	-9.4	-5.2
Deep white matter hyperintensities	HTML, TSV	Image, TSV	BED	119	-5.1	-0.9
Delta electroencephalogram power	HTML, TSV	Image, TSV	BED	7	-4.2	-0.0
Depression x herpes simplex 1 infection interaction	HTML, TSV	Image, TSV	BED	3	-2.3	0.0
Depressive symptoms x herpes simplex 1 infection interaction	HTML, TSV	Image, TSV	BED	4	-3.2	0.0
Diastolic blood pressure x dichotomous lifestyle risk score interaction (1df test)	HTML, TSV	Image, TSV	BED	1	-1.3	0.0
Diastolic blood pressure x dichotomous lifestyle risk score interaction (2df test)	HTML, TSV	Image, TSV	BED	1	-1.3	0.0
Diastolic blood pressure x educational attainment (graduated college) interaction (2df)	HTML, TSV	Image, TSV	BED	4	-2.3	0.0
Diastolic blood pressure x educational attainment (some college) interaction (2df)	HTML, TSV	Image, TSV	BED	3	-3.6	0.0
Diastolic blood pressure x quantitative lifestyle risk score interaction (1df test)	HTML, TSV	Image, TSV	BED	11	-2.2	0.0
Diastolic blood pressure x quantitative lifestyle risk score interaction (2df test)	HTML, TSV	Image, TSV	BED	14	-2.1	0.0
Dickkopf-related protein 1 levels	HTML, TSV	Image, TSV	BED	24	-5.7	-1.6
Diffuse plaques	HTML, TSV	Image, TSV	BED	23	-4.4	-0.6
Disease free survival in colon cancer	HTML, TSV	Image, TSV	BED	2	-4.2	-0.1
Early age-related macular degeneration	HTML, TSV	Image, TSV	BED	7	-3.2	0.0
Electrocardiogram morphology (amplitude at temporal datapoints)	HTML, TSV,	Image, TSV	BED	1221	-18.0	-13.9
Endometriosis or depression (pleiotropy)	HTML, TSV	Image, TSV	BED	243	-4.4	-0.3
Endothelial cell-specific molecule 1 levels	HTML, TSV	Image, TSV	BED	9	0.0	0.0
Eosinophil cationic protein levels	HTML, TSV	Image, TSV	BED	2	-1.9	0.0
Epstein-Barr virus EA-D antibody levels	HTML, TSV	Image, TSV	BED	5	-2.5	0.0
Epstein-Barr virus VCA p18 antibody levels	HTML, TSV	Image, TSV	BED	5	-5.3	-1.3
Esophageal or stomach cancer	HTML, TSV	Image, TSV	BED	23	-3.6	0.0
Essential hypertension (time to event)	HTML, TSV	Image, TSV	BED	66	-2.9	0.0
Evening vs. morning chronotype (self-assessed)	HTML, TSV	Image, TSV	BED	26	-4.2	-0.1
Evening vs. morning chronotype (sMEQ score)	HTML, TSV	Image, TSV	BED	47	-2.9	0.0
Externalizing behaviour score	HTML, TSV	Image, TSV	BED	13	-3.1	0.0
Facial pigmentation measurement (polar light)	HTML, TSV	Image, TSV	BED	8	-3.4	0.0
Facial pigmentation measurement (UV light)	HTML, TSV	Image, TSV	BED	8	-3.4	0.0
Falling risk	HTML, TSV	Image, TSV	BED	109	-3.7	-0.2
Fatty acid-binding protein, adipocyte levels	HTML, TSV	Image, TSV	BED	2	-2.5	0.0
Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass	HTML, TSV	Image, TSV	BED	72	-4.0	-0.1
Fibroblast growth factor 23 levels	HTML, TSV	Image, TSV	BED	7	-3.4	0.0
Fibroblast growth factor 5 levels	HTML, TSV	Image, TSV	BED	13	-4.0	-0.1
Fibrosis-4 index in high alcohol intake	HTML, TSV	Image, TSV	BED	118	-5.6	-1.6
Follicle stimulating hormone in healthy women	HTML, TSV,	Image, TSV	BED	77	-7.0	-2.9
Follistatin levels	HTML, TSV	Image, TSV	BED	5	-2.8	0.0
Forns index in high alcohol intake	HTML, TSV	Image, TSV	BED	127	-5.3	-1.4
Fractures (paediatric)	HTML, TSV	Image, TSV	BED	40	-4.8	-0.6
Galanin peptide levels	HTML, TSV	Image, TSV	BED	43	-4.9	-0.7
Galectin-3 levels	HTML, TSV	Image, TSV	BED	6	-3.6	0.0
Glucagon levels in response to oral glucose tolerance test (30 minutes)	HTML, TSV	Image, TSV	BED	28	-2.5	0.0
Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-120 minutes)	HTML, TSV	Image, TSV	BED	87	-3.5	0.0
Glucagon levels in response to oral glucose tolerance test (decremental area under the curve for 0-30 minutes)	HTML, TSV	Image, TSV	BED	52	-4.0	0.0
Glycosuria in pregnancy (offspring genotype effect)	HTML, TSV	Image, TSV	BED	3	-4.0	-0.2
Gout (combined type)	HTML, TSV	Image, TSV	BED	28	-3.3	0.0
Gout (normal type)	HTML, TSV	Image, TSV	BED	11	-2.8	0.0
Graft survival time in renal transplantation (donor effect)	HTML, TSV	Image, TSV	BED	4	-3.0	0.0
Graft survival time in renal transplantation (donor effect) x APOL1 genotype interaction	HTML, TSV	Image, TSV	BED	34	-3.0	0.0
Gut microbiota alpha diversity (Chao1 index)	HTML, TSV	Image, TSV	BED	122	-3.6	0.0
Gut microbiota alpha diversity (PD_whole_tree index)	HTML, TSV	Image, TSV	BED	105	-3.0	0.0
Gut microbiota alpha diversity (Shannon index)	HTML, TSV	Image, TSV	BED	20	-5.2	-1.0
Gut microbiota (bacterial taxa, hurdle binary method)	HTML, TSV	Image, TSV	BED	688	-3.0	0.0
Gut microbiota (bacterial taxa, rank normal transformation method)	HTML, TSV	Image, TSV	BED	455	-2.8	0.0
Gut microbiota beta diversity (weighted UniFrac distance)	HTML, TSV	Image, TSV	BED	29	-3.1	0.0
Gut microbiota relative abundance (Bacteroides)	HTML, TSV	Image, TSV	BED	45	-5.8	-1.8
Gut microbiota relative abundance (Bifidobacterium)	HTML, TSV,	Image, TSV	BED	57	-8.9	-4.7
Gut microbiota relative abundance (Blautia)	HTML, TSV	Image, TSV	BED	29	-3.1	0.0
Gut microbiota relative abundance (Coprococcus)	HTML, TSV	Image, TSV	BED	18	-2.5	0.0
Gut microbiota relative abundance (Dorea)	HTML, TSV	Image, TSV	BED	160	-3.2	0.0
Gut microbiota relative abundance (Eubacterium belonging to family Erysipelotrichaceae)	HTML, TSV	Image, TSV	BED	38	-2.8	0.0
Gut microbiota relative abundance (Faecalibacterium)	HTML, TSV	Image, TSV	BED	24	-2.1	0.0
Gut microbiota relative abundance (Oscillospira)	HTML, TSV	Image, TSV	BED	43	-3.5	0.0
Gut microbiota relative abundance (Parabacteroides)	HTML, TSV,	Image, TSV	BED	46	-6.0	-2.1
Gut microbiota relative abundance (Prevotella)	HTML, TSV	Image, TSV	BED	68	-4.5	-0.5
Gut microbiota relative abundance (Ruminococcus belonging to family Erysipelotrichaceae)	HTML, TSV	Image, TSV	BED	76	-3.8	0.0
Gut microbiota relative abundance (Ruminococcus belonging to family Lachnospiraceae)	HTML, TSV	Image, TSV	BED	32	-3.7	0.0
Gut microbiota relative abundance (Streptococcus)	HTML, TSV	Image, TSV	BED	41	-2.7	0.0
Gut microbiota relative abundance (Sutterella)	HTML, TSV	Image, TSV	BED	18	-2.5	0.0
Gut microbiota relative abundance (unassigned genus belonging to family Clostridiales)	HTML, TSV,	Image, TSV	BED	79	-6.6	-2.7
Gut microbiota relative abundance (unassigned genus belonging to family Lachnospiraceae)	HTML, TSV	Image, TSV	BED	30	-2.3	0.0
Gut microbiota relative abundance (unclassified genus belonging to family Clostridiaceae)	HTML, TSV,	Image, TSV	BED	51	-8.7	-4.5
Gut microbiota relative abundance (unclassified genus belonging to family Erysipelotrichaceae)	HTML, TSV	Image, TSV	BED	109	-4.8	-0.6
Gut microbiota relative abundance (unclassified genus belonging to family Lachnospiraceae)	HTML, TSV	Image, TSV	BED	42	-5.7	-1.5
Gut microbiota relative abundance (unclassified genus belonging to family Ruminococcaceae)	HTML, TSV	Image, TSV	BED	35	0.0	0.0
Gut microbiota relative abundance (unclassified genus belonging to the order Clostridiales)	HTML, TSV,	Image, TSV	BED	81	-6.7	-2.6
Hand grip strength (Mahalanobis distance)	HTML, TSV	Image, TSV	BED	52	-2.8	0.0
Heat shock 27 kDa protein levels	HTML, TSV	Image, TSV	BED	2	-4.8	-1.1
Helicobacter pylori OMP antibody levels	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Helicobacter pylori UREA antibody levels	HTML, TSV	Image, TSV	BED	11	-2.1	0.0
Herpes simplex virus 6 IE1B antibody levels	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Herpes simplex virus 7 U14 antibody levels	HTML, TSV	Image, TSV	BED	6	-3.9	0.0
Hip bone mineral content accrual during adolescent growth spurt	HTML, TSV	Image, TSV	BED	26	-2.7	0.0
Hip bone mineral density and total body fat mass (bivariate analysis)	HTML, TSV	Image, TSV	BED	57	-5.0	-1.0
HOMA-B (corrected for HOMA-IR)	HTML, TSV	Image, TSV	BED	103	-5.4	-1.2
Hypo-HDL-cholesterolemia	HTML, TSV	Image, TSV	BED	5	-2.1	0.0
Hypotension and cognitive impairment	HTML, TSV	Image, TSV	BED	3	-2.0	0.0
Inflammatory biomarkers (multivariate analysis)	HTML, TSV	Image, TSV	BED	95	-5.0	-0.8
Interleukin-10 receptor B levels	HTML, TSV	Image, TSV	BED	3	-5.6	-1.4
interleukin-18 receptor 1 levels	HTML, TSV	Image, TSV	BED	5	-3.6	0.0
Interleukin-27 levels	HTML, TSV	Image, TSV	BED	10	-3.9	0.0
Kidney cancer	HTML, TSV	Image, TSV	BED	12	-2.5	0.0
Kidney injury molecule 1 levels	HTML, TSV	Image, TSV	BED	15	-4.0	0.0
Lean nonalcoholic fatty liver disease	HTML, TSV	Image, TSV	BED	12	-3.3	0.0
Lectin-like oxidized LDL receptor 1 levels	HTML, TSV	Image, TSV	BED	2	-3.2	0.0
Left-handedness	HTML, TSV	Image, TSV	BED	157	-3.9	0.0
Leukoderma in response to rhododendrol	HTML, TSV	Image, TSV	BED	42	-5.2	-1.0
Levodopa-induced dyskinesia in levodopa treated Parkinson's disease	HTML, TSV	Image, TSV	BED	37	-3.6	0.0
Levodopa wearing off effect (motor symptom score change) in Parkinson's disease (response to zonisamide)	HTML, TSV	Image, TSV	BED	1	-3.4	0.0
Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide)	HTML, TSV	Image, TSV	BED	5	-3.2	-0.2
Liver fibrogenesis (alpha smooth muscle actin levels)	HTML, TSV,	Image, TSV	BED	19	-8.0	-3.8
Liver fibrosis (total hepatic collagen content)	HTML, TSV	Image, TSV	BED	19	-2.8	0.0
Long QT syndrome	HTML, TSV	Image, TSV	BED	74	-6.1	-1.9
Low density lipoprotein cholesterol levels (on statin treatment)	HTML, TSV	Image, TSV	BED	2	-2.0	0.0
Low hand grip strength (60 years and older) (EWGSOP)	HTML, TSV	Image, TSV	BED	16	-2.8	0.0
Low hand grip strength (60 years and older) (FNIH)	HTML, TSV	Image, TSV	BED	4	-2.8	0.0
Lymphocytic leukemia	HTML, TSV	Image, TSV	BED	29	-4.4	-0.2
Machado-Joseph disease (age at onset)	HTML, TSV	Image, TSV	BED	32	-3.8	0.0
Macrophage colony-stimulating factor 1 levels	HTML, TSV	Image, TSV	BED	5	-3.7	0.0
Macroscopic brain infarct	HTML, TSV	Image, TSV	BED	21	-3.4	0.0
Male puberty timing (age at voice breaking MTAG)	HTML, TSV	Image, TSV	BED	417	-4.2	-0.0
Male puberty timing (early vs. average onset facial hair)	HTML, TSV	Image, TSV	BED	176	-4.8	-0.6
Male puberty timing (early vs. average onset voice breaking)	HTML, TSV	Image, TSV	BED	111	-4.6	-0.6
Male puberty timing (late vs. average onset facial hair)	HTML, TSV	Image, TSV	BED	114	-3.2	0.0
Male puberty timing (late vs. average onset voice breaking)	HTML, TSV	Image, TSV	BED	62	-3.8	0.0
Matrix metalloproteinase-10 levels	HTML, TSV	Image, TSV	BED	8	-5.0	-1.1
Matrix metalloproteinase-12 levels	HTML, TSV	Image, TSV	BED	16	0.0	0.0
Matrix metalloproteinase-1 levels	HTML, TSV	Image, TSV	BED	2	-3.0	0.0
Matrix metalloproteinase-3 levels	HTML, TSV	Image, TSV	BED	1	-2.2	0.0
Matrix metalloproteinase-7 levels	HTML, TSV	Image, TSV	BED	14	-6.1	-1.9
Maximum stenosis	HTML, TSV	Image, TSV	BED	6	-5.2	-1.0
Mean area of carotid plaque	HTML, TSV	Image, TSV	BED	32	-3.2	0.0
Mean arterial pressure x educational attainment (some college) interaction (2df)	HTML, TSV	Image, TSV	BED	4	-3.2	0.0
Mean degree of stenosis	HTML, TSV	Image, TSV	BED	2	-1.9	0.0
Mean reticulocyte volume	HTML, TSV,	Image, TSV	BED	1286	-37.2	-33.0
Mean spheric corpuscular volume	HTML, TSV,	Image, TSV	BED	1799	-40.0	-35.8
Melusin levels	HTML, TSV	Image, TSV	BED	11	-4.3	-0.1
Memory decline	HTML, TSV	Image, TSV	BED	17	-2.0	0.0
Mental disorder (without autoimmune disease)	HTML, TSV	Image, TSV	BED	9	-2.2	0.0
Merkel cell polyomavirus VP1 antibody levels	HTML, TSV	Image, TSV	BED	2	-3.2	0.0
Metamizole-induced agranulocytosis	HTML, TSV	Image, TSV	BED	8	-2.4	0.0
Metamizole-induced agranulocytosis or neutropenia	HTML, TSV	Image, TSV	BED	5	-3.5	0.0
Microscopic brain infarct	HTML, TSV	Image, TSV	BED	18	-3.8	0.0
Midline nonsyndromic craniosynostosis	HTML, TSV	Image, TSV	BED	10	-3.3	0.0
Migraine and/or diastolic blood pressure	HTML, TSV	Image, TSV	BED	58	-5.7	-1.6
Migraine and/or pulse pressure	HTML, TSV	Image, TSV	BED	77	-3.0	0.0
Migraine and/or systolic blood pressure	HTML, TSV	Image, TSV	BED	75	-4.2	-0.3
Migraine with aura and/or pulse pressure	HTML, TSV	Image, TSV	BED	3	-2.3	0.0
Migraine without aura and/or diastolic blood pressure	HTML, TSV,	Image, TSV	BED	20	-6.3	-2.4
Migraine without aura and/or pulse pressure	HTML, TSV	Image, TSV	BED	3	-2.3	0.0
Monocyte chemoattractant protein-4 levels	HTML, TSV	Image, TSV	BED	13	-2.3	0.0
Motor fluctuations in levodopa treated Parkinson's disease	HTML, TSV	Image, TSV	BED	7	-3.0	0.0
Myeloid clonal hematopoiesis	HTML, TSV	Image, TSV	BED	32	-4.1	-0.1
Myeloperoxidase levels	HTML, TSV,	Image, TSV	BED	5	-6.4	-2.2
Myocardial fractal dimension (slice 2)	HTML, TSV	Image, TSV	BED	2	-2.4	0.0
Myocardial fractal dimension (slice 3)	HTML, TSV	Image, TSV	BED	24	-3.8	0.0
Myocardial fractal dimension (slice 4)	HTML, TSV	Image, TSV	BED	37	-4.2	-0.0
Myocardial fractal dimension (slice 5)	HTML, TSV	Image, TSV	BED	43	-4.0	-0.1
Myocardial fractal dimension (slice 6)	HTML, TSV	Image, TSV	BED	44	-3.9	-0.2
Myocardial fractal dimension (slice 7)	HTML, TSV	Image, TSV	BED	11	-3.7	0.0
Myocardial fractal dimension (slice 8)	HTML, TSV	Image, TSV	BED	9	-4.0	0.0
Myocardial fractal dimension (slice 9)	HTML, TSV	Image, TSV	BED	1	-3.7	0.0
Myoglobin levels	HTML, TSV	Image, TSV	BED	3	-3.0	-0.1
Neuropathologic traits (pleiotropy)	HTML, TSV	Image, TSV	BED	31	-4.0	0.0
Neuropathy x type 2 diabetes interaction	HTML, TSV	Image, TSV	BED	2	-2.1	0.0
Non-alcoholic fatty liver disease activity score in non-alcoholic fatty liver disease	HTML, TSV	Image, TSV	BED	33	-2.7	0.0
Nonalcoholic steatohepatitis	HTML, TSV	Image, TSV	BED	21	-3.2	0.0
Noncognitive aspects of educational attainment	HTML, TSV	Image, TSV	BED	708	-4.6	-0.4
Non-Hodgkin's lymphoma	HTML, TSV	Image, TSV	BED	81	-3.6	0.0
Non-tuberculous mycobacterial pulmonary disease	HTML, TSV	Image, TSV	BED	57	-3.6	0.0
Osteoarthrosis (time to event)	HTML, TSV	Image, TSV	BED	2	-3.2	-0.2
Ovarian cancer-related tumor marker CA 125 levels	HTML, TSV	Image, TSV	BED	14	-3.5	0.0
Pappalysin-1 levels	HTML, TSV	Image, TSV	BED	83	-4.7	-0.9
Parent of origin effect on receptive language ability (maternal)	HTML, TSV	Image, TSV	BED	4	-3.2	0.0
Parent of origin effect on receptive language ability (paternal)	HTML, TSV	Image, TSV	BED	49	-2.8	0.0
Parkinson's disease progression (cognitive)	HTML, TSV	Image, TSV	BED	13	0.0	0.0
Parkinson's disease progression (composite)	HTML, TSV	Image, TSV	BED	35	-2.5	0.0
Parkinson's disease progression (motor)	HTML, TSV	Image, TSV	BED	18	-3.3	0.0
Peak hip bone mineral content	HTML, TSV	Image, TSV	BED	13	-3.2	0.0
Pentraxin-related protein PTX3 levels	HTML, TSV	Image, TSV	BED	1	-2.4	0.0
Percent liver fat	HTML, TSV	Image, TSV	BED	4	-2.5	0.0
Peripheral arterial disease x type 2 diabetes interaction	HTML, TSV	Image, TSV	BED	6	-3.5	0.0
Periventricular white matter hyperintensities	HTML, TSV	Image, TSV	BED	355	-4.3	-0.1
Physical aggression in schizophrenia	HTML, TSV	Image, TSV	BED	3	-4.5	-0.3
Physiological dysregulation (Mahalanobis distance)	HTML, TSV	Image, TSV	BED	14	-5.4	-1.2
Platelet-derived growth factor subunit B levels	HTML, TSV	Image, TSV	BED	17	-4.2	-0.0
Platelet endothelial cell adhesion molecule levels	HTML, TSV	Image, TSV	BED	3	-3.2	0.0
Platelet reactivity in response to clopidogrel treatment	HTML, TSV	Image, TSV	BED	54	-3.5	0.0
Polycystic ovary syndrome (metabolic subtype)	HTML, TSV	Image, TSV	BED	1	-2.6	0.0
Polycystic ovary syndrome (reproductive subtype)	HTML, TSV	Image, TSV	BED	5	-4.6	-0.6
Polyomavirus 2 JC VP1 antibody levels	HTML, TSV	Image, TSV	BED	4	-3.0	0.0
Postprandial triglyceride response	HTML, TSV	Image, TSV	BED	7	-1.8	0.0
Preeclampsia (fetal genotype effect)	HTML, TSV	Image, TSV	BED	16	-3.1	0.0
Preeclampsia (maternal genotype effect)	HTML, TSV	Image, TSV	BED	75	-5.7	-1.6
Problematic alcohol use	HTML, TSV	Image, TSV	BED	329	-4.2	-0.0
Problematic alcohol use (MTAG)	HTML, TSV	Image, TSV	BED	388	-4.0	-0.1
Proheparin-binding EGF-like growth factor levels	HTML, TSV	Image, TSV	BED	2	-1.4	0.0
Pro-interleukin-16 levels	HTML, TSV	Image, TSV	BED	14	-2.2	0.0
Proportion of activated microglia (inferior temporal cortex)	HTML, TSV	Image, TSV	BED	75	0.0	0.0
Proportion of activated microglia (midfrontal cortex)	HTML, TSV	Image, TSV	BED	30	-3.9	-0.1
Proteinase-activated receptor 1 levels	HTML, TSV	Image, TSV	BED	9	-3.1	0.0
P-selectin glycoprotein ligand 1 levels	HTML, TSV,	Image, TSV	BED	10	-6.2	-2.3
Pulse pressure x educational attainment (some college) interaction (2df)	HTML, TSV	Image, TSV	BED	3	-1.4	0.0
QT dynamics during exercise	HTML, TSV	Image, TSV	BED	56	-6.1	-1.9
QT dynamics during recovery from exercise	HTML, TSV	Image, TSV	BED	30	-4.0	-0.0
Rate of cognitive decline in Alzheimer's disease	HTML, TSV,	Image, TSV	BED	999	-6.3	-2.1
Receptive language ability	HTML, TSV	Image, TSV	BED	17	-2.6	0.0
Receptor for advanced glycosylation end products levels	HTML, TSV	Image, TSV	BED	39	-4.0	-0.4
Rectal cancer	HTML, TSV	Image, TSV	BED	99	-3.3	0.0
Relative carbohydrate intake	HTML, TSV,	Image, TSV	BED	40	-6.7	-3.0
Relative fat intake	HTML, TSV,	Image, TSV	BED	25	-6.8	-2.9
Relative sugar intake	HTML, TSV,	Image, TSV	BED	46	-6.2	-2.4
Renin levels	HTML, TSV	Image, TSV	BED	4	-3.2	0.0
Response to antiepileptic drugs in genetic generalized epilepsy	HTML, TSV	Image, TSV	BED	11	-2.6	0.0
Response to antiepileptic mood-stabilizing treatment in bipolar disorder	HTML, TSV	Image, TSV	BED	36	-4.7	-0.5
Response to lamotrigine and valproic acid in genetic generalized epilepsy	HTML, TSV	Image, TSV	BED	15	-3.4	0.0
Response to lamotrigine in genetic generalized epilepsy	HTML, TSV	Image, TSV	BED	53	-3.7	0.0
Response to levetiracetam in genetic generalized epilepsy	HTML, TSV	Image, TSV	BED	37	-3.0	0.0
Response to radiotherapy in nasopharyngeal carcinoma (acute oral mucositis)	HTML, TSV	Image, TSV	BED	30	-5.2	-1.1
Response to valproic acid in genetic generalized epilepsy	HTML, TSV,	Image, TSV	BED	29	-13.8	-9.9
Retinopathy x type 2 diabetes interaction	HTML, TSV	Image, TSV	BED	25	-3.0	0.0
Self-harm ideation	HTML, TSV	Image, TSV	BED	3	-2.4	0.0
Sensory peripheral neuropathy in microtubule targeting agent-treated breast cancer	HTML, TSV	Image, TSV	BED	32	-5.0	-0.8
Serum 25-Hydroxyvitamin D levels x season interaction	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Serum 25-Hydroxyvitamin D level variance	HTML, TSV	Image, TSV	BED	12	-3.7	0.0
Serum docosahexaenoic fatty acid concentration in metabolic syndrome	HTML, TSV	Image, TSV	BED	84	-4.4	-0.2
Serum linoleic acid concentration in metabolic syndrome	HTML, TSV	Image, TSV	BED	38	-2.4	0.0
Serum omega-3 polyunsaturated fatty acid concentration in metabolic syndrome	HTML, TSV	Image, TSV	BED	29	-5.1	-1.0
Serum omega-6 polyunsaturated fatty acid concentration in metabolic syndrome	HTML, TSV	Image, TSV	BED	5	-3.4	-0.6
Serum omega-6 to omega-3 polyunsaturated fatty acid ratio in metabolic syndrome	HTML, TSV	Image, TSV	BED	15	-2.2	0.0
Serum polyunsaturated fatty acid concentration x Mediterranean diet adherence interaction in metabolic syndrome	HTML, TSV	Image, TSV	BED	73	-4.1	-0.2
Serum polyunsaturated fatty acid concentration x sex interaction in metabolic syndrome	HTML, TSV	Image, TSV	BED	23	-3.6	0.0
Serum total polyunsaturated fatty acid concentration in metabolic syndrome	HTML, TSV	Image, TSV	BED	3	-3.0	0.0
Sex hormone-binding globulin levels adjusted for BMI	HTML, TSV,	Image, TSV	BED	2014	-14.9	-10.7
Shoulder impingement syndrome	HTML, TSV	Image, TSV	BED	78	-3.2	0.0
SIR2-like protein 2 levels	HTML, TSV	Image, TSV	BED	2	-3.6	0.0
Spondin-1 levels	HTML, TSV	Image, TSV	BED	2	-1.8	0.0
Spontaneous coronary artery dissection	HTML, TSV	Image, TSV	BED	78	-5.6	-1.4
ST2 protein levels	HTML, TSV,	Image, TSV	BED	23	-10.8	-6.9
Stent thrombosis in response to clopidogrel treatment	HTML, TSV	Image, TSV	BED	6	-3.0	0.0
Subcortical volume (min-P)	HTML, TSV,	Image, TSV	BED	319	-6.6	-2.6
Subcortical volume (MOSTest)	HTML, TSV	Image, TSV	BED	587	-6.1	-1.9
Sum of carotid plaque area	HTML, TSV	Image, TSV	BED	49	-4.5	-0.3
Sum of stenosis	HTML, TSV	Image, TSV	BED	48	-5.6	-1.4
Sweet taste preference	HTML, TSV	Image, TSV	BED	10	-4.0	0.0
Systolic blood pressure x dichotomous lifestyle risk score interaction (1df test)	HTML, TSV	Image, TSV	BED	24	-4.1	0.0
Systolic blood pressure x dichotomous lifestyle risk score interaction (2df test)	HTML, TSV	Image, TSV	BED	24	-4.1	0.0
Systolic blood pressure x educational attainment (graduated college) interaction (2df)	HTML, TSV	Image, TSV	BED	4	-4.8	-1.2
Systolic blood pressure x educational attainment (some college) interaction (2df)	HTML, TSV	Image, TSV	BED	7	-3.7	0.0
Systolic blood pressure x quantitative lifestyle risk score interaction (1df test)	HTML, TSV	Image, TSV	BED	29	-2.9	0.0
Systolic blood pressure x quantitative lifestyle risk score interaction (2df test)	HTML, TSV	Image, TSV	BED	38	-2.7	0.0
Tafenoquine efficacy in P. vivax malaria (recurrence by 4 months)	HTML, TSV	Image, TSV	BED	19	-5.0	-0.9
Tafenoquine efficacy in P. vivax malaria (recurrence by 6 months)	HTML, TSV	Image, TSV	BED	3	-2.3	0.0
T-Cell Immunoglobulin and Mucin domain 1 levels	HTML, TSV	Image, TSV	BED	20	-2.1	0.0
Theta EEG coherence	HTML, TSV	Image, TSV	BED	14	-3.2	0.0
Theta electroencephalogram power	HTML, TSV	Image, TSV	BED	10	-2.9	0.0
Thrombin-induced platelet aggregation	HTML, TSV	Image, TSV	BED	1	-3.4	0.0
Thrombomodulin levels	HTML, TSV	Image, TSV	BED	17	-3.4	0.0
Tissue factor levels	HTML, TSV	Image, TSV	BED	7	-3.2	0.0
Tissue-type plasminogen activator levels	HTML, TSV	Image, TSV	BED	11	-5.1	-0.9
TNF-related activation-induced cytokine levels	HTML, TSV	Image, TSV	BED	15	-2.0	0.0
TNF-related apoptosis-inducing ligand levels	HTML, TSV	Image, TSV	BED	5	-4.3	-0.4
TNF-related apoptosis-inducing ligand receptor 2 levels	HTML, TSV	Image, TSV	BED	8	-2.7	0.0
Total testosterone levels	HTML, TSV,	Image, TSV	BED	1509	-8.1	-3.9
TPE interval (recovery after exercise)	HTML, TSV	Image, TSV	BED	2	-1.1	0.0
TPE interval (response to exercise)	HTML, TSV	Image, TSV	BED	22	-3.6	0.0
TPE interval (resting)	HTML, TSV	Image, TSV	BED	146	-4.9	-0.7
Tumor necrosis factor levels	HTML, TSV	Image, TSV	BED	20	-5.9	-1.7
Tumor necrosis factor ligand superfamily member 14 levels	HTML, TSV	Image, TSV	BED	1	-3.7	-0.5
Tumor necrosis factor receptor superfamily member 6 levels	HTML, TSV	Image, TSV	BED	7	-5.0	-0.8
Ultradistal forearm bone mineral density	HTML, TSV	Image, TSV	BED	104	-4.9	-0.7
Urine 6-bromotryptophan levels in chronic kidney disease	HTML, TSV	Image, TSV	BED	10	-4.3	-0.4
Urokinase plasminogen activator surface receptor levels	HTML, TSV	Image, TSV	BED	13	-5.9	-1.8
Walking pace	HTML, TSV,	Image, TSV	BED	298	-6.4	-2.2
Youthful appearance (self-reported)	HTML, TSV	Image, TSV	BED	325	-4.8	-0.9

Cell type classes:

Blood	Lung	Breast
Cardiovascular	Prostate	Neural
Liver	Digestive tract	Others